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Vascular risk factors inducing a state of chronic cerebral hypoperfusion and 
metabolic stress are thought to influence the onset and progression of 
Alzheimer’s disease (AD).  To investigate the complex molecular changes 
underpinning cellular adaptation to metabolic stress, the first aim of this thesis 
was to define the proteomic response of the SH-SY5Y human neuroblastoma cell 
line after exposure to the metabolic challenge of oxygen glucose deprivation 
(OGD). 958 proteins across multiple subcellular compartments were detected 
and quantified by label-free liquid chromatography mass spectrometry (LC-MS). 
The levels of 130 proteins were significantly increased (P<0.01) after OGD and 
the levels of 63 proteins were significantly decreased (P<0.01) while expression 
of the majority of proteins (765) was not altered. Ingenuity Pathway Analysis 
identified novel protein-protein interactomes involved with mitochondrial 
energy production, protein folding, and protein degradation, indicative of 
coherent and integrated proteomic responses to the metabolic challenge. 
Approximately one third (61) of the differentially expressed proteins were 
associated with the endoplasmic reticulum and mitochondria. Electron 
microscopic analysis of these subcellular structures showed morphologic 
changes consistent with the identified proteomic alterations.  
 
Pertinent to AD research, amyloid binding alcohol dehydrogenase (ABAD) was 
found to be significantly increased in response to OGD.  ABAD is emerging as a 
key player in mitochondrial dysfunction in AD, yet full understanding of the 
biochemical pathways in which this protein is involved remain elusive.  Using 
immunoprecipitation coupled to LC-MS (IP-MS), the second aim of the thesis 
was to characterise the ABAD protein interactome in SH-SY5Y cells and its 
response to metabolic stress. 67 proteins were identified as potential ABAD 
interactors under control conditions, and 69 proteins were identified as 
potential ABAD interactors under OGD conditions.  The Database for 
Annotation, Visualization and Integrated Discovery (DAVID) was used to 
xviii 
 
determine the subcellular locations and biological functions of the ABAD 
interacting proteins in control and OGD conditions. DAVID identified the nuclei 
and mitochondria to contain the greatest number of changes in ABAD 
interacting proteins following OGD.  “Glucose Metabolic Process” (GO:0006006) 
was the top functional cluster for ABAD interacting proteins in both control and 
OGD conditions.   Independent immunoprecipitations, western blotting, 
immunohistochemistry and electron microscopy were used to validate specific 
protein interactions.     
 
OGD was found to initiate a novel interaction between ABAD and glucose-
regulated protein 75 (GRP75), a finding confirmed in human AD tissue.  GRP75 
is a mitochondrial protein and marker of the mitochondrial associated 
membrane (MAM), a specialised region between the mitochondria and the ER.  
The MAM is known to be enriched with presenilin proteins, involved in the 
proteolytic cleavage of amyloid precursor protein (APP).   These data were used 
to generate an “ABAD-GRP75-MAM hypothesis of mitochondrial dysfunction in 
AD”, which might provide a novel link between chronic metabolic stress, ABAD, 
mitochondrial dysfunction and the onset / progression of AD.   The third aim of 
the thesis was to test this novel hypothesis.  Western blotting revealed APP to 
be significantly decreased following OGD, concurrent with an increase in ABAD 
protein levels.  Over-expression of ABAD protein in SH-SY5Y cells was used to 
test whether the increased levels of ABAD following OGD were the driving force 
behind APP down-regulation.  ABAD over-expression in SH-SY5Y cells was 
found to have no detectable effect on APP.  Conversely, electron microscopy 
revealed a dynamic response of the MAM to metabolic stress.  This result, along 
with the interaction of ABAD with GRP75, and the enrichment of presenilins at 
the MAM, suggests that this specialised membrane region may have an 




The data presented within this thesis provide the first comprehensive analysis 
of the proteomic and morphologic response of human SH-SY5Y cells to 
prolonged metabolic challenge.  The lack of acute ischemic cell death in this in 
vitro model makes the data particularly pertinent to the compromised energy 
metabolism associated with slowly evolving neurodegenerative disorders, 
including Alzheimer’s disease.  The generation of novel hypotheses from highly 
descriptive proteomic investigations provides a powerful platform for discovery 
based research, a strategy that is becoming increasingly important for the 















Chapter 1:  Introducing Alzheimer’s 














Chapter 1:  Introducing Alzheimer’s disease, the Mitochondria, and Proteomics   
 
1.1 Dementia, Ageing and Cognitive Decline: A Historical Perspective 
 
Dementia, derived from the Latin de- (meaning without) and -mens (meaning 
mind), is not a modern disorder.  Historical texts as early as those of Plato saw 
descriptions of forgetfulness as a natural human disorder of ageing.  At the end 
of the 19th century, despite ageing and cognitive decline having been on the 
scientific and philosophical agenda since 400 B.C., the term “dementia” was still 
being used to describe any unspecific psychological decline.  When this 
dementia was seen in the elderly, it was described simply as “senile dementia” 
(Berrios, 1990).  However, from the 1860’s onwards, work attempting to 
separate features of “dementia” and “senile dementia” was beginning to emerge.  
Of particular importance was the work of Marcé (1863), who described the 
gross structure of the ageing demented brain to be altered, with significant 
softening and shrinkage, thus providing the first descriptions of cerebral 
atrophy in dementia.   
 
The modern definition of dementia is the loss or decline in memory and other 
cognitive abilities which have a significant negative impact on daily functioning 
(Qiu et al., 2007).   Dementia is now broken down and classified into different 
subtypes, including Vascular Dementia, Dementia with Lewy Bodies, and 
Alzheimer’s Disease (AD).  It can be challenging to distinguish between these 
different types of dementia due to the overlap in cognitive symptoms.  However, 
advances in neuropsychological evaluation and neuroimaging markers are 
beginning to provide a more accurate basis for differentiating between AD and 





1.2 Alzheimer’s Disease: Prevalence and Pathophysiology 
 
1.2.1 Incidence and Classification of Alzheimer’s disease 
 
AD is the most common and most severe form of dementia.  It is predicted by 
the Alzheimer’s Association that if treatments for AD don’t drastically improve, 
the number of people suffering from this disease worldwide will increase from 
approximately 26 million sufferers currently, to over 100 million by the year 
2050.  AD brains exhibit extensive neuronal degeneration, which is grossly 
manifested in the significant atrophy and shrinkage of the brain (Figure 1.1).  
These changes in gross structure are accompanied by progressive cognitive 
dysfunctions, including memory loss, language difficulties, and psychiatric 
changes such as depression, delusions and agitation (Burns and Iliffe, 2009).  
 
AD is broadly categorised into two types: early onset AD and late onset AD.  
Early onset AD occurs in younger patients (usually less than 60 years of age), 
and accounts for less than 5% of all AD cases in Western population (Heckmann 
et al., 2004).  Early onset AD is caused by mutations in genes encoding the 
amyloid precursor protein (APP) and presenilin proteins (PS1 and PS2).  
Mutations in these genes are penetrant and, if present, will result in the early 
onset of AD (Tanzi and Bertram, 2005).  The identification and mapping of the 
APP and presenilin genes aberrant in early onset AD have been invaluable in 
extending our understanding of the pathological mechanisms underpinning the 
neurodegeneration seen in AD, and formed the basis of the “amyloid cascade 







Figure 1.1 Structural and cognitive characterisation of Alzheimer’s disease. 
A.  Gross structural analysis of AD brains shows significant atrophy and 
shrinkage compared to normal, healthy brains.  Adapted from (Mattson, 2004).  
B.   Details of the progressive cognitive decline from initial mild cognitive 
impairments to very severe AD (Burns and Iliffe, 2009). 
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The majority of AD cases are of the late-onset variety, the causes of which are 
not yet understood, but are likely to be a combination of genetic, environmental 
and social risk factors.  Genetic risk factors for late-onset AD are widely 
investigated, however the apolipoprotein E (APOE) gene remains the best 
characterised.   Carriers of the E4 allele of the APOE gene are at significantly 
higher risk of developing AD compared to APOE3 carriers (the allele which 
appears to have little effect on AD risk) and APOE2 carriers (the allele affording 
some protection against AD) (Kim et al., 2009).   The dawn of genome-wide 
association studies (GWAS) has enabled screening for many other genetic risk 
factors for AD,  the results of which are collated in the publicly available AlzGene 
database (Bertram et al., 2007).   
 
Epidemiological studies have identified numerous environmental and social risk 
factors for late onset AD including traumatic head injury (Plassman et al., 2000), 
education level (Ngandu et al., 2007), dietary factors (Luchsinger and Mayeux, 
2004) and environmental pollutants.  Indeed, a recent  study has shown that 
levels of dichlorodiphenyldichloroethylene (DDE), the metabolite of the 
pesticide dichlorodiphenyltrichloroethane (DDT) that has been banned in the 
United States since 1972, were elevated in patients suffering AD (Richardson et 
al., 2014).  In order to fully understand the interplay between so many potential 
risk factors for AD, large-scale longitudinal population based studies are 
needed.  One such study is the Lothian Birth Cohort, which will provide social, 
medical and biochemical insight into the various features required for healthy 
cognitive aging from data collated over individual lifetimes (Deary et al., 2007) 
 
Despite the large number of potential genetic, environmental and social risk 
factors for late-onset AD, it is believed that the biggest risk factor for this 
devastating condition is ageing itself.  One theory proposed to explain aging as a 
risk factor for AD is that young brains contain higher levels of growth factors 
and effective cell repair mechanisms that afford provide protection against 
neurodegeneration (Mucke, 2009).   
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Another plausible explanation for the link between ageing and AD is the 
increased incidence of vascular disorders in aged individuals (Breteler, 2000).   
Vascular disorders including hypertension, atrial fibrillation, high cholesterol 
and atherosclerosis induce a sub-lethal state of cerebral hypoperfusion, thereby 
reducing the delivery of oxygen, glucose and other nutrients required for energy 
metabolism.  This state of chronic cerebral hypoperfusion (CCH) disrupts 
normal cell function and results in a state of metabolic stress that is thought to 
significantly increase the risk of developing late-onset AD  (de la Torre, 2002b).  
The link between vascular disorders and AD has led to the proposal of the 
Vascular hypothesis of AD, discussed in more detail in Section 1.3.2.     Research 
focussed on understanding the biochemical changes underpinning cellular 
dysfunction in response to metabolic stress will be important in the pursuit of 
therapeutic interventions to alter the course of hypoperfusion related 
neurodegenerative processes.  
 
1.2.2 Key Pathological Features of Alzheimer’s disease  
 
 
The standard pathological hallmarks of AD were first described by Alois 
Alzheimer in 1906.  Macroscopically, there is clear evidence of extensive brain 
atrophy (Figure 1.1).  Microscopically, the three major pathological hallmarks of 
AD are: loss of neuronal integrity, extracellular amyloid plaques and 
intracellular neurofibrillary tangles (Holtzman et al., 2011).  The presentation of 
these pathologies occur at different time points in the aging process, and are 
often present before the onset of cognitive symptoms (Figure 1.2).  It is 
therefore proposed that these AD biomarkers act in concert, and when a 
threshold of pathologies is met, the cognitive decline into AD begins (Perrin et 





Found in the extracellular space, amyloid plaques are traditionally considered 
to be the classic hallmark of AD (Figure 1.2).  Plaques are composed of 
aggregated amyloid-beta (Aβ) peptides produced from the pathological cleavage 
of APP by β- and γ- secretase enzymes (Figure 1.3).  Alternatively, APP can be 
processed through the non-amyloidogenic pathway, where α-secretase cleaves 
APP within the Aβ peptide domain, preventing Aβ generation (Querfurth and 
LaFerla).   
 
Amyloidogenic and non-amyloidogenic APP processing takes place in different 
locations throughout the cell.  Following transcription and translation, nascent 
APP moves from the ER to the plasma membrane.  At the cell membrane, APP is 
either cleaved non-amyloidogenically by α-secretases, or is endocytosed.  
Amyloidogenic processing of APP occurs during its transit from the plasma 
membrane through the endocytic organelles, where the β- and γ-secretases are 
located.  Alternatively, endocytosed APP can be recycled back to the plasma 
membrane or degraded in lysosomes (Haass et al., 2012).  Inhibiting APP 
endocytosis through mutations in the YENPTY c-terminal motif inhibits APP 
endocytosis, and decreases the production of Aβ.  This finding suggests a 
functional endocytic system is integral to amyloidogenic-APP processing (Perez 
et al., 1999).    
 
On the basis of the abundant accumulations of amyloid plaques in AD brains, the 
amyloid cascade hypothesis of AD was proposed (Hardy and Higgins, 1992).  
This hypothesis states that amyloid plaques are the driving force behind AD 
pathophysiology, with neuronal cell death and synapse loss occurring 
downstream of plaque formation.  The details of this hypothesis and the 




Figure 1.2 The pathological hallmarks of Alzheimer’s disease.                 
A.  Characteristic hallmarks of AD include the extracellular accumulation 
of amyloid plaques and the presence of intracellular tangles of 
hyperphosphorylated tau. (from BrightFocus Foundation, 2000 – 2013)  
B. The progressive cognitive decline associated with AD from mild 
cognitive impairment (MCI) to mild, moderate (Mod.) and severe (Sev.) 
cognitive dysfunction corresponds to clinical dementia ratings (CDR) 0 – 
3, as shown.  These cognitive changes are associated with heavy amyloid 
plaque burden (red line), increasing abundance of neurofibrillary 
tangles (blue line) and synapse and neuronal loss (green line).   Adapted 








Figure 1.3 APP processing pathways.  In the non-amyloidogenic pathway, APP is 
cleaved by α-secretase within the amyloid sequence, producing non-toxic sAPPα and a C-
terminal fragment C83.  C83 is then cleaved by γ-secretase to produce p3 and the APP 
intracellular domain (AICD). Amyloidogenic cleavage of APP by β-secretase produces 





In addition to amyloid plaque formation, the other major pathological hallmark 
of AD is the presence of intracellular neurofibrillary tangles (NFTs).  The major 
component of NFTs is the microtubule associated protein tau.  Under 
physiological conditions, tau plays an important role in the stabilisation of 
microtubules and the maintenance of effective axonal transport of signalling 
molecules, organelles and other essential cellular components.  Tau protein 
moves on and off microtubules in a dynamic equilibrium, controlled by the 
kinases and phosphatases that determine its phosphorylation state (Ballatore 
et al., 2007).  
 
Under pathological conditions, tau becomes hyperphosphorylated, detaches 
from microtubules and aggregates into NFTs.  This process can disrupt axonal 
transport and adversely affect normal cell functioning, ultimately resulting in 
neuronal cell death (Spires-Jones et al., 2009).   NFTs have been shown to 
develop in a hierarchical pattern through brain regions associated with 
learning and memory.  The entorhinal cortex is the first brain region affected 
by NFTs, with the pathology sequentially spreading through the regions of the  
hippocampus, and finally to the neocortex.  The NFT induced loss of neurons in 
these distinct brain regions is thought to result in disconnection of neuronal 
signalling circuits, inducing the defects in memory and higher functioning that 
is characteristic of AD (Pooler et al., 2013).   
 
Linked to this tau induced disconnection of neural circuits, loss of neuronal 
integrity is the third common pathological hallmark of AD (Figure 1.2).   
Neuronal atrophy in vulnerable brain regions, including the hippocampus and 
the cerebral cortex, causes regional decreases in volume, a feature that is 
detectable with magnetic resonance imaging (MRI).  Indeed, MRI studies have 
revealed that medial temporal lobe atrophy is an early marker of AD, present in 
individuals suffering only very mild cognitive symptoms, and the rate of this 
early atrophy can be indicative of later cognitive decline (Jack et al., 1997, Fox et 
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al., 1999).  Progression from MCI to severe AD is also characterised by 
significant loss of synapses.  This synaptic loss has been shown to be the 
pathological hallmark of AD that correlates most robustly with pre-mortem 
symptoms of cognitive decline (Selkoe, 2002).  Synapse loss in AD can be caused 
as a direct result of neuronal death, but recent research also suggests that  
soluble Aβ and tau (as opposed to the aggregated forms of these proteins)are 
also heavily involved (Koffie et al., 2011, Pooler et al., 2014). 
 
AD can also be characterised neurochemically.  In the early 1970s, it was 
reported that there were substantial deficits in choline acetyltransferase, the 
enzyme responsible for the synthesis of the neurotransmitter acetylcholine, in 
the amygdala, hippocampus and cortex of AD brains (Davies and Maloney, 
1976).  This research was extended in the 1978 landmark study by Perry et al. 
which showed a significant correlation between post-mortem cholinergic 
neuronal loss and AD patients’ pre-mortem mental state scores (Perry et al., 
1978).  These findings formed the basis of the “cholinergic hypothesis” of AD, 
which states that the disorders of learning and memory seen in AD may be 
attributable to dysfunctions of the cholinergic neurons in the basal forebrain 
(Muir, 1997).  The cholinergic hypothesis forms the foundation of three of the 
four commercially available drug treatments of AD, discussed in more detail 
below.   
 
Understanding the evolution of the pathological hallmarks of AD, and being able 
to identify these in the clinic, is an important step towards early diagnosis of 
this devastating disorder.  However, in order to develop novel neuroprotective 
treatment strategies, the causes of the neuronal and synaptic degeneration need 






1.3 Conflicting Theories on the Causes of Alzheimer’s disease  
 
1.3.1 The Amyloid Cascade Hypothesis 
 
The amyloid cascade hypothesis of AD proposes that the cerebral accumulation 
of neurotoxic Aβ is the initial event in AD pathophysiology.  Other features of 
AD, such as the formation of NFTs, cognitive decline and neuronal cell death, are 
thought to be by-products of the preceding Aβ deposition (Hardy and Higgins, 
1992).  The strongest evidence for this hypothesis comes from the identification 
of mutations in the APP and presenilin genes, which if present, cause early onset 
AD.  Research shows that expression of these mutations alter APP processing, 
causing increased production of the 42–43 amino acid form of Aβ, the main 
component of amyloid plaques found within the AD brain (Hardy, 1997).  
Clinically, late onset AD cases are almost identical to early onset AD cases, thus 
suggesting that alterations in APP processing are likely to drive the 
neurodegenerative processes in both conditions.     
 
Experimental and clinical data have also provided support for the amyloid 
cascade hypothesis of AD.  Pivotal experiments carried out in vitro 
demonstrated that the application of Aβ to neuronal cell cultures was highly 
toxic (Yankner et al., 1989, Yankner, 1996).  Additionally, APP-overexpressing 
or Aβ–overproducing transgenic mice develop cognitive deficits alongside 
plaque formation in the hippocampus and the cerebral cortex (German and 
Eisch, 2004).  
 
Evidence of a direct relationship between APOE genes, (a major risk factor in 
late onset AD), cerebral amyloid burden and AD provides further support for 
the amyloid hypothesis of AD.  People carrying the APOE4 allele of the gene are 
at significantly higher risk of developing AD (Kim et al., 2009).  A series of 
experiments carried out in APP transgenic mice showed the human APOE genes 
to be associated with the level  of cerebral Aβ burden, with APOE4 mice having 
the highest levels of Aβ (Bales et al., 2009).   
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However, the validity of the amyloid cascade hypothesis has been brought into 
question in recent years.  Despite Aβ plaques being considered to be the main 
neuropathological hallmark of AD, the accumulation of these plaques correlates 
poorly with the severity of dementia (Arriagada et al., 1992, Giannakopoulos et 
al., 2003).  Indeed, post-mortem studies have shown cognitively normal 
individuals to have an Aβ plaque load sufficient for AD diagnosis (Katzman et al., 
1988).  Moreover, drug trials directed at the clearance of amyloid plaques in the 
hope of treating AD patients have repeatedly failed, adding to the scepticism 
surrounding the relationship between amyloid pathology and late onset AD.   
 
The amyloid hypothesis also fails to fully acknowledge the role of 
hyperphosphorylated tau protein in the pathogenesis of AD.  Importantly, 
where there is an apparent lack of correlation between amyloid plaque density 
and severity of cognitive dysfunction, the spatiotemporal pattern of NFT 
accumulation correlates much more closely with dementia severity (Gomez-Isla 
et al., 1997, Braak and Braak, 1995, Giannakopoulos et al., 2003).  An elegant 
study using the entorhinal-hippocampal systems, analysed the spatial and 
temporal evolution of plaque and tangle formation in the human brain.  In early 
stages of the disease, NFTs were seen before the development of plaques, and in 
none of the cases were plaques seen before tangles (Schonheit et al., 2004, 
Braak and Del Tredici, 2011).  This finding conflicts with the postulation of the 
amyloid hypothesis that the formation of NFTs occurs as a by-product of 
amyloid plaque formation.   
 
In light of the criticisms associated with the traditional amyloid hypothesis, it is 
now suggested that soluble Aβ species (dimers, trimers and dodecamers – 
collectively known as amyloid-derived diffusible ligands , ADDLs) may be the 
culprit neurotoxic amyloid species involved in AD (Klein et al., 2001).  ADDLs 
are found at increased concentrations in the cerebral spinal fluid of AD patients 
compared to non-demented age-matched controls (Georganopoulou et al., 
2005), and cerebral microinjection of these oligomeric amyloid species induces 
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significant disruption of long-term potentiation in the rat hippocampus (Walsh 
et al., 2002).  More recently, research showed amyloid dimers (the most 
abundant form of soluble oligomeric Aβ isolated in AD cortical tissue) to induce 
tau hyperphosphorylation and microtubule disruption in cultured rat 
hippocampal neurons, a phenomenon averted in tau siRNA cultures (Jin et al., 
2011).  These data suggest that oligomeric Aβ might be an upstream driver of 
tau pathology, and a key feature of the neuronal dysfunction associated with AD.      
    
Despite the arguments for and against the amyloid cascade hypothesis, and the 
recent efforts to update the thinking in this field, the reality remains that despite 
more than two decades of amyloid based research, there is still a severe lack of 
effective AD treatments.  Many view this as evidence of a fundamental error in 
our understanding of AD pathogenesis, forcing researchers to look for 
alternative theories to explain the causes and progression of late onset AD.   
 
 
1.3.2  The Vascular Hypothesis  
 
The central dogma associated with vascular theories of AD is that atherosclerosis 
and other vascular disorders evolving with advancing age reduce blood flow to the 
brain over many years (chronic cerebral hypoperfusion, CCH).  De la Torre captures 
the culmination of vascular disorders and CCH on the brain in his Critically Attained 
Threshold of Cerebral Hypoperfusion (CATCH) hypothesis of neurodegeneration (de 
la Torre, 2000).  CATCH is the point at which brain circulation is impaired to an 
extent where oxygen, glucose and other nutrients are delivered sub-optimally to 
neurons, leading to a downward spiral of metabolic and cognitive decline, with the 
accompanying pathology associated with AD.   The CATCH associated disruption of 
glucose uptake and usage in AD brains has been well documented by positron 
emission tomography (PET).  PET studies have shown glucose uptake in AD brains 
to be massively reduced compared to normal, aged matched controls, with a 
significant correlation found between glucose uptake and scores on mini-mental 
state examination (Kadir et al., 2011) (Figure 1.4).    
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Once CATCH is initiated, the onset and progression of cognitive symptoms and 
neurodegeneration are thought to be based on a culmination of factors relating 
to each individual, including:  
 Genetic profile - APOE4 carriers at significantly higher risk of 
developing AD (Kim et al., 2009) 
 Gender - AD has an increased prevalence in women, thought to be 
linked to the sudden drop in oestrogen following the menopause, 
however the increased life expectancy of women compared to 
men has hindered interpretation of the epidemiological data 
(Barron and Pike, 2012)  
 Lifestyle choices - including alcohol intake, smoking, fitness level 
and diet.  See (Pope et al., 2003) for a review.    
 
The culmination of vascular disorders that results in CATCH leads to a cascade 
of cellular events that are detrimental to brain function, including mitochondrial 
dysfunction, oxidative stress, decreased production of adenosine triphosphate 
(ATP), signal transduction defects, and neurotransmission failure (Aliev et al., 
2003) (Figure 1.4).  A CATCH induced energy crisis is also associated with an 
increased production of reactive oxygen species (ROS).  Mitochondria are a 
natural source of ROS, and under CATCH conditions, mitochondrial production 
of ROS increases, which in turn induces further damage to mitochondrial 
proteins (discussed in more detail below).  
 
Increased ROS in the cell can cause damage and misfolding of proteins, which 
accumulate in the endoplasmic reticulum, and induce the unfolded protein 
response (UPR).  The UPR is mediated by glucose-regulated proteins (GRPs), the 
most common of which are GRP78 (also referred to as BiP) and GRP94.  These 
proteins are up-regulated in response to the accumulation of misfolded proteins 
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in the ER lumen (Zhang and Kaufman, 2006).  The UPR is integral to cell survival 
as excessive accumulation of these damaged proteins in the ER lumen can 
prevent the timely inactivation of UPR, resulting in prolonged reductions in 
protein synthesis (Ron and Walter, 2007).  Importantly, research has shown the 
key chaperones involved in the UPR to decrease in abundance with advancing 
age (Naidoo et al., 2008), suggesting a reduced ability for elderly brains to deal 
with the accumulations of damaged proteins under CATCH conditions. 
 
Evidence supporting a connection between oxidative stress and the pathological 
protein hallmarks of AD is beginning to emerge.  An in vitro model of oxidative 
stress involving the application of Hydroxynonenal (HNE) (a product of lipid 
peroxidation) to the human NT-2 cell line induced a significant increase in BACE1 
protein, (the β-secretase enzyme involved in amyloidogenic processing of APP to 
produce neurotoxic Aβ) with consequent increase in  Aβ peptides (Tamagno et al., 
2005).  In addition, in vivo studies using a rat model of chronic cerebral 
hypoperfusion showed reduced cerebral blood flow to significantly increase the 
levels of BACE1 and Aβ compared to sham operated controls (Zhiyou et al., 2009). 
 
Tau processing is also adversely affected by oxidative stress, with increased levels 
of tau phosphorylation detected in an in vitro model of chronic oxidative stress 
involving the inhibition of glutathione synthesis (Su et al., 2010).  In vivo, induction 
of transient cerebral hypoperfusion in the triple transgenic AD mice has been 
shown to increase tau phosphorylation at serine212 and threonine214, a tau epitope 
associated with paired helical filaments in AD patients.   
 
Despite the growing focus on vascular disorders and CATCH in relation to AD, the 
underlying biological mechanisms relating chronic cerebral hypoperfusion to 
impaired mitochondrial function and neurodegeneration remain unknown.   
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Figure 1.4 The vascular theory of Alzheimer’s Disease.  A.  Positron emission 
tomography images showing the glucose uptake in healthy brains and AD brains 
in living subjects (reds and yellows indicate high glucose uptake).  Glucose 
uptake is massively decreased in AD brains. Adapted from (Mattson, 2004). B.   
Vascular risk factors reduce oxygen and glucose delivery to cells, leading to ATP 
depletion, reactive oxygen species (ROS) production, dysfunctions in synaptic 
transmission, accumulation of damaged proteins in the endoplasmic reticulum, 
BACE1 up-regulation and Aβ overproduction, and increased tau 
phosphorylation.  Adapted from (de la Torre, 2008).  
17 
1.3.3  Alternative Hypotheses associated with Alzheimer’s disease 
 
Alternative hypotheses associated with AD exist that either precede or build 
upon the amyloid and vascular hypotheses discussed above.    The cholinergic 
hypothesis, first proposed in 1982, suggests that the loss of cholinergic activity 
in the brains of AD patients might account for the disruptions in learning and 
memory associated with this disease (Bartus et al., 1982).  This cholinergic 
hypothesis gave rise to the only drugs that are currently available in the 
management of mild to moderate AD (discussed in more detail below).  
However, the failure of these drugs to fully arrest the progression of AD 
somewhat undermines a causative role for the cholinergic hypothesis in AD. 
 
Another early theory of AD was the Prion hypothesis, based on observations 
that the protein accumulations and neurodegenerative processes in AD are 
similar to those seen in human prion diseases (Jarrett and Lansbury, 1993).  
Recent experiments showing that intra-cerebral injection of Aβ containing 
extracts from AD patients into mice induces amyloidosis and pathology has 
provided support for the seeding capabilities Aβ (Meyer-Luehmann et al., 2006).  
Further work in this field confirming the potential for Aβ transmissibility would 
have huge consequences for the future management and treatment of AD.  
 
There are many hypotheses of AD, however a truly causative trigger for this 
disease remains elusive.   It is well established that the single biggest risk factor 
for AD age.  This fact has led to the proposal of an age based hypothesis of AD, 
which states that aberrant cognitive decline is driven in three key stages: an 
initiating injury, followed by a chronic neuroinflammatory response, and finally, 
a discontinuous cellular change (Herrup, 2010).  This final step marks the onset 
of neurodegeneration, and the subsequent synaptic and neuronal loss that is so 





1.4 Prognosis and Treatments for Alzheimer’s disease Patients  
 
Despite an abundance of different hypotheses surrounding AD, there is still no 
effective treatment strategy for this devastating disease.  However, two main 
classes of drugs have been developed that can improve the cognitive symptoms 
of AD patients: acetylcholinesterase inhibitors and N-methyl-D-aspartate 
(NMDA) receptor antagonists.   
 
The development of acetylcholinesterase inhibitors for the treatment of AD is 
based on the findings that cholinergic signalling pathways  in the cerebral cortex 
of AD patients are compromised (Perry et al., 1978).  Acetylcholinesterase 
inhibitors aim to reduce the breakdown of acetylcholine by 
acetylcholinesterase, thus increasing the concentration of acetylcholine 
available for cholinergic neurotransmission (McGleenon et al., 1999).  
Donepezil, rivastigmine, and galantamine are the three cholinesterase inhibitors 
that are most frequently used to treat AD patients.  These drugs have been 
shown to have small beneficial effects on cognition, function, and behavioral 
outcomes, however only when administered to patients with mild cognitive 
symptoms.  Although stabilization of AD symptoms occurs with these drug 
treatments, the effects are not sustained.  There are also significant side effects, 
including nausea, dizziness, headache and weight loss (Doody, 2003).  
 
In contrast to the disruption of cholinergic neurotransmission, overstimulation 
of NMDA receptors by glutamate has also been implicated in AD.  Glutamate is 
the main excitatory neurotransmitter in the brain, and is centrally involved in 
learning and memory processes (Riedel et al., 2003).  However, under 
pathological conditions, persistent depolarisation of neurons releases the 
magnesium block of the NMDA receptor, causing increased levels of 
intracellular calcium, and inducing cell death by excitotoxicity.  Cell death by 
excitotoxicity is implicated in AD, and led to the development of memantine, a 
NMDA receptor antagonist, for the treatment of AD (Hynd et al., 2004).  
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Memantine is used in moderate to severe AD cases, however its clinical efficacy 
is still debated (Tampi and van Dyck, 2007). 
 
Other potential avenues for AD treatments include reducing the production of 
Aβ through inhibition of β- and γ-secretases, reducing Aβ aggregation, 
promoting the removal of Aβ from the brain with immunotherapy and reducing 
tau aggregation and phosphorylation(Mangialasche et al., 2010).  There have 
been many failures of clinical trials investigating chemical compounds for the 
treatment of AD.  In the summer 2012, Johnson & Johnson and Pfizer failed to 
show any benefit of bapineuzumab, a new antibody drug targeting the amyloid 
plaques with a view to stimulating the immune system to clear them.  Soon 
after, Eli Lilly announced that solanezumab, a drug that targets amyloid-β 
peptides with a view to blocking their aggregation to plaques, had not 
successfully slowed the memory decline associated with AD (Callaway, 2012).  
The failure of these clinical trials has raised questions as to the validity of Aβ as 
a target for AD drug development and highlights the urgent need for the 
development of novel biomarkers and treatment strategies for AD.      
 
1.5 Mitochondria, Oxidative Stress and Alzheimer’s disease  
 
1.5.1 Mitochondria: Essential Organelles in Aerobic Respiration  
 
Mitochondria are membrane bound organelles often colloquially described as 
the “powerhouses” of the cell due to their role in converting organic material 
into ATP, the cellular energy currency.  Mitochondria are composed of an inner 
matrix containing a complex mixture of enzymes and chemical species, an 
impermeable inner membrane which requires protein transporters to 
translocate molecules across it and a permeable outer membrane. 
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There are three stages of aerobic respiration: glycolysis, the Krebs cycle and the 
electron transport chain.  Glycolysis, occurring in the cytoplasm, involves the 
breakdown of glucose to pyruvate via nine distinct enzymatic reactions.  
Glycolysis produces a total of 4ATP molecules, however uses 2ATP within the 
glycolytic process, therefore the net ATP production is just 2ATP (Pelicano et al., 
2006).  Glycolysis itself is an anaerobic process.  Once pyruvate is formed, cells 
continue respiration in either an aerobic or anaerobic manner, depending on 
the cell type and the cellular environment.   
 
 
In the presence of oxygen, cells with aerobic capabilities proceed to the Krebs 
cycle, the second respiratory process, occurring in the mitochondrial matrix.  
The Krebs cycle (also known as the citric acid or tricarboxylic acid cycle) begins 
with the transfer of pyruvate across the mitochondrial membranes into the 
matrix, where it is converted into acetyl-coenzyme A (acetyl-CoA) by the 
pyruvate dehydrogenase multienzyme complex:  
 
 
2 Pyruvate + 2 coenzyme A + 2NAD+ -> 2 acetyl-CoA +2CO2 + 2 NADH 
 
 
Production of acetyl-CoA allows the Krebs cycle to proceed with the reaction 
between acetyl-CoA and oxaloacetate to form citric acid, a reaction mediated by 
the enzyme citrate synthase.  The Krebs cycle then proceeds via seven further 
enzymatic reactions, producing three NADH, one FADH2 and one ATP per 









The final stage of aerobic respiration involves the production of the bulk of 
cellular ATP via the electron transport chain (ETC).  The ETC is a system of 
protein complexes located on the inner mitochondrial membrane including: 
 Complex I  - NADH coenzyme Q reductase 
 Complex II - succinate dehydrogenase 
 Complex III - cytochrome bc1 complex  
 Complex IV - cytochrome c oxidase  
 Complex V - ATP synthase 
 
Energy for ATP synthesis is derived from oxidation of the NADH and FADH2 
produced during the earlier processes of glycolysis and the Krebs cycle. The ETC 
begins at complex I, where NADH is oxidised to NAD, with the released electron 
being passed into the ETC.  The protein complexes of the ETC act as electron 
carriers.  Each complex is at a successively lower energy level, therefore as 
electrons are passed from one complex to another, energy is released.  
Coenzyme-Q10 acts an electron carrier, transferring electrons from complex I 
and complex II, to complex III (Murphy et al., 1999).  Cytochrome C is 
responsible for the movement of electrons between complex III and complex IV 
(Mehta and Li, 2009).  The energy generated from electron transfer between 
complexes is then used to move hydrogen ions, released following the oxidation 
of NADH and FADH2, across the inner mitochondrial membrane into the 




Figure 1.5  The Krebs cycle and the electron transport chain.           
A. Diagrammatic overview of the enzymatic reactions involved in the 
Krebs cycle.  Metabolic intermediates are shown in boxes.  B.  
Mitochondrial electron transport occurs via a series of protein 
complexes, which use the energy generated from electron transfer to 
pass hydrogen ions into the intermembrane space.  The resulting 
electrochemical gradient is used by complex V (ATP synthase) to 
generate ATP.  
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The increasing concentration of hydrogen ions in the intermembrane space 
forms a concentration gradient, giving the ions electrical potential energy.  This 
potential energy is released when hydrogen ions pass back across the inner 
mitochondrial membrane via ATP synthase (Complex V), and is used to produce 
ATP (Mehta and Li, 2009).  Oxygen acts as the final electron acceptor, and 
together with the hydrogen ions, water is formed.  The ETC consumes 
approximately 85% of cellular oxygen, with about 5% of this oxygen converted 
to ROS, discussed below. 
 
Neurons need exceptionally high ATP levels in order to sustain their many 
functional processes, including axonal transport, maintenance of ion gradients 
and membrane potentials and the loading, release and recycling of vesicles in 
synaptic transmission.  Neurons have only limited glycolytic capacity, with the 
majority of neuronal ATP produced by oxidative phosphorylation  (Santos et 
al.).  Healthy mitochondria, along with a steady supply of oxygen and glucose 




1.5.2 Mitochondria and Reactive Oxygen Species: a paradoxical 
relationship   
 
Reactive oxygen species are molecules and free radicals (species with an 
unpaired electron) derived from molecular oxygen.  Under normal conditions 
the brain has a solid defence against ROS, including dietary free radical 
scavengers and enzymatic antioxidants such as glutathione peroxidase, 




In the mitochondria, the electron transport chain constantly channels electrons 
through the series of protein complexes in the generation of ATP.  Occasionally 
this process leaks single electrons which can reduce oxygen to form the 
superoxide anion (O2−•).  Under normal conditions, superoxide dismutase 
(SOD) can eliminate O2−• by converting it to hydrogen peroxide (H2O2).  The 
hydrogen peroxide can then be converted to oxygen (O2) and water (H2O) by 
catalase (Warner et al., 2004) (Figure 1.6).  If partial reduction of H2O2 occurs, 
the hydroxyl radical (OH•) is formed, which is an extremely powerful oxidant 
that can cause extensive cellular damage (Turrens, 2003).   
 
Under conditions of cell stress, the ETC can become dysfunctional and ROS 
homeostasis is disrupted.  Paradoxically, damaged mitochondria produce more 
ROS, which can overwhelm the antioxidant defence system, leading to a vicious 
cycle of further mitochondrial dysfunction and further ROS production.  The 
oxidative stress caused by disrupted redox balance can induce dysfunction in 
membrane receptors, DNA damage, membrane lipid peroxidation and 
cytochrome C release from mitochondria, which induces apoptotic cell death 
(Lin and Beal, 2006). 
 
Figure 1.6 Common cellular antioxidant pathways and the vicious 




Peroxiredoxins (Prxs) are another family of antioxidant enzymes which have 
reductase activity towards hydrogen peroxide.  Prxs exist in 6 different 
isoforms, and the location of these varies within the human brain.  Prx I is 
mainly located within astrocytes, whereas PrxII is expressed in neurons across 
many regions, including the cerebral cortex and hippocampus (Lee et al., 2011).  
In addition to antioxidant defence, PrxII has recently been shown to be 
significantly increased in the brains of AD patients (Krapfenbauer et al., 2003).  
An increase in antioxidant protein PrxII in AD brains may be indicative of 
increased oxidative stress in the affected tissue, thus providing support for the 
CATCH hypothesis of AD.   Further work will need to be undertaken in order to 
determine the mechanism and function of this PrxII up-regulation.   
 
1.5.3 Mitochondria, Ageing and Alzheimer’s disease 
 
The most consistent risk factor for AD is ageing itself, with mitochondria 
thought to contribute to the ageing process.  The “free radical theory of ageing”, 
posits that oxidative damage accrues in cells and tissues over time, contributing 
to age-dependent physiological decline in neuronal function (Harman, 1956).  
As discussed above, the mitochondria are a major source of ROS production, and 
are therefore a prime target for ROS damage, resulting in a compounding effect 
whereby damaged mitochondria produce more ROS, increasing cellular 
oxidative damage and inducing further mitochondrial damage (Van Remmen 
and Richardson, 2001).   
 
A correlate of the free radical theory of ageing is the mitochondrial theory of 
ageing, which focuses on the accumulation of mitochondrial DNA (mtDNA) 
mutations with advancing age (Linnane et al., 1989).  Mitochondrial DNA 
encodes 13 essential polypeptides of the oxidative phosphorylation system, 
including subunits of complexes I, III, IV and V, as well as the necessary RNA 
machinery (2 rRNAs and 22 tRNAs) for their translation within the 
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mitochondria (Taylor and Turnbull, 2005).  Quantitative evidence for the 
mitochondrial theory of ageing was shown by Lin et al. who found a larger 
number of mtDNA mutations in the brains of elderly subjects than young 
subjects, with the activity of cytochrome c oxidase negatively correlating with 
increasing mutational burden (Lin et al., 2002).  There may well be significant 
overlap between the mitochondrial and free radical theories of ageing, given 
that mtDNA itself is highly susceptible to oxidative damage (Van Remmen and 
Richardson, 2001). 
 
Functional investigations corroborate with the mitochondrial and free radical 
theories of ageing, with numerous groups showing evolving mitochondrial 
dysfunction with advancing age.  In aged mice, mitochondrial complexes I, III 
and IV show significant decreases in function compared to younger controls 
(Navarro et al., 2002).  A similar result was found in the cortex of rhesus 
monkeys, where complex I and complex IV activity was significantly decreased 
with advancing age (Bowling et al., 1993).   
 
In addition to the accumulation of mtDNA mutations and oxidative damage with 
advancing age, mitochondrial dysfunction is also directly implicated in human 
AD.   The brains of AD patients show decreased cytochrome c oxidase activity, 
oxidative damage and reduced metabolism.  Intriguingly, these mitochondrial 
disturbances are seen in advance of amyloid plaque formation (Celsi et al., 
2009). Electron microscopy studies have also shown gross morphological 
changes in mitochondria of AD patients.  A significant number of these 
mitochondria from AD patients show disrupted cristae, the surface of which 
contain the apparatus of the ETC for ATP production, potentially leading to the 
energy crisis observed in AD (Baloyannis, 2006).   
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Mitochondria are also important regulators of apoptosis and cytosolic calcium 
concentration, both of which are implicated in neurodegeneration.  Several 
proteins are involved in mitochondrial control of calcium homeostasis including 
the mitochondrial calcium uniporter (MCU) (which rapidly moves Ca2+ into the 
matrix, driven by the negative charge of the mitochondrial membrane potential 
established by the electron transport chain) (Patron et al., 2013); the voltage 
dependent anion channel (VDAC) protein (which mediates the movement of 
calcium ions across the outer mitochondrial membrane) (Shoshan-Barmatz et al., 
2010); and the permeability transition pore (PTP) (known for its key role in the 
induction of apoptosis and release of cytochrome c, the PTP also acts to release 
calcium and maintain homeostasis) (Celsi et al., 2009).   
 
Calcium levels within the mitochondria can be controlled by a specialised 
membrane region between the mitochondria and the endoplasmic reticulum 
known as the “mitochondria associated membrane” (MAM).   Pyruvate 
dehydrogenase, α-ketoglutarate and isocitrate dehydrogenases are key members of 
the Krebs cycle that are activated by calcium, therefore close links between the 
mitochondria and the endoplasmic reticulum, widely considered to be an 
intracellular Ca2+ store (Verkhratsky, 2005) seem reasonable.   
 
Mitofusin 2 (MFN2) is present at the MAM and is involved in ER–mitochondria 
tethering, by both homotypic interactions and heterotypic interactions with MFN1 
(Rizzuto et al., 2012).  The MAM also contains high levels of Ca2+-binding 
chaperones, including calnexin, calreticulin and BiP.  These proteins enable the 
MAM to serve as a high capacity Ca2+ binding store, ensuring ample Ca2+ is present 
at the MAM, ready for transfer to the mitochondria.  Inositol 1,4,5-trisphosphate 
receptor (IP3R) is the MAM protein responsible for mediating the release of Ca2+ 
from the ER to the mitochondria on stimulation by inositol 1,4,5-trisphosphate 
(Hayashi et al., 2009). 
 
28 
Endoplasmic reticulum sigma 1 receptor (Sig1R) is also enriched at the MAM and 
forms a complex with BiP.  Following Ca2+ release from the ER, Sig1R dissociates 
from BiP and binds to the activated IP3R, preventing damage and degradation of 
the receptor and allowing sustained calcium release (Rizzuto et al., 2012).  Glucose 
regulated protein 75 (GRP75) is also present at the MAM and functions as a link 
between IP3R and voltage dependent anion channels (VDACs) in the outer 
mitochondrial membrane.  The close proximity of IP3R and VDAC allow Ca2+ 
released from endoplasmic reticulum to be readily taken up into the mitochondria 
(Figure 1.7).  For a detailed review see (Hayashi et al., 2009). 
 
Importantly for AD research, presenilin proteins (components of the γ-secretase 
complex involved in APP processing) have been located at the MAM (Area-
Gomez et al., 2009).  This enrichment of presenilins at the MAM, as well as its 
role in mitochondrial calcium uptake and cholesterol metabolism, suggests that 
the MAM may well be involved in the pathogenesis of AD.  It is therefore 
important to consider changes in this dynamic membrane region in studies 















Figure 1.7  Simplified representation of the Mitochondrial Associated 
Membrane (MAM).  Ca2+binding chaperones such as calnexin, calreticulin and BiP 
are enriched at the MAM.  The MAM therefore functions as a high capacity Ca2+ pool 
for subsequent signalling to the mitochondria.  IP3R mediates the release of Ca2+ 
from the ER, which can then be taken up into the mitochondria via the VDAC 
channels.   







1.5.4 ABAD Protein: Bridging the gap between Aβ, mitochondrial 
dysfunction and Alzheimer’s disease? 
 
Aβ is best known for its aggregation into the extracellular cerebral plaques that 
are so famously associated with AD.  However, research suggests that 
intracellular Aβ may also have an important role to play in the pathophysiology 
of AD.    Intracellular Aβ has been detected in the brains of AD patients, and this 
intracellular Aβ appears to accrue before the appearance of NFTs and 
extracellular amyloid plaques.  The identification of possible targets for this 
intracellular Aβ is therefore important to advance understanding of cellular 
dysfunction in AD.   
 
 
In a seminal study, Yan et al. used the yeast two-hybrid system to identify a 
direct interaction between Aβ and a member of the 17β-hydroxysteroid 
dehydrogenasereductase family, which they later named “amyloid binding 
alcohol dehydrogenase” (ABAD) (Yan et al., 1997).   ABAD, also known as 
endoplasmic reticulum associated amyloid-β binding protein (ERAB) or 17β-
hydroxysteroid dehydrogenase type 10 (HSD17B10), is an NAD-dependent 
enzyme involved in the oxidation and reduction of alcohol groups from 
substrates such as steroids, alcohols and fatty acids.  This wide range of ABAD 
substrate specificity is indicative of its role in numerous metabolic processes, 
including beta-oxidation fatty acids and sex steroid metabolism (Marques et al., 
2008).   
 
 
X-ray crystallography has been used to elucidate the structure of ABAD protein 
in the presence of co-factor NAD and an excess of Aβ1-40 (Lustbader et al., 2004).  
ABAD consists of a six stranded β sheet surrounded by α-helices, forming a 
typical Rossman fold site associated with enzymatic activity (Figure 1.8).  
Interestingly, NAD was not found to be interacting with ABAD in the crystal 
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structure, a finding attributed to the distortion of ABAD structure in the 
presence of Aβ.  (Figure 1.8) (Lustbader et al., 2004).   
 
In addition to crystal structure , subcellular localisation can provide insight into 
potential functions of novel proteins.  Colocalisation studies have shown ABAD 
to be localised to the endoplasmic reticulum and mitochondria, as well as 
showing a more diffuse distribution across the cell membrane, cytosol and 
nucleus, as identified in ABAD-overexpressing neuroblastoma cells (Yan et al., 
1999).  Importantly, this research showed ABAD to change subcellular locations 
under different environmental conditions.  Specifically, on addition of Aβ to the 
cell culture system, ABAD appears to move away from the ER and accumulate 
close to the cell membrane, a result confirmed by subcellular fractionation (Yan 
et al., 1997, Yan et al., 1999).  This finding introduces an important concept, 
namely that ABAD may change its subcellular location, and therefore its 
function, under different environmental conditions.   
 
The mitochondrial location of ABAD has resulted in experiments investigating 
the effect of the novel Aβ – ABAD interaction on mitochondrial function.   
Application of Aβ to ABAD overexpressing COS cells induced suppression of 
mitochondrial function, when compared to non-overexpressing cells.  Similarly, 
in experiments using neuroblastoma cells (which constitutively express ABAD), 
the Aβ induced mitochondrial dysfunction was ameliorated through blockade of 
ABAD with an anti-ABAD antibody (Yan et al., 1997).  The interaction of ABAD 
and Aβ, and the negative effects this relationship has on mitochondrial function, 
suggests ABAD may be an important player in AD.  Investigations using human 
AD brain tissue show significantly increased levels of ABAD compared to age-
matched controls (Yan et al., 1997).   In addition to the in vitro findings, the Aβ – 
ABAD interaction is also found in human AD tissue, with confocal and 
immunogold electron microscopy showing these proteins to colocalise within 
the mitochondria of AD patients (Figure 1.8)  (Lustbader et al., 2004). 
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Figure 1.8  The structure of ABAD protein and evidence of its colocalisation 
with Aβ.  A.  A ribbon diagram showing the alpha-heices (green) and beta-sheets 
(blue) contained within an ABAD monomer.  The LD. LE and LF loops are also shown.   
B.  Superimposed image showing the distortion of the NAD binding site in human 
ABAD bound with Aβ (pink) compared to rat ABAD bound with the cofactor NAD 
(blue).  The predicted Aβ-binding loop is shown in yellow, NAD is shown as a stick 
model.  C.  ABAD and Aβ colocalise in the cerebral cortex of Alzheimer’s disease 
patients (200x).  Adapted from (Lustbader et al., 2004) 
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In contrast to the previously discussed mitochondrial dysfunction associated 
with increased ABAD expression, research suggests that in metabolically 
challenging conditions, increased levels of ABAD can be protective.  This was 
demonstrated in an in vitro study where COS cells overexpressing ABAD had 
significantly better viability when placed in hypoglycaemic medium than control 
vector transfected cells (Du Yan et al., 2000).  It may therefore be hypothesised 
that the increase in ABAD found in the brains of AD patients may be due to the 
metabolically challenging conditions associated with the previously described 
critically attained threshold of cerebral hypoperfusion (CATCH) hypothesis.  In 
order to determine whether ABAD is a possible target for amelioration of 
mitochondrial dysfunction, further work needs to be carried out in order to 
determine both ‘how’ and ‘why’ ABAD is increased in AD tissue. 
 
The evidence of increased ABAD protein in AD brains, the negative effect of 
ABAD overexpression on mitochondrial function in the presence of Aβ, and the 
evidence of ABAD and Aβ both colocalising to the mitochondria in the brains of 
AD patients suggests that this protein is an important target for further research 
in the field of AD.  The cause and function of increased ABAD expression in AD 










1.5.5 The Biochemical Links between Vascular Risk Factors, 
Mitochondrial Dysfunction and Alzheimer’s disease Remain Elusive  
 
Mitochondrial involvement in the production of ROS, the susceptibility of 
mtDNA damage with age, the role of mitochondria in calcium homeostasis, the 
presence of presenilins at the MAM and the direct interaction Aβ with 
mitochondrial protein ABAD, all indicate that this complex organelle is an 
attractive mediator of cellular dysfunction and neurodegeneration.  However, 
the driving force behind the described mitochondrial dysfunctions associated 
with ageing and AD remains elusive.  The previously described CATCH 
hypothesis suggests that advancing age, alongside co-morbid vascular 
disorders, induce suboptimal delivery of energy substrates to neurons.  A main 
outcome of CATCH is mitochondrial dysfunction, with knock on effects of  ROS 
production, oxidative stress, protein damage and aggregation, cell ionic pump 
deficiencies, signal transduction failure and ultimately neurodegeneration (de la 
Torre, 2002a). 
 
This vascular theory of mitochondrial dysfunction in AD is attractive given that 
the chronic reduction in blood flow and resulting oxidative damage occurs over 
many years, thus potentially accounting for the late onset of sporadic AD 
symptoms.  Developing appropriate model systems for the characterisation of 
the biochemical changes occurring under conditions of cerebral hypoperfusion 
and metabolic stress will provide insight as to the possible molecular pathways 
which underpin the mitochondrial dysfunction associated with ageing and AD.   
 
 
1.6 Experimental Models of Cerebral Metabolic Stress  
 
As previously discussed, neurons require a constant supply of oxygen, glucose 
and other nutrients in order to meet their exceptionally high ATP demands.  
Disturbances in cerebral blood flow disrupt the delivery of these substrates that 
are vital for ATP production, thus inducing a state of metabolic stress and 
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cellular dysfunction.  The extent of the neuronal dysfunction and damage in 
response to metabolic stress depends on the severity and duration of 
hypoperfusion episode.  An acute, intense cerebral metabolic challenge during 
conditions such as ischemic stroke can induce irreversible neuronal damage and 
infarction (van der Worp and van Gijn, 2007).   In contrast, age-related vascular 
disorders resulting in sub-lethal cerebral hypoperfusion induce a more mild but 
chronic metabolic impairment that is thought to contribute to the evolution of 
neurodegenerative disease (Beal et al., 1993).  Numerous experimental models 
have been developed in order to investigate the neurochemical cascades 
initiated by both acute and chronic metabolic challenges.  An assessment of the 
various models appropriate for investigations of chronic metabolic challenge in 
relation to AD is provided below.   
 
1.6.1 In vivo Models of Mild Metabolic Stress   
 
In humans, blood is supplied to the brain through the two internal carotid 
arteries and the two vertebral arteries.  The internal carotid arteries principally 
supply the cerebrum, whereas the vertebral arteries join to form the basilar 
artery which runs along the midline of the brain and connects with the Circle of 
Willis.   The Circle of Willis gives rise to three pairs of arteries, the anterior, 
middle, and posterior cerebral arteries.  These arteries divide into progressively 
smaller arteries and arterioles which penetrate the brain tissue supplying blood 
to the corresponding regions of the cerebral cortex  (Bear et al., 2007).  The 
complete Circle of Willis, as well as the extensive branching of the posterior, 
anterior, and middle cerebral arteries allows blood flow to circumvent any 
blockages, thus maintaining a steady supply of oxygen, glucose and nutrients to 




Rodent models of reduced blood flow (rather than the full occlusion models 
used in stroke research) have been developed in order to examine the effects of 
CCH on neuronal function as it occurs in human ageing and AD.  Bilateral 
common carotid artery occlusion (BCCAO) in the rat is a widely used model of 
CCH.  The rat has a complete Circle of Willis, therefore stenosis, or ligation, of 
the common carotid arteries affords incessant, but reduced, cerebral blood flow 
(Farkas et al., 2007).   
 
The BCCAO model has successfully been used to investigate the effect of CCH on 
learning and memory processes, an important area of research in relation to the 
cognitive decline associated with AD.  A significant number of studies have 
shown BCCAO rats to cover longer swim paths and longer escape latencies in 
the Morris water maze task, indicative of compromised spatial learning  (Farkas 
and Luiten, 2001).  Biochemical analysis of the brains of these rats also show 
memory disturbances to correlate with down-regulation of proteins associated 
with neuronal signalling, learning and memory (Liu et al., 2005).  In addition, 
the levels of BACE1 and Aβ are significantly increased in BCCAO rats compared 
to sham operated controls (Zhiyou et al., 2009), a result which demonstrates the 
utility of this animal model in investigating the links between CCH, amyloid 
processing and AD. 
 
The BCCAO model of cerebral hypoperfusion has generated a large amount of 
data, however there are drawbacks associated with this model.  Firstly, damage 
to the visual pathway in BCCAO rats has hampered interpretation of 
behavioural assessment (Davidson et al., 2000).  Furthermore, despite recent 
advances in the development of conditional genetic manipulations in the rat 
brain (Schonig et al., 2012), the availability of successful transgenic rat models 
is severely limited.  Thus, the ability to carry out informative genetics research 
in the BCCAO rat model is limited.  Induction of BCCAO in the many genetically 
modified mouse strains would overcome this limitation.  However, 
underdevelopment of the posterior communicating arteries of the Circle of 
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Willis of these animals means BCCAO induces severe ischemia rather than the 
desired CCH (Farkas et al., 2007). 
 
To overcome the lack of complete Circle of Willis, and therefore the limitation of 
BCCAO use in mice, the bilateral common carotid artery stenosis (BCAS) 
technique for CCH induction was developed.  In this model, small wire 
microcoils are wound around the common carotid arteries, inducing stenosis 
rather than occlusion of the vessels.  The degree of hypoperfusion is adjustable 
according to the tightness of the microcoil winding (Shibata et al., 2004).   
Behavioural testing in these BCAS mice after 1 month of hypoperfusion showed 
significant impairment in performance on the 8-arm radial maze task, indicative 
of spatial working memory dysfunction (Shibata et al., 2007).  Studies extending 
this research suggest that the impairment of spatial working memory may be 
induced by disruption of white matter components (Coltman et al., 2011). 
 
The success of the BCAS microcoil technique has allowed this procedure to be 
carried out in transgenic mice models of AD, providing a platform for more 
detailed analysis of the interplay between CCH, cognitive decline and amyloid 
processing.   For example, BCAS has been used in combination with the 
C57BL/6-Tg(Thy1-APPSwDutIowa) (Tg-SwDI) mouse model of AD, where a 
build-up of amyloid occurs on the walls of cerebral blood vessels as well as the 
cortex and hippocampus.  Induction of CCH in these animals causes 
microinfarcts which were not found in the Tg-SwDI mice without BCAS or WT 
mice with BCAS (Okamoto et al., 2012).  This combinatorial approach of CCH 
and transgenic modelling of AD promises to be an exciting research avenue in 
determining the biological processes relating vascular risk factors associated 






1.6.2 In vitro Models of Mild Metabolic Stress 
 
There are obvious limitations in the modelling of chronic neurodegenerative 
disorders in vitro.  Most pertinently in the case of AD as a vascular disorder, is the 
lack of blood vessels in the cell culture set up.  In addition, unless co-culturing is 
undertaken, the lack of glial cells might also prove important as research uncovers 
further roles for these cells in early AD dysfunction (Farfara et al., 2008).     
 
However, for the purpose of gaining a mechanistic insight into the cellular events 
pertinent to the early stages of AD, there are numerous advantages to in vitro 
modelling.  Firstly, the cellular microenvironment can be closely controlled, with 
manipulations easily and precisely made within an experimental setting.  Secondly, 
detailed morphological changes can be observed and recorded in a time-dependent 
manner throughout experimental protocols.  Thirdly, secreted factors that are lost 
in in vivo cell sampling are easily obtainable from surrounding cell culture media, 
adding a further dimension to the material available for analysis.  Finally, cultured 
cells are more accessible and amenable to informative research techniques such as 
electrophysiology, confocal and electron microscopy, which can be used in the 
pursuit of gaining mechanistic insight into cellular functions. 
 
2-Deoxyglucose (2-DG) is a glucose analog which is  used as a competitive 
inhibitor of glycolysis, restricting the availability of glucose at the cellular level, 
and inducing energy depletion and metabolic stress (Guo and Mattson, 2000).  
2-DG is often used in investigations into cancer treatment strategies, where 
inhibition of glycolysis is beneficial (Ben Sahra et al., 2010).  2-DG has also been 
employed in neurodegenerative research investigating the cellular changes 




Oxygen-glucose deprivation (OGD) is another technique used to model 
metabolic challenge in vitro.   OGD is induced in vitro through the replacement of 
cell culture media with a suitable glucose-free alternative solution and 
incubation of this cell preparation in an anaerobic chamber (Goldberg and Choi, 
1993).  The duration of OGD can be controlled to model mild, moderate or 
severe metabolic challenges, with the extent of cell damage dependent on both 
the period of OGD and  the re-oxygenation interval (Lushnikova et al., 2004).  
OGD has been successfully utilised in investigations of metabolic challenge 
across a range of in vitro set ups, including immortalised neuronal cell lines 
(Dohm et al., 2006), individual and mixed neuronal – glial cultures (Katchanov 
et al., 2001, Bell et al., 2011) and  organotypic slice cultures (Cimarosti et al., 
2005). 
 
The severity of metabolic insult and the cell death processes induced in 
response to the 2-DG and the OGD metabolic challenges was recently 
characterised.    2-DG plus oxygen deprivation induced acute ischemia in 
primary neuronal cultures, whereas classic OGD using glucose-free culture 
medium plus oxygen deprivation induced delayed ischemia.  Both in vitro 
models showed markers of necrosis, apoptosis, and autophagy in a dose 
dependent manner according to the duration of the challenge. (Meloni et al., 
2011).    This data shows the OGD challenge to induce a slowly evolving cellular 
dysfunction that may be more relevant to research concerned with the cellular 
dysfunction associated with ageing and neurodegeneration.  







1.6.3 The SH-SY5Y Cell Line and its use in Modelling Neurodegenerative 
Disease 
 
In order to model neurodegenerative disease in in vitro systems, the neuronal cell 
culture need to morphologically mature, preferably with the presence of extended 
neurites and the ability to form synapses with other neurons.  Biochemically, the 
cells should express the human genome / proteome, with capabilities of detecting 
normal and pathological proteins under various experimental and control 
conditions.   
 
SH-SY5Y cells are human in origin, from a neuroblastoma cell source (Borland et al., 
2008), and possess many of the proteomic and functional properties of neurons, 
including neuronal marker activity, expression of  neurofilament proteins and also 
nerve growth factor receptors (Xie et al.).  Indeed, previous hypoxia experiments 
using SH-SY5Y cells successfully showed decreased sAPPα secretion with 
significantly decreased expression of ADAM10, the protein widely accepted to be α-
secretase in the APP cleavage pathway (Webster et al., 2002).   
SH-SY5Y cells can be differentiated in order to produce a culture system that more 
closely resembles mature neurons with extensive neurite outgrowths and 
increased expression of neuronal markers such as synaptophysin and NeuN, a 
postmitotic neuronal marker (Figure 1.9).  Not only are these neuronal proteins 
increased in expression following differentiation, they also change location, moving 
from the cytoplasm to soma and neurites, potentially indicative of altered function 
in differentiated SH-SY5Y cells (Cheung et al., 2009).  These factors suggest some 
utility in the differentiation of SH-SY5Y cells when they are to be used in 




However, cellular differentiation is associated with a number of issues that 
might impact on the interpretation of experimental results, especially in a study 
concerning the global proteomic changes within the SH-SY5Y cell culture 
system.  Differentiation affects the regulation of survival signalling pathways, 
with increased phosphorylation of Akt, a protein with central importance in 
processes including glucose metabolism, cell proliferation, apoptosis and 
transcription.  Similarly, the phosphorylation of JNK proteins is found to be 
significantly changed following RA differentiation of SH-SY5Y cells (Cheung et 
al., 2009).  JNK proteins are stress activated, therefore potentially play an 
important role in the cellular response to experimental changes in the 
environment.  In studies investigating the protein responses to cell stress, 
including oxidative and metabolic stress, differentiation may therefore be 
undesirable, due to the potential for artefacts in the proteomic data from the 







Figure 1.9 Differentiation of SH-SY5Y cells with retinoic acid 
(RA). A.  Undifferentiated SH-SY5Y cells growing at approximately 
80% confluency.  Neurite outgrowths are evident between cells, with 
some characteristic clustering of neuroblastoma cell growth present.  
B. Differentiated SH-SY5Y cells show more extensive neurite 
outgrowths, however the gross morphology is not dissimilar to 





SH-SY5Y cells have been used in a range of studies to characterise the different 
neuronal cell death mechanisms in response to different stimuli.  Short et al. 
employed mass spectrometry with SH-SY5Y cells to assess the proteomic basis of 
apoptosis in these cells in response to staurosporine exposure (Short et al., 2007).  
Another study investigating cell death mechanisms used SH-SY5Y cells and OGD to 
demonstrate necrosis to be induced following a severe ischemic insult of 32-hours of 
OGD (Fordel et al., 2007).  OGD and SH-SY5Y cells have also been used in experiments 
seeking to characterise the role of calcium homeostatic disruptions in cellular 
dysfunction and neuronal cell death following ischemic challenges.  For example, 
Dantrolene, a drug known to block the release of calcium ions from their stores in the 
endoplasmic reticulum, was shown to partially protect cells from neurotoxicity and 
cell death following OGD exposure (Wang et al., 2002).   
 
These studies demonstrate the utility of SH-SY5Y cells, in combination with a range 
of experimental interventions, and proteomic technology, to uncover the biochemical 
processes underlying cellular dysfunction.  In particular, the plethora of recent 
studies utilising OGD and SH-SY5Y cells to model mild, moderate and severe 
metabolic challenges, demonstrates the great utility of this cell line in interrogating 
the underlying dysfunctions following ischemic insults (Webster et al., 2002), (Iwata 
et al., 1998), (Guzy et al., 2005).  A clear gap in the current literature however, is a 
large scale, comprehensive analysis of the proteomic response following different 














1.7 Quantitative Proteomics in Alzheimer’s disease Research 
 
1.7.1 The Evolution of Proteomics Research 
 
Proteomics is described as “the study of protein properties (expression level, post-
translational modification, interactions etc.) on a large scale to obtain a global, 
integrated view of disease processes, cellular processes and networks at the 
protein level” (Blackstock and Weir, 1999).   At a basic level, proteomic studies 
are based on protein separation from complex samples, protein identification, 
and finally protein quantification and analysis. 
 
Early proteomics research was primarily concerned with the isolation and 
identification of proteins present within a complex mixture.  This era of 
research was defined by the development of gel-based protein separation 
techniques in the 70’s,  known as two-dimensional electrophoresis (2-DE) 
(O'Farrell, 1975).  2-DE involves the separation of proteins in the first 
dimension by their isoelectric point, and in the second dimension according to 
their molecular weight.  Proteins are then recognized as individual spots 
separated across a polyacrylamide gel and can be isolated for identification.   
 
The protein identification method conventionally used following 2-DE was 
Edman degradation, which involves the sequential removal of amino acid 
groups from the N-terminal of the protein , followed by amino acid 
identification by chromatography (Edman, 1949).  However, Edman 
degradation is a time consuming, low throughput approach to protein 
identification, requiring multiple steps of proteolytic digestion, peptide 
fractionation, and peptide sequencing (Bandeira et al., 2008).  This technique 
has now been largely superseded by mass spectrometry, which provides a high-
throughput platform for protein identification and quantitation.    
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Knowledge of named proteins present in a biological sample is important in 
developing our understanding of biological processes.  However, this 
information provides limited insight into the dynamic nature of the proteomic 
response to experimental conditions and disease states.  To address this, the 
field has now evolved to “2nd generation proteomics”, characterised by the use 
of quantitative MS-based methods to measure changes in protein abundance in 
response to experimental intervention or disease states (Lamond et al., 2012). 
 
A large proportion of the current 2nd generation proteomic research uses 2-DE 
for protein separation.  The development of gel scanners and analysis software 
has allowed for highly reproducible assessment of protein spot intensity, and 
therefore protein abundance, across different conditions.  The significantly 
altered protein spots can then be selected, extracted from the gel, and processed 
for identification by mass spectrometry (Morris et al., 2010).  This 2-DE, 
coupled to mass spectrometry, has significantly advanced our understanding of 
the proteomic basis of neuronal cell function and dysfunction across a range of 
model systems.  These include in vitro investigations of the proteomic basis of 
apoptotic cell death (Short et al., 2007), characterisation of the proteomic 
changes underpinning spinal cord injury in the rat (Kang et al., 2006), extending 
to the detection of specific protein changes occurring in the white matter of 
schizophrenic patients compared to controls (Clark et al., 2007). 
 
However, despite the important insights into the proteomics of neuronal 
function provided by these studies, there are significant limitations associated 
with this 2-DE coupled to mass spectrometry proteomic technique.  2DE-based 
proteomics fails to detect low abundance proteins, such as regulatory proteins 
and receptors, which are crucial to cell function.  In addition, small proteins and 
hydrophobic proteins are notoriously difficult to detect and analyse with 2-DE.  
Importantly, membrane proteins are also not readily amenable to 2-DE analysis, 
due to their poor solubility in protein extraction buffers (Beranova-Giorgianni, 
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2003).  Finally, and not insignificantly, 2-DE methods are very labour-intensive 
and often unrewarding due to the variability in gel quality affecting the 
reproducibility of protein abundance detection.  2-DE is relatively low 
throughput which is inadequate when large numbers of highly variable clinical 
samples are needed to adequately power the investigation.    
 
In an effort to overcome the limitations of 2-DE, proteomics research is now 
moving away from gel-based protein separation and pursuing liquid-
chromatography as an alternative separation technique (Patterson, 2003).  This 
process, coupled to mass spectrometry-based protein identification, is known as 
tandem liquid chromatography – mass spectrometry, or LC-MS/MS.  In LC-
MS/MS, proteins in biological samples are converted to peptides by enzyme 
digestion.  Liquid chromatography (LC) is then used to separate the peptides.  In 
the LC stage, peptides are passed through a column packed with a hydrocarbon 
support resin.  Peptides interact with the hydrocarbons in the resin, with polar 
peptides binding weakly and less polar peptides binding strongly.  Peptide 
separation occurs through the sequential elution of peptides from the column 
using an increasingly polar solution.    
 
The separated peptides are ionized by electrospray (electrospray ionization – 
ESI) before being further sorted in the linear ion trap (based on mass and 
charge), stored in the c-trap and finally being released into the orbitrap for 
detection.  To gain more detailed data from the peptide spectra, parent peptides 
can then be fragmented into further smaller parts in the collision chamber, 
followed by a second round of mass / charge ratio measurement.  The 
information gained from peptide fragment spectra provides insight into the 
peptide sequences, which can be accurately used to search protein sequence 
databases for matching peptides (Figure 1.10).   A protein can then be identified 
by the multiple independently sequenced peptides present in a sample (Xie et 
al., 2011, Dancik et al., 1999). 
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Figure 1.10 Diagrammatic representation of the tandem Liquid Chromatography – Mass Spectrometry System.   
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1.7.2 Quantitative LC-MS/MS Proteomics: to label or not to label? 
 
 
In addition to providing wide coverage of the proteins present in complex 
samples, LC-MS/MS can also be used to gain information as to the expression 
levels of proteins.  Numerous approaches exist to label proteins in advance of 
LC-MS/MS, facilitating quantitative comparisons of relative protein abundance 
between samples.  Examples of commonly used protein labelling techniques 
include: stable isotope labelling by amino acids in cell culture (SILAC); isotope-
coded affinity tags (ICAT); and isobaric tags for relative and absolute 
quantification (iTRAQ).  These protein labelling techniques in LC-MS/MS are 
associated with numerous shortcomings, including complex sample 
preparation, requirement for high sample concentration and reduced coverage 
due to incomplete labelling (Patel et al., 2009). 
 
Quantitative label-free LC-MS/MS has recently been developed in order to 
overcome the limitations associated with the protein labelling techniques.  
Label free LC-MS/MS allows peptides present in a complex protein digest 
mixture to be measured and the abundance of proteins identified across 
different samples.  Label-free protein quantification is often carried out in 
relative terms, whereby protein abundance is expressed relative to a reference / 
control sample.  There are two widely used techniques for label-free 
quantification, either (a) counting the number of fragment spectra identifying 
peptides from a specific protein, or (b) measuring and comparing the signal 
peak intensities of peptide ions from a particular protein (Matzke et al., 2013). 
 
Spectral counting involves counting the number of fragment ion spectra that 
map to a particular protein across multiple LC-MS/MS analyses.  This method of 
protein quantification is based on the premise that proteins present at high 
levels will produce more MS spectra from their constitutive peptides.  
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Therefore, relative quantification is accomplished through direct comparisons 
of spectral counts between samples (Bantscheff et al., 2007).  Although this 
spectral count method of label-free protein quantification seems intuitive, the 
method assumes that the linearity of protein abundance and peptide spectrum 
count is the same for every protein.  The reality is that spectrum counts are 
different for every peptide, and therefore acceptable quantification using this 
method requires observation of many spectra for each individual protein 
(Bantscheff et al., 2007).  
 
In the peak intensity method, the ion chromatograms for every peptide are 
taken from the LC-MS/MS run and their mass spectrometric peaks are 
combined.  The height of the peptide spike is used as an indication of protein 
abundance.  These peak intensity values can then be compared to their 
respective signals in other samples, thus generating relative, quantitative data 
(Bantscheff et al., 2007).  Matzke et al.  provide a comprehensive examination of 
the merits and challenges associated with the two quantification approaches, 
and the computational tools that can be used with each (Matzke et al., 2013).  
 
 
1.7.3 Proteomics in Alzheimer’s disease Research 
 
 
Proteomic technology in its many guises has been widely applied to the field of 
AD research (Butterfield et al., 2003).  A popular strategy in the pursuit of 
biomarkers of AD is to interrogate the proteomic profile of various brain regions 
in post-mortem human AD tissue.  A recent study used LC-MS/MS to investigate 
the proteomic changes occurring in the hippocampus in AD brains compared to 
controls.  The biological processes assigned to the significantly altered proteins 
included “cellular metabolic processes” and “oxidative phosphorylation”, 
indicative of the significant metabolic alterations occurring in AD (Begcevic et 
al., 2013). Similarly, proteomics has been used to investigate the protein 
changes in the cortex of AD patients, where mitochondrial protein changes were 
detected, including an increase in ABAD protein (Andreev et al., 2012).  
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The cerebral spinal fluid (CSF) of AD patients, due to its direct contact with the 
brain, has also been used in proteomic investigations to uncover potential 
biomarkers of AD.  2DE-MS/MS analysis of CSF from ante-mortem AD-patients 
and controls identified significant changes in proteins involved with Aβ 
transport and inflammation to be significantly affected by AD (Finehout et al., 
2007).     
 
However, there are significant barriers faced by researchers searching to 
identify novel biomarkers for AD.  Firstly, proteomic analysis of post-mortem 
AD brain tissue and ante-mortem CSF from AD patients presenting cognitive 
symptoms represent late stages of disease development.  At these points in 
disease progression, extensive neurodegeneration has probably already 
occurred, and thus proteomics will primarily be investigating either dead or 
dying tissue.  Secondly, a conclusive diagnosis of AD can only be made post-
mortem when a comprehensive assessment of amyloid plaque and tau-tangle 
burden can be made.  It is therefore difficult to test biomarkers and drug targets 
in clinical trials as the AD patient group is likely to be a homogenous mix of 
different dementia subtypes.   Finally, identification of healthy controls is 
integral to the successful pursuit of clinical biomarkers.  The evolving nature of 
AD neurodegeneration over time presents a major challenge in the search for 
control subjects as there is no test to rule out the potential for future 
neurodegeneration in these individuals.   
 
When all of these factors are considered alongside the low n numbers 
associated with human studies, and the high variability of human samples, it is 
clear that proteomic analysis of models of the early stages of AD would be more 
appropriate in the search for early disease biomarkers and strategies for 




Proteomic technology has been used in conjunction with the many transgenic 
mice models of AD in an attempt to uncover the complex cerebral alterations 
occurring in AD (Chang et al., 2013, Sizova et al., 2007)  Interestingly, iTRAQ 
proteomics using the triple transgenic AD mouse model (containing mutations 
in presenilin-1, amyloid precursor protein and tau) has shown many of the 
dysregulated proteins in the brains of these mice to be involved with the control 
of energy metabolism (Martin et al., 2008).  This finding is consistent with the 
human proteomic data, which also indicates proteins involved in energy 
processes to be disrupted in AD (Andreev et al., 2012).  .  
 
The logical progression of the research theme of metabolic disruption in AD 
would be the large-scale proteomic analysis of the animal models of chronic 
cerebral hypoperfusion.  However, only limited proteomic studies have been 
carried out in these models.  The promising microcoil BCAS mouse model of 
chronic cerebral hypoperfusion has  been used in a microarray study 
investigating the genomic changes in white matter (Reimer et al., 2011), 
however these BCAS mice are yet to receive full attention through large-scale 
proteomics research.   In the rat BCCAO model, the response of individual 
proteins important to AD have been assessed by enzyme linked immunosorbent 
assay (ELISA) and western blotting (Zhiyou et al., 2009), however no proteomic 
- mass-spectrometry study has been carried out to characterise the global 
proteomic response to this stimulus.   
 
Large-scale proteomic analyses of in vitro models of hypoperfusion would be 
similarly useful in identifying the key processes underpinning early cellular 
dysfunction in relation to metabolic stress.  A recent study investigated the 
changes in small ubiquitin-like modifier protein (SUMO) interacting proteins 
following OGD using SILAC-based proteomics.  This study identified SUMO3 to 
interact with numerous transcription factors, which were themselves modified 
by OGD (Yang et al., 2012).  This study is clearly important in extending our 
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specific understanding of post-translational modification mediated by 
SUMOylation following metabolic stress.  However the power of proteomics lies 
in its role as a hypothesis generator, allowing cellular processes to be examined 
in an investigative, un-biased manner, providing opportunity for discovery of 
novel protein changes and biomarkers of disease states.     
 
The field of AD research is at something of a crossroads.  The extensively 
investigated amyloid cascade hypothesis has failed to produce effective 
treatments for this devastating disease.  Researchers have thus been forced to 
look elsewhere for novel theories as to the biochemical basis for the cognitive 
decline and neurodegeneration associated with AD.   The vascular hypothesis of 
AD is promising, but much research still needs to be undertaken in order to 
establish the primary events that link metabolic challenge with the associated 
mitochondrial and cellular dysfunctions.  The role of proteomics as a hypothesis 
generator ideally positions this technology at the forefront of future AD 
research.  
 
1.8 Summary, Aims and Hypotheses 
 
Vascular disorders inducing a state of chronic cerebral hypoperfusion are associated 
with Alzheimer’s disease, as described in the Critically Attained Threshold of Cerebral 
Hypoperfusion (CATCH) hypothesis of neurodegeneration.   The cellular changes and 
biochemical pathways underpinning the metabolic stress induced by CATCH, in 
relation to the onset and progression of Alzheimer’s disease, remain to be 
determined.  Using established in vitro cell culture techniques, this thesis will 
characterise the cellular response to mild and moderate metabolic stress, and 
investigate the proteomic changes that underpin cellular dysfunction in relation to 




Aim 1:   To characterise the response of human SH-SY5Y cells to oxygen – glucose 
deprivation, an in vitro model of metabolic stress.  Using a combination of functional 
assays, subcellular morphological analyses and large – scale LC-MS proteomics, this 
research will offer insight into the adaptive cellular response to metabolic stress.  
The descriptive proteomic data will provide a platform for novel hypothesis 
generation as to the vascular contributions to cellular dysfunction in AD, a relatively 
understudied area of AD research.  
 
Aim 2:   To characterise the protein interactome of amyloid binding alcohol 
dehydrogenase (ABAD) under control conditions and conditions of metabolic stress 
through the use of immunoprecipitation coupled to LC-MS (IP-MS).  ABAD is the 
protein of choice for this interactome analysis due to its significant up-regulation in 
response to metabolic stress, a result obtained following the completion of Aim 1.  
The results of this proteomic investigation will expose the protein processes in which 
ABAD is involved, thus providing insight as to possible points of intervention that 
might avert the course of ABAD induced mitochondrial dysfunction in AD.  
 
Aim 3:  To build on the ABAD proteomic data gained through the completion of Aims 
1 and 2, and test the novel hypothesis that increased ABAD expression may affect the 
expression levels and processing of APP.     This hypothesis will be tested through 
transfection of ABAD into SH-SY5Y cells, and subsequent investigation of the effect of 


















2.1 Cell Culture 
Unless otherwise stated, all standard growth media used was obtained from 
Invitrogen (Paisley, UK) and was pre-warmed to 37°C before contact with cells.  
SH-SY5Y cells were routinely maintained in standard 75cm2 cell culture treated 
flasks (Greiner Bio One, Stonehouse, UK) within a continuous flow incubator at 
37°C, 5% CO2.  Cell growth and adhesion was monitored under the Leica DM IL 
inverted microscope.  Growth medium was replaced bi-weekly. 
 
2.1.1 Standard Cell Culture Procedures  
 
SH-SY5Y cells, supplied at passage 29 from American Type Culture Collection (ATCC, 
Manassas, USA) were stored in liquid nitrogen until required.  On defrosting, cells 
were grown and routinely cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 2mM L-Glutamine, 100 U/ml Penicillin, 100mg/ml Streptomycin 
and Fetal Bovine Serum (FBS) (referred to as complete media).   
 
2.1.2 Passaging of Cells 
 
On reaching 80% confluency, cells were passaged using the standard trypsinisation 
method.  Flasks were washed with 10ml un-supplemented DMEM to remove any 
residual FBS followed by incubation for 3 – 4mins with trypsin / 
ethylenediaminetetraacetic acid, until all cells dispersed into solution.  10ml of 
complete media was added to the flasks, and the cell suspension centrifuged at 200 g 
for 7mins.  The pellet was re-suspended in 5ml complete media, and 1ml added to 
24ml complete media for seeding into new 75cm2 flasks.    
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2.1.3 Liquid Nitrogen Cell Storage and Retrieval 
2.1.3 Liquid Nitrogen Cell Storage and Retrieval 
Cells not immediately required for experimental procedures were trypsinised as 
described in Section 2.1.2 and centrifuged down to a pellet (200 g, 7mins).  Cells were 
gently vortexed into 5ml complete medium and 1ml 5% dimethyl sulfoxide (DMSO) 
solution (per 75cm2 flask stripped).  1ml aliquots of cell solutions were then snap 
frozen in cryogenic storage vials and placed in liquid nitrogen for long term storage.  
Cells were revived by warming in a 37°C water-bath until thawed, and then diluted in 
10ml complete medium.  This new cell suspension was then washed of residual 
DMSO through a centrifugal step (200 g, 7mins), and the pellet resuspended in 5ml of 
complete medium.  New 75cm2 culture flasks were set up with 1ml cell suspension 
seeded in 24ml complete media. 
 
2.1.4 Oxygen – Glucose Deprivation (OGD) 
 
On reaching passage 35, 80% confluent flasks were stripped of cells using the 
trypsinisation method (Section 2.1.2) and cells centrifuged out of solution to 
pellet (200 g, 7mins).  Cells were then resuspended in 6ml complete growth 
media and vortexed gently to ensure complete re-suspension.  The number of 
cells was determined using a haemocytometer.  The cells were seeded onto 
poly-D-lysine coated flat bottomed 96 well plates (Thermo-Fisher Scientific, 
Loughborough, UK) at a density of 125, 000 cells per well in 200µl complete 
medium.  The plates were incubated overnight (37°C, 5% CO2). 
 
After overnight seeding, complete media was replaced in all wells with glucose free 
DMEM solution and the plate gently shaken.  Cells were then incubated in either 
glucose-containing or glucose-free DMEM under either normoxic (37°C, 5% CO2) or 
hypoxic (37°C, 95% N2, 5% CO2) conditions.  The solutions used for the hypoxic 
condition were pre-equilibrated overnight in the hypoxic chamber before application 
to cells.  The cells remained under control (normoxic) and experimental (hypoxic) 
conditions for 1hr, 3hr, 6hr, 9hr or 18hr durations. 
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2.1.5 MTS Assay: Assessment of Mitochondrial Function 
The MTS assay is a colour change reaction whereby the tetrazolium salt (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium inner salt (MTS) is reduced to formazan, a soluble product forming a 
dark purple solution.  The more viable cells that remain after OGD, the more 
dehydrogenase activity occurs, thus producing a more intense colour change (higher 
optical density (OD) reading).  Therefore, measuring the OD of wells following MTS 
assay gives a good indication of mitochondrial function. 
Following OGD treatments, all media in all wells was replaced with 200µl fresh 
complete media, and 20µl of CellTiter 96 AQueous One Solution Cell 
Proliferation Assay (MTS) (Promega, Madison, USA) was added to each well.  
The plates were then incubated for 1hr in normoxic conditions (37°C, 5% CO2), 
followed by optical density readings taken at 490λ using an Dynex MRX plate 
reader (Dynex Technologies Ltd., Worthing, UK).  The presence of any cells in 
the eluted solution following OGD was assessed using a Leica DM IL inverted 
microscope. 
 
2.1.6 Trypan Blue: Cell Death Assessment 
 
During harvesting of OGD cells for proteomics (Section 2.4.1), the total number of 
dead cells was assessed using a trypan blue stain (Invitrogen, Paisley, UK).  Once cells 
were collected and resuspended in HBSS, 100µL of this solution was removed and 
added to a 1.5ml eppendorf tube.  20µL of trypan blue solution was added to the cell 
solution and left to equilibrate for 5mins at room temperature.  Using a 
haemocytometer, the number of dead cells (stained blue) was counted and the 






2.1.7 Oxygen Depletion Recordings: Internal Controls 
 
In order to begin biochemical analysis on the OGD treated cells, the experiments 
carried out in 96 well plates needed to be scaled up to a 75cm2 culture flask set up.  
This allowed larger numbers of cells to be treated and subsequently collected for 
proteomic analysis.  Oxygen depletion curves from media in 96 well plates and in 
75cm2 culture flasks were recorded and compared.   
 
96 well plates were seeded as previously described for the MTS assay study (Section 
2.1.5).  The reduction in pO2 of the glucose free solution above the cells was 
measured using a fiberoptic dual oxygen-temperature sensing probe (OxyLite 2000 E 
Series, Oxford Optronix, Oxford, UK).  The OxyLite system is based upon the principle 
that light emitted by the fluorescent probe will be quenched in the presence of local 
oxygen.  The amount of quenching recorded is proportional to the pO2 in the vicinity 
of the fluorescent compound (from User Manual for the Oxylite 2000 E series, 
Revision 1.2 2006).  PO2 measurements are temperature dependent, therefore all 
measurements were automatically compensated for temperature by the OxyLite 
instrument.  Recordings were taken every 10 seconds over a 3.5hr period, 
representing the initial phase of OGD when O2 is moving out of solution.  The O2 
optimisation was repeated in 70 - 80% confluent 75cm2 flasks (as will be used for 















Figure 2.1 pO2 depletion profiles are comparable between 96 well 
plates and 75cm2 flasks.  Over the first 2 hours following OGD onset, oxygen 
depletion occurs marginally faster in the 96 well plate set up than 75cm2 
flasks.  After 2 hours of OGD, pO2 levels decrease at the same rate from wells 
and flasks, and by 3h post OGD onset, pO2 is reduced in both experimental set 
ups to severely hypoxic levels, and remain at this level for the duration of the 








2.2  Biochemistry  
 
2.2.1  Protein Assay 
 
The amount of protein present in samples was determined using a BCA 
(bicinchoninic acid) Protein Assay Reagent kit (Thermo Fisher Scientific, 
Loughborough, UK). A serial dilution of 2mg/ml bovine serum albumin (BSA) was 
carried out to produce a set of protein standards of the following concentrations: 
2mg/ml, 1.5 mg/ml, 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml and 0mg/ml.  
These standards, along with protein samples (diluted to either 1 in 10 or 1 in 25), 
were loaded in triplicate onto a 96-well plate.   200µL of the working reagent was 
added and the plate was incubated at 37°C for 30mins. The absorbance of the 
solutions was measured at 562nm on a Dynex MRX plate reader (Dynex Technologies 
Ltd., Worthing, UK). Values obtained from protein standards were used to generate a 
standard curve from which the protein concentration of the samples was calculated. 
 
2.2.2  Western Blotting 
 
Protein assay results were used to prepare samples in 15µL aliquots containing 10µg 
of protein, with 0.5µL of 2x Laemelli buffer per µL of sample solution.  Proteins were 
denatured from their globular structure to a linear formation on a hot-block (10mins, 
70°C) to promote clean migration down through the gel.  14.5µL of samples were 
loaded onto NuPAGE 4-12% Bis-Tris precast polyacrylamide 15 well gels (Invitrogen, 
Paisley, UK) along with molecular weight marker (Li-Cor, Cambridge, UK) using a 
25µL Hamilton Syringe.  The gels were mounted in XCell SureLock™ Mini-Cells 
(Invitrogen, Paisley, UK) and proteins separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) in NuPAGE 
morpholineethanesulfonic acid (MES) running buffer (Invitrogen, Paisley, UK).  The 
electrophoresis step was run at 60V for 3h.  Proteins were electro-transferred to 
nitrocellulose membrane (Bio-Rad, Hemel Hempstead, UK) at 30V for 1hr using the 
XCell II™ Blot Module system (Invitrogen, Paisley, UK) in tris-glycine transfer buffer. 
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Proteins were visualised on the nitrocellulose membrane using Ponceau S solution.  
Any membranes with evidence of unsuccessful transfer or uneven protein loading 
were discarded and the samples re-run.   Membranes were incubated in 20ml 
Odyssey blocking buffer (Li-Cor, Cambridge, UK) diluted 1:1 with Phosphate Buffered 
Saline (PBS) for 1hr.  Membranes were then incubated with primary antibody 
solutions containing the optimised dilution of primary antibody in 10ml blocking 
buffer diluted 1:1 with PBS: 0.1% tween-20.  An appropriate loading control antibody 
of either GAPDH or α-tubulin was also added to the primary antibody solution, a 
choice made based on the avoidance of cross reactivity between antibody host-
species .  The membranes were incubated overnight at room temperature whilst 
being gently agitated on a shaker.   
 
Primary antibodies were removed and the membranes washed 6 times for 5mins in 
PBS: 0.1% tween-20 solution.  Appropriate fluorescent secondary antibodies (Li-Cor, 
Cambridge, UK) were diluted 1:5000 in blocking buffer and incubated with the 
nitrocellulose membranes at room temperature for 1hr.  The secondary antibody 
solution was then removed and the membrane wash steps repeated, with the final 
wash in PBS only.  The membranes were dried between blotting paper pads and 
imaged using the Odyssey infrared scanning system (Li-Cor, Cambridge, UK).  
 
2.2.3  Immunocytochemistry 
 
25mm coverslips (VWR, Leicester, UK) were coated with poly-d-lysine and 
placed in 6 well plates (Greiner Bio One, Stonehouse, UK).  150 000 SH-SY5Y 
cells suspended in complete media were seeded onto the coverslips.  After a 3hr 
adherence phase, 3ml of complete media was added to the wells, and the cells 





Coverslips were washed in glucose free DMEM and cells were exposed to control 
or OGD conditions as described in Section 2.1.4.  Following OGD, coverslips were 
rinsed in pre-warmed PBS and fixed in 4% paraformaldehyde, pH 6.9, for 
10mins at room temperature.  The paraformaldehyde was removed and the 
coverslips were stored in PBS at 4°C until all samples were collected and ready 
for immunocytochemistry.   
 
Immunocytochemistry was carried out at room temperature, with all wash steps 
carried out using PBS.  Cells were quenched in 50mM ammonium chloride – PBS 
solution for 10mins, washed three times, and permeabilised in 0.1% tritonX.  
Cells were then washed again and incubated for 1hr in blocking solution: 0.1% 
PBS tween, 0.3M glycine, 2% bovine serum albumin.  Cells were then washed 
and incubated in 50µL primary antibodies for 1hr.  Coverslips were washed 5 
times to remove excess primary antibody, and then incubated with secondary 
antibodies for 1hr.  Coverslips were then incubated with DAPI (Invitrogen, 
Paisley, UK) for 10mins.  Finally, cells were washed a further five times, rinsed in 
water, dried and mounted onto glass slides using ProLong Gold (Invitrogen, 
Paisley, UK) and left to dry overnight at room temperature before confocal 
imaging.  
 
2.3  Molecular Biology  
 
2.3.1  Bacterial Transformation  
 
Myc-DDK tagged human HSD17B10 (ABAD) cDNA clone was purchased from 
Origene as pCMV-Entry vector along with the equivalent empty pCMV6-Entry 
vector (Figure 2.2) (Origene Technologies, Rockville, USA).  The lyophilised 
vector was rehydrated in 10µL sterile distilled water.  1ng of DNA was added to 
30µL of chemically competent Top10 cells and left to incubate on ice for 30mins.  
Transformation of the DNA into the Top10 cells was then carried out using the 
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heat shock method: 39°C, 45 seconds.  Following heat shock treatment, the 
transformed cells were incubated on ice for a further 2mins, then added to 
200µL Luria-Bertani (LB) media, and incubated for 1hr at 37°C with vigorous 
shaking (200rpm). 
 
Transformed cells were then spread onto LB agar plates containing 25µg/ml 
kanamycin.  After overnight cultivation at 37°C, individual colonies were 
selected for plasmid propagation.  Colonies were incubated for 8h in 5ml LB 
media, supplemented with kanamycin, at 37°C with vigorous shaking (200rpm).  
This starter culture was diluted 1:1000 into LB medium and grown overnight at 
37°C with vigorous shaking (200rpm).     
 
 
Figure 2.2  Vectors used in the ABAD overexpression study.  A. Empty 
pCMV6-entry vector used for mock transfections in the main study.  B.  
Myc-DDK tagged human HSD17B10 (ABAD) vector used for ABAD 






2.3.2  Maxi Prep: Qiagen HiSpeed® Plasmid Purification  
 
Bacterial cells were harvested by centrifugation at 6000 g for 15mins at 4°C .  
The bacterial pellet was resuspended in 10ml buffer P1 supplemented with 
RNAase A and LyseBlue reagent.  10ml of lysis buffer P2 was added to the 
bacterial solution and mixed thoroughly.  10ml of protein precipitation buffer 
P3 was added to the bacterial cell lysate and mixed thoroughly.  The lysate was 
incubated for 10mins at room temperature in a capped QIA filter cartridge to 
allow bacterial protein, genomic DNA and detergent to precipitate out of 
solution.  The cell lysate was filtered through the QIA filter cartridge into a 
HiSpeed Maxi Tip pre-equilibrated with 10ml QBT allowing the cleared cell 
lysate to enter the Maxi Tip resin by gravity flow.  The HiSpeed Maxi Tip was 
then washed with 60ml Buffer QC by gravity flow.  The ABAD DNA was then 
eluted from the Maxi Tip using 15ml buffer QF.   
 
The eluent was incubated with 10.5ml isopropanol for 5mins at room 
temperature to precipitate the DNA.  The eluate / isopropanol mixture was 
filtered in the QIAprecipitator and the DNA was washed in 70% ethanol.  Using 
the plunger, air was passed through the filter in order to try out the suspended 
ABAD DNA.  The concentrated DNA was eluted from the QIAprecipitator using 
TE buffer directly into a 2.5ml eppendorf tube, and DNA content was 









2.3.3  Transfecting ABAD DNA into SH-SY5Y cells 
 
Transfections were carried out according to the Lipofectamine 2000 DNA 
Transfection Reagent Protocol (Invitrogen, Paisley, UK).  SH-SY5Y cells were 
seeded at 70% confluency in 6 well plates (Greiner Bio One, Stonehouse, UK) 
and left to adhere overnight.  For the control transfection, 2 tubes were set up: 
tube A containing 900µL Opti-MEM medium (Invitrogen, Paisley, UK) and 18µg 
of control DNA and tube B containing 900µL Opti-MEM and 18µL Lipofectamine 
reagent (Invitrogen, Pailey UK).  Tubes A and B were added together and 
incubated at room temperature for 5mins.  300µL of the DNA – lipid complex 
was added to each well of the 6 well plate, which was then incubated for 24 or 
48h under standard growth conditions (37°C, 5% CO2 in a humidified 
incubator).  The same procedure was carried out for the ABAD DNA 
transfections.       
 
Following 24 or 48hr transfection, media was removed from the cells and 
replaced with 1.5ml fresh complete media.  Cells were then collected using the 
cell scraper method, and the cell solutions from each well transferred to 
individual 1.5ml eppendorfs and centrifuged for 3mins at 6000g.     The 
supernatant was discarded and cells homogenised in 50µL RIPA buffer (50mM 
Tris-HCL, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS, 
supplemented with 1x protease inhibitor cocktail (Promega, Southampton, UK) 
and PMSF) using a cordless motor pestle (Sigma-Aldrich, Dorset, UK).  Samples 
were then centrifuged at 14,000 g for 15mins at 4°C and the supernatant 
recovered.   Protein concentrations of the samples were determined using the 






2.4 Proteomics:  Liquid Chromatography – Mass Spectrometry (LC-MS) 
 
2.4.1 Sample Collection and Homogenisation 
 
15 million cells were seeded in 75cm2 cell culture in complete media, and left to 
adhere overnight.  Prior to OGD, complete media was removed from the flasks and 
replaced with glucose free DMEM solution as a wash step to remove any residual 
glucose.  Flasks were then incubated in 20ml DMEM + Glucose or DMEM – Glucose, 
both of which were supplemented with fetal bovine serum.  The flasks were 
incubated in either normoxic (37°C, 5% CO2) or hypoxic (37°C, 95% N2, 5% CO2) 
conditions (for controls and OGD samples, respectively) for 6 or 18h.  The + / - 
Glucose DMEM solutions were pre-equilibrated overnight in normoxic or hypoxic 
conditions.   
 
Following OGD and control incubations, cells were immediately scraped and 
centrifuged at 200 g for 7mins.  The cell pellets were resuspended in HBSS and 
centrifuged again. The pellet was resuspended in 1ml HBSS and transferred to a 
1.5ml eppendorf tube for final centrifugation wash step and pellet collection at 
6000g for 3mins.  The supernatant was removed and pellet snap frozen for 
storage until homogenisation. 
 
Protein pellets were defrosted on ice.  100µL 8M urea (Sigma-Aldrich, Dorset, 
UK) was added to each sample and homogenised using a cordless motor pestle 
(Sigma-Aldrich, Dorset, UK).  Samples were then centrifuged at 14,000 g for 
15mins at 4°C and the supernatant recovered.   Protein concentrations of the 





2.4.2 Sample Preparation for LC-MS 
 
Protein samples (140µg) were made up to 100µL in 8M urea.   Samples were 
diluted with 235µL water, 20µL ammonium bicarbonate (1M), and 20µL 
dithiothreithol (200mM).  This sample solution was incubated for 30mins at 
room temperature allowing the proteins to be reduced.  Cysteine residues were 
alkylated with 20µL iodoacetamide (500mM), and finally 5µg trypsin (Promega 
(Southampton, UK) was added to the samples.  The sample – trypsin mixture 
was incubated overnight at 37°C to allow the proteins to be enzymatically 
digested to peptides.   
 
After trypsin digestion, peptides were washed in a reverse phase column.  1ml 
buffer B (90% acetonitrile (Thermo-Fisher Scientific, Loughborough, UK), 10% 
water, 0.25% Tri-fluoro acetic acid (Sigma-Aldrich, Dorset, UK), 0.1% formic acid 
(Merck, Darmstadt, Germany) was run through the column followed by 2ml 
buffer A (97.5% water, 2.5% acetonitrile, 0.1% formic acid).  400µL sample was 
added to the column.  1ml buffer A was passed through the column, with final 
elution and collection of peptides in 1ml buffer B.  Filtered peptides were dried 
overnight by Speed Vac and stored at −20 °C. 
 
2.4.3 LC-MS Proteomic Data Collection 
Proteomic data was collected on an automated micro-LC–MS/MS system, using 
a 1200 series micro-WPS autosampler and a binary micro-pump (Agilent 
Technologies, Palo Alto, CA) coupled to an LTQ-Orbitrap hybrid mass 
spectrometer (Thermo-Fisher, San Jose, CA). Peptides were reconstituted in 
20µL of buffer A (97.5% H2O, 2.5% acetonitrile, 0.1% formic acid) and sonicated 
for 15mins.  8μl of peptide mixture was loaded onto a 75μm (internal 
diameter) × 10 cm capillary Picotip column (New Objective, Cambridge, MA), in-
house-packed with C18 reverse-phase resin (Pursuit C18; 5 μm particles; 200-Å 
pore size; Varian, UK) at flow rate of 5μl/min. After sample loading, the flow 
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rate was reduced to ~100–200 nl/min using a vented column - precolumn 
arrangement. 
The high performance – liquid chromatography (HPLC) separation was 
provided by a gradient between buffer A and buffer B (90% acetonitrile, 10% 
H2O, 0.025% trifluoroacetic acid, 0.1% formic acid). The peptide mixtures were 
separated on a 140min gradient from 0% to 65% Buffer B. 
The mass spectrometer was operated in data-dependant mode, with a single MS 
scan (400–2000 m/z) followed by MS/MS scans in the linear ion trap on the 5 
most abundant ions and dynamic excluded for 120 s. 
 
The mass spectrometer was operated by Dr Thierry Le Bihan,  
University of Edinburgh 
 
2.4.4 Global Proteomic Data Analysis 
All LC-MS data were analyzed using a label-free intensity-based approach with 
Progenesis (version 4.0 Nonlinear Dynamics, Newcastle, UK), under randomized 
conditions. The MS/MS data were searched using MASCOT versions 2.3 (Matrix 
Science Ltd, London, UK) against a human subset of the NCBI database 
(downloaded on 12 January 2011) with 34,281 sequences using a maximum 
missed-cut of 2. Variable methionine oxidation, STY phosphorylation, protein N-
terminal acetylation, and fixed cysteine carbamidomethylation were used in all 
searches. 
 
Protein conflict (peptides shared between different proteins) was solved as 
follows: conflict resulting from multiple sequence assignment to the same peak - 
only the sequence having the highest score was kept. Conflict resulting from 
same peptide sequences assigned to different proteins - the assignment was 
singly attributed to the protein that had the highest number of peptides.  
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Regarding the label-free quantitation, the total number of features (i.e., intensity 
signal at a given retention time and m/z) was reduced to MSMS peaks with 
charge of 2, 3, or 4+ and only the five most intense MSMS spectra per ‘Feature’ 
were kept. The subset of multicharged ions (2+, 3+, and 4+) was extracted from 
each LC-MS run and the ions intensities summed for normalization.  Protein 
quantitation was performed as follows: for a specific protein, the associated 
unique peptide ions were summed to generate an abundance value. The 
measured protein abundances were transformed using an ArcSinH function (as 
the method of detection can generate a significant amount of near zero 
measurement for which a log transform is not ideal). The within-group means 
were calculated to determine the fold change.   Significant changes in protein 
expression (P<0.01) between control and OGD experimental groups were 
determined for each time point (6 and 18h) using Student’s T-test. 
 
2.4.5 Analysis of Protein Subcellular Localisation  
 
All 958 proteins identified by LC-MS/MS by at least two or more peptides were 
uploaded to the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) (http://david.abcc.ncifcrf.gov15) to determine subcellular 
localization based on gene ontology (GO). Protein clusters founded on 
subcellular localization with DAVID scores >2 were used. Proteins significantly 








2.4.6 Ingenuity Pathway Analysis (IPA) 
 
Ingenuity Pathway Analysis (IPA) is a web-based software programme that 
enables analysis and integration of large proteomic datasets, providing detailed 
information on putative signalling pathways and biological processes associated 
with detected protein changes (http://www.ingenuity.com).  IPA 
algorithmically generates protein interactomes based on direct (physical 
interactions and associations) and indirect (no physical interaction between 
proteins, however the change in expression of one protein effects the 
expression of another protein) interactions between proteins.  Proteins within 
an IPA network are represented as symbols, with the shape of the symbol 
indicative of the protein classification.  The protein symbols are colour coded 
depending on the direction of protein regulation: up-regulated proteins are red, 
down-regulated proteins are green, with the depth of shading of the protein 
symbol positively correlating to the magnitude of the fold change (Figure 2.3).  
IPA generates a score for each interactome, which is a putative measure of 
probability (see Deighton et al16 for critical analysis). 
 
 
In the present study, protein identifiers of all the proteins significantly altered 
after 18h OGD (P<0.01) were uploaded with their corresponding fold change 
values to IPA (http://www.ingenuity.com).  Protein interactomes were 









Figure 2.3  Proteomic interactome generation using Ingenuity Pathway Analysis (IPA) A.    Example IPA interactome generated from the 
significantly altered proteins in SH-SY5Y cells following staurosporine treatment (Deighton et al., 2010).  Red nodes indicate significantly 
increased proteins, green nodes indicate significantly decreased proteins, colorless nodes are proteins inserted by IPA to improve coherence of 
network.  B.  Figure legend for the shapes of protein nodes and relationships between proteins (http://www.ingenuity.com)
71 
 
2.5  Proteomics: Immunoprecipitation - Mass Spectrometry (IP-MS) 
 
2.5.1  Sample Collection & Homogenisation 
 
15 million SH-SY5Y cells were seeded overnight in standard 75cm2 cell culture 
treated flasks (Greiner Bio One, Stonehouse, UK).  Cells were exposed to 18h 
OGD or control conditions, and harvested as described in Section 2.4.1.   Cells 
from two equivalent 75cm2  flasks were combined for each IP.  The sample 
collection process was repeated until 3 OGD samples, 3 control samples and a 
negative control sample for both control and OGD conditions had been collected.  
Cell pellets were snap frozen for storage until homogenisation and protein assay.   
 
Cell samples were homogenised in 400µL RIPA buffer (50mM Tris-HCL, 150mM 
NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS, supplemented 1x 
protease inhibitor cocktail (Promega, Southampton, UK) and PMSF using a 
cordless motor pestle (Sigma-Aldrich, Dorset, UK).  Samples were centrifuged at 
14,000 g for 15mins at 4°C and the supernatant recovered.  Total protein content 
of each sample was determined as described in Section 2.2.1.  Based on the 
protein assay results, all samples were normalised to the sample with the lowest 
total protein content (2060µg) and made up to a final volume of 400µL.  1mg/ml 









2.5.2  Immunoprecipitation & In-gel Trypsin Digestion  
 
40µL ABAD antibody (Santa Cruz Biotechnology, Heidelberg, Germany) was 
added to each sample.  40µL RIPA buffer was added to the two negative control 
samples.  Samples were incubated on a mechanical tube roller overnight at 4°C. 
 
Illustra MicroSpin G-50 columns (GE Healthcare, Little Chalfont, UK) were 
thoroughly rinsed with distilled water and flushed with ice-cold PBS using 
centrifugation.  140µL sepharose bead suspension (Sigma-Aldrich, Dorset, UK) 
was added to each spin column and centrifuged.  Ice-cold, filter sterilised PBS 
was added to the columns and centrifuged to thoroughly wash the beads, a 
process repeated 5 times.  Beads were incubated with 500µL RIPA buffer for 1hr 
at 4°C.  Following this blocking step, spin columns were centrifuged and the 
RIPA buffer flow through discarded.  The 400µL of protein – ABAD antibody 
solution (or the 400μl protein-no antibody negative control solution) was added 
to the beads and incubated for 3h at 4°C.   
 
Beads were washed twice in ice-cold RIPA buffer, followed by a wash in RIPA 
buffer supplemented with 500mM NaCl.  The final washes were carried out in 
RIPA buffer followed by 20mM Tris.  To elute, 75μl of 1x SDS sample buffer was 
added to the beads, gently vortexed, and boiled for 5mins.  IP proteins were 
collected by centrifugation at 2800rpm for 1min.    
 
The immunoprecipitated protein samples were loaded onto a precast polyacrylamide 
gel and exposed to pulse electrophoresis (60 volts, 15mins) to remove any 
impurities.  The gel was washed in distilled water for 5 mins with orbital shaking.  
This wash was repeated two more times before removing the water and adding 30ml 
SimplyBlue SafeStain (Invitrogen, Paisley, UK).  The gel was incubated with the stain 
for 1hr at room temperature with orbital shaking.  The gel was removed from the 
stain solution and placed in 2% w/v NaCl destain solution overnight at room 
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temperature with orbital shaking.  The destain solution was removed and replaced 
with distilled water for 1hr at room temperature on the orbital shaker.    
 
The gel was placed on a clean glass plate and the gel bands containing the 
immunoprecipitated proteins were excised using a sterile scalpel.  Each gel piece 
was cut into further smaller gel pieces and transferred to sterile 1.5ml eppendorf 
tube.   Gel pieces were shrunk by incubation with 200µL methanol for 10mins. 
The methanol was removed and replaced with 200µL 50mM ammonium 
bicarbonate for 10mins.  The ammonium bicarbonate was removed and the 
methanol – ammonium bicarbonate incubation cycle was repeated twice more.  
The final ammonium bicarbonate solution was removed and 100µL 20mM DTT 
in 50mM ammonium bicarbonate was added to the gel pieces.  This protein 
reduction step was carried out at 60°C for 30mins.  The DTT solution was 
replaced with 200µL methanol and incubated for 10mins.  To alkylate the 
cysteines of the proteins, the methanol was removed and 100µL of 50mM 
iodoacetamide diluted in 50mM ammonium bicarbonate was added to the gel 
pieces.  Incubation occurred for 1hr in the dark.  The alkylating solution was 
replaced with 200µL methanol until all off the gel pieces had shrunk and turned 
white.  The methanol was removed and the gel pieces were left to air dry.    
 
A sterile syringe and needle (Thermo-Fisher Scientific, Loughborough, UK) were 
used to add 0.5ml 50mM ammonium bicarbonate to a 25µg trypsin vial 
(Promega, Southampton, UK).  The trypsin solution was transferred to a sterile 
1.5ml eppendorf tube and an additional 0.5ml 50mM ammonium bicarbonate 
was added.  30µL of the trypsin solution was added to the gel pieces and 
incubated for 30mins at 4°C.  Enough 50mM ammonium bicarbonate was then 
added to fully cover the gel pieces and the trypsin digestion was left overnight at 





Gel digest solutions were transferred to a new, sterile 1.5ml eppendorf.  50µL of 
1% w/v formic acid was added to the solution and incubated for 10mins.  The 
solution was then transferred back to the previous tube and 50µL of 1% w/v 
formic acid in 1:1 dH20: methanol was added.  The solutions were incubated for 
15mins.  This process was repeated once more.  Samples were loaded into a 
speedvac and spun at 45°C until all fluids were removed.  The resulting extracts 
were kept at -80°C until LC-MS analysis.   
 
2.5.3 IP-MS Proteomic Data Collection 
 
Proteomic data was collected on a nano-HPLC-MS/MS using an on-line system 
consisting of a nano-pump (Dionex Ultimate 3000, Thermo-Fisher Scientific, 
Loughborough, UK) coupled to a QExactive instrument (Thermo-Fisher 
Scientific, Loughborough, UK) with a pre-column of 300 µm x 5 mm (Acclaim 
Pepmap, 5 µm particle size) connected to a column of 75 µm x 50 cm (Acclaim 
Pepmap, 3 µm particle size).  Peptides were reconstituted in 5µl of Buffer A 
(97.5% H2O, 2.5% acetonitrile, 0.1% formic acid) to give final concentration of 1 
µg/µl. The samples were filtered with Millex filter before subjecting to HPLC-MS 
analysis.  
 
Samples were analysed on a 2hr gradient in data dependent analysis (1 survey 
scan at 70k resolution followed by the top 5 MS/MS).  The HPLC separation was 
provided by a gradient between buffer A and buffer B (90% acetonitrile, 10% 
H2O, 0.025% trifluoroacetic acid, 0.1% formic acid). Peptide mixture was 
separated on a 140min gradient from 0% to 65% Buffer B.  The mass 
spectrometer was operated in data-dependant mode, with a single MS scan 
(400–2000 m/z) followed by MS/MS scans in the linear ion trap on the 5 most 
abundant ions and dynamic excluded for 120 s.  Protein identification and label-
free quantification was as previously described in Section 2.5.3. 
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2.5.4  IP-MS Protein Enrichment Analysis 
An enrichment ratio was calculated for every protein in each independent IP 
sample compared to the associated negative control.  The frequency distribution 
of log enrichment scores was calculated, and a Z score > 1 was used as the 
inclusion criterion for protein enrichment in samples compared to negative 
controls (Appendix A).    
 
The protein frequency library (PFL) database was used to reduce the chance of 
false discovery through non – specific protein - protein interactions.  The PFL 
objectively evaluates whether proteins identified in an IP study are genuine 
protein interactor rather than binding non-specifically 
(www.proteinfrequencylibrary.com).  Searching the database for proteins 
known to be immunoprecipitated under our specific experimental conditions 
(human derived cell line, whole cell fraction and sepharose bead support) 
resulted in detection frequency values being assigned to all of the 
immnoprecipitated proteins in the present study.  A detection frequency of 
≤25% set as the inclusion criteria for consideration in the final dataset.     
 
2.6  Imaging 
 
2.6.1 Light Microscopy: SH-SY5Y Gross Morphological Assessment 
 
The temporal profile of gross morphological changes following each OGD exposure in 
wells and flasks was recorded with a Leica DM IL inverted microscope.  Images were 
taken before and immediately after each OGD exposure at x10 and x20 magnification.  
Images of the eluted solutions were also recorded to determine the number of cells 





2.6.2 Confocal Microscopy 
 
Confocal images were acquired with a Nikon A1R confocal laser scanning 
microscope (Nikon UK, Kingston Upon Thames, Surrey, UK) using a x60/1.4 NA 
oil immersion plan-apopchromat.  For multicolour images a channel series 
protocol was used to minimise bleed through, the same high voltage gain 
settings were applied to control and treated samples.  DAPI was excited with a 
401 nm laser and signal collected from 425-475 nm; Alexafluor 488 was excited 
with a 488 nm laser and signal collected from 500-550 nm; Alexafluor 568 was 
excited with a 561nm laser and signal collected from 570-620 nm.  Z-stacks 
were acquired with a resolution of 0.3 x 0.3 x 0.27µm in x, y and z respectively 
from 10 cells for each coverslip (n = 3 controls; n = 3 OGD plus negative controls 
from separate experiments for each condition).   
  
Images were viewed and analysed with Image J (National Institutes of Health 
open software).  A custom-written ImageJ macro that utilised the colocalisation 
threshold plugin was employed to generate a pseudocoloured image stack in 
which colocalised pixels were identified in cyan.  These image stacks were then 
projected using a Z-projection and thresholded using the Otsu method to 
determine real staining from background (Otsu, 1979).  For protein 
colocalization analysis, cells were manually outlined (excluding the nucleus) to 
determine the percent colocalisation of proteins of interest in the cell bodies.  
For analysis of the change in protein localisation in the nucleus, images were 
thresholded as described, and the image within the Z-stack containing the most 
complete nuclear cross section was selected.  Nuclei were manually outlined 
and the percentage of the area stained with the protein of interest was 
calculated.  Morphological changes in the colocalization patterns key proteins 
were analysed with a semi-quantitative scale.  Cell images were coded and 
graded by 3 blinded observers as colocalized pixels appearing "lacy", having 




2.6.3 Electron Microscopy 
 
SH-SY5Y cells for electron microscopy were harvested using the trypsinisation 
method (Section 2.1.2) and fixed with 4% paraformaldehyde and 5% 
glutaradehyde in 0.08 M sodium cacodylate buffer, pH 7.2.  Once fixed, cells 
were centrifuged, supernatant removed and replaced with a 3% agar solution.  
The gels were set at 4°C for 5 minutes before being cut into 1 mm3 blocks, which 
were subsequently embedded and cut into 70 nm sections.  Sections were 
collected on 300 mesh copper grids, stained with Reynold’s lead citrate and 
contrasted with uranyl acetate.  
 
The sections were evaluated on a JEOL CX -100 II transmission electron 
microscope at 40000x magnification.  Cells were chosen from grid squares in a 
predetermined pattern until the organelles from a total of 50 cells had been 
assessed for each OGD and time-matched control sample.  Mitochondria and 
endoplasmic reticulum were graded as “normal”, “swollen” or “abnormal”, 
whereas the nuclear envelope was graded as “normal”, “swollen” or “blebbing”.  
The presence of autophagic vacuoles, lipid droplets and any evidence of 
mitochondrial – endoplasmic reticulum interactions were also noted.  The 
evaluator was blinded to the treatment condition of all samples.   
 
EM samples were processed and evaluated by evaluated by M. McCulloch, 
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Chapter 3:  Investigating the proteomics of metabolic stress and mitochondrial 
dysfunction 
3.1  Background and Aims of the Chapter 
 
Energy is required for almost all cellular reactions that occur within the body.  
The neurons of the brain are highly metabolically active cells, and rely on ATP 
produced by the mitochondria to meet these high energy demands (Fiskum et 
al., 1999).  Energy production in the brain is maintained through the constant 
supply of oxygen and glucose delivered to the neurons via the cerebral 
vasculature.  It is this glucose, together with oxygen, which forms the basis of 
ATP production in the mitochondria (de la Torre, 2000).    Acute cerebral 
ischemia (i.e. a reduction of oxygen and glucose availability) is known to induce 
irreversible damage to neurons through disruption of the metabolic pathways 
vital for cell function.  The effects of chronic cerebral hypoperfusion are less 
well understood, however it is thought that many neurodegenerative diseases, 
including AD, might be caused by a disruption of mitochondrial function linked 
to a persistent reduction in cerebral blood flow (Fiskum et al., 1999).  The 
underlying biological mechanisms relating this chronic hypoperfusion to 
impaired mitochondrial function and neurodegenerative diseases remain 
unknown.   This chapter will therefore aim to:  
 
 Determine the effect of oxygen – glucose deprivation (OGD) on human 
SH-SY5Y cells, and to specifically explore the effect of varying degrees of 
OGD severity on mitochondrial function 
 Investigate the proteomic changes underpinning moderate and severe 
mitochondrial and cellular dysfunction 
 Utilise bioinformatics to interrogate the protein pathways integral to 









3.2.1 Oxygen - Glucose Deprivation (OGD) 
SH-SY5Y cells were seeded in 96 well plates and exposed to a range of oxygen 
glucose deprivation (OGD) intensities, (notably 3hr, 6hr, 9hr, 12hr or 18hr OGD 
durations) as described in Section 2.1.  Control cells underwent the same 
handling and experimental protocols, however were incubated in an equivalent 
glucose-containing media under normoxic conditions for the stated time course.   
 
3.2.2 Light Microscopy: SH-SY5Y Gross Morphological Assessment 
Gross morphological changes to cells following the different OGD durations 
were examined using light microscopy as outlined in Section 2.6.1.  Multiple 
images were captured of cells at each time point in 96 well plates (taken before 
MTS assay) and 75cm2 flasks (taken before sample collection for proteomics).   
 
3.2.3 MTS Assay: Assessment of Mitochondrial Function 
For the assessment of mitochondrial function following OGD, MTS assays were 
carried out as described in Section 2.1.5.  The MTS assay is a colour change 
reaction whereby a tetrazolium salt (3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) is 
reduced to formazan, a soluble product forming a darker, more purple solution.  
The reduction of the tetrazolium salt is dependent upon the oxidation on NADH 
by a fully functioning complex I on the mitochondrial electron transport chain.  
If mitochondrial dysfunction occurs, the colour change reaction is less intense, 
and recorded as such via optical density readings taken using a Dynex MRX 
plate reader (Dynex Technologies Ltd., Worthing, UK) at 490λ.  The design and 






Figure 3.1 Time course of mitochondrial function assay.  OGD was induced at time 
‘0h’ and maintained for 3, 6, 9, 12, and 18h.  The MTS assay was incubated for 1hr, after 






3.2.4 Electron Microscopy: Ultra structural Morphological Assessment 
SH-SY5Y cells were exposed to OGD using the same paradigm as the LC-MS 
study (Section 2.4.1).   Samples were collected immediately after 3, 9 and 18h of 
OGD and fixed with 4% paraformaldehyde and 5% glutaradehyde in 0.08 M 
sodium cacodylate buffer, pH 7.2.  Once fixed, cells were centrifuged, 
supernatant removed and replaced with a 3% solution of agar.  Gels were cut 
into 1mm³ blocks and processed for EM.  
 
EM images were acquired on a JEOL CX -100 II transmission electron 
microscope.  The evaluator was blinded to the treatment condition of all 
samples.  Cells were chosen from grid squares in a predetermined pattern. 50 
cells were assessed from each treatment.  For each cell the condition of 
mitochondria and rough endoplasmic reticulum (ER) was assessed.  The 
presence / absence of autophagosomes and lipid droplets were also recorded. A 
Chi-Squared 3 x 2 matrix was used to test the null hypothesis that OGD would 
have no effect on the ultrastructure of organelles.  
 
3.2.5 Trypan Blue: Cell Death Assessment  
Trypan blue staining was carried out to assess the extent of cell death occurring after 
each OGD time point (Section 2.1.6).  A haemocytometer was used to calculate the 
percentage of stained and unstained cells for each OGD and time matched control 
sample.      
 
3.2.6 Liquid Chromatography - Mass Spectrometry (LC-MS) 
Based on the OGD characterisation, SH-SY5Y cells treated with 6hr OGD (n = 6) and 
18hr OGD (n = 6) as well as time matched control samples (n = 6 for each control 
time point) were collected as described in Section 2.4.2.  Each sample was 
homogenised in 8M urea and protein assayed using the Pierce BCA Protein Assay Kit 




Samples were further processed and purified prior to LC/MS protein detection as 
described in Section 2.4.2.  Quantitative proteomic data for each OGD and control 
sample was collected using high throughput liquid chromatography coupled to mass 
spectrometry.  Protein identification and analysis of different protein intensities was 
carried out using the Progenesis software package (Nonlinear, Newcastle, UK).  
   
3.2.7 Western Blotting 
 
Western blotting was performed on the original control and OGD samples used in the 
LC-MS study to confirm that the changes in peptide levels detected by the mass 
spectrometer are reflected in the changes in total protein levels.  5μg of total protein 
was loaded onto the gels and standard western blotting procedures were then 
carried out as detailed in Section 2.2.2.   The specific antibodies used in this study are 
listed in Table 3.1.  The fluorescence intensity of the protein bands was detected 







    
UQCRC1 0.46 Invitrogen, 459140 1 : 5000 
UQCRC2 0.31 Abcam, ab14745 1 : 5000 
    
VDAC1 0.26 Abcam, ab14734 1 : 2000 
TOM22 0.46 Abcam, ab57523 1 : 5000 
    
GRP78 1.53 Cell Signalling, 3183 1 : 1000 
GRP84 1.49 Cell Signalling, 2104 1 : 1000 
 






3.2.8 Statistical Analysis 
 
MTS & Trypan Blue Assay:  MTS results of mitochondrial function and trypan blue 
data addressing cell viability following OGD treatments were expressed as a 
percentage of contemporaneous time matched controls.  Statistically significant 
changes in mitochondrial function and cell viability between control and 
experimental groups were detected using a two-tailed Students t-test using 
GraphPad Prism, version 5. 
 
Electron Microscopy:  Following blind assessment of organelle morphology, a Chi-
Squared 3 × 2 matrix was used to test the null hypothesis that OGD would have no 
effect on the ultrastructure of organelles.  The Chi-Squared analysis was done using 
GraphPad Prism, version 5. 
 
LC-MS Proteomics: Students t-tests were carried out in Microsoft Excel version 
2010 to determine significant differences in protein expression between control and 
OGD experimental groups.  A stringent probability of p < 0.01 was considered as 
statistically significant in order to reduce the detection rate of false positives. 
Proteins found to be significantly changed at p < 0.01 were uploaded to Ingenuity 
Pathway Analysis (IPA) software, where functional protein networks were 
generated.  Statistics carried out in Microsoft Excel were validated in GraphPad 
Prism, version 5.   
 
Western Blotting:  Significant changes in protein abundance as detected by western 
blotting and densitometry analysis were determined with a two-tailed Students t-test 









3.3.1 Mitochondrial Function, Cell Viability and Morphology after OGD  
 
Normal mitochondrial function was significantly reduced in SH-SY5Y cells 
following OGD relative to time-matched control cells (p<0.0001, at each time 
point analysed), with longer durations of OGD inducing more severe 
mitochondrial dysfunction (Figure 3.2).  Viability of SH-SY5Y cells treated with 
OGD was quantified using Trypan Blue staining (Figure 3.2).  Minimal cell death 
was detected after OGD, with 91% of cells remaining viable following 18h OGD. 
 
Consistent with the trypan blue analysis, gross morphological assessment 
shows at no time point is global cell death seen across a cell population (Figure 
3.3).  After 3- and 6 hours OGD, cell bodies remain elongated and adhered, with 
evidence of neurite outgrowth and interconnections present between cells.  At 
9h OGD cell bodies appear shrunken, with fewer neurites and inter cellular 
connections formed.  This phenotype is then consistently observed at 12 and 
18-hours.  At 9, 12 and 18-hours of OGD, the cellular response is heterogeneous, 
with a mixture of healthy and damaged cells in each condition.   
 
Ultra-structural morphological changes in subcellular organelles were analysed 
relative to time-matched controls by electron microscopy following OGD.  With 
increasing OGD duration, the number of cells displaying abnormal endoplasmic 
reticulum was significantly increased (Chi-Square, p<0.01) (Figure 3.4).  SH-SY5Y 
cells also showed changes in mitochondrial morphology with increasing OGD 
duration (Figure 3.4).   It should be noted that even after 18h OGD exposure, only 
26% of cells displayed abnormal ER, and only 34% had abnormal mitochondria.  
Analysis of the EM samples for the presence / absence of autophagy and lipid 
droplets showed evidence of both of these features.  However, there was no 
detectable change in the presence of autophagic vacuoles or lipid droplets 





Figure 3.2 The effect of increasing duration of OGD on mitochondrial 
function and cell death.  A. MTS assays following OGD exposure reveal 
mitochondrial function to be significantly reduced as a function of OGD 
duration, p<0.0001, n = 8.  Results are expressed as mean percentage of 
controls, +/- SEM.  B.  Cell viability is maintained up to 12h OGD, with an 
increase in cell death detected by trypan blue after 18h OGD.  Data are 
presented as mean +/- SEM, n = 3 for each time point.  All data are expressed 
as a percentage of contemporaneous time matched controls ( * p<0.05, *** p 





Figure 3.3 Temporal profile of morphological changes assessed 
visually using light microscopy.  Before OGD induction, cells are healthy, 
with stretched cell bodies and neurite outgrowths (green arrows).  There is 
little difference in SH-SY5Y morphology following 3 and 6-hours OGD.  With 
increasing OGD duration, cell morphology becomes progressively irregular, 
with shrunken cell bodies and retracted neurites (red arrows).  The cell 
populations following longer time points are heterogeneous, with a mixture 








Figure 3.4 The endoplasmic reticulum (ER) and mitochondria 
display progressive morphological changes following oxygen glucose 
deprivation (OGD).  A. OGD induced increases in the number of cells 
containing swollen and abnormal ER.  Significant changes in the 
distribution of “normal”, “swollen” and “abnormal” ER within cells was 
seen after 3, 9, and 18h OGD compared to the time matched controls (* 
p<0.05  ** p<0.01, X2, n = 50 cells for each condition)  B.  The occurrence 
of mitochondrial morphological abnormality increases following longer 
OGD durations (n = 50 cells for each condition) C.  Representative 
electron micrographs of the three grades of ER morphology. Scale bar = 
0.1μm.  D.  Representative electron micrographs of the three grades of 












Figure 3.5 Evidence of autophagy and lipid droplets are detected 
across all control and OGD cells.  A. 9 and 18h of OGD increases the 
number of cells containing autophagic vacuoles, however there is little 
difference between control and OGD cells (n = 50 cells for each condition)   
B.  The presence of lipid droplets is observed consistently in all cells after 
each OGD exposure (n = 50 cells for each condition)   C.  Representative 
electron micrograph of an autophagic vacuole (white arrow).  Scale bar = 
1μm.  D.  Representative electron micrograph of the appearance of lipid 









3.3.2 Overview of the LC-MS Proteomic Data 
 
A total of 958 proteins were identified across all samples with two or more 
peptides by LC-MS (Appendix B).  Minimal protein changes were observed 
following 6h OGD, with only 14 proteins significantly altered in expression level 
(p<0.01) (Table 3.2).  Following 18h OGD, 193 proteins were significantly 
altered in expression level (p<0.01), with 130 proteins increased and 63 
proteins decreased.  For 765 proteins, no significant differences were observed 
between control and OGD samples after 18h OGD.  The significantly increased 
and decreased proteins following 18h OGD are listed by subcellular location in 
Table 3.3 and Table 3.4 respectively. 
 
The subcellular distributions of all 958 proteins identified by LC-MS were 
examined using DAVID software.  Proteins were detected from across many 
subcellular compartments, including the nuclear lumen, cytoskeleton, 
mitochondria, endoplasmic reticulum, Golgi apparatus, ribosomes and vesicles 
(Figure 3.6).   Similar assessment of the 193 significantly altered proteins 
following 18h OGD indicates that organelles are not uniformly affected by the 
metabolic challenge.  None of the 197 detected nuclear lumen proteins were 
significantly altered after 18h OGD, whilst 41% of the 56 detected endoplasmic 
reticulum proteins and 32% of the 118 detected mitochondrial proteins were 










Figure 3.6 Subcellular distribution of all detected proteins contrasted with 
subcellular distribution of proteins significantly altered after 18h oxygen glucose 
deprivation (OGD) relative to their original levels in time matched control samples 
(p<0.01).  A. Liquid chromatography mass spectrometry (LC-MS) detected 958 proteins 
from across many subcellular compartments, demonstrating the utility of LC-MS in 
providing a global overview of cellular proteomics.  B.  Organelles are differentially 
affected by 18h OGD. The 193 significant altered proteins were not distributed evenly 
across subcellular compartments: the endoplasmic reticulum and the mitochondria 
contained the largest proportion of significantly altered proteins, whereas no significant 




3.3.3 Translation Initiation Factors are Significantly Down-regulated 
following 6h OGD 
 
Only 14 proteins were found to be significantly altered in expression level 
following 6h OGD (Table 3.2).  This small number of significantly altered 
proteins needs to be treated with caution:  with 958 proteins detected in the 
study, and at a significance threshold set at p<0.01, approximately 10 proteins 
would be expected to be “significantly altered” by chance alone.  Therefore the 
reliability of this small dataset is limited.   
 
However, a cautious inspection of the 14 changed proteins appears to show a 
functional response of proteins involved in protein synthesis pathways.  
Eukaryotic initiation factors EIF1, EIF4A1 and EIF3I are all significantly down-
regulated following 6h OGD, and remain down-regulated following 18h OGD to a 
similar or greater extent (Figure  3.7).  Other proteins involved in processes 
related to protein synthesis are detected as significantly down-regulated 

























P41567 EIF1 eukaryotic translation initiation factor 1 0.0035 0.72 Protein biosynthesis 
Q9Y678 COPG1 coatomer subunit gamma 0.0038 0.75 ER – Golgi transport 
A6NKG5 RTL1 retrotransposon-like protein 1 0.0016 0.75 Organism development 
Q8IV08 PLD2 phospholipase D3 0.0010 0.76 Lipid metabolism 
P20290 BTF3 transcription factor BTF3 isoform B 0.0013 0.77 Transcription 
P60842 EIF4A1 eukaryotic initiation factor 4A-I 0.00003 0.77 Protein biosynthesis 
Q15427 SF3B4 splicing factor 3B subunit 4 0.0099 0.81 mRNA processing 
P62841 RPS15 40S ribosomal protein S15 0.0019 0.83 Translation initiation 
Q9Y696 CLIC4 chloride intracellular channel protein 4 0.0079 0.84 Ion transport 
P31689 DNAJA1 dnaJ homolog subfamily A member 1 0.0062 0.85 Protein folding 
Q13347 EIF3I eukaryotic translation initiation factor 3  0.0025 0.85 Protein biosynthesis 
P13639 EEF2 elongation factor 2 0.0067 0.88 Protein biosynthesis 
Q15365 PCBP1 poly(rC)-binding protein 1 0.0033 0.92 RNA splicing 







Figure 3.7 Significant regulation of proteins involved in protein 
synthesis following 6h and 18h OGD.  6h OGD induces significant 
decreases in abundance of eukaryotic translation initiation factors 
EIF1, EIF31 and EIF4A1.  These decreases remain following 18h OGD.  






Table 3.3: Proteins Significantly Increased with 18h OGD 
 
Uniprot 
Accn No. Gene Name Protein Name p-value 
Fold 
change Protein Function 
MITOCHONDRIA: 
P30048 PRDX3 Peroxiredoxin III 0.0006 1.57 Cell redox homeostasis 
P61604 HSPE1 10kDa Heat Shock Protein 6.1E-06 1.51 Stress response 
P18859 ATP5J ATP synthase-coupling factor 6 0.0016 1.44 ETC complex V 
O75489 NDUFS3 NADH-ubiquinone oxidoreductase 30kDa subunit 0.0030 1.38 ETC complex I 
P24752 ACAT1 Acetyl-CoA acetyltransferase 9.1E-05 1.38 Ketone body metabolism 
P09622 DLD Dihydrolipoyl dehydrogenase 0.0051 1.36 Gycine cleavage 
Q9UJZ1 STOML2 Stomatin-like protein 2 0.0052 1.36 Receptor binding 
P09972 ALDOC Fructose-bisphosphare aldolase C 0.0061 1.34 Glycolysis 
P38606 ATP6V1A V-type proton ATPase catalytic subunit A 0.0067 1.33 ATP hydrolysis transport 
P13804 ETFA Electron transfer flavoprotein subunit alpha 0.0005 1.33 Respiratory ETC 
P30084 ECHS1 Enoyl-CoA hydratase 0.0043 1.33 Fatty acid metabolism 
P40926 MDH2 Malate dehydrogenase 0.0009 1.32 Citric acid cycle 
P10809 HSPD1 60kDa Heat Shock Protein 0.0012 1.31 Protein folding 
P62258 YWHAE 14-3-3 protein epsilon 0.0056 1.30 Apoptosis 
P04181 OAT Orthinine aminotransferase  0.0012 1.30 Amino acid biosynthesis 
Q13011 ECH1 Delta (3,5)-delta(2,4)-dienoyl-CoA isomerase 0.0048 1.28 Lipid metabolism 
Q99714 HSD17B10 3-hydroxyacyl-CoA dehydrogenase type 2 0.0037 1.27 Lipid metabolism 
P07954 FH Fumarate hydratase 0.0038 1.27 Citric acid cycle 
P30044 PRDX5 Peroxiredoxin 5 0.0014 1.26 Redox homeostasis 
P42765 ACAA2 3-ketoacyl-CoA thiolase 0.0067 1.26 Lipid metabolism 
P25325 MPST 3-mercaptopyruvate sulfurtransferase 0.0012 1.25 Response to Toxins 
P30086 PEBP1 Phosphatidylethanolamine binding protein 1 0.0067 1.24 Protease inhibition 
P25705 ATP5A1 ATP synthase subunit alpha 0.0019 1.21 ETC complex V 
Q06830 PRDX1 Peroxiredoxin 1 0.0009 1.20 Redox Homeostasis 
P43686 PSMC4 26S protease regulatory subunit 6B 0.0007 1.20 Protein degradation 
Q16718 NDUFA5 NADH-ubiquinone oxidoreductase 13kDa subunit 0.0022 1.20 ETC complex I 
O00154 ACOT7 Cytosolic acyl-coenzyme A thioester hydrolase 0.0009 1.19 Acyl-CoA hydrolysis 
Q00610 CLTC Clathrin heavy chain 1 4.9E-05 1.16 Endocytosis 
P12277 CKB Creatine Kinase B type 0.0027 1.16 Creatine metabolism 
ENDOPLASMIC RETICULUM: 
O60568 PLOD3 Procollagen-lysine 2-oxoglutarate 5-dioxygenase 3 7.7E-05 1.87 Lysyl hydroxylation 
P27797 CALR Calreticulin 1.0E-07 1.56 Protein folding 
P11021 GRP78 Glucose regulated protein 78 3.9E-05 1.53 Protein complex assembly 
P14625 GRP94 Glucose regulated protein 94 5.5E-05 1.49 Protein transport 
P30101 PDIA3 Protein disulphide isomerase A3 2.7E-05 1.45 Protein folding 
Q16799 RTN1 Reticulon 1 0.0055 1.41 Neuron differentiation 
Q8NBS9 TXNDC5 Thioredoxin-domain containing protein 5 0.0017 1.40 Cell redox homeostasis 
P13667 PDIA4 Protein disulphide isomerase A4 1.4E-05 1.38 Cell redox homeostasis 
Q9Y2B0 CNPY2 Protein canopy homolog 2 0.0051 1.38 Protein binding 
Q15084 PDIA6 Protein disulfide isomerase A6 6.1E-06 1.37 Chaperone 
P54920 NAPA Alpha soluble NSF attachment protein 0.0003 1.35 ER-golgi vesicle transport 
P14314 PRKCSH Glucosidase 2 subunit beta 0.0016 1.33 Glycoprotein formation 
Q9NQC3 RTN4 Reticulon 4 0.0033 1.32 Neurogenesis / apoptosis 
Q14697 GANAB Neutral alpha-glucosidase AB/GNAB protein 0.0018 1.27 Glycoprotein cleavage 
P07237 P4HB Protein disulfide-isomerase 0.0073 1.25 Redox homeostasis 
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 0.0007 1.23 ER stress response 




P30040 ERP29 Endoplasmic reticulum resident protein 29 0.0003 1.23 ER protein folding 
P55072 VCP Valosin-containing protein 0.0069 1.15 ER stress response 
RIBOSOMES: 
P69905 HBA1 Haemoglobin subunit alpha 0.0003 1.97 O2 transport 
VESICLE: 
O15240 VGF Neurosecretory protein VGF 0.0035 1.39 Cell-cell interactions 
P08133 ANXA6 Annexin 6 0.0075 1.18 Ca2+ binding 
P21281 ATP6V1B2 V-type proton ATPase subunit B 0.0098 1.16 H+ ion transport 
P07900 HSP90AA1 Heat Shock Protein HSP90-alpha 0.0030 1.11 Stress response 
Q9BTT0 ANP32E Acidic leucine-rich nuclear phosphoprotein 32E 0.0034 1.08 Phosphatase inhibitor 
CYTOSKELETON: 
P52907 CAPZA1 F-actin capping protein subunit alpha 1 0.0039 1.35 Protein complex assembly 
P16949 STMN1 Stathmin 0.0029 1.32 Microtubule disassembly 
Q9Y230 RUVBL2 RuvB like 2 0.0037 1.31 Transcription 
P47756 CAPZB F-actin-capping protein subunit beta 3.2E-05 1.25 Protein complex assembly 
Q03252 LMNB2 Lamin B2 0.0076 1.24 Cytoskeleton regulation 
Q16352 INA Alpha-internexin 4.9E-05 1.24 Neurogenesis 
P07437 TUBB  Tubulin beta chain 0.0016 1.23 Microtubule constituent 
P36405 ARL3 ADP-ribosylation factor-like protein 3 0.0071 1.23 Cell Division 
P61163 ACTR1A Alpha centractin 0.0029 1.23 Vesicle mediated transport 
Q9UJU6 DBNL Debrin-like protein 0.0095 1.18 Endocytosis 
Q16658 FSCN1 Fascin 0.0018 1.18 Cytoskeleton organisation 
P62158 CALM Calmodulin 0.0059 1.17 Calcium modulation 
Q9BZK7 TBL1XR1 F-box like/WD repeat containing protein TBL1XR1 0.0046 1.17 Protein degradation 
P49773 HINT1 Histidine triad nucleotide-binding protein 1 0.0002 1.15 Signal transduction 
P43487 RANBP1 Ran-specific GTPase-activating protein 0.0029 1.15 Signal transduction 
SPLICEOSOME: 
Q07955 SRSF1 Serine/Arginine rich splicing factor 1 1.1E-05 1.42 mRNA splicing 
Q01081 U2AF1 Splicing factor U2AF 35kDa subunit 0.0062 1.23 mRNA splicing 
Q15029 EFTUD2 116kDa U5 small nuclear ribonucleoprotein  0.0069 1.19 mRNA splicing 
PROTEOSOME: 
Q15008 PSMD6 26s proteasome non ATPase regulatory subunit 6 0.0053 1.61 Protein degradation 
P17980 PSMC3 26S protease regulatory subunit 6A 0.0071 1.27 Protein degradation 
Q13200 PSMD2 26S proteasome non-ATPase regulatory subunit 2 0.0005 1.22 Protein degradation 
P54727 RAD23B UV excision protein RAD23 homolog B 0.0009 1.22 Protein degradation 
Q99460 PSMD1 26S proteasome non-ATPase regulatory subunit 1 0.0002 1.18 Protein degradation 
O00231 PSMD11 26S proteasome non-ATPase regulatory subunit 11 0.0008 1.18 Protein degradation 















Name Protein Name p-value 
Fold 
change Protein Function 
MITOCHONDRIA: 
P21796 VDAC1 Voltage-dependent anion selective channel protein 1 0.0079 0.26 Ion transport 
P22695 UQCRC2 Cytochrome b-c1 complex subunit 2 0.0017 0.31 ETC complex III 
P31930 UQCRC1 Cytochrome b-c1 complex subunit 1 0.0097 0.46 ETC complex III 
Q9NS69 TOM22 Translocase of outer membrane 22kDa subunit  0.0027 0.46 Protein transport  
Q9Y3E5 BIT1 Peptidyl-tRNA hydrolase 2 0.0038 0.51 Apoptosis 
P02786 TFRC Transferrin receptor protein 1 0.0002 0.58 Endocytosis 
O75534 CSDE1 Cold shock domain containing protein E1 1.0E-06 0.62 Transcription 
Q9Y6H1 CHCHD2 Coiled-coil helix–coiled-coil helix domain protein 2 0.0099 0.70 Unknown 
P11310 ACADM Medium chain specific acyl-CoA dehydrogenase 0.0084 0.79 Lipid metabolism 
ENDOPLASMIC RETICULUM: 
Q81V08 PLD3 Phospholipase D3 0.0016 0.61 Lipid degradation 
Q96AG4 LRRC59 Leucine rich repeat-containing protein 59 0.0048 0.64 ER membrane interactions 
P13637 ATP1A3 Na+/K+ ATPase alpha (III) subunit 0.0008 0.67 ATP hydrolysis catalyst 
P04843 RPN1 Ribophorin 1 0.0094 0.68 Glycosyltransferase activity 
RIBOSOMES: 
P63173 RPL38 60s ribosomal protein L38 0.0001 0.65 Protein biosynthesis 
P62249 RPS16 40S ribosomal protein S16 7.9E-05 0.70 Protein biosynthesis 
P35544 FAU Ubiquitin-like protein FUB 1 0.0012 0.70 Ubiquitination modulation 
P62263 RPS14 40S ribosomal protein S14 0.0004 0.74 Protein biosynthesis 
P62829 RPL23 60S ribosomal protein L23 5.3E-05 0.74 Protein biosynthesis 
P62266 RPS23 40S ribosomal protein S23 0.0004 0.76 Protein biosynthesis 
P46781 RPS9 40S ribosomal protein S9 0.0002 0.78 Protein biosynthesis 
P08708 RPS17 40S ribosomal protein S17 0.0004 0.80 Protein biosynthesis 
P42766 RPL35 60S ribosomal protein L35 0.0018 0.82 Protein biosynthesis 
P26373 RPL13 60S ribosomal protein L13 0.0004 0.84 Protein biosynthesis 
VESICLE: 
P07355 ANXA2 Annexin A2 0.0038 0.49 Ca2+ binding 
P62491 RAB11A Ras-related protein Rab 11A 0.0026 0.76 Endocytic cycling 
P07858 CTSB Cathepsin B 0.0053 0.85 Protein degradation 
CYTOSKELETON: 
P06493 CDK1 Cyclin-dependent kinase 1 0.0022 0.57 Cell cycle control 
P28289 TMOD1 Tropomodulin 1 0.0005 0.64 Cytoskeleton organisation 
Q01518 CAP1 Adenylyl cyclase-associated protein 1 4.7E-06 0.70 Signal transduction 
Q9UQE7 SMC3 Structural maintenance of chromosomes protein 3 0.0084 0.71 Cell cycle 
P18206 VCL Viniculin 0.0067 0.78 Cell adhesion 
Q01082 SPTBN1 Spectrin beta chain brain 1 0.0092 0.81 Cytoskeleton movement 
SPLICEOSOME: 
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 2.9E-06 0.58 mRNA processing 
Q9UKM9 RALY RNA-binding protein Raly 0.0014 0.66 mRNA splicing 
Q86V81 THOC4 THO complex subunit 4 0.0007 0.75 mRNA splicing 
O43143 DHX15 Pre-mRNA splicing factor ATP-dep. RNA helicase 5.5E-06 0.78 mRNA splicing 




3.3.4 Key Mitochondrial Energy Metabolism Proteins are Significantly 
Altered following 18h OGD 
 
193 proteins showed significant changes in abundance between control samples 
and samples treated with 18h OGD.   The large number of significantly altered 
proteins allows functional protein-protein interactions to be defined using IPA 
software.  IPA generated 10 protein interactomes (Appendix C).  Three high-
scoring interactomes (IPA scores > 40) highlight a shift in mitochondrial energy 
production, enhanced endoplasmic reticulum stress and ribosomal dysfunction 
which are discussed in more detail below. 
 
38 mitochondrial proteins (out of 118 detected; assigned using the GO term 
mitochondrion GO:0005739) were significantly altered following OGD (18h): 29 
were increased and 9 were decreased.  VDAC1 and TOM22, proteins involved in 
mediating the movement of metabolites across the mitochondrial membrane, 
were significantly reduced after OGD. UQCRC1 and UQCRC2, integral 
components of complex III of the electron transport chain (ETC), were also 
significantly reduced.  Coordinated changes in other regions of the ETC were 
observed after 18h OGD treatment:   ETC complex V proteins ATP5J and 
ATP5A1, and ETC complex I proteins NDUFS3 and NDUFA5 were all 
significantly increased (p<0.01, Figure 3.8).  Western blotting of the original 
samples sent to LC-MS confirmed these detected energy metabolism protein 
changes (Figure 3.9). 
 
The highest scoring protein interactome generated by IPA features some of the 
alterations in energy production described above, namely increases in Complex  
V proteins (including ATP5J and ATP5A1) and decreases in Complex III proteins 
(UQCRC1 and UQCRC2) (Figure 3.10).  This Energy Production Interactome also 
highlights interactions between altered components of the ETC and other 
cellular machinery.  UQCRC1 and UQCRC2 both interact with RTN4, a protein 




regulated following OGD.  UQCRC2 is also shown to interact with up-regulated 
RUVBL2, a cytoskeletal protein involved in numerous cellular activities 
including transcription and cellular transformation.  The Energy Production 
Interactome also contains a cluster of ribosomal proteins that are distinct but 
intersect with the ribosomal interactome described below. 
 
Concurrent with the dysregulation of the oxidative phosphorylation pathway 
outlined above, 18h OGD also induces alterations in mitochondrial proteins 
involved in lipid and ketone metabolism.  Acetyl-CoA acetyltransferase 1 
(ACAT1) and 3-hydroxybutyrate dehydrogenase type 2 (BDH), key proteins 
involved in ketone metabolism, are significantly up-regulated following 18h 
OGD (P<0.01 and p<0.05, respectively) (Figure 3.11).  The 4 proteins involved in 
mitochondrial beta-oxidation of fatty acids also showed altered expression 
profiles following 18h OGD.  Acyl-CoA dehydrogenase (ACAD), the enzyme 
involved in the first step of fatty acid beta-oxidation, was significantly down-
regulated , whereas Enoyl CoA hydratase (ECHS1), Hydroxyacyl CoA 
Dehydrogenase (HSD17B10),  and 3-ketoacyl-CoA thiolase (ACAA2) were all 





Figure 3.8 Bidirectional changes in the proteins of the electron transport chain (ETC).  A. 18h OGD causes significant 
increases in complex 1 (NDUFS3 and NDUFA5) and complex 5 (ATP5A1 and ATP5J) proteins, with concurrent decreases in 
complex III proteins UQCRC1 and UQCRC2.  B.  Scatter plots of the protein changes detected by LC-MS between control and 
OGD (18h).  Each data point represents an independent sample with the mean abundance line shown.  (** p<0.01, T-test, n = 6 





Figure 3.9 Western Blot confirmation of selected LC-MS detected protein changes 
associated with energy production and metabolic stress.    UQCRC1, UQCRC2, 
VDAC1 and TOM22 are all detected by LC-MS as significantly down-regulated following 
18h OGD.  Western blotting of the original samples sent for LC-MS analysis confirms 
these results with an independent experimental technique.  (* above western blots 






Figure 3.10 Energy Production Interactome.  A.  One of the highest scoring Ingenuity 
Pathway Analysis (IPA) networks gained from the 18hr OGD proteomic data set is 
presented.  The network contains numerous proteins involved in mitochondrial energy 
production.  The coloured nodes indicate proteins detected in our study as significantly 
altered by OGD. Red nodes are up-regulated proteins, green nodes are down-regulated.  
Un-shaded nodes were manually inserted by IPA to augment functional coherence. Only 
direct protein – protein interactions were included in the analysis.  B.  Complex III 
subunits 1 and 2 (UQCRC1 / UQCRC2) interact with RTN4 and RUVBL2, both are 





Figure 3.11 Ketone metabolism and fatty acid beta-oxidation proteins are 
significantly altered by OGD.  A.  Key proteins involved in ketone metabolism (ACAT 
and BDH) are significantly up-regulated in SH-SY5Y cells challenged with OGD (18h).  B.  
ACAD, the first protein in the process of beta-oxidation of fatty acids, is significantly 
decreased following OGD (18h).  The subsequent three proteins (ECHS1, HSD17B10 & 






3.3.5 Protein Homeostasis Pathways are Significantly Altered following 
18h OGD  
 
23 ER proteins (out of 56 detected; assigned using the GO term Endoplasmic 
reticulum GO:0005783) were significantly altered following 18h OGD: 19 were 
increased and 4 were decreased.  A number of proteins centrally involved in the 
UPR were significantly increased, including, GRP78 (aka BiP / HSPA5), GRP94 
(aka HSP90B1), PDIA3 and PDIA4 (p<0.01) (Figure 3.12). Western blotting 
confirmed the significant up-regulation of GRP78 and GRP94 (Figure 3.13).   
Other proteins including CALR, UGGT1, ERP29, ERP44 and VCP that are integral 
to ER stress response and protein folding were significantly increased.   
 
Multiple proteins that play a role in protein degradation were significantly 
altered following OGD (18h).  Protein subunits of the 20S and 19S core 
structures of the 26S proteasome (PSMA5, PSMC3, PSMC4, PSMD1, PSMD2, 
PSMD6 and PSMD11) were increased.  These proteasomal proteins, along with 
proteins involved in the UPR and heat shock response following OGD dominate 
the high scoring, Protein Folding and Degradation Interactome generated by IPA 











3.3.6 Ribosomal Protein Alterations are Detected following 18h OGD 
 
11 ribosomal proteins (out of 82 detected; assigned using the GO term Ribosome 
GO:0005840) were significantly altered following 18h OGD: 1 was increased 
and 10 were decreased.  The decreased ribosomal proteins were associated 
with both the 60S (RPL38, RPL23, RPL35 and RPL13) and 40S (RPS1, RPS14, 
RPS23, RPS9 and RPS17) ribosomal subunits (Figure 3.14).  These down-
regulated ribosomal proteins feature prominently in another of the high scoring 
energy production protein interactome generated by IPA (Figure 3.10).  An 
additionally important feature of this Ribosomal Interactome is the cluster of up-
regulated peroxidases (PRDX1, PRDX2 and PRDX5) (Figure 3.14) involved in 
redox homeostasis and protecting neurons from oxidative insults.  For a review 





Figure 3.12 Protein folding and degradation interactome.  A.  A high scoring 
Ingenuity Pathway Analysis (IPA) network generated from the 18hr OGD proteomic 
data contained proteins involved in protein folding and degradation.  B.  Key 
proteins involved in protein folding and the endoplasmic reticulum stress response 
(GRP78 / GRP94 / PDIA3 / PDIA4) are significantly altered by OGD (18h). Each data 










Figure 3.13 Western Blot Confirmation of selected LC-MS detected protein 
changes associated with protein folding and ER stress.    GRP78 and GRP94 are 
detected by LC-MS as significantly up-regulated following 18h OGD.  Western 
blotting of the original samples sent for LC-MS analysis confirms these results with 
an independent experimental technique (* above western blots indicate OGD 




Figure 3.14 40S Ribosome Interactome.  A.  A further high scoring IPA network 
was dominated by the down-regulation of 40S ribosomal proteins and cell stress 
response proteins.  B.  Representative ribosomal proteins (RPS9 / RPS16) and 
the cellular stress response proteins (PRDX1 / PRDX2) are significantly altered 
by OGD (18h). Each data point represents an independent sample (** p<0.01, *** 






In the present study, undifferentiated SH-SY5Y cells were exposed to OGD and 
the proteomic changes underpinning mitochondrial dysfunction were 
examined.  The absence of pilot data, and thus the unknown coefficient of 
variance associated with the proteomic set up, limited the utility of a priori 
power analysis in determining an appropriate detectable fold change cut-off for 
this study.  A stringent p-value of p<0.01 was therefore chosen to reduce the 
risk of detection of false positives within the proteomic data.  At present there is 
no accepted standard for identifying and reporting significant changes within 
the proteomic literature, with a range of p-value and fold change cut-offs 
employed to detect important and relevant protein responses (Andreev et al., 
2012, James et al., 2012b, Wishart et al., 2012, Liao et al., 2004).  The need for 
careful experimental design in proteomic research is discussed in more detail in 
Section 6.    
 
The present study showed SH-SY5Y cells to be exceptionally robust under 
conditions of metabolic stress.  The light microscopy and trypan blue assays 
show that despite significant reductions in mitochondrial function, there was 
little evidence of a global cell death response.  This robust nature of SH-SY5Y 
cells demonstrated in the initial characterisation phase allowed the evolving 
proteomic changes occurring in response to OGD induced metabolic stress to be 
defined, in the absence of cell death.  Further work, including the inclusion of 
positive control experiments, as well as additional characterisation of the 
cellular response to OGD (for example, recording changes in mitochondrial 
membrane potential, or measuring the rate of reactive oxygen species 
production) would provide a more complete insight as to the cellular response 




Protein synthesis machinery is regulated following a moderate metabolic 
challenge (6h OGD) 
 
6h OGD exposure induced moderate mitochondrial dysfunction in the SH-SY5Y 
cells compared to time matched controls.  However, despite the significant 
reduction in mitochondrial function, LC-MS proteomics detected only minimal 
protein changes, with only 14 proteins significantly altered in expression level 
(p<0.01).  Within the list of nearly 1000 detected proteins, approximately 10 
proteins would be expected to be altered by chance alone at a significance level 
of p<0.01.  However, cautious inspection of the 14 significantly altered proteins 
identified eukaryotic initiation factors EIF1, EIF4A1 and EIF3I all to be 
significantly down-regulated following 6h OGD.  These proteins remain down – 
regulated to a similar or greater extent at 18h OGD treatment, suggesting a 
functional relevance at 6h OGD.   
 
Eukaryotic translation initiation factors (EIFs) are involved in the assembly of 
ribosomal complexes.  EIF1 has been shown to promote an open conformation 
of the ribosomal complex that then scans the mRNA sequence in search of the 
start codon.  Once the start codon has been recognised, EIF1 is released, and the 
ribosome stabilises around the mRNA, allowing translation to begin (Passmore 
et al., 2007).   The significant down regulation of the EIFs following 6h OGD may 
be an initial attempt by the cell to conserve energy through disruption of the 
protein synthesis processes.   
 
However, following 18h OGD, of the 193 significantly altered proteins, 130 of 
these were significantly up-regulated.  This data suggests that key proteins 
needed to respond to metabolic stress are still being translated, despite the 
decreased levels of EIFs in the earlier stages of OGD.  Significant decreases in the 
ribosomal machinery itself are detected following 18h OGD (discussed later in 
this section).  It is therefore possible that these early decreases in EIFs might be 
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indicative of later ribosomal and cellular dysfunction.  Further work using EIF 
overexpression and knockdown would be useful in determining the full effect of 
EIF dysregulation on cellular function.    
 
 Significant mitochondrial protein changes accompany the decrease in 
mitochondrial function under conditions of severe metabolic stress (18h OGD) 
 
Concurrent with the large reduction in mitochondrial function and the 
mitochondrial swelling observed with EM, the proteomic data showed many 
significant changes in mitochondrial proteins following at 18h OGD.  Two of the 
most markedly decreased proteins following 18h OGD were subunits 1 and 2 
(UQCRC1 and UQCRC2) of ETC complex III, a result confirmed by western blot 
analysis.  Complex III is the third component of the ETC located within the inner 
mitochondrial membrane. Complex III mediates the transfer of electrons from 
ubiquinone to cytochrome C, and in doing so translocates a proton into the 
inner-membrane space and contributes to the generation of the electrochemical 
gradient used for the production of ATP (Iwata et al., 1998).  Down-regulation of 
the complex III subunits might therefore be a proteomic correlate of the 
mitochondrial dysfunction recorded with the MTS assay.   
 
Complex III is also intrinsically involved in the generation of reactive oxygen 
species (ROS) from the mitochondria during hypoxia, which can be highly 
damaging to the cellular architecture if antioxidant systems become 
overwhelmed (Guzy et al., 2005).  A significant decrease in UQCRC1 and 
UQCRC2 might therefore be an attempt by the cells to reduce the production of 
ROS from the mitochondria under these metabolically stressful conditions.  
Interestingly, UQCRC1 has also been recorded as significantly decreased in the 
brains of AD patients (Kim et al., 2000).  The similar decrease in UQCRC1 
expression observed in AD patients and cells in vitro following OGD may provide 
a link between chronic oxidative challenge and the onset and progression of AD.   
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The Energy Production Interactome (Figure  3.10) also highlights putative 
functional protein-protein interactions between UQCRC1, UQCRC2 and reticulon 
4 (RTN4, a protein increased following 18h OGD).  RTN4 is increased in 
hippocampal neurons of AD patients(Gil et al., 2006) and is known to interact 
with BACE1, reducing Aβ40 and Aβ42 levels(Murayama et al., 2006).  The 
dysregulation of RTN4 following a metabolic challenge (18h OGD), its 
interaction with complex III proteins, and its potential role in APP processing, 
highlights RTN4 as a compelling target for future investigation.   
 
Mitochondrial complex I and V proteins were significantly increased in 
expression after OGD in sharp contrast to the reduction in complex III proteins.  
Complex I is the first protein complex of the ETC, and initiates the transfer of 
electrons through the ETC, generating the energy required for oxidative 
phosphorylation.  The process is initiated through binding and oxidation of 
NADH, with the concurrent transfer of 2 electrons from NADH to ubiquinone, 
and the translocation of 4 protons into the intermembrane space (Janssen et al., 
2006).  An increase in Complex I proteins following OGD may reflect a 
compensatory mechanism to counteract the impact of decreased complex III 
proteins on energy production.  Similarly, the increase in Complex V proteins 
may reflect a compensation for down-regulated Complex III proteins or a 
general remodelling of the ETC, as has previously been shown in studies 
investigating ischemic preconditioning (Arrell et al., 2006).   Functional assays 
of the five complexes that constitute the ETC, in ischemic conditions will need to 
be carried out to confirm whether such remodelling occurs.  Furthermore, 
determining the regulatory mechanisms of these protein changes could provide 
valuable insight that would allow therapeutic intervention to alter the course of 





Changes in lipid and ketone metabolism proteins indicate a possible shift in energy 
processes under conditions of severe metabolic stress (18h OGD)  
 
In addition to the proteomic changes occurring in the mitochondrial electron 
transport chain, the metabolic challenge of 18h OGD induced changes in 
abundance of mitochondrial proteins associated with lipid and ketone 
metabolism.  The changes in these proteins (ACAT1 in ketone metabolism, and 
ACADM, ECH1, HSD17B10 and ACAA2 in lipid metabolism) indicate a shift 
towards utilising lipid and ketone bodies as alternative sources of energy for 
SH-SY5Y cells faced with glucose restriction.   
 
The availability of alternative cerebral energy sources is likely to be important 
in preventing cells hitting the point where energy provision is insufficient for 
cell survival, described by De la Torre as the Critically Attained Threshold of 
Cerebral Hypoperfusion, (CATCH) (de la Torre, 2000).   CATCH is the point at 
which brain circulation is impaired to an extent where oxygen, glucose and 
other nutrients are delivered sub-optimally to neurons, leading to a downward 
spiral of metabolic and cognitive decline, with the accompanying pathology 
associated with AD.  If alternative energy sources such as ketones could be 
utilised by neurons, it is feasible that CATCH could be avoided, and that 
restoration of neuronal metabolism to a level which meets the energy 
requirements of these cells might be achieved.   
 
The potential therapeutic role for ketones in neurodegenerative diseases is 
beginning to be investigated.  In AD, accumulation of amyloid fragment AB1-42 is 
toxic to neurons, especially to those associated with learning and memory 
formation within the hippocampus.  In vitro work has shown ketone body d-B-
hydroxybutyrate to be neuroprotective to hippocampal neurons exposed to 
Aβ42 in culture (Kashiwaya et al., 2000). The basis of this protection is unclear, 
however, it may be linked to the finding that Aβ 1-42 induces phosphorylation 
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of pyruvate dehydrogenase (PDH), causing PDH inhibition and a block in the 
early stages of the citric acid cycle (Hoshi et al., 1997).  Ketones have the ability 
to bypass blocks in the citric acid cycle, ensuring a continuation of NADH 
production for oxidative phosphorylation.  
 
In addition, recent studies using  the  triple transgenic mouse model of AD 
demonstrated that induction of ketogenesis through use of a 2-deoxy-D-glucose 
diet increased levels of ketone metabolizing enzymes, activated non-
amyloidogenic APP processing pathways, reduced Aβ pathology and reduced 
oxidative stress (Yao et al., 2011).  Our results show that under metabolic 
challenge cells up regulate proteins associated with ketone metabolism, 
potentially in an attempt to source alternative energy supplies when faced with 
long term OGD.  When taken with the other ketone related experimental 
findings discussed here, it is clear that ketones and ketone metabolism provide 
an attractive avenue for further work in efforts to overcome the neuronal 
energy crisis in AD, both as an alternative energy source when glucose delivery 
is impeded by CCH, and also as a potential novel neuroprotectant.   
 
To utilise ketones as an alternative energy source in the brain, acetoacetate and 
b-hydroxybutyrate (the main ketone bodies used for energy) need to be 
synthesised from acetyl-coA.  Acetyl-coA is released following beta-oxidation of 
fatty acids, a four step process within the mitochondrial matrix requiring beta-
oxidation enzymes at each stage (namely, ACAD, ECH1, HSD17B10 and ACAA2).  
Each of these beta-oxidation enzymes, as noted above, was significantly altered 
following 18h OGD.  What is observed in the beta-oxidation protein changes is 
that Acyl CoA Dehydrogenase (ACAD, the first protein in the enzyme chain) is 
down-regulated following 18h OGD.  The 3 following proteins are up-regulated, 
in what may be construed as a compensatory up-regulation profile.  Why the 
cells might benefit from a down-regulation of ACAD at the front end of the beta-
oxidation pathway, when production of acetyl coA for ketogenesis would appear 
to be a good option for an alternative energy source, remains to be elucidated.   
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Of note, the third beta-oxidative enzyme HSD17B10 (also known as amyloid 
binding alcohol dehydrogenase, ABAD), was significantly up-regulated following 
OGD.  ABAD is emerging as an important player in AD, shown to directly interact 
with Aβ in the mitochondria of AD patients and AD transgenic mouse models.  
Inhibition of the ABAD-Aβ interaction suppresses induced apoptosis by 
increasing levels of Aβ, and conversely overexpression of ABAD in transgenic 
mice with high levels of Aβ has been shown to cause heightened neuronal 
oxidative stress and memory impairments (Lustbader et al., 2004).  The direct 
involvement of ABAD in AD pathophysiology makes ABAD a very interesting 
candidate to investigate further in terms of its up-regulation upon metabolic 
challenge.   
 
Beta-oxidation of fatty acids is a process traditionally recognised to occur in 
the liver, with subsequent delivery of these ketone bodies to the brain.  Here it 
is demonstrated that the SH-SY5Y neuroblastoma cell line express the enzymes 
needed for beta-oxidation, indicating a capability of these neuronal cells to 
bypass the liver and carry out beta-oxidation of fatty acids to produce ketones 
themselves.  If this were to be the case, the source of fatty acids for beta-
oxidation from within the cell line needs to be established.   
 
Fatty acids are stored in dynamic organelles called lipid droplets within cells.  
Lipid droplets rapidly form when there are increased levels of free fatty acids, 
in a process involving  budding from the endoplasmic reticulum membrane 
(Martin and Parton, 2006).  During nutrient shortages it is known that cellular 
lipids stored within lipid droplets are hydrolysed to fatty acids for energy 
supply.  EM analysis showed lipid droplets to be present in SH-SY5Y cells 
under both control and OGD conditions, suggesting lipid droplets to potentially 




Lipid droplets are also a main site of cholesterol storage, and are involved in 
the regulation of the amount of free cholesterol within the cell (Martin and 
Parton, 2006).  Cholesterol has been shown to influence the processing of APP. 
In vivo work showed that rabbits fed with 1% cholesterol have increased 
BACE1 levels (Ghribi et al., 2006).  It might therefore be hypothesised that lipid 
droplets, and their role in cholesterol homeostasis, might influence Aβ 
generation in AD.  Indeed, ultra-structural examination of AD tissue identified 
the number of lipid droplets to be higher in neurons positive for Aβ than in 
neurons with little Aβ immunoreactivity (Gomez-Ramos and Asuncion Moran, 
2007).   The specific role of the lipid droplets within the SH-SY5Y cells 
examined in this study remains to be elucidated.  However, the storage of lipids 
within these droplet structures, and their role in cholesterol homeostasis may 
provide important insight into part of the cellular changes in AD.   
 
Another cellular tactic to obtain energy substrates during an energy crisis is to 
induce autophagy, where proteins and organelles are broken down in 
lysosomes to obtain free energy (Zechner and Madeo, 2009).  Recent work 
investigating both lipid droplets and autophagy showed a complex interplay 
between the two components, termed macrolipophagy.  Inhibition of 
autophagy in in vitro hepatocyte cells caused increased fat storage in lipid 
droplets, and lipid droplet structural proteins were demonstrated to be co-
localised with autophagic compartments (Singh et al., 2009).   
 
If SH-SY5Y cells are capable of beta-oxidation of fatty acids to produce the 
excess acetyl coA needed for ketogenesis, it is possible that macrolipophagy 
might be the source of fatty acids to drive this process.  The case for the 
prediction of an involvement of autophagy in lipid metabolism being involved 
in the response of cells to OGD is strengthened by the fact that endoplasmic 
reticulum stress triggers autophagy (Yorimitsu et al., 2006), discussed in more 
detail below.  Electron microscopy images reveal the presence of lipid droplets 
and autophagosomes in the majority of SH-SY5Y cells.  Coupled to the 
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compelling proteomic changes associated with lipid and fatty acid metabolism, 
there is evidence for a switch to alternative energy metabolism in SH-SY5Y 
cells in response to oxygen – glucose deprivation.     
 
Key mitochondrial pore forming proteins are significantly decreased under 
conditions of severe metabolic stress (18h OGD)  
 
Key pore forming proteins VDAC1 and TOM22 were significantly down-
regulated following OGD, a result confirmed by western blot analysis.  VDAC 
proteins are located in the outer mitochondrial membrane and form a pore for 
the movement of substances in and out of the mitochondria.  Studies using 
liposomes carrying the VDAC channel proteins show VDAC channels to be 
targeted by pro-apoptotic Bax and Bak, causing the channel to open and 
allowing the passage of pro-apoptotic cytochrome c  (Shimizu et al., 1999).  It 
may therefore be hypothesised that the significant down-regulation of VDAC1 
following 18h OGD may be an apoptosis aversion mechanism, reducing the 
availability of VDAC to bind Bax and Bak, and averting the release of cytochrome 
c.   
 
TOM22 is another mitochondrial pore forming proteins that is significantly 
decreased following 18h OGD treatment.   A recent study utilising a bacterial 
two-hybrid assay identified TOM22 to be a mitochondrial receptor of pro-
apoptotic BAX.  Moreover, antisense knock-down of TOM22 expression 
inhibited the BAX – mitochondrion association and prevented apoptosis (Bellot 
et al., 2007).  It might therefore be hypothesised that the significant down-
regulation on TOM22 in the 18hr OGD model is an attempt by the cells to avoid 
the initiation of BAX mediated apoptosis.  This hypothesis is supported by the 
lack of cell death observed by the trypan blue assay following 18h OGD.  
However, further work investigating the specific associations of BAX and 
TOM22 under both control and OGD conditions, as well as specific measure of 




ER stress response proteins are central to the response of SH-SY5Y cells to severe 
metabolic stress (18h OGD) 
 
A major proteomic response in the endoplasmic reticulum was identified 
following OGD.  The ER stress response (also known as the unfolded protein 
response, UPR) is a cellular reaction activated to clear misfolded proteins that 
accumulate in the ER under conditions of cell stress, thus returning the cell to a 
state of proteostasis(Scheper et al., 2011).  Two central molecular chaperones, 
GRP78 and GRP94, involved in the early and late stages of the UPR respectively 
were up-regulated following OGD in SH-SY5Y cells (as well as numerous other 
UPR proteins and ER stress proteins) (Figure 3.12 – 3.13).  These data are 
consistent with recent results from OGD in mixed primary cortical cultures 
where increases in both GRP78 and GRP94 were also detected (Badiola et al., 
2011).   
 
The induction of the UPR in response to OGD was also implied in the electron 
microscopic data.   The ER demonstrated a progressive morphologic swelling 
that significantly increased after longer durations of OGD exposure compared to 
time-matched controls.  An expanded ER forms an important part of the UPR as 
it enables larger numbers of misfolded proteins to be incorporated within the 
ER membrane, thus increasing cellular capacity to deal with abundant protein 
damage (Schuck et al., 2009).  A larger ER volume also reduces the 
concentration of protein intermediates, therefore reducing the risk of protein 
aggregate formation(Apetri and Horwich, 2008).  The morphological 
observation of enlarged ER, along with the significant increase in UPR proteins 
GRP78 and GRP94 detected in this proteomic data provide telling insights into 





There is emerging evidence that levels of the proteins centrally involved in the 
UPR are adversely affected with increasing age.  In the cerebral cortex of aged 
C57 / B6 mice, a 30% decrease in GRP78 was recorded when compared to 
young (3 month) old mice (Naidoo et al., 2008).  The present study 
demonstrates increases in UPR proteins to be centrally involved in the cellular 
response to a metabolic challenge.  It is therefore feasible to hypothesise that if 
the levels of these UPR proteins are declining with age, then neurons will be 
less capable of coping with a metabolic challenge such as the decrease in 
oxygen and glucose delivery to the brain, as experienced during chronic 
cerebral hypoperfusion.  This may therefore lead to suboptimal activation of 
the UPR process, resulting in the accumulation of misfolded proteins, as seen in 
neurodegenerative diseases such as AD.   
 
In addition to the protein folding and repair function of GRP78 (aka BiP) 
discussed here, this protein also plays a role at the mitochondrial associated 
membrane (MAM).  The MAM is a specialised membrane region between the 
mitochondria and the endoplasmic reticulum, thought to mediate ER – 
mitochondrial calcium signalling (Rizzuto et al., 2012).  GRP78, along with 
calreticulin (another ER chaperone), are both found enriched at the MAM, and 
are also both significantly up-regulated following 18h OGD.  The role for these 
proteins at the MAM, due to their ability to bind Ca2+, is to serve as a high 
capacity Ca2+ binding store. This ensures ample Ca2+ is present in pools at the 
MAM, ready for transfer to the mitochondria (Hayashi et al., 2009). 
 
The significant increase in GRP78 and calreticulin following OGD may therefore 
be indicative of increased Ca2+ release from the ER to the mitochondria under 
conditions of metabolic stress.  The increased release of Ca2+ would deplete the 
Ca2+ pools, therefore more GRP78 and calreticulin is needed to restore the high 
Ca2+ concentrations at the MAM.  Interestingly, VDAC1, the MAM protein 
responsible for Ca2+ uptake to the mitochondria, is significantly down-regulated 
with 18h OGD.  Conversely, GRP75, the MAM protein tethering IP3R and VDAC1 
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is unchanged with OGD treatment.    Further work needs to be carried out in 
order to reconcile the apparently inconsistent protein changes occurring at the 
MAM under conditions of metabolic stress.  Despite the apparently incongruent 
protein changes detected at the MAM, the present study clearly shows that this 
specialised membrane region between the ER and the mitochondria may play 
an important role in the cellular response to metabolic stress.  
 
The importance of the described protein changes at the MAM in relation to 
metabolic stress, and possibly AD, is enhanced by the recent identification of 
presenilin proteins at this specialised membrane region.  Experimental evidence 
shows that mutations in presenilin genes, akin to those seen in early onset AD, 
cause presenilin to interact with IP3R, stimulating excess calcium release from 
the ER (Cheung et al., 2008). 
 
In accord with activation of the UPR, an up-regulation of numerous proteins 
involved in proteasomal degradation was highlighted by the Protein Folding and 
Degradation Interactome.  Proteins of the 20S and 19S (core and regulatory) 
subunits that constitute the 26S proteasome were increased, suggesting 26S 
proteasomal degradation to be a fundamental mechanism for degrading the 
misfolded proteins that accumulate in response to metabolic challenge.  There is 
a long-standing hypothesis that protein aggregates in the diseased brain impair 
the protein degradation function of the 26S proteasome (Taylor et al., 2002, 
Ciechanover and Brundin, 2003, Valera et al., 2005).  The proteomic data 
presented here demonstrates proteasomal proteins to be up-regulated 
following a metabolic challenge.  It is therefore possible to hypothesize that any 
proteasomal response to metabolic challenge might be adversely affected in the 
presence of protein aggregates associated with neurodegenerative diseases, 
such as AD.  In this situation, the cellular capacity to cope with metabolic stress 




Decreases in ribosomal proteins suggest a decrease in protein translation under 
conditions of severe metabolic stress (18h OGD) 
 
A coordinated response following 18h OGD was also observed in the ribosomal 
proteome.  Numerous ribosomal proteins that constitute the core ribosomal 
machinery were down-regulated, and in line with this, several eukaryotic 
initiation factors central to protein synthesis were also decreased.  It is well 
established that cells undergoing severe metabolic stress experience a down-
regulation of protein translation, which can be reversible in more resistant 
brain areas, and irreversible in vulnerable regions (Paschen et al., 2003).  
Further work involving a recovery phase would need to be undertaken in order 
to understand whether the decrease in protein synthesis machinery is a survival 
mechanism to conserve energy, or whether it ultimately pushes the cells down a 
cell death route.  The proteomic data does suggest that activation of the UPR 
correlates with a decrease in global protein synthesis, perhaps to deal with the 
accumulation of misfolded proteins (Zhang and Kaufman, 2006).  
 
The proteomic data contained within the ribosomal interactome revealed a 
significant up-regulation of peroxiredoxins 1, 2 and 5 (PRDX1, PRDX2 and 
PRDX5).  Peroxiredoxins play a key role in the cellular antioxidant defence 
system, converting hydrogen peroxide into oxygen, and averting the formation 
of hydroxyl radicals  (Bell and Hardingham, 2011).  Thus the increases in Prdx 
proteins may have a protective role in the cellular response to chronic 
metabolic stress.   Indeed previous studies have shown PrxII to suppress the 
generation of ROS in the PC12 neuronal cell line (Simzar et al., 2000).     
 
PrdxII has also been found significantly increased in frontal cortex tissue from 
human AD brains (Krapfenbauer et al., 2003).  In the opening chapter it was 
hypothesised that this increase in PrdxII may serve as an indicator of oxidative 
stress in the brains of these patients.  The corroborative increase in PrxII in this 
OGD study of metabolic stress provides further evidence for this theory.  
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Moreover, recent research into PrxII expression found that increases in this 
protein can be mediated by an interaction between ABAD and Aβ.  This work 
used transgenic mice expressing solely mAPP (Tg mAPP), ABAD (Tg ABAD), 
both mAPP and ABAD (Tg mAPP/ABAD) or non-transgenic littermate controls 
(non-Tg) to investigate the effect of these genetic combinations on PrxII 
expression.  PrxII was found consistently up-regulated in the Tg mAPP and Tg 
mAPP/ABAD mice compared to the PrxII expression in the Tg ABAD transgenic 
animals or the non-Tg littermates.  Further experiments showed that PrxII 
overexpression provides a level of protection to neuronal cells in culture from 
the neurotoxic Aβ peptide (Yao et al., 2007). 
 
The present study provides the first comprehensive analysis of the proteomic 
and morphological response of human SH-SY5Y cells to prolonged metabolic 
challenge.  The LC-MS proteomics results show alterations and interactions in 
mitochondrial, endoplasmic reticulum, and ribosomal proteins under conditions 
of metabolic stress.   Electron transport chain (ETC) proteins displayed 
bidirectional changes (Complex I and V proteins increased and Complex III 
proteins decreased) in response to OGD.  Other mitochondrial proteins involved 
in lipid and ketone metabolism were also increased suggesting the potential of 
these cells to utilise alternative energy sources in hypoglycaemic conditions.  ER 
stress response proteins along with proteins involved in 
proteasomal/ubiquitination degradation formed an important part of the up-
regulated proteomic response to the metabolic challenge of OGD.  The 
significant increase in ABAD protein, alongside its known interactions with Aβ 
and their effects on mitochondrial function and PrxII levels indicate this protein 






These interesting protein changes detected by LC-MS were validated using 
western blotting, with relative protein abundance calculated through 
densitometry analysis and normalisation to a loading control (either GAPDH or 
alpha-tubulin).  A possible limitation of this validation technique is that these 
common loading control proteins have been shown to be altered across a range 
of models of neurodegeneration.  Future studies might therefore use the 
alternative approach of normalisation using total protein analysis to avoid 
possible skewing of the data (Eaton et al., 2013).   
 
The discussed protein changes provide insight into the complex molecular 
alterations underpinning cellular adaptation to metabolic stress.  The lack of 
acute ischemic cell death in our in vitro model of neuronal metabolic stress 
makes the proteomic results particularly pertinent to non-fatal, sustained 
ischemic challenges and the compromised energy metabolism associated with 
slowly evolving neurodegenerative disorders such as AD (de la Torre, 2010).    
 
However, caution must be exercised in the extrapolation of the present data to 
cerebral ischemia in vivo.  The SH-SY5Y cells used in this research are from a 
neuroblastoma cell line with significant glycolytic capabilities, which may well 
affect the cellular response to the metabolic challenge of OGD.  Further 
validation experiments therefore need to be carried out in order to determine 
the physiological relevance of the protein changes recorded in this model 
following OGD.   Differentiation of SH-SY5Y cells into a more neuronal 
phenotype has been shown to induce a sixfold increase in cellular oxygen 
consumption, indicative of a shift to oxidative phosphorylation as their energy 
production process rather than glycolysis (Xun et al., 2012).  Differentiation 
might therefore help to overcome the limitation of the neuroblastoma origins of 
SH-SY5Y cells in future studies of metabolic stress.  However, as previously 
discussed in Section 1.6.3, there are also limitations of differentiation that might 




It is important to remember that no single cell culture system can fully model 
the complexity of cerebral tissue and its response to substrate deprivation. 
Additional proteomic and biochemical analyses across a range of different cell 
types and model systems would enhance our understanding of the proteomic 
response to metabolic stress described here.   
 
Data from this chapter are published in the Journal of Cerebral Blood Flow and 









Chapter 4:  Examining ABAD Interacting 














Chapter 4:  Examining ABAD Interacting Proteins and their Response to 
Metabolic Stress 
 
4.1  Background and Aims of the Chapter 
 
The use of LC-MS proteomics to investigate the global proteomic changes 
underpinning mitochondrial dysfunction in an in vitro model of metabolic stress 
was described in Chapter 3.  A key finding from this study was the significant 
up-regulation of amyloid binding alcohol dehydrogenase (ABAD) protein under 
conditions of metabolic stress.  ABAD is emerging as a key player in AD and is 
known to interact with amyloid beta (Aβ), resulting in significant mitochondrial 
dysfunction (Lustbader et al., 2004).  The 3×Tg-AD mouse model of AD shows 
that ABAD and Aβ levels are increased in the mitochondria before the 
appearance of the classic amyloid plaque pathology typically associated with AD 
(Yao et al., 2009).  ABAD is an attractive target for the amelioration of 
mitochondrial dysfunction and altering the course of AD progression, however 
the detailed biochemical pathways in which this protein is involved remain 
elusive.  This chapter will therefore aim to: 
 Investigate the protein – protein interactions of ABAD under control 
conditions and in response to OGD induced metabolic stress  
 Confirm key ABAD protein interactions in independent samples and in 
human AD tissue 
 Generate novel hypotheses as to the role of ABAD in normal cell function 







4.2.1 Preliminary Study: ABAD Immunoprecipitation 
15 million SH-SY5Y cells were seeded overnight in standard 75cm2 cell culture 
treated flasks (Greiner Bio One, Stonehouse, UK).  Without any treatment, cells 
were scraped and collected using the protocol described in Section 2.4.1.    The 
cell sample was homogenised in 400μl RIPA buffer (50mM Tris-HCL, 150mM 
NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS, supplemented with 
protease inhibitors and PMSF).  Samples were centrifuged at 12000RPM for 
15mins at 4°C and the supernatant recovered.  Total protein content of each 
sample was determined using the Pierce BCA Protein Assay Kit (Thermo 




3 separate IPs were carried out to determine whether ABAD protein was being 
immunoprecipitated by the ABAD antibody suspended on the bead support: 
 IP a: 200μg protein, 10μl ABAD antibody (Santa Cruz, sc-7689) (Normal) 
 IP b: 200μg protein, 10μl RIPA buffer (no antibody control) 
 IP c: No protein, 150μl RIPA buffer, 10μl antibody (no sample control) 
 
 
Immunoprecipitation of ABAD was carried out as described in Section 2.5.  The 
immunoprecipitated samples, along with the protein extracts from the original, 
flow through and wash steps of the immunoprecipitation were analysed by 
western blot according to the protocol described in Section 2.2.2.  The successful 
immunoprecipitation of ABAD protein was tested using ABAD antibody 
(ab10260).  To conclusively determine whether ABAD was being successfully 
immunoprecipitated in the experimental set up, the original and 
immunoprecipitated samples were fully separated on a precast polyacrylamide 
gel using electrophoresis, as described in Section 2.2.2.   The proteins were 
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stained for 1hr in SimplyBlue SafeStain (Invitrogen, Paisley, UK) followed by 
incubation 2% w/v NaCl destain solution overnight at room temperature with 
orbital shaking.   
 
The gel band at 27kDa (molecular weight of ABAD) in each lane was carefully 
excised and transferred to a sterile 1.5ml eppendorf tube.  Proteins were then 
exposed to the in-gel digestion protocol described in Section 2.5.2.  The final 
digested protein samples were dried in a speedvac, and sent to LC-MS for 
confirmation of ABAD immunoprecipitation.     
 
4.2.2 Main Study: Sample Preparation for Immunoprecipitation – Mass 
Spectrometry (IP-MS) 
15 million SH-SY5Y cells were seeded overnight in standard 75cm2 cell culture 
treated flasks as previously described.  Cells were exposed to 18h OGD or control 
conditions and harvested as described in Section 2.4.1.  After centrifugation, cells 
from two 75cm2  flasks were harvested and combined for each IP.  The sample 
collection process was repeated until 3 control samples, 3 OGD samples and a 
negative control sample for both conditions had been collected (Figure 4.1).  Cell 
pellets were snap frozen for storage until homogenisation and protein assay.   
 
Sample pellets were homogenised and protein assayed.  Based on protein assay 
results, all samples were normalised to the sample with the lowest total protein 
content (2060μg) and made up to a final volume of 400ul.  40μl ABAD antibody 
(Santa Cruz Biotechnology, Heidelberg, Germany) was added to each sample.  
40μl RIPA buffer was added to the two negative control samples.  Samples were 
incubated on a mechanical tube roller overnight at 4°C.  Immunoprecipitations 
and in-gel protein digestions were carried out as described in Section 2.5.  The 
final digested protein samples were dried in a speedvac, and stored at -80°C 





Figure 4.1 IP-MS study design.  3 control samples (normoxic, 
with glucose) and 3 OGD samples (no oxygen, no glucose) 
underwent immunoprecipitation.  Eluted samples were cleaned by 
“pulse electrophoresis” into a polyacrylamide gel, and the proteins 






4.2.3 Main Study: Investigating ABAD Interacting Partners with IP-MS 
Peptides were reconstituted in 5µl of Buffer A (97.5% H2O, 2.5% acetonitrile, 
0.1% formic acid) to give final concentration of 1µg/µl.   The peptide mixtures 
were filtered before proteomic data collection on a nano-HPLC-MS/MS as 
described in Section 2.5.3.   The MS/MS peptide data were searched using 
MASCOT versions 2.4 (Matrix Science Ltd, London, UK) against a human subset 
of the NCBI database. 
 
 
4.2.4 IP-MS Quantification, Analysis and Inclusion Criteria  
LC-MS label-free quantification was performed using Progenesis 4.0 (Nonlinear 
Dynamics, Newcastle, UK).  For each protein, the associated unique peptide ions 
were summed to generate a protein abundance value in each sample. This 
abundance value was then transformed using an ArcSinH function to give the 
final protein abundance value that is comparable across samples. 
 
An enrichment ratio was calculated for every protein in each independent IP 
sample compared to the associated negative control.  The frequency distribution 
of log enrichment scores was calculated, and a Z score > 1 was used as the 
inclusion criterion for protein enrichment in samples compared to negative 
controls (Appendix A). 
 
The protein frequency library (PFL) database was used to reduce the chance of 
false discovery through non – specific protein - protein interactions.  The PFL 
objectively evaluates whether proteins identified in an IP study are genuine 
protein interactor rather than binding non-specifically 
(www.proteinfrequencylibrary.com).  Searching the database for proteins 
known to be immunoprecipitated under our specific experimental conditions 
(human derived cell line, whole cell fraction and sepharose bead support) 
resulted in detection frequency values being assigned to all of the 
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immunoprecipitated proteins in the present study.  A detection frequency of 
≤25% set as the inclusion criteria for consideration in the final dataset.     
 
4.2.5 Confirmatory Immunoprecipitations: Independent Control, OGD 
and Human Samples 
Several ABAD interacting proteins identified by IP-MS were chosen for 
verification in independent control and OGD samples. The OGD protocol was 
repeated, with 3 control and 3 OGD samples being collected and processed for 
IP.  The IP protocol was repeated as per the original study, with negative control 
samples containing goat anti-MAG primary antibody (Santa Cruz Biotechnology, 
Heidelberg, Germany).  ABAD immunoprecipiated samples were probed with 
the antibodies shown in Table 4.1. 
 
ABAD immunoprecipitations were repeated using brain tissue from the frontal 
cortex of subjects with either an AD diagnosis or no cognitive impairment 
obtained from the Alzheimer Disease Research Center at Massachusetts General 
Hospital.  Tissue was homogenised in RIPA buffer and protein assayed to 
determine total protein content of samples as previously described in Section 
2.2.1.  All human tissue was handled in agreement with local and national IRB 
guidelines.  Four AD cases and four cognitively normal controls were included in 
this study, with a negative control containing goat anti-MAG primary antibody 
(Santa Cruz Biotechnology, Heidelberg, Germany) run for the control and AD 
















Proteins Interacting only in Control Samples   
CALR 2.98 2 Abcam ab9484 1 : 1000 
CDK5RAP2 5.86 3 Millipore 06-1398 1 : 1000 
     
Proteins Interacting only in OGD Samples   
GRP75 3.88 3 Abcam ab75158 1 : 500 
VDAC2 3.43 2 Abcam ab37985 1 : 1000 
      
 
Table 4.1 Details of the antibodies used in the validation of the IP-MS study. 
 
 






Control    
911 M 82 3.3 I Non-demented 
989 F 76 3.3 I Non-demented 
1136 M 86 3.3 I Non-demented 
1301 M 85 3.3 II Non-demented 
      
Alzheimer’s disease     
602 M 90 3.4 V Demented 
612 M 95 3.3 VI Demented 
614 F 69 2.4 VI Demented 
618 M 84 4.4 V Demented 
      
 
Table 4.2 Details of the human control and AD cases used in the validation 





4.2.6 Electron Microscopy 
SH-SY5Y cells were exposed to OGD using the same paradigm as the original LC-
MS study, detailed in Section 2.4.1.   Samples were collected immediately after 3, 
9 and 18h of OGD and fixed with 4% paraformaldehyde and 5% glutaradehyde 
in 0.08 M sodium cacodylate buffer, pH 7.2.  Once fixed, cells were centrifuged, 
supernatant removed and replaced with a 3% solution of agar.  Gels were cut 
into 1mm³ blocks and processed for EM.  
 
EM sections were evaluated on a JEOL CX -100 II transmission electron 
microscope.  The evaluator was blinded to the treatment condition of all 
samples.  Cells were chosen from grid squares in a predetermined pattern. 50 
cells were assessed from each treatment.  For each cell the condition of the 
nuclear membrane was assessed.  A Chi-Squared 3 x 2 matrix was used to test 
the null hypothesis that OGD would have no effect on the structure of the 
nuclear membrane.  
 
4.2.7 Immunocytochemistry, Confocal Microscopy & Colocalisation 
Analysis  
 
SH-SY5Y cells were seeded onto 25mm coverslips (VWR, Leicester, UK) 
overnight and treated with 18h OGD or control conditions the following day.  
For immunocytochemistry, SH-SY5Y cells were fixed with 4% 
paraformaldehyde for 10mins at room temperature.  Cells were then quenched 
in 50mM ammonium chloride – PBS solution for 10mins, washed three times in 
PBS, and permeabilised in 0.1% tritonX.  Cells were washed again and incubated 
for1hr in blocking solution: 0.1% PBS tween, 0.3M glycine, 2% bovine serum 
albumin.  Cells were then washed and incubated in 50µL primary antibodies for 
1hr: ABAD (ab10260, abcam, 1:500) and GRP75 (ab53098, abcam, 1:500).  
Coverslips were washed 5 times to remove excess primary antibody, and then 
incubated with secondary antibodies for 1hr: goat anti mouse 488 (1:500) and 
donkey anti rabbit 594 (1:1000).  Coverslips were then incubated with DAPI 
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(Invitrogen, 1:1000) for 10mins.  Finally, cells were washed a further five times, 
rinsed in water, dried and mounted onto glass slides using ProLong Gold 
(Invitrogen, Paisley, UK) and left to dry overnight at room temperature.   
Confocal images were acquired with a Nikon A1R confocal laser scanning 
microscope (Nikon UK, Kingston Upon Thames, Surrey, UK) and analysed using 
Image J (National Institutes of Health open software) as described in Section 
2.6.2.  For nuclear protein localisation analysis, confocal Z-stacks were 
examined and the section containing the most complete nuclear cross section 
was selected.  Using Image J, nuclei were manually outlined and the percentage 
of the area containing ABAD staining was calculated.  For the analysis of changes 
in the colocalization patterns of key proteins associated with the mitochondrial 
– associated membrane, confocal images were analysed with a semi-
quantitative scale.  Cell images were coded and graded by 3 blinded observers 
as colocalizaed pixels appearing "lacy", having “few puncta”, or being “very 
punctate”.   
 
4.2.8 Statistical Analysis 
 
IP-MS Enrichment Ratios:  For each IP sample, the number of proteins identified 
with 2 or more peptides was determined.  The protein enrichment ratio for each 
protein was calculated (abundance of protein in the IP sample divided by the 
abundance of that protein in the negative control).  The frequency distribution of log 
enrichment ratios was plotted using GraphPad Prism, version 5, and proteins with a 
Z-score > 1 were included as potential ABAD interactors (Appendix A).  
 
Confirmatory Immunoprecipitations:  Enrichment ratios were calculated for IP’d 
samples compared to the negative control sample.  Significant changes in enrichment 
ratios between control vs OGD IP samples and control vs AD tissue were determined 




Western Blotting:  Significant changes in protein abundance as detected by western 
blotting and densitometry analysis were determined with a two-tailed Students t-
test, using GraphPad Prism, version 5. 
 
Electron Microscopy:  Following blind assessment of nuclear envelope morphology, 
a Chi-Squared 3 × 2 matrix was used to test the null hypothesis that OGD would have 
no effect on the ultrastructure of this membrane. 
 
Confocal Microscopy:  Significant changes in ABAD localisation to the nucleus 
following OGD was tested using a two-tailed Students t-test.  Following blind 
assessment of staining appearance, a Chi-Squared 3 × 2 matrix was used to test the 
null hypothesis that OGD would have no effect on the ABAD and GRP75 colocalisation 















4.3.1 Preliminary Data: LC-MS Confirms Successful ABAD 
Immunoprecipitation   
To confirm the successful immunoprecipitation of ABAD in advance of the full 
IP-MS study, a sample of whole cell lysate (original), the IP flow through eluents, 
the IP samples (IPa, IPb and IPc), and eluents from the two wash stages in the IP 
protocol were run out on a western blot gel.  ABAD was probed using the 
ab10260 (abcam) antibody (Figure 4.2).  However, ABAD is detected at 27kDa, 
which coincides with the molecular weight of the immunoglobulin heavy chain 
of the antibody used to precipitate ABAD in the IP.  The western blot data is 
therefore inconclusive as to the successful immunoprecipitations of ABAD in 
this experimental set up.   
 
Validation of successful ABAD immunoprecipitations was achieved by excising 
the predicted ABAD bands and sending them for mass spectrometry analysis.  
ABAD protein (3-hydroxyacyl co-A dehydrogenase type-2) was identified only 
in IPa sample, and not in either of IPb or IPc negative control samples (Figure 
4.2).  This data confirms successful ABAD immunoprecipitation under the 





Figure 4.2 Preliminary Data: LC-MS Confirms the successful ABAD 
immunoprecipitation under the proposed IP experimental conditions. A.   Whole 
cell lysate (original), IP flow through eluents, IP samples and wash step eluents are 
probed with ABAD antibody.  ABAD is detected at 27kDa (red box) in the original and 
flow through A and B samples.  However, the ABAD band coincides with the IgG 
antibody light chain in the IP samples, therefore successful ABAD IP cannot be 
conclusively determined.    B.  ABAD (3-hydroxyabyl-CoA dehydrogenase type-2) is 
present only in sample IPa (containing cell lysate, beads and ABAD antibody).  ABAD 
protein is not immunoprecipitated in the control samples IPb (containing cell lysate, 






4.3.2 The ABAD Interactome under Normoxic – Normoglycaemic 
Conditions 
 
67 proteins were identified as potential ABAD interactors under normoxic – 
normoglycaemic control conditions following enrichment analysis compared to 
negative controls and inclusion based on a detection frequency cut off of ≤25% 
(Boulon et al., 2010) (Table 4.3).  Of these, 18 proteins were considered “likely” 
interactions (immunoprecipitating with ABAD in all 3 experimental replicates, 
confidence score = 3); 36 proteins were considered “probable” interactions 
(immunoprecipitating with ABAD in 2 of the replicates, confidence score = 2); 
and 13 proteins were considered “possible” interactions (immunoprecipitating 
with ABAD in 1 replicate, confidence score = 1) (Figure 4.3).   
 
These “likely” and “probable” ABAD interacting partners were clustered into 
functional groups using DAVID software.  Glucose metabolic process (n = 7), Cell 
Redox Homeostasis (n=3), Regulation of Neurogenesis (n = 4) and Oxidation – 
reduction (n = 6) were all identified as significant functional clusters (DAVID 
score >1.3, p<0.05) (Figure 4.4).   
 
Analysis of the subcellular distribution of the “likely” and “probable” ABAD 
interacting proteins under control conditions shows ABAD to be interacting 
with proteins across many subcellular locations, including the plasma 
membrane, nucleus, mitochondria, vesicles and endoplasmic reticulum (Figure 
4.5).   Gross assessment of ABAD subcellular location by confocal microscopy 
concurs with the proteomic data, showing ABAD to be located throughout the 
cells, with the outline of the cells discernible, potentially suggesting ABAD 





4.3.3 The ABAD Interactome in Response to Oxygen – Glucose 
Deprivation 
69 proteins were identified as potential ABAD interacting proteins under OGD 
conditions following enrichment analysis as previously described (Table 4.4).  
Of these, 23 proteins were considered “likely” interactions; 28 proteins were 
considered “probable” interactions; and 18 proteins were considered “possible” 
interactions (Figure 4.3).   
 
The “likely” and “probable” ABAD interacting partners under OGD conditions 
were clustered into functional groups using DAVID software.  Under metabolic 
stress,  “glucose metabolic process” (n = 4, score 2.06) remained the top 
functional cluster for ABAD interactions.  The other significant functional cluster 
was identified as “RNA processing” (n = 8, score 1.36) (Figure 4.4).   Subcellular 
location analysis of the “likely” and “probable” ABAD interacting proteins 
following OGD treatment shows ABAD continuing to interact with proteins from 
across many organelles.  However, OGD treatment induces large increases in the 
number of ABAD interactions in the nucleus and the mitochondria, and a 
reduction in the number of interactions occurring in the cytosol (Figure 4.5).   
 
Direct comparisons of all of the interacting proteins in control and OGD samples 
showed 28 proteins to be stably interacting with ABAD under both conditions 
(Figure 4.7).  Chi-squared analysis shows the control and OGD interactomes to 
be significantly similar before and after OGD, χ² = 56.4, p<0.0001 (Figure 4.7).  
Proteins commonly interacting with ABAD under both control and OGD 
conditions are identified in italics in Tables 4.3 and 4.4.  This significant 
commonality between ABAD interactions pre- and post-OGD is reflected in the 
protein subcellular analysis, where in each organelle there are proteins which 
stably interact with ABAD under both experimental conditions (Figure 4.5).   
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Figure 4.3 Summary of the ABAD interactions found in each of the control and OGD samples. The confidence of the ABAD 
protein interactions was determined by the number of samples the interaction was detected in.  A.  Under control conditions 18  
“likely”  ABAD protein interactions were detected in all 3 independent IP samples; 36 “probable” ABAD interactions were detected in 
2 IP samples; and 13 “possible” ABAD interactions were identified in only 1 IP sample.  B.  Under OGD conditions, 23 ABAD protein 
interactions were deemed “likely, 28 were found to be “probable” interactions and 18 “possible” ABAD interactions were detected. 
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Table 4.3 ABAD interacting partners under control conditions ranked according to 
detection frequency.  Proteins in italics are found commonly interacting with ABAD 
between control and OGD conditions. 






ABAD interacting proteins found in 3 Control Samples 
PGAM1 phosphoglycerate mutase 1 1.91 0 
OTUB1 ubiquitin thioesterase OTUB1 1.35 0 
PCK2 phosphoenolpyruvate carboxykinase [GTP], mitochondrial 1.04 0 
OXSR1 serine/threonine-protein kinase OSR1 0.89 0 
CDK5RAP2 CDK5 regulatory subunit-associated protein 2 0.77 0 
AGL glycogen debranching enzyme 0.40 0 
CYB5R3 NADH-cytochrome B5 Reductase 0.25 0 
STAT1 signal transducer and activator of transcription 1-alpha/beta 0.68 4 
TMOD2 tropomodulin-2  0.37 4 
PPP2CA serine/threonine-protein phosphatase 2A catalytic subunit alpha 1.09 7 
RAB5C ras-related protein Rab-5C 0.28 7 
GNAI3 guanine nucleotide-binding protein G(k) subunit alpha 0.47 11 
IPO4 importin-4 2.25 14 
GDIA1 rho GDP-dissociation inhibitor 1 0.66 18 
ARPC5L actin-related protein 2/3 complex subunit 5-like protein 0.43 21 
ELAVL4 ELAV-like protein 4 0.21 21 
ACTR3 actin-related protein 3 0.20 21 
GSTP1 glutathione S-transferase P 3.12 25 
ABAD interacting proteins found in 2 Control Samples 
CALR calreticulin  0.47 0 
UCHL1 ubiquitin carboxyl-terminal hydrolase isozyme L1 0.46 0 
MAPRE1 microtubule-associated protein RP/EB family member 1 0.41 0 
CS citrate synthase 0.32 0 
HMGB2 high mobility group protein B2 0.22 0 
DDX42 ATP-dependent RNA helicase DDX42  0.20 0 
PDI protein disulfide-isomerase  0.19 0 
TMPO thymopoietin isoform gamma 0.16 0 
DPYSL2 dihydropyrimidinase-related protein 2 0.12 0 
MDN1 midasin 0.11 0 
CACYBP calcyclin-binding protein 0.10 0 
PDIA6 protein disulfide-isomerase A6 0.09 0 
MDH2 malate dehydrogenase 0.69 4 
OLA1 obg-like ATPase 1 0.17 4 
PRDX6 peroxiredoxin-6 0.11 4 
CORO7 coronin-7  0.11 4 
CBR1 carbonyl reductase [NADPH] 1 0.10 4 
CPN3 copine-3  0.10 4 
PA2G4 proliferation-associated protein 2G4 0.49 7 
TPI1 triosephosphate isomerase 0.15 7 
PAICS multifunctional protein ADE2 0.25 11 
HMG1 high mobility group protein B1 0.22 11 
ABCF1 ATP-binding cassette sub-family F member 1 0.21 11 
GNB1 guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 0.11 11 
PGK1 phosphoglycerate kinase 1 0.76 18 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 0.53 18 
GARS glycyl-tRNA synthetase 0.22 18 
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RAB1A ras-related protein Rab-1A 0.08 18 
U2AF2 splicing factor U2AF 65 kDa subunit  0.16 21 
NAP1L1 nucleosome assembly protein 1-like 1 0.55 25 
UBA1 ubiquitin-like modifier-activating enzyme 1 0.48 25 
EWSR1 RNA-binding protein EWS 0.37 25 
EZR ezrin 0.26 25 
UBAP2L ubiquitin-associated protein 2-like 0.21 25 
RBBP4 histone-binding protein RBBP4 0.12 25 
ARF1 ADP-ribosylation factor 1 0.11 25 
ABAD interacting proteins found in 1 Control Sample 
CEP250 centrosome-associated protein CEP250  1.04 0 
ACOT7 cytosolic acyl coenzyme A thioester hydrolase isoform hBACHb  0.08 0 
FLOT1 flotillin-1  0.11 0 
CEP128 hypothetical protein LOC145508  0.56 0 
ACADM medium-chain specific acyl-CoA dehydrogenase, mitochondrial 0.30 0 
MARCKS myristoylated alanine-rich C-kinase substrate  0.16 0 
LYN tyrosine-protein kinase Lyn 0.15 4 
VDAC1 voltage-dependent anion-selective channel protein 1 0.10 4 
ALDOB fructose-bisphosphate aldolase A  0.20 7 
STOML3 stomatin-like protein 2  0.13 7 
OST4 dolichyl-diphosphooligosaccharide--protein glycosyltransferase  0.19 11 
ARPC1B actin-related protein 2/3 complex subunit 1B 0.24 18 




Table 4.4 ABAD interacting partners under OGD conditions ranked according to 
detection frequency.  Proteins in italics are found commonly interacting with ABAD 









ABAD interacting proteins found in 3 OGD Samples 
CKB creatine kinase B-type  1.51 0 
ACADM medium-chain specific acyl-CoA dehydrogenase, mitochondrial 0.73 0 
MMSDH methylmalonate-semialdehyde dehydrogenase [acylating] 1.02 0 
MDN1 midasin  0.77 0 
CYB5R3 NADH-cytochrome b5 reductase 0.54 0 
OSBPL8 oxysterol-binding protein-related protein 8 6.12 0 
PCK2 phosphoenolpyruvate carboxykinase [GTP], mitochondrial 1.27 0 
PGAM1 phosphoglycerate mutase 1  1.25 0 
PC pyruvate carboxylase, mitochondrial 0.73 0 
OTUB1 ubiquitin thioesterase OTUB1  1.19 0 
MTHFD1L monofunctional C1-tetrahydrofolate synthase, mitochondrial  0.73 4 
STAT1 signal transducer and activator of transcription 1-alpha/beta 1.84 4 
GRP75 heat shock protein 75 kDa, mitochondrial 0.59 7 
PPP2CA serine/threonine-protein phosphatase 2A catalytic subunit 3.24 7 
IPO4 importin-4  3.22 14 
GDIA1 rho GDP-dissociation inhibitor 1  0.60 18 
CHD4 chromodomain-helicase-DNA-binding protein 4  0.70 18 
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ARPC5L actin-related protein 2/3 complex subunit 5-like protein  0.84 21 
ELAVL4 ELAV-like protein 4 0.61 21 
GSTP1 glutathione S-transferase P  6.65 25 
HNRNPA0 heterogeneous nuclear ribonucleoprotein A0  1.26 25 
NAP1L1 nucleosome assembly protein 1-like 1  1.17 25 
SMARCC2 SWI/SNF complex subunit SMARCC2 2.29 25 
ABAD interacting proteins found in 2 OGD Samples 
NT5DC2 5'-nucleotidase domain-containing protein 2  0.59 0 
AARS2 alanyl-tRNA synthetase, mitochondrial  0.70 0 
AGPS alkyldihydroxyacetonephosphate synthase 0.47 0 
DARS2 aspartyl-tRNA synthetase, mitochondrial  0.52 0 
CDK1 cell division protein kinase 1 0.75 0 
CPSF3 cleavage and polyadenylation specificity factor subunit 3  0.64 0 
MRPP1 mitochondrial ribonuclease P protein 1  0.62 0 
TBRG4 protein TBRG4 0.58 0 
SAP30BP SAP30-binding protein 0.46 0 
TRIP13 thyroid receptor-interacting protein 13 0.79 0 
CS citrate synthase  0.60 0 
CORO7 coronin-7  0.65 0 
OXSR1 serine/threonine-protein kinase OSR1  0.92 0 
CLPX ATP-dependent Clp protease ATP-binding subunit clpX-like 0.91 4 
COPB1 coatomer subunit beta  0.75 4 
SEPT2 septin-2  0.75 4 
GNAI3 guanine nucleotide-binding protein G(k) subunit alpha  0.60 11 
AP2B1 AP-2 complex subunit beta 0.98 18 
PPP1R9B neurabin-2  1.23 18 
PGK1 phosphoglycerate kinase 1 0.51 18 
PDI protein disulfide-isomerase  0.58 18 
PSMC3 26S protease regulatory subunit 6A  0.87 21 
HSP105 heat shock protein 105 kDa  0.49 21 
KPNA2 importin subunit alpha-2  0.74 21 
EIF2AK2 interferon-induced, double-stranded RNA-activated kinase 0.76 21 
VDAC2 voltage-dependent anion-selective channel protein 2 0.54 21 
DPM1 dolichol-phosphate mannosyltransferase  0.46 25 
ARF1 ADP-ribosylation factor 1  0.76 25 
ABAD interacting proteins found in 1 OGD Sample 
ENPF centromere protein F  0.70 0 
DDX41 probable ATP-dependent RNA helicase DDX41  0.52 0 
Nup107 nuclear pore complex protein Nup107  0.51 4 
DPF2 zinc finger protein ubi-d4  0.50 4 
LYN tyrosine-protein kinase Lyn 0.62 4 
EIF3L eukaryotic translation initiation factor 3 subunit L  0.55 7 
PFKM 6-phosphofructokinase, muscle type 0.52 11 
NSUN2 tRNA (cytosine-5-)-methyltransferase NSUN2 0.47 11 
VPS35 vacuolar protein sorting-associated protein 35  0.48 11 
HMG1 high mobility group protein B1  0.46 11 
ACTR1A alpha-centractin  0.48 18 
ALB serum albumin preproprotein  1.04 18 
UBE2O ubiquitin-conjugating enzyme E2 O  0.51 18 
RAB1A ras-related protein Rab-1A 0.47 18 
U2AF2 splicing factor U2AF 65 kDa subunit 0.68 21 
THOC4 THO complex subunit 4  0.92 25 
RBBP4 histone-binding protein RBBP4 0.52 25 







Figure 4.4 Functional clustering of the ABAD interacting proteins under control 
and OGD conditions.    “Likely” and “Probable” ABAD interacting proteins were 
uploaded to DAVID software and analysed for functionality.  Clusters with a score > 1.3 
are shown as these are equivalent to a significance of p<0.05 (the DAVID score is 





 Figure 4.5 ABAD protein – protein interactions are found across many subcellular organelles.  “Likely and “Probable” ABAD interacting proteins 
were uploaded to DAVID and analysed by subcellular compartment.  A.  Under control conditions ABAD interacts with proteins originating in many 
subcellular organelles.  B.  Following OGD treatment, ABAD continues to interact with proteins from many subcellular organelles, however there are 
large increases in the number of ABAD interactions occurring in the mitochondria and the nucleus.  Unique: protein interactions only occurring in 





Figure 4.6 Diffuse ABAD staining shown by immunocytochemistry.  A.  SH-SY5Y cells were nuclear 
stained with DAPI and co-stained with ABAD antibody ab10260.  A diffuse distribution of ABAD is seen that is 
absent in the no primary antibody negative control B. The ABAD immunostain with ABAD antibody ab52243 








Figure 4.7 The ABAD protein interactome is significantly similar pre- and post-
OGD: a chi-squared analysis.  A.  27 proteins are commonly detected as interacting 
with ABAD under both control and OGD conditions.  B.  Using a 2 x 2 contingency table 
a Chi-squared analysis can be carried out.  The result is a Chi-squared value of 56.4, 
p<0.0001.  The null hypothesis is rejected, therefore it can be stated that there is 







4.3.4 Nuclei and Mitochondria contain the Largest Changes in ABAD 
Interacting Proteins following OGD  
The largest number of OGD induced changes in ABAD interacting proteins are 
found in the nuclei and mitochondria of SH-SY5Y cells.  In the nucleus, 3 
proteins stably interact with ABAD under control and OGD conditions:  
glutathione S-transferase P (GSTP1), signal transducer and activator of 
transcription 1 (STAT1) and midasin (MDN1).  6 nuclear proteins uniquely 
interact with ABAD under control conditions: ATP-dependent RNA helicase 
DDX42 (DDX42), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), high 
mobility group protein B2 (HMGB2), obg-like ATPase 1 (OLA1), proliferation-
associated protein 2G4 (PA2G4) and ubiquitin carboxyl-terminal hydrolase 
(UCHL1).   
 
Following OGD, 14 new nuclear proteins were found to interact with ABAD: 
chromodomain-helicase-DNA-binding protein 4 (CHD4), heterogeneous nuclear 
ribonucleoprotein A0 (HNRNPA0), SWI/SNF complex subunit SMARCC2 
(SMARCC2), 26S protease regulatory subunit 6A (PSMC3), cell division protein 
kinase 1 (CDK1), cleavage and polyadenylation specificity factor subunit 3 
(CPSF3), importin subunit alpha-2 (KPNA2), neurabin-2 (PPP1R9B), SAP30-
binding protein (SAP30BP), septin-2 (SEPT2), thyroid receptor-interacting 
protein 13 (TRIP13), high mobility group protein B1 (HMG1), histone-binding 
protein RBBP4 (RBBP4) and splicing factor U2AF 65 kDa (U2AF2) (Figure 4.8).  
Using biological functions ascribed by DAVID and Uniprot, these ABAD 
interacting proteins can be broadly categorised into 4 groups: transcription & 
translation; regulation of apoptosis; protein transport and protein processing; 
and cell cycle / other (Figure 4.8).   Confocal microscopy analysis confirms 
ABAD localisation in the nucleus, and also shows the amount of ABAD in the 




To investigate whether the large increase in nuclear ABAD protein interactions 
was due to damage to the nuclear membrane, ultra-structural morphological 
analysis was undertaken using electron microscopy.  With increasing OGD 
duration, the number of cells displaying abnormal nuclear membranes was 
significantly increased compared to the equivalent time matched controls (Chi-
Square, *p<0.05, **p<0.01, Figure 4.10).  However, despite this increase in 
nuclear membrane swelling and blebbing, it should be noted that even after 18h 
OGD exposure, 49% of cells maintained a “normal” nuclear membrane structure. 
 
In the mitochondria, 5 proteins stably interact with ABAD under control and 
OGD conditions:  glutathione-S-transferase P (GSTP1), NADH-cytochrome b5 
reductase 3 (CYB5R3), phosphoenolpyruvate carboxykinase [GTP] (PCK2), 
serine/threonine-protein phosphatase 2A catalytic subunit (PPP2CA), and 
medium-chain specific acyl-CoA dehydrogenase (ACADM).  2 mitochondrial 
proteins uniquely interact with ABAD under control conditions: glycyl-tRNA 
synthetase (GARS) and malate dehydrogenase (MDH2).   
 
Following OGD, 13 new mitochondrial proteins were found to interact with 
ABAD:  creatine kinase B-type (CKB), heat shock protein 75 (HSP75 / GRP75), 
methylmalonate-semialdehyde dehydrogenase [acylating] (MMSDH), 
monofunctional C1-tetrahydrofolate synthase  (MTHFD1L), pyruvate 
carboxylase (PC), alanyl-tRNA synthetase (AARS2), 
alkyldihydroxyacetonephosphate synthase (AGPS), aspartyl-tRNA synthetase 
(DARS2), ATP-dependent Clp protease ATP-binding subunit clpX-like (CLPX), 
mitochondrial ribonuclease P protein 1 (MRPP1), protein TBRG4 (TBRG4) and 
voltage-dependent anion-selective channel protein 2 (VDAC2).  Using biological 
functions ascribed by Uniprot, these ABAD interacting proteins can be broadly 
categorised into 4 groups:  fatty acid oxidation & lipid metabolism; Krebs cycle 
& gluconeogenesis; protein biosynthesis & protein folding; and induction of 




Figure 4.8 Nuclear ABAD protein – protein interactions.  A.  Under control conditions, the ABAD interactions occurring in the nucleus can be 
broadly categorised as involved with “Transcription & Translation”, “Regulation of Apoptosis”, “Protein Transport & Protein Processing” and “Cell 
Cycle & Other”.  B.  Under OGD conditions the same broad categories apply to the ABAD interacting proteins.  Many more ABAD protein interactions 
are found in the nucleus under conditions of metabolic stress.  Proteins shown in bold are found interacting with ABAD under both control and OGD 




Figure 4.9  ABAD protein is found at increased levels 
in the nucleus following OGD.  A.  Consistent with the 
increased numbers of ABAD protein interactions occurring 
in the nucleus following OGD, the immunostaining of 
ABAD within the nucleus was markedly increased 
following OGD treatment compared to controls. n = 20 
cells in each condition.  B. Representative images of 
increased ABAD immunostaining in the nucleus of SH-




Figure 4.10 The nuclear membrane displays progressive morphological changes following oxygen glucose 
deprivation (OGD).  A. OGD induced increases in the number of cells containing swollen and blebbing nuclear 
membranes.  Significant changes in the distribution of “normal”, “swollen” and “blebbing” nuclear membranes within 
cells was seen after 3, 9, and 18h OGD compared to the time matched controls (* p<0.05  ** p<0.01, X2, n = 50 cells in 
each condition)  B.  Representative electron micrographs of the three grades of nuclear membrane morphology. Scale 




Figure 4.11 Mitochondrial ABAD protein – protein interactions.  A.  Under control conditions, the ABAD interactions occurring in the 
mitochondria can be broadly categorised as involved with “Fatty Acid Oxidation & Lipid Metabolism”, “Krebs Cycle and Gluconeogenesis”, 
“Protein Biosynthesis & Protein Folding” and “Regulation of Apoptosis & Other”.  B.  Under OGD conditions the same broad categories apply to the 
mitochondrial ABAD interacting proteins.  Many more ABAD protein interactions are found in the mitochondria under conditions of metabolic 
stress.  Proteins shown in bold are found interacting with ABAD under both control and OGD conditions.  The full protein names corresponding to 
their gene names shown here can be seen in Tables 4.3 and 4.4. 
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4.3.5 ABAD Interacts with Proteins Involved in Trafficking and Transport  
“Protein Transport” and “Vesicle Mediated Transport” are two other functional 
groups ascribed to DAVID interacting proteins under control and OGD 
conditions, respectively.  Under control and OGD conditions, ABAD stably 
interacts with proteins associated with coronin-7 (CORO7), importin-4 (IPO4), 
NADH-cytochrome b5 reductase 3 (CYB5R3), ADP-ribosylation factor 1 (ARF1) 
and ras-related protein Rab-1A (RAB1A).  Under control conditions only, ABAD 
interacts with actin-related protein 3 (ACTR3), ras-related protein Rab-5C 
(RAB5C), ezrin (EZR) and thymopoietin (TMPO).  Following OGD, ABAD loses 
these interactions, however gains interactions with AP-2 complex subunit beta 
(AP2B1), coatomer subunit beta (COPB1) and importin subunit alpha-2 
(KPNA2).  These proteins can be grouped into the following broad categories: 
endoplasmic reticulum – Golgi transport; vesicle mediated transport; actin 





Figure 4.12  ABAD forms interactions with key proteins involved in protein trafficking.   A.  Under control conditions ABAD 
interacts with proteins involved in numerous aspects of protein trafficking and endocytosis, “ER-Golgi Transport”, “Vesicle Mediated 
Transport”, “Actin Networks & Protein Anchors” and “Nuclear Protein Import”.  B.  Under OGD conditions the same broad categories 
apply to the ABAD interactions associated with protein transport., with many of the interactions remaining stable following OGD 
treatment.  Proteins shown in bold are found interacting with ABAD under both control and OGD conditions.  The full protein names 
corresponding to their gene names shown here can be seen in Tables 4.3 and 4.4.  
154 
 
4.3.6 ABAD Interacts with Alzheimer’s Related Protein CDK5RAP2 under 
Control Conditions 
Under control conditions, IP-MS shows ABAD to interact with CDK5RAP2, a 
protein thought to regulate the activity of cyclin dependent kinase (CDK5) 
(Table 4.3).  Western blotting of independent control and OGD samples shows 
CDK5RAP2 to be significantly reduced under conditions of OGD, and the 
interaction with ABAD to be lost under these conditions of metabolic stress 
(Figure 4.13).   
 
4.3.7 ABAD Interacts with GRP75 under OGD Conditions  
The IP-MS data shows an interaction between ABAD and GRP75 following OGD 
treatment that is absent in control samples (Table 4.4). GRP75 is found in the 
mitochondria, but is also considered to be a marker of the mitochondrial 
associated membrane.  Independent immunoprecipitations were carried out in 
order to validate this novel ABAD – GRP75 interaction.  Western blot analysis of 
the samples show levels of GRP75 to be unaffected by OGD, and confirms the 
interaction of ABAD and GRP75 following OGD treatment (Figure 4.14).   
 
Immunocytochemistry provided further evidence for this novel ABAD – GRP75 
interaction.  Colocalisation analysis shows ABAD and GRP75 to colocalise under 
control and OGD conditions, with a trend towards less colocalisation following 
OGD treatment (Figure 4.15).  GRP75 is a mitochondrial protein, with the lacy 
green staining indicative of the typical mitochondrial morphology expected with 
fluorescent microscopy.  Following, OGD treatment, the colocalisation pattern of 
ABAD to GRP75 is significantly more punctate along the mitochondria (Figure 





4.3.8  Evidence of ABAD – GRP75 interaction in Human Tissue 
 
Immunoprecipitations were carried out using human brain samples to 
investigate whether the ABAD and GRP75 interaction is seen in the human 
brain, and to also investigate whether this interaction is affected by AD.   
Western blot analysis of the human samples shows the abundances of ABAD 
and GRP75 to be unchanged in the AD samples.  The IP results show GRP75 
protein to interact with ABAD in control and AD tissue, with a significant 
decrease in the amount of immunoprecipitated GRP75 protein in the AD 
samples (Figure 4.16).    
 
4.3.9 Other ABAD Interactions Detected with LC-MS Remain Unconfirmed 
In addition to GRP75 and CDK5RAP2, the interactions of other biologically 
important ABAD interacting proteins identified by IP-MS were tested in the 
independent control and OGD samples.  IP-MS detected endoplasmic reticulin 
protein calreticulin (CALR) to interact with ABAD under control conditions, and 
voltage dependent anion channel 2 (VDAC2) to interact with ABAD under OGD 
conditions.  In the independent samples, calreticulin failed to show any 
interaction with ABAD under control conditions but did appear to interact with 
ABAD under OGD conditions.  However, the calreticulin also interacts with the 
negative control antibody MAG under OGD conditions, therefore the ABAD – 
CALR interaction appears to be non-specific (Figure 4.17).  VDAC2 showed 
ABAD interaction across all samples, including the negative control (Figure 
4.18).  This ABAD interaction also appears to be non-specific and remains 







Figure 4.13  The IP-MS predicted interaction of ABAD with CDK5RAP2 under control conditions is confirmed in independent 
samples. A. Western Blot analysis for CDK5RAP2 (Original Samples) shows a significant decrease in this protein following OGD treatment.  
B.  Immunoprecipitation confirms the  ABAD – CDK5RAP2 interaction to occur only in control conditions C. Enrichment analysis of 
CDK5RAP2 levels in control IPs compared to negative controls and in OGD IPs compared to negative controls shows significantly greater 









Figure 4.14  The IP-MS predicted interaction of ABAD with GRP75 under OGD conditions is confirmed in independent samples. 
A. Western Blot analysis for GRP75 (Original Samples) shows no significant change in the levels of this protein between control and 
OGD conditions.  B.  Immunoprecipitation confirms the  ABAD – GRP75 interaction to occur only in OGD samples C. Enrichment analysis 
of GRP75 levels in OGD IPs compared to negative controls and in control IPs compared to negative controls shows significantly greater 










Figure 4.15  Confocal analysis of the colocalisation of ABAD and GRP75.  
A. ABAD and GRP75 proteins colocalise in SH-SY5Y cells under both control 
and OGD conditions.  The colocalisation was unaffected by OGD, however 
there appears to be a trend towards less protein colocalisation under 
conditions of metabolic stress.  B.  Although the ABAD – GRP75 is not 
significantly affected by OGD, the appearance of the colocalisation pattern is 
changed under conditions of metabolic stress.  Following OGD, the ABAD – 
GRP75 colocalisation staining was significantly more punctate compared to 






Figure 4.16  Assessing the effect of Alzheimer’s disease on ABAD, GRP75 and 
their interaction.  A.  ABAD protein abundance was unchanged between human 
control and AD brain tissue. B.   GRP75 protein abundance was unchanged between 
human control and AD brain tissue. C. The confirmatory ABAD IP is inconclusive due 
to the masking of the ABAD protein band by the heavy IgG chain.  GRP75 and ABAD 
interact in human control and AD brain samples.  The amount of GRP75 
immunoprecipitated in AD samples is significantly less that in controls (* p< 0.05, T-






Figure 4.17  The IP-MS predicted interaction of ABAD with calreticulin is unconfirmed in independent control and OGD samples.       
A. Western Blot analysis for calreticulin (Original Samples) shows no effect of OGD on the level of this protein compared to controls.  B. 
Immunoprecipitation shows calreticulin and ABAD do not interact in control samples.  Under OGD conditions, ABAD and calreticulin appear 
to interact, however calreticulin is also seen in the negative control sample containing supposedly unrelated MAG protein, therefore C. there is 





Figure 4.18  The IP-MS predicted interaction of ABAD with VDAC2 is unconfirmed in independent control and OGD samples. A. 
Western Blot analysis for calreticulin (Original Samples) shows no effect of OGD on the level of this protein compared to controls.  B. 
Immunoprecipitation shows calreticulin and ABAD do not interact in control samples.  Under OGD conditions, ABAD and calreticulin appear 
to interact, however calreticulin is also seen in the negative control sample containing supposedly unrelated MAG protein, therefore C. there 
is no significant enrichment of calreticulin in either the normoxic – normoglycaemic controls or in the OGD samples.  (n = 3 in each 
condition)  
4.4 Discussion 
This study provides the first comprehensive analysis of the protein – protein 
interactions of ABAD, a protein identified as an important player in 
mitochondrial dysfunction and AD.  The characterisation of the response of SH-
SY5Y cells to OGD carried out in Chapter 3 demonstrated the robustness of SH-
SY5Y cells to external stressors.  This resilience has allowed the response of the 
ABAD interactome to be extensively examined when challenged with prolonged 
OGD.  Following LC-MS confirmation that ABAD protein was being successfully 
immunoprecipitated in the experimental set up, the full scale IP-MS study was 
undertaken.  The discovery of a complex ABAD interactome that is altered 
following OGD provides insight into the possible roles this protein plays under 
conditions of metabolic stress.   
 
ABAD was originally identified within the endoplasmic reticulum, and 
consequentially named endoplasmic reticulum associated amyloid-binding 
protein (ERAB) (Yan et al., 1997).  Using liver tissue, subcellular fractionation 
studies extended our understanding of ABAD distribution identifying ABAD 
enrichment in mitochondrial as well as ER fractions (Oppermann et al., 1999).  
Concurrent with this early research, the present study shows ABAD to interact 
with proteins located in both the mitochondria and the endoplasmic reticulum 
under control conditions.   ABAD was also found to interact with proteins 
located within other organelles, including the nucleus, golgi apparatus and the 
plasma membrane.  This wide distribution of ABAD interactions across the cell 
is backed up by images obtained by immunocytochemistry, which shows a 







DAVID analysis identified “Glucose Metabolic Process” (GO:0006006) to be the 
top functional cluster ascribed to the ABAD interacting proteins under both 
control and OGD conditions.  Proteins glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and triosephosphate isomerase (TPI) are found within 
this top cluster.  GAPDH and TPI are enzymes that catalyse two consecutive 
steps in the glycolytic pathway, a process resulting in the production of 
pyruvate for entry into the Krebs cycle.  ABAD interacts with both of these 
proteins under control conditions, however following OGD, loses the 
interactions with these key glycolytic enzymes.  It might therefore be 
hypothesised that the interaction of these proteins with ABAD might be 
indicative of a modulatory role for ABAD in the glycolytic pathway.  For 
example, under control conditions, ABAD may somehow suppress the glycolytic 
pathway, whereas after OGD, the dissociation of ABAD from GAPDH and TPI 
allows these enzymes to undertake their functions in anaerobic energy 
metabolism.  A novel role for ABAD in metabolic homeostasis is not an 
unrealistic hypothesis given that transgenic mice overexpressing ABAD are 
shown to have higher baseline levels of ATP (Du Yan et al., 2000) Further work 
assessing the activity of GAPDH and TPI enzymes under control and OGD 
conditions in the presence and absence of ABAD would need to be undertaken 
in order to test this hypothesis.   
 
“Cell Redox Homeostasis” (GO:0045454) is the second functional cluster 
ascribed by DAVID analysis to the ABAD interacting proteins under control 
conditions.  Reactive oxygen species are molecules derived from molecular 
oxygen that react with and damage DNA, lipids and proteins (Magder, 2006).  If 
oxygen is reduced by one electron, the superoxide anion (O2−•) is produced, the 
precursor of most ROS.  Reactions of O2−• with the antioxidant superoxide 
dismutase produces hydrogen peroxide (H2O2) which can either be reduced to 
water (H2O ) or partially reduced to form the hydroxyl radical (OH•), an 
extremely powerful oxidant that can cause extensive cellular damage (Turrens, 




major site of ROS production, which under normal conditions is kept in 
homeostasis by the cells antioxidant systems.  Under conditions of stress, such 
as cerebral hypoperfusion and ischemia, a vicious cycle of cellular injury is 
induced, whereby mitochondrial dysfunction causes increased reactive oxygen 
species production, which further impairs mitochondrial function.  This cycle of 
events is thought to be one of the mechanisms linking cerebral hypoperfusion, 
mitochondrial dysfunction and neurodegeneration (Fiskum et al., 1999).    
 
Peroxiredoxin-6 (Prx6) is an important protein identified as an ABAD interactor 
that falls into this “Cell Redox Homeostasis” cluster.  Peroxiredoxins are a 
universally expressed group of proteins involved in the reduction and removal 
of oxidants within the cell.  Prx6 is unique among the peroxiredoxin family: in 
addition to its peroxidase function, Prx6 also shows phospholipase A2 (PLA2) 
activity (Chen et al., 2000).  PLA2 activity results in the cleavage of fatty acids 
from phospholipids (Sun et al., 2004).  Given the role of ABAD in beta oxidation 
of fatty acids, and the PLA2 activity of Prx6, it appears logical that these two 
proteins would be present in each other’s vicinity within the cell.  A synergistic 
interplay between ABAD and Prx6 based around the supply and oxidation of 
fatty acids is logical, however the interaction is lost under conditions of 
metabolic stress, where utilisation of fatty acids as an alternative energy 
sources would be most useful.  It might therefore be suggested that the function 
of the ABAD – Prx6 interaction (and loss of interaction under conditions of 
metabolic stress) is more complex than first thought.  
 
Prx6 has recently been shown to be significantly modified by 4-hydroxynonenal 
(HNE) in the hippocampi of AD patients compared to controls (Perluigi et al., 
2009).  HNE is a highly reactive electrophilic aldehyde formed as a result of lipid 
peroxidation, and is thought to play a key role in oxidative protein damage.  
Following OGD, it may be this HNE modification of Prx6 that disrupts the 
interaction with ABAD after treatment with OGD.  Further work needs to be 




conditions, and whether this modification has an effect of the ABAD – Prx6 
interaction.  The binding of Prx6 to ABAD, plus the oxidative modification of 
Prx6 in AD tissue indicates that this novel protein – protein interaction may play 
an important role in maintaining cell redox homeostasis.  The loss of this 
interaction following OGD treatment may be indicative of the disruption in 
redox homeostasis under conditions of metabolic stress, providing insight into a 
possible mechanism linking ABAD, mitochondrial dysfunction and 
neurodegenerative disease.   
 
Interestingly, ABAD protein has previously been linked to peroxiredoxins in AD 
research.  Peroxiredoxin II (Prx2) was found at increased levels in transgenic 
mice expressing both mutant APP and ABAD compared to littermate controls.  
Intriguingly, the level of Prx2 could be normalised by blocking the ABAD-Aβ 
interaction (Yao et al., 2007).  This result shows that the expression level of 
peroxiredoxins can be affected by ABAD - Aβ interaction.  It would therefore be 
interesting to test whether the induction of metabolic stress induces interplay 
between Prx6 and Prx2: It could be hypothesised that the loss of ABAD – Prx6 
interaction under OGD conditions allows for an ABAD – Aβ interaction to take 
place, inducing an increase in Prx2 protein similar to that seen in the transgenic 
model.   
 
In addition to Prx6, protein disulphide isomerase (PDI) and protein disulphide 
isomerase A6 (PDIA6) are found to interact with ABAD, and are grouped into 
the “cell redox homeostasis” functional cluster.  Protein disulphide isomerases 
caltalyse the reduction (breaking), oxidation (forming) and isomerisation 
(rearranging) of protein disulphide bonds, which are imperative to correct 
protein folding (Andreu et al., 2012).  PDIA6 interacts with ABAD only in control 
samples, whereas PDI interacts with ABAD under both control and OGD 
conditions.   PDI is involved in the endoplasmic reticulum stress response, a 
process initiated in response to an accumulation of misfolded proteins in the ER 




(GRP78) and glucose regulated protein 94 (GRP94) are significantly up-
regulated following OGD, indicative of the activation of the ER stress response 
(Chapter 3, (Herrmann et al., 2013a)).  The stable interaction of ABAD with PDI 
under both control and OGD conditions suggests ABAD may also be involved in 
the ER stress response, providing a further link between ABAD, metabolic 
stress, protein misfolding and neurodegeneration.  PDI has been investigated 
specifically in the brains of AD patients.   In these patients a nitric oxide group is 
added to the protein (S-nitrosylation) resulting in inhibition of PDI function and 
accumulation of misfolded proteins (Uehara et al., 2006).  The present study 
shows PDI to be involved in the cell response to metabolic stress, which may 
also involve ABAD, inferred through its stable interaction with PDI.  If the 
function of PDI is inhibited (eg. through S-nitrosylation) then the defence 
mechanism against metabolic stress will also be impeded, potentially leading to 
neurodegenerative disease.   
 
Linked to “Cell Redox Homeostasis”, “Oxidation – Reduction” is another 
significant functional cluster associated with the ABAD interacting proteins 
under control conditions.  Malate dehydrogenase (MDH2) is included in the 
“Oxidation – Reduction” functional cluster, and is found to interact with ABAD 
under control conditions.  MDH2 is a Krebs cycle enzyme, responsible for the 
oxidation of malate to oxaloacetate and the concurrent reduction of NAD+ to 
NADH.  Interestingly, ABAD is also found to interact with citrate synthase (CS), 
another Krebs cycle enzyme which catalyses the combination of oxaloacetate 
and acetyl-CoA to form citrate, allowing the cycle to continue.  However, the 
ABAD interaction with CS is stable across control and OGD conditions, whereas 
ABAD only appears to interact with MDH2 in control samples.   
 
The identification of ABAD interactions within the Krebs cycle led to an 
inspection of the original LC-MS OGD dataset described in Chapter 3, to see 
whether OGD affects the expression profiles of MDH2 and CS, as well as the 




regulated following OGD; aconitase and isocitrate dehydrogenase to be 
unchanged; with fumerase and malate dehydrogenase being significantly up-
regulated with OGD treatment.  α-ketoglutarate dehydrogenase, succinyl-CoA 
synthetase and succinate dehydrogenase were undetected in the LC-MS study 
(Figure 4.19).    
 
Combining information from the IP-MS and LC-MS studies suggests that ABAD 
may play a role in modulating key enzymes of the Krebs cycle under conditions 
of metabolic stress.  When ABAD remains interacting with CS under OGD 
conditions, the enzyme is down-regulated, whereas when the ABAD interaction 
with MDH2 is lost, the enzyme is up-regulated.  Further work needs to be 
carried out in order to establish the precise consequences of the ABAD 
interactions with the Krebs cycle enzymes.  Interestingly, autopsy and 
assessment of the brains of AD patients shows the enzymes of the Krebs cycle to 
be significantly altered compared to controls.  Concurrent with the protein 
changes presented here, MDH activity was significantly increased (P<0.01), 
however isocitrate dehydrogenase, an enzyme unchanged following treatment 
with OGD was significantly decreased in the end-stage Alzheimer’s brains 
(Bubber et al., 2005).  The biological mechanisms underlying these changes 
remain to be confirmed.  However, the loss of the ABAD – MDH interaction 
under OGD conditions, and the subsequent increase in MDH expression, might 
provide insight into how metabolic stress influences the enzymes of the Krebs 
cycle, possible providing a link between chronic cerebral hypoperfuson, 













Figure 4.19  Krebs cycle proteins and their interacting partners are altered by 
OGD.   ABAD is found to stably interact with citrate synthase under control 
and OGD conditions (solid line), however this protein is significantly 
decreased following OGD treatment (purple arrow).  ABAD also interacts 
with malate dehydrogenase under control conditions, however this 
interaction is lost following OGD (dotted line).  Malate dehydrogenase is 
significantly increased following OGD treatment.  Other proteins of the Krebs 
cycle were either unchanged following OGD treatment (horizontal arrow), or 
were not detected in the protein samples by mass spectrometry (question 







The other significant functional cluster associated to the ABAD interacting 
proteins under control conditions is “Regulation of Neurogenesis” 
(GO:0050767).  It seems counterintuitive that ABAD, a protein predominantly 
researched in relation to AD and neurodegeneration, might also be involved in 
the regulation of neurogenesis.   However, research has shown that many of the 
key players in neurodegenerative disease, including Alzheimer’s related 
presenilins and tau proteins, are also involved in the modulation of brain 
plasticity.   CDK5 regulatory subunit-associated protein 2 (CDK5RAP2) is a key 
ABAD interacting protein found within this cluster.  CDK5RAP2 can significantly 
affect the intracellular localisation and substrate specificity of cyclin-dependent 
kinase-5 (Cdk5), a key player in pathogenic tau hyperphosphorylation and 
aggregation (Kraemer et al., 2011, Noble et al., 2003).   
 
Due to the high interest in linking metabolic stress and tau aggregation in AD, 
the ABAD-CDK5RAP2 interaction was followed up in independent control and 
OGD samples.  Confirmatory imunoprecipitations and western blot analysis 
validate the ABAD - CDK5RAP2 interaction in control samples, with this 
interaction lost following OGD treatment.  Reproducing this finding with a 
reverse co-IP would strengthen the evidence for this novel protein – protein 
interaction.  The release of CDK5RAP2 from its interaction with ABAD under 
conditions of metabolic stress may perhaps enable CDK5RAP2 to modulate 
Cdk5 activity, with important implications for tau phosphorylation.  
Furthermore, research recently demonstrated that knocking down Cdk5 in 
triple-transgenic AD mice strongly reduced the number of tau neurofibrillary 
tangles in the hippocampi of these animals (Piedrahita et al., 2010).  It is now 
important to follow up the discovery of a CDK5RAP2 – ABAD interaction in 
order to understand how this interaction might impact on tau processing under 






Under OGD conditions, “RNA Processing” (GO:0006396) was found to be a 
significant functional cluster of ABAD interacting proteins in addition to 
“Glucose Metabolic Process” (GO:0006006).  Of particular interest, splicing 
factor U2AF 65kDa subunit (U2AF2) was shown to interact with ABAD in two 
out of the three OGD IP samples, whereas this protein only interacted with 
ABAD in one out of three control samples.  U2AF2 is involved in the splicing of 
tau transcripts (Wang et al., 2004).  Tau exon 10 encodes one of four 
microtubule-binding repeats found in tau protein.  Inclusion of exon 10 results 
in tau proteins that contain four microtubule binding repeats (4R).  Exclusion of 
exon 10 results in tau protein containing only 3 microtubule binding repeats 
(3R).  Alternate splicing of the tau transcript tightly controls the ratio of 3R and 
4R tau isoforms, and alterations in this ratio can lead to tau aggregation and 
neurodegeneration (Zhou et al., 2008, Glatz et al., 2006).  Mining the original 
OGD LC-MS proteomic data described in Chapter 3 shows that U2AF2 is 
unchanged in response to both 6h and 18h OGD.  However, a significant increase 
in ABAD protein in conjunction with the U2AF2 – ABAD interaction following 
OGD might be indicative of alterations in tau exon10 splicing.  Changes in 
splicing could potentially disrupt the fine balance of 3R and 4R tau isoforms, 
potentially leading to tau accumulation and neurodegeneration (Figure 4.20).   
 
Furthermore, following OGD, ABAD is shown to interact with cyclin dependent 
kinase 1 (CDK1), a protein intricately involved in cell cycle regulation and 
apoptosis (Sakurikar et al., 2012).  It is known that uncontrolled activation of 
CDK1 can cause cells to prematurely undergo mitosis, resulting in apoptosis.  
Additionally, CDK1 can influence apoptotic pathways directly via modulation of 
the Bcl-2 proteins (Castedo et al., 2002).  With regard to neurodegeneration, 
unregulated expression and activation of CDK1 has been seen in neurofibrillary 
tangle-bearing neurons from AD brains (Vincent et al., 1997).  The interaction of 
ABAD with CDK1 under OGD conditions is therefore potentially important with 
regard to apoptosis and also neurodegeneration.  The specific nature of the 
interaction needs to be further investigated in order to determine whether the 




 Of the 8 proteins contained within the “RNA processing” cluster, 4 are identified 
as nuclear proteins: splicing factor U2AF 65 kDa subunit (U2AF2), cleavage and 
polyadenylation specificity factor (CPSF3), heterogeneous nuclear 
ribonucleoprotein A0 (HNRNPA0) and neurabin-2 (PPP1R9B).  This finding is 
congruent with the initial subcellular categorisation of ABAD interacting 
proteins which showed a large increase in the number interactions occurring in 
the nucleus following OGD treatment.  Randomised and blind confocal 
microscopy analysis further confirms the presence of ABAD in the nucleus, with 
nuclear ABAD staining found to be markedly increased following OGD 
treatment.   
 
Electron microscopy was used to assess the structural integrity of the nuclear 
envelope following OGD, ensuring that ABAD localisation to the nucleus was 
functionally relevant, rather than an artifact of aberrant protein distribution due 
to membrane damage.  The electron microscopy results show an increase in 
nuclear envelope swelling and blebbing with longer OGD durations.   The 
nucleus can be targeted during cell death processes where pro-apoptotic 
proteins can regulate the disassembly of nuclear structures including the 
nuclear membrane (Andrade et al., 2010).  The significant increase in nuclear 
blebbing might be indicative of the induction of apoptosis in the SH-SY5Y cells 
following the longer exposures to metabolic stress.   However, it is also 
important to note that despite these morphological changes, the nuclear 












Figure 4.20 ABAD interactions within the nucleus. Under both 
control and OGD conditions ABAD is found to interact with importin, a 
protein mediating protein transport across the nuclear membrane.  It 
might be hypothesised that ABAD is transported into the mitochondria 
via its interaction with importins.  Once inside the nucleus ABAD can 
interact with CDK1 and U2AF2, proteins involved in apoptosis and tau 
processing, respectively.  These ABAD protein interactions may be 









The intact nuclear envelope in these cells suggests that functional protein 
import / export machinery is still required to move proteins across the nuclear 
membrane.  The IP-MS data shows ABAD to consistently interact with importin-
4 under both control and OGD conditions (Tables 4.3 and 4.4).  Importins are 
centrally involved in the shuttling of proteins from the cytoplasm to the nucleus 
(Kohler and Hurt, 2007) and the original LC-MS study demonstrates importin-4 
to be unaffected by OGD (Chapter 3, (Herrmann et al., 2013a)).  The stable 
interaction of importin-4 and ABAD suggests ABAD may move routinely from 
the cytoplasm to the nucleus.  However, the large increase in ABAD interactions 
within the nucleus following OGD treatments along with the significantly 
increased ABAD localization to the nucleus (as confirmed with confocal 
microscopy) may indicate a change in ABAD function under conditions of 
metabolic stress.   
 
In addition to the nucleus, the mitochondria also showed a large increase in 
ABAD interactions following OGD.  The ABAD interactions with mitochondrial 
proteins can be broadly grouped into 4 categories: Fatty Acid Oxidation & Lipid 
Metabolism, Krebs Cycle & Gluconeogenesis, Protein Biosynthesis & Protein 
Folding, and Regulation of Apoptosis.  The “Krebs Cycle and Gluconeogenesis” 
interactions have already been discussed in relation to the DAVID functional 
groups these proteins falls into.  Within the “Fatty Acid Oxidation & Lipid 
Metabolism” mitochondrial sub-category, ABAD is shown to interact with Acyl-
Coenzyme A Dehydrogenase (ACADM).  ACADM initiates the first step in the 
beta-oxidation of fatty acids, a process which involves ABAD in the third stage 
(Houten and Wanders, 2010). An interaction between ABAD and ACADM 
therefore seems logical since they are closely related in function, participating 
in the same biochemical pathway of fatty acid oxidation.  More detailed 
experiments would need to be carried out to ensure these proteins are directly 
interacting rather than indirectly being precipitated as part of a “beta – 




Within the “Protein Biosynthesis & Protein Folding” mitochondrial subgroup, 
ABAD is found to interact with glucose regulated protein 75 (GRP75) under 
OGD conditions, a result confirmed in independent IP samples.  Reproducing 
this finding with a reverse co-IP would strengthen the evidence for this novel 
interactiontion between ABAD and GRP75.  GRP75 is a member of the heat 
shock 70 protein family and is traditionally thought to be located in the 
mitochondria, contributing to the successful translocation and folding of 
imported proteins (Wiedemann et al., 2004, Mizzen et al., 1991).  Based on the 
results from the IP-MS study, the interaction of ABAD and GRP75 was 
investigated in human brain tissue.  Western blot analysis showed GRP75 to 
interact with ABAD in both control and AD tissue, with a significant decrease in 
the amount of GRP75 immunoprecipitated in the AD tissue, despite the 
apparent increase in ABAD protein level in AD.  The decreased levels of GRP75 
IP’d in AD tissue may be due to a disruption of the ABAD – GRP75 interaction in 
the AD brain.  Furth investigation of more samples needs to be carried out in 
order to confirm a change in ABAD – GRP75 interactions, and to assess the 
functional relevance of this finding in relation to AD.   
 
In addition to its role in mitochondrial protein import, GRP75 has been found 
enriched at the mitochondrial associated membrane (MAM), an area of 
membrane interaction between the mitochondria and the endoplasmic 
reticulum (Hayashi et al., 2009).   The key MAM functions are in mediating lipid 
transport and calcium signalling (Voelker, 2005, Patergnani et al., 2011), both of 
which are integral to maintaining cellular homeostasis.  Analysis of the ABAD – 
GRP75 confocal images identifies a significant increase in the number of cells 
displaying a punctate pattern of ABAD – GRP75 colocalisation along the outline 
of the mitochondria (Figure 4.15).  This punctate colocalisation may be a 
correlate of the ABAD – GRP75 interaction occurring at the specific MAM region 
following OGD treatment.  Higher resolution imaging techniques, such as 




Re-inspection of the EM images taken for the analysis of nuclear membrane 
blebbing shows evidence of ER – mitochondrial interaction in SH-SY5Y cells 
following OGD.  There are insufficient examples to quantify whether the 
presence of MAM changes in response to OGD, however representative images 
of the interaction are shown in Figure 4.21. 
 
 
Figure 4.21 Electron micrographs show evidence of the Mitochondrial Associated 
Membrane (MAM) is SH-SY5Y cells following OGD treatment. 
 
A recent and significant advance in AD research was the localisation of 
presenilin-1 (PS1) and presenilin-2 (PS2) to the MAM (Area-Gomez et al., 2009).  
The presenilins form the catalytic component of γ-secretase, a protein complex 
responsible for the cleavage of APP within its transmembrane domain to release 
the neurotoxic amyloid-beta peptide (De Strooper, 2003).  The discovery of 
presenilins at the MAM, along with the newly identified ABAD – GRP75 
interaction, leads to the proposal that the MAM might be a novel site of APP 
cleavage and could therefore be the initial point of contact between ABAD and 
Aβ.  The ABAD – Aβ complex would then be in an ideal position on the outer 
mitochondrial membrane to move inside the mitochondria and mediate the well 
documented mitochondrial dysfunction characteristic of AD (Figure 4.22) 










Figure 4.22 The ABAD – GRP75 – MAM hypothesis of mitochondrial dysfunction 
in Alzheimer’s disease.  GRP75 and presenilins are enriched at the MAM.  Following 
OGD, ABAD is localised to the MAM and interacts with GRP75.  The hypothesis 
suggests that APP may also localise to the MAM following OGD where it is cleaved by 
presenilins.  The amyloid beta peptides produced from this APP cleavage can then 
interact with ABAD and be transported into the mitochondria, inducing the 










Further post-proteomic investigations need to be undertaken in order to 
validate and extend this ABAD – GRP75 - MAM hypothesis of mitochondrial 
dysfunction under conditions of metabolic stress.  Numerous research questions 
need to be addressed, including: 
 
 Is APP protein affected by OGD and / or the associated ABAD up-
regulation? 
 Does the presence of the MAM change under OGD conditions? 
 Are ABAD & APP enriched at the MAM?  
 
The ABAD – GRP75 - MAM hypothesis of mitochondrial dysfunction under 
conditions of metabolic stress suggests both ABAD and APP to be present at the 
MAM.  APP is found at the plasma membrane and can be internalised by 
endocytosis.  Research shows that the majority of amyloidogenic cleavage of 
APP occurs in endosomes, with the mildly acidic nature of these organelles 
providing the optimum environment for BACE1 mediated cleavage of APP (De 
Strooper et al., 2010).  Interestingly, the present study shows ABAD to not only 
interact with proteins at the plasma membrane, but also with proteins involved 
in protein trafficking and endocytosis.  Of particular pertinence is the 
interaction of ABAD and AP2B1, which is only detected under conditions of 
metabolic stress.  AP2B1 is the beta subunit of the AP2 protein complex, which 
itself is involved in cargo selection and vesicle formation, as well as playing a 
role in binding clathrin to vesicle membranes.   
 
 
The location of APP at the plasma membrane and the components of the γ-
secretase complex being located intracellularly (including at the MAM) is part of 
the “spatial paradox” associated with APP processing (Cupers et al., 2001).  The 
interaction of ABAD with trafficking proteins (including AP2B1) could provide 




intracellularly towards the MAM, thus feeding into the ABAD – GRP75 - MAM 
hypothesis of mitochondrial dysfunction.   
Since the discovery of the ABAD – Aβ interaction and the deleterious effects of 
this interaction on mitochondrial function, ABAD has been a focus of much AD 
research.  In order to fully understand the role of ABAD in AD, an appreciation 
of its subcellular location and interaction partners needed to be established.  
Using state of the art proteomic technology, the present study provides a 
comprehensive analysis of the ABAD protein interactome, and how these 
interactions change in response to prolonged metabolic stress.  This large scale 
IP-MS proteomics study has provided an excellent platform for the generation of 
novel hypotheses of the biological function of ABAD proteins.  The proposed 
ABAD– GRP75 - MAM hypothesis might be particularly important in providing 
the elusive link between metabolic stress, mitochondrial dysfunction and AD.  











Chapter 5:  Investigating a Possible Role 
















Chapter 5:  Investigating a Possible Role for ABAD in APP processing 
 
5.1  Background and Aims of the Chapter 
 
Amyloid binding alcohol dehydrogenase (ABAD) is a protein found at increased 
levels in the brains of Alzheimer’s disease (AD) patients (Yan et al., 1997), and 
through its interaction with amyloid-beta (Aβ), mediates mitochondrial 
dysfunction (Lustbader et al., 2004).  In Chapter 3, LC-MS revealed ABAD to be 
significantly up-regulated in response to a severe, but non-lethal oxygen-
glucose deprivation (OGD) stimulus, concurrent with a significant decrease in 
mitochondrial function.  In Chapter 4, ABAD was found to interact with glucose 
regulated protein 75 (GRP75), a protein enriched at the mitochondrial 
associated membrane (MAM).  This interaction was confirmed in human brain 
tissue.  Presenilin proteins are also enriched at the MAM, suggesting this region 
may be involved in APP processing.  
 
APP is also processed within the endocytic pathway, where the mildly acidic 
environment of the endosomes provides the optimum environment for β-
secretase mediated cleavage of APP (De Strooper et al., 2010).  Significantly, the 
data presented in Chapter 4 showed ABAD to interact with numerous proteins 
involved in protein trafficking (Figure 4.12).  The synchronised location of APP 
and ABAD at various sites throughout the cell led to the hypothesis that 
increased ABAD expression might have an effect on the expression levels and 
processing of APP.     This chapter will therefore aim to:  
 
 Determine the effect of ABAD protein overexpression in SH-SY5Y cells on 
APP expression  
 Explore the response of the mitochondrial associated membrane to 






5.2 Methods  
 
5.2.1 Western Blotting  
Western blots were used to investigate changes in expression of APP and ABAD 
in independent control and OGD samples according to the protocol described in 
Section 2.2.2.  Western blotting was also used to determine transfection 
efficiency in ABAD over-expressing SH-SY5Y cells.   Details of the antibodies 
used are shown in Table 5.1.  The intensity of the bands was assessed using 
Odyssey application software (version 3.0; Li-Cor, Cambridge, UK).  APP 





   
ABAD Abcam ab10260 1 : 500 
APP Millipore MAB348 1 : 1000 
MYC Sigma, M4439 1 : 5000 
a tubulin Abcam ab4074 1 : 50000 
      
 
Table 5.1 Antibodies used to probe the effect of ABAD 
overexpression on amyloid precursor protein 
 
5.2.2 APP – ABAD Immunoprecipitation 
Immunoprecipitation of ABAD was carried out as described in Section 2.5.2.  
The immunoprecipitated samples, along with the protein extracts from the 
original, flow through and wash steps of the immunoprecipitation were probed 
for APP (1:1000 dilution, Millipore MAB348) by western blot, according to the 






5.2.3 Bacterial Transformation & SH-SY5Y Transfection  
Transformation of the both the pCMV6-empty entry vector and pCMV6-ABAD 
vector into competent Top10 was carried out using the heat-shock method, as 
described in Section 2.3.1.  For transfections, SH-SY5Y cells were seeded at 70% 
confluency in 6-well plates, and left to adhere overnight.  ABAD DNA or empty 
vector controls were transfected into cells using the Lipofectamine 2000 DNA 
Transfection Reagent Protocol (Invitrogen, Paisley, UK). 
 
Following transfection, media was removed from cells and replaced with 1.5ml 
complete media.  Cells were collected and cells homogenised in 50μl RIPA buffer 
(50mM Tris-HCL, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% 
SDS, supplemented with protease inhibitors and PMSF).  Samples were then 
centrifuged at 12000RPM for 15mins at 4°C and the supernatant recovered.   
Protein concentrations of the samples were determined using the Pierce BCA 
Protein Assay Kit (Section 2.2.1).      
 
5.2.4 Electron Microscopy 
Cells for electron microscopy (EM) were treated with 3-, 9- and 18h OGD as 
described in Section 2.5.1, with a time-matched control collected for each time 
point.  EM sections were evaluated on a JEOL CX -100 II transmission electron 
microscope.  The evaluator was blinded to the treatment condition of all 
samples.  Cells were chosen from grid squares in a predetermined pattern. 50 
cells were assessed from each treatment.  For each cell, the extent of ER – 
mitochondrial interaction was assessed and graded as either absent, possibly 
present (where the image was inconclusive) or abundant.  A Chi-Squared 3 x 2 
matrix was used to test the null hypothesis that OGD would have no effect on 






5.2.5 Statistical Analysis 
 
Western Blotting:  Significant changes in protein abundance as detected by western 
blotting and densitometry analysis were determined with a two-tailed Students t-test 
using GraphPad Prism, version 5. 
 
Electron Microscopy:  Following blind assessment of the extent of mitochondria and 
endoplasmic reticulum interaction, a Chi-Squared 3 × 2 matrix was used to test the 
null hypothesis that OGD would have no effect on the interaction of these organelles.  
This Chi-Squared analysis was carried out in GraphPad Prism, version 5. 
 
 
5.3 Results  
 
5.3.1 APP is Significantly Decreased following OGD, Concurrent with an 
Increase in ABAD Expression 
Western blotting of independent control and OGD samples demonstrates levels 
of APP to be significantly decreased under conditions of metabolic stress.  
Densitometry analysis coupled with a student’s T-test showed this decrease in 
APP to be highly significant (p<0.001) (Figure 5.1). ABAD protein appears to 
increase in the independent OGD samples, however this this increase fails to 
reach statistical significance (Figure 5.1).    
 
5.3.2 APP and ABAD Do Not Directly Interact in SH-SY5Y cells  
The IP-MS screen for candidate ABAD interactors described in Chapter 4 did not 
detect an ABAD – APP interaction.  To verify this result, a direct investigation of 
a possible ABAD – APP interaction using immunoprecipitation (IP) on 
independent samples was conducted. The results confirmed that there is no 
direct interaction of ABAD and APP in either control or OGD treated samples 





Figure 5.1:  APP is significantly reduced concurrent with an 
increase in ABAD expression following OGD.  A. Western blot 
analysis of independent control and 18hr OGD samples show APP 
to be significantly reduced, p<0.001.  B. ABAD protein appears to 
be increased in independent samples following 18h OGD, however 
this increase fails to reach statistical significance.  Bands marked 








Figure 5.2:  ABAD and APP do not directly interact in either control 
or OGD SH-SY5Y cell samples. A. Western blotting for APP in the 
original samples used for immunoprecipitation confirm APP down-
regulation following OGD treatment.  B. Immunoprecipitation fails to 
detect an interaction between ABAD and APP in either control or OGD 








5.3.3 Pilot Data: ABAD Overexpression Affects the Expression of Mature and 
Soluble APP  
 
ABAD protein was successfully overexpressed in SH-SY5Y (Figure 5.3).  The 
band predicted to be over-expressed myc –tagged ABAD was confirmed by 
concurrent western blotting for the myc epitope (Figure 5.3).  Calculation of 
transfection efficiency showed ABAD to be over-expressed by 47.2% of 
endogenous ABAD levels at 24h post transfection, and by 47.4% at 48h post-
transfection (Figure 5.3). 
 
Once successful ABAD overexpression was established in SH-SY5Y cells, the 
effect of increased ABAD on APP expression was investigated in a pilot study.  
Western blot analysis at 24h post ABAD transfection, showed there to be no 
change in APP expression compared to non-transfected controls (Figure 5.4).  At 
48h post ABAD transfection, the 130kDa band of mature APP appears to be lost 
and the 120kDa band of soluble APP (sAPP) appears to be increased in two out 






Figure 5.3:  ABAD levels are successfully increased following 
transfection.  A. Lipofectamine transfection of ABAD DNA into SH-SY5Y 
cells successfully overexpresses ABAD at 24 and 48h post transfection 
(TF = Transfected).  B.  Western blotting for the myc tag confirms the 
overexpression of ABAD at 24 and 48h post transfection.  C.   Calculation 
of transfection efficiency shows the lipofectamine - TrueOrf origene 
vector to stably overexpress ABAD with 47% efficiency at 24 and 48h 





Figure 5.4:  Pilot ABAD transfection data.  A. At 24h post transfection 
there is no effect of ABAD overexpression on mature, soluble or 
immature APP.   B. At 48h post ABAD transfection, the mature APP band 
appears to be lost, with increased levels of soluble and immature APP in 







5.3.4 Main Study:  The Changes in APP Induced by ABAD Overexpression in 
the Pilot Study are not replicated in Separate ABAD Transfected Samples   
 
The results from the pilot study of reduced mature APP and increased soluble 
and immature APP following 48h of ABAD overexpression failed to be 
reproduced in a replicate experiment using increased numbers of samples (n = 
5 per group) and more rigorous controls (cells transfected with an empty 
pCMV6-ENTRY vector) (Figure 5.5).   
 
5.3.5 The Mitochondrial Associated Membrane is Present in SH-SY5Y cells and 
is affected by Metabolic Stress 
 
Electron microscopy analysis shows evidence of endoplasmic reticulum – 
mitochondrial interactions occurring in SH-SY5Y cells.  Under mild and 
moderate metabolic stress (3- and 9h OGD, respectively), the number of cells 
displaying ER – mitochondrial interactions is significantly decreased (Chi-
Square, p<0.01).  Following 18h OGD, the occurrence of the ER – mitochondrial 
interaction increases, returning to comparable levels to those seen in control 











Figure 5.5:  ABAD transfection data.  A. ABAD is successfully 
overexpressed in the five transfected samples, with endogenous ABAD 
unaffected by the transefection process.  B.  The up-regulation of ABAD in 
confirmed by the presence of the myc tag in the ABAD overexpressing 
samples.  C.  Two bands of APP are detected across transfected and mock 
transfected samples suggesting the vector transfection affects APP levels.  
D. Densitometry analysis of total APP shows no effect of ABAD 
overexpression on APP, compared to mock transfected controls.    (n = 5 





Figure 5.6:  The presence of the mitochondrial associated membrane 
(MAM) is affected by OGD induced metabolic stress.   A. OGD induces 
significant decreases in the number of cells showing presence of MAM.  The 
presence of MAM was categorised as “absent”, “possible presence“ and 
“present”.  (** p<0.01,  *** p<0.0001, X2, n = 50 cells for each condition)  B.  
Representative electron micrographs of the MAM in SH-SY5Y cells.  Scale bar = 







Chapter 3 identified ABAD to be significantly up-regulated in response to 
prolonged metabolic stress (18h OGD).  Chapter 4 then found ABAD to interact 
with proteins involved with endoplasmic reticulum – Golgi transport and vesicle 
mediated transport.  In addition to interactions with protein trafficking 
proteins, ABAD was also shown to interact with GRP75, a protein enriched at 
the MAM, following OGD.  The MAM has recently been shown to contain 
presenilin proteins involved in the proteolytic cleavage of APP.  The 
synchronised location of APP and ABAD at various sites throughout the cell led 
to the hypothesis that OGD, and the resulting increase in ABAD protein 
expression, might have an effect on the expression levels and processing of APP.   
 
Consistent with the first part of the working hypothesis, a significant decrease in 
APP expression was detected following 18h OGD.   The antibody used in this 
study detects three APP isoforms: immature ~110kDa, sAPP ~120kDa and 
mature APP ~130kDa.  The abundance of all three of these APP isoforms was 
significantly decreased following 18h OGD.   
 
On the basis of the significantly decreased APP expression with OGD treatment, 
immunoprecipitations were used to probe for a possible interaction between 
ABAD and APP.  Exposing a direct interaction between these two proteins would 
provide invaluable insight into a novel mechanism underpinning the APP 
reduction.  However, these IP experiments failed to detect a direct interaction 
between the APP and ABAD proteins.  Repeating this experiment with a reverse 
co-IP would strengthen the conclusion that APP and ABAD do not directly 
interact.   The lack of direct interaction between APP and ABAD does not rule 
out the possibility that increases in ABAD following OGD may lead to decreased 
expression of APP.  ABAD is an enzyme with a broad array of substrates, 




application of physiological concentrations of 17β-estradiol to R-75-1 human 
breast carcinoma cell (a cell line containing a high level of oestrogn receptors), 
the amount of the amino-terminal cleavage product of APP (soluble APP) was 
significantly increased in the culture medium (Jaffe et al., 1994).   This result 
indicates that the substrates of ABAD can have a significant effect on APP 
processing.  Therefore, despite the lack of direct interaction of ABAD and APP, 
the significant increase in ABAD protein following OGD may still indirectly affect 
the expression level of APP. 
 
The potential for an indirect action of ABAD on APP processing led to the study 
of the possible effect of increased ABAD expression on APP.  The pilot data was 
promising, appearing to show a change in ratio between mature, soluble, and 
immature APP.  The mature APP isoform is lost in two of the three ABAD over-
expressing samples, with the sAPP and immature APP appearing to be to be 
darker, indicative of increased amounts of these isoforms.   
 
Regrettably however, the pilot results failed to be reproduced in a more 
extensive transfection study involving increased sample numbers and more 
rigorous control (control cells were transfected with an empty TrueOrf origene 
vector Figure 2.2).  In this study, only two clear APP bands were detected across 
all samples as opposed to the previously detected three bands.  This result 
suggests that the transfection process produces experimental artefacts that 
alter the expression of endogenous APP, and highlights the importance of 
rigorous experimental controls to avoid false interpretations of experimental 
artefacts.  Repeating the western blots on a lower percentage gel might separate 
the APP isoforms more effectively, providing further insight as to which of the 






It is therefore concluded that the ABAD overexpression seen in response to 18h 
OGD does not directly affect the expression or processing of APP.   There must 
therefore be other important processes that are initiated under conditions of 
metabolic stress that mediate the observed decrease in APP levels.   
 
Of major importance to AD research, the decrease in APP may be attributable to 
an increase in proteolytic cleavage, either via the amyloidogenic or non-
amyloidogenic pathway.  The proteomic data collected in Chapter 3 sheds little 
light on whether either of these APP proteolytic processing pathways is 
activated following 18h OGD.  However, research from other groups has shown 
a significant decrease in α-secretase enzume ADAM10 following 8h OGD in SH-
SY5Y cells, with no change in β-secretase BACE1 enzyme activity or expression, 
and a significant increase in γ-secretase activity (Lee et al., 2006).  Similar 
studies investigating the expression and activity of the APP secretase enzymes 
in our OGD cell culture, along with assessment of Aβ levels, would clarify the 
potential role of APP proteolytic processing in the observed APP down-
regulation following 18h OGD.    
 
Autophagy could be another possible process accounting for the decreased APP 
expression following 18h OGD.  Autophagy describes the process by which 
cellular constituents are targeted to lysosomes for degradation.   APP at the 
plasma membrane is endocytosed, where it is either amyloidogenically 
processed in the endocytic organelles, recycled back to the plasma membrane, 
or degraded in lysosomes (Haass et al., 2012).  The electron microscope data 
described in Chapter 3 identified the presence of autophagosomes in the SH-
SY5Y cells, however the number of autophagosomes was not altered in response 
to OGD, suggesting this route of APP degradation may not be the prime cause of 
the decreased APP expression seen here following 18h OGD.   Repeating the 




Alternatively, the ubiquitin - proteasome protein degradation pathway may be 
another possible mediator of the APP down-regulation following 18h OGD.  
Ubiquitination involves a sequence of enzymatic reactions including ubiquitin-
activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin-
protein ligase (E3). Research has shown that F-box and leucine rich repeat 
protein2 (FBL2) (part of the E3 ubiquitin complex) interacts with APP, 
mediating its ubiquitination and subsequent proteasomal degradation 
(Watanabe et al., 2012).  The proteomic characterisation of SH-SY5Y cells 
described in Chapter 3 identified significant increases in 26s proteasome 
proteins, with Protein Folding and Degradation being a significant interactome 
identified by Ingenuity Pathway Analysis.  It is therefore possible that the 
significant decreases in APP following OGD might be due to ubiquitin - 
proteasome protein degradation. 
 
The lack of effect of ABAD overexpression on APP protein levels in the present 
study is disappointing.  However, the data presented here is by no means futile.  
The results from the transfection experiments show SH-SY5Y cells to be capable 
of successful ABAD over-expression, with almost 50% transfection efficiency at 
24h.  This data provides a solid basis for further investigative studies into the 
mitochondrial and cellular dysfunction associated with ABAD overexpression in 
AD. 
 
Using the proteomic data described in the previous chapters as a hypothesis 
generator, a logical next experiment would be to investigate whether ABAD 
overexpression has any effect on the significant down-regulation of CDK5RAP2 
seen following 18h OGD.   ABAD is shown to interact with CDK5RAP2 under 
control conditions, however following OGD, this interaction is lost, ABAD is 
significantly up-regulated, and CDK5RAP2 is significantly down-regulated 
(Figure 4.13,).  CDK5RAP2 affects the localisation and substrate specificity of 
cyclin-dependent kinase-5 (Cdk5), a protein involved in tau 




2003).  Following up this line of research in the ABAD overexpressing cells 
might therefore provide insight into potential links between the ABAD protein 
and tau pathology, two important elements in cellular dysfunction related to AD.   
 
An important finding from the previous chapter was that following OGD, ABAD 
interacts with GRP75, a protein enriched at the MAM (Figure 4.14).  This result 
was confirmed in human control and AD tissue.  Confocal microscopy showed 
the ABAD – GRP75 colocalisation to have a significantly more punctate 
appearance along the surface of the lacy GRP75 stained mitochondria, possibly 
indicative of the distinct colocalisation of these proteins at the MAM.    
 
Based on these findings, electron microscopy was used to assess the effect of 
mild, moderate and severe OGD on the mitochondrial associated membrane.  
Following mild (3h OGD) and moderate (9h OGD) metabolic challenge, the 
number of cells showing evidence of MAMs was significantly decreased 
compared to time matched controls (Chi-Square, p<0.01).   
 
The dynamic nature of the MAM suggests it is responsive to changes in the 
cellular environment.  In addition to Ca2+ homeostasis, the MAM is also involved 
in cholesterol metabolism, with acyl-CoA:cholesterol acyltransferase (ACAT) 
being  highly enriched in this membrane region (Hayashi et al., 2009).  
Cholesterol homeostasis is important for cell survival as accumulation of free 
cholesterol can be toxic to cells.  To prevent accumulation and toxicity, ACAT 
converts cholesterol to cholesterol esters, are then exist within lipid droplets in 
cells (Chang et al., 2006).  However, ACAT mediated cholesterol esterification 
requires ATP as a cofactor (Chang et al., 1997), therefore under conditions of 
low ATP availability, this process may be shut down.  The reduction in presence 
of MAM, as evidenced by electron microscopy, may well be an ultra-structural 





Research shows cholesterol processing to be aberrant in AD.  Circulating total 
cholesterol and cholesterol esters in the brain are increased in AD patients, but 
the reasons for these changes are unknown (Schon and Area-Gomez, 2013).  
Further characterisation of the ACAT enriched MAM and its alterations under 
conditions of metabolic stress might therefore provide further insight into the 
cholesterol changes that are linked to AD.   
 
The MAM also plays a key role in ER – mitochondrial Ca2+ crosstalk, with the 
close proximity of the ER – mitochondrial membranes allowing Ca2+ released 
from the ER to be directly taken up into the mitochondria.  Mitochondrial Ca2+ 
levels are important in regulating many cellular functions, including ATP 
production and cell death (Patergnani et al., 2011).  Prolonged increases in 
mitochondrial Ca2+ causes the mitochondrial permeability transition pore (PTP) 
to open, a crucial step in the process of apoptotic cell death (Kim et al., 2003).  It 
might therefore be hypothesised that the recovery of MAM abundance to 
control levels following 18h OGD may be part of an apoptotic mechanism to 
initiate programmed cell death following severe metabolic challenge.  
 
The enrichment of presenilins at the MAM, the interaction and colocalisation of 
ABAD to important MAM proteins, the role of the MAM in cholesterol 
homeostasis, and the adaptive nature of the MAM under conditions of metabolic 
stress all suggest that this protein enriched membrane region may have an 
important role to play in AD.  If indeed the decrease in APP described in the 
present chapter is due to amyloidogenic proteolytic processing, then the ABAD – 
GRP75 – MAM hypothesis of mitochondrial dysfunction described in Chapter 4 
may well be valid.  This hypothesis suggests that following prolonged OGD, 
ABAD localises to the MAM via its interaction with GRP75.  BACE-1 cleaved APP 
may also then localise to the MAM following OGD, where it is further cleaved by 
presenilins to form Aβ.  These Aβ peptides then interact with ABAD and are 
transported into the mitochondria, inducing the mitochondrial dysfunction that 




The biochemical basis for the significant reduction in APP processing following 
OGD treatment remains to be elucidated.  Furthermore, future studies involving 
MAM fractionation followed by western blotting for ABAD protein enrichment, 
both before and after OGD treatment, would help to test the proposed 
hypothesis.  Additionally, blocking the interaction of ABAD and GRP75, and 
monitoring the effect this intervention has on the OGD induced mitochondrial 

















Chapter 6:  Discussing the Utility of the 
Present Studies and Future Proteomic 
Investigations in enhancing our 












6.1 Reviewing the research findings and their impact on our 
understanding of Alzheimer’s disease  
 
Epidemiological studies have identified vascular disorders inducing a state of 
chronic cerebral hypoperfusion to be important risk factors for late-onset AD 
(Breteler, 2000),  however the underlying biological mechanisms for this 
remain elusive.  The aim of the present research was to establish the proteomic 
basis of cellular dysfunction under conditions of metabolic stress, and 
determine whether the detected protein changes can provide insight into how 
chronic cerebral hypoperfusion might be linked to AD.   
 
6.1.1 Chronic metabolic stress induces mitochondrial protein changes 
that are also seen in post-mortem Alzheimer’s disease brains 
A major limitation of AD research is that biochemical investigations of the 
human brain are limited to post-mortem tissue analysis.  Beyond the general 
limitations of working with human tissue (homogeneity of samples, protein 
degradation, and limitations of experimental controls), there is the overriding 
yet unavoidable drawback that this is dead tissue at the end-stage of the 
disease.  Proteomics research on such tissue is useful in identifying end-stage 
biomarkers, but has limited utility in uncovering the underlying causes of 
cellular dysfunction.   However, the value of these post-mortem AD proteomics 
studies is greatly enhanced when interpreted in conjunction with an 
investigative intervention study, such as oxygen-glucose deprivation (OGD) 







OGD is an established in vitro model of chronic cerebral hypoperfusion, where 
the experimental conditions and can be tightly controlled to produce 
exceptionally reproducible proteomic data.  The initial study presented here 
identified proteins involved in mitochondrial energy production, protein 
folding, and protein degradation to be significantly altered in response to OGD.  
For example, specific protein changes were detected within the electron 
transport chain, consistent with the significant mitochondrial dysfunction 
recorded following OGD treatment.  Increases in abundances were seen in 
proteins from complex I and complex V, and significant decreases found in 
complex III proteins.  These bidirectional protein changes demonstrate a direct 
link between disrupted oxygen and glucose delivery to cells and the alterations 
in mitochondrial function that are common in AD.   
 
Not only are these protein changes important in uncovering potential causes of 
mitochondrial dysfunction under conditions of metabolic stress, but also they 
extend our understanding of mitochondrial dysfunction in AD.  Post-mortem 
analysis of AD brain tissue identifies a decrease in ETC complex III, however the 
causes of this reduction were, until now, unknown.  The present proteomics 
study provides direct evidence for a reduction in cellular oxygen and glucose 
delivery to cause a down-regulation of complex III subunits.  It is therefore 
feasible that the vascular disorders that are known to be risk factors for AD 
induce a state of chronic cerebral hypoperfusion, disrupting the delivery of 
oxygen and glucose to neurons, thus driving the decrease in complex III 
expression found in post-mortem AD brains.  The present research has 
therefore extended our understanding of the proteomic basis of mitochondrial 
dysfunction in response to OGD, which is directly relevant to the mitochondrial 






However, further work clearly needs to be undertaken in order to fully elucidate 
the mechanisms underpinning these mitochondrial protein changes.  Individual 
activity of each mitochondrial complex would provide further insight as to the 
functional relevance of the described up- and down-regulated proteins.  
Furthermore, the IPA network analyses described in Chapter 3 identify many 
novel putative protein – protein interactions.  Future work validating and 
interrogating the role of these interactions in the altered ETC proteins would 
potentially uncover novel sites of intervention to avert the mitochondrial 
dysfunction under conditions of metabolic stress.     
 
6.1.2 Chronic metabolic stress induces the endoplasmic reticulum stress 
response: implications for proteostasis mechanisms in Alzheimer’s 
disease 
 
Mitochondria clearly play an important role in both normal cell function and in 
the dysfunction associated with AD.  However, AD is primarily thought of as a 
disease associated with protein misfolding and aggregation, with amyloid 
plaques and tau tangles considered key hallmarks of the disease.  Cellular 
proteostasis is maintained through the normal functioning endoplasmic 
reticulum.  Understanding the proteomic basis of endoplasmic reticulum 
function and the response of ER proteins to reduced oxygen and glucose 
environments is therefore integral to understanding how vascular risk factors 








The ER stress response (also known as the unfolded protein response, UPR) is 
an ER mediated process involved in clearing misfolded proteins and returning 
the cell to a state of proteostasis (Scheper et al., 2011).  Two central molecular 
chaperones, GRP78 and GRP94, involved in the early and late stages of the UPR 
respectively,  were significantly up-regulated following OGD, indicative of the 
initiation of the UPR in response to metabolic stress.  Concurrent with this 
proteomic data, electron microscopy images show swelling of the endoplasmic 
reticulum lumen following OGD.  Enlarged endoplasmic reticulum can 
accommodate more unfolded proteins, with the larger area reducing the risk of 
aggregation of protein intermediates (Bernales et al., 2006).  Therefore, both 
proteomic and morphologic data show that cellular deprivation of oxygen and 
glucose initiates the UPR.  
 
The described UPR activation under cellular stress conditions is not in itself 
novel.  However, what is unique about the present system is that the cells 
undergo periods of chronic oxygen and glucose depletion in the absence of cell 
death.    It would therefore be worth investigating whether the activation of the 
UPR is serving to avert the cellular dysfunction and ultimate cell death that 
would normally be associated with an accumulation of misfolded proteins 
under conditions of cell stress.    
 
Once again, consideration of this UPR proteomic data alongside animal and 
human AD studies serves to advance our understanding of how vascular risk 
factors might be linked to AD.  In our in vitro model of chronic cerebral 
hypoperfuson, the UPR is activated to deal with the accumulation of damaged 
proteins casued by metabolic stress.  It is therefore hypothesised that this UPR 
activation plays an important part in averting cell death within our system.  The 
same may well be true in AD.  Age associated vascular risk factors can reduce 
cerebral blood flow, and therefore oxygen and glucose delivery to the brain, 




misfolded proteins that are dealt with through a functioning UPR.  Data 
acquired from mice studies shows evidence of decreased expression of UPR 
proteins with advancing age (Naidoo et al., 2008).  This age associated decline in 
expression of UPR proteins, alongside a continued state of cerebral 
hypoperfusion, would lead to a build-up of damaged and aggregating proteins, 
causing increased cellular stress, and eventually neurodegeneration.   
 
Clearly more work needs to be undertaken to validate this hypothesis.  
However, it is clear that the proteomic data gained from the present research 
has provided a feasible hypothesis that may significantly advance our 
understanding of how vascular risk factors are linked to protein aggregation 
and AD.   
 
6.1.3 ABAD protein: the link between vascular risk factors and 
Alzheimer’s disease? 
 
Amyloid binding alcohol dehydrogenase (ABAD) was significantly increased 
following severe metabolic challenge.  ABAD is emerging as an important player 
in mitochondrial dysfunction and AD.  The second phase of research reported 
here used protein immunoprecipitation coupled to LC-MS to identify many 
novel ABAD protein interactions under control and OGD conditions.  Functional 
analysis showed ABAD and its interacting partners to be involved in glucose 
metabolic processes, cell redox homeostasis and RNA processing.  ABAD was 
found to interact with important proteins already linked to neurodegeneration, 
a result which implicates ABAD as a potentially important link between 






A limitation of the ABAD protein interactions are studied in homogenised tissue, 
potentially resulting in the generation of non-physiologically relevant protein 
interactions. Additionally, the ABAD protein interactions are seen in isolation, 
without consideration of the subcellular compartments or the many competing 
protein interactions that occur within intact cells. Moreover, in the example of 
the ABAD – GRP75 interaction, colocalisation analysis only shows the proteins 
to be located in the same subcellular region, and is not indicative of direct 
protein interactions.  
  
A more informative future study would be to use ffluorescence lifetime imaging 
microscopy (FLIM), a technique based on Förster resonance energy transfer 
(FRET). Fluorescence lifetime is the amount of time a molecule spends in an 
excited state before returning to ground state, with the release of a photon.  
FRET describes the transfer of energy from the excited state molecule to 
another nearby molecule, which usually occurs over distances less than ~10 nm 
(Sun et al., 2011).  FRET therefore provides a sensitive tool for investigating 
protein – protein interactions in living cells that would be useful in further 
validation of the ABAD – GRP75 interaction.  However, there are limitations 
associated with this technique.  For example, the large size of fluorescent 
protein tags can interfere with the protein – protein interaction of interest, thus 
risking the creation of false negative data.  Similarly, it is possible that the 
fluorescent tags might interact with each other, therefore creating false positive 
data (Piston and Kremers, 2007).  These factors need to be carefully considered 
and the appropriate control experiments undertaken in any research utilizing 







6.1.4 Assessing the utility of proteomics as a hypothesis generator in 
researching the vascular basis of Alzheimer’s disease  
 
In the present study, the interaction of ABAD with proteins involved in the 
endocytic pathways and at the mitochondrial associated membrane (MAM) 
(both of which have been linked to the amyloidogenic processing of APP) led to 
the hypothesis that metabolic stress and the overexpression of ABAD may 
impact on the proteolytic cleavage of APP.  The experiments in the final data 
chapter found OGD to significantly reduce APP protein levels within SH-SY5Y 
cells.   Unfortunately, the hypothesis that an overexpression of ABAD might be 
involved in this decrease in APP expression was not confirmed.  It might 
therefore be concluded that the utility of proteomics as a hypothesis generator 
is limited in this case.  However, the proteomic data also implicated the MAM as 
a possible player in the cellular response to metabolic stress.  This result was 
confirmed in the adaptive response of the MAM detected under conditions of 
metabolic stress with electron microscopy, providing tangible evidence of the 
utility of proteomics in meaningful hypothesis generation.   
 
In the wider research field, the utility of proteomics in enhancing our 
understanding of the vascular risk factors associated with AD greatly depends 
on the tissue and the models being investigated.  Quantitative LC-MS in cortical 
samples of AD brains identified 197 proteins to be significantly altered in 
abundance compared to control brain samples. These proteins were involved in 
various processes including regulation of protein phosphorylation, lipid 
metabolism, energy production, and cell death (Andreev et al., 2012). The 
identification of proteins involved in energy production suggests some level of 
metabolic challenge, but with the high variability and co-morbidities in human 
brain samples it is difficult to pinpoint specific causes of individual protein 
changes.  Moreover, proteomic data from post-mortem tissue provides little 
insight into the potentially modifiable disease processes occurring early in 




A further complexity in the use of proteomics to identify biomarkers of AD 
comes from the difficulty in identifying appropriate, healthy, aged-matched 
control tissue.  The nature of neurodegeneration in AD is that cellular 
dysfunction and disease processes evolve over time.  It is therefore impossible 
to predict whether an individual’s brain tissue represents a true “healthy” 
control rather than simply being at an earlier stage in the neurodegenerative 
process.     
 
As an alternative to the use of human tissue for research into the proteomic 
basis of AD, animal models can be developed to extend our understanding of the 
cellular changes occurring in the earlier stages of AD progression.   For example, 
proteomic analyses of APP/PS-1 double transgenic mice at 9 months (prior to 
Aβ deposition) and 12 months of age (post Aβ deposition) have been used to 
model the earlier and later stages of AD.   Many of the significantly altered 
proteins were involved in energy production pathways, most pertinently being 
the bidirectional change in ATP synthase subunits, which were decreased in the 
younger Tg mice and increased in the older Tg mice (Robinson et al., 2011).   
 
In addition to the Tg mouse models of AD, numerous models of reduced 
cerebral blood flow exist that would allow the effect chronic cerebral 
hypoerfusion (CCH) on the brain to be directly analysed with proteomics.  
Despite the existence of these useful animal models of CCH, relatively few large 
scale proteomics-based studies have been conducted with them. Future 
proteomics studies using these animal models will certainly be complementary 
to the various studies completed on human tissues and in cell culture.  However, 
it may be still challenging to draw direct parallels between the different 
proteomic data sets. Indeed, each cell culture, human and animal model have 
their strengths and weaknesses, and the most useful strategy going forward will 
be to use combinations of models and techniques to study the disease processes 




6.2 The extent to which LC-MS proteomics can advance our 
understanding of Alzheimer’s disease greatly depends on 
appropriate experimental design and data handling strategies 
 
The experimental evolution of this thesis, from large-scale LC-MS research to 
focussed analysis of ABAD – APP processing, provides evidence that proteomics 
can advance our understanding of the biological processes linking vascular risk 
factors and AD.  The success of this proteomic research is largely dependent on 
the level of experimental rigour upstream of LC-MS, and the down-stream data 
analysis strategies.   In numerous other proteomic studies, fundamental 
weaknesses and arbitrary design decisions are present, which skew the 
interpretation of the proteomic data, and potentially produce misleading 
results.  In order to assess whether LC-MS proteomics can truly provide insight 
into the biological mechanisms underlying AD, it is important to critically 
appraise the current accepted protocols of LC-MS data acquisition and analysis.   
 
6.2.1  Assessing the reproducibility of LC-MS protein detection 
If proteomic studies are to provide insight into complex biological mechanisms, the 
LC-MS platform itself has to be highly reproducible in the detection of protein 
abundance.  The design of the human cell line in vitro study provides a unique 
opportunity to examine internal variability of the LC-MS system.  SH-SY5Y cells were 
exposed to OGD for a short duration (6h) and a longer duration (18h). Linear 
regression analysis of the control data from this study demonstrates the high 
technical reproducible the LC-MS system between samples (Figure 6.1).   The effect 
of abundance on the reproducibility of protein detection was analysed using the in 
vitro proteomic data.  It is generally accepted that lower abundance proteins are less 
reproducibly detected than higher abundance proteins(Wang et al., 2010).  Our data 
shows that the lowest abundance proteins do indeed show a slight increase in 






6.2.2 Considering the trade-off between reducing variance and the 
number of proteins remaining for analysis  
The first common step in proteomic data dissection is exclusion of proteins identified 
with fewer than two peptides.  Though seemingly arbitrary, this exclusion criterion is 
important for two reasons: firstly, removal of 1-peptide proteins increases the 
security of the LC-MS data to identify true protein levels and avoid false detections.  A 
single peptide feature may be found in several different proteins or protein isoforms, 
therefore a truly definitive identification is less likely (Mallick and Kuster, 2010).  
Secondly, this cut-off significantly reduces the variance within the dataset, increasing 
the power to detect subtle protein changes, as demonstrated through the analysis of 
contemporaneous cell culture and mouse model LC-MS data (Figure 6.2).  However, 
there is clearly a trade-off between reducing variance and the number of proteins 
remaining for analysis.  Extending the inclusion criterion to identification of proteins 
with 3 or more peptides further reduces variance, however also drastically reduces 
the number of proteins available for further analysis by nearly half of those originally 

















Figure 6.1 LC-MS protein detection is highly reproducible with 
protein abundance having minimal effect of detection.  A.  The 
mean protein abundances from control cohorts from the 6hr and 18hr 
OGD experiments were plotted against together to demonstrate the 
reproducibility of protein quantitation using LC-MS technology.  B.  
Lower abundance proteins are detected with higher variability across 
control samples than higher abundance proteins, however the overall 







Figure 6.2:  2+ peptide identification inclusion criteria reduces 
variance.  Increasing the number of peptides used to identify a protein 
increases the confidence of the identification, reduces the number of 
proteins available for statistical analysis and reduces variance. A.  Using the 
common inclusion criteria of proteins identified with at least 2 peptides 
reduces the mean variance from 17% to 12% in the in vitro cell line model of 
CCH.  B.   Similarly, the same inclusion criterion applied to mouse whole 
brain proteomic data reduces the mean variance from 24% to 17%.  More 
stringent inclusion criteria of proteins identified with 3 or more peptides has 
minimal effect on the overall variance of the data set, with a reduction of 1% 
and 2% in the cell line and whole brain respectively.   All data shown for 
control groups.  Mouse whole brain neuroproteomic data was generously 





6.2.3 Upstream tissue processing is associated with increases in variance 
structure, limiting the ability to detect subtle protein changes 
 
Understanding the sources of variance in protein detection is important in order to 
allow experimental steps to be taken to limit this variance and increase the ability to 
detect small protein changes.   Sample processing techniques including microvessel 
dissection (Hartz et al., 2012), mitochondrial enrichment (James et al., 2012a) or 
synaptosomal fractionation(Ansari and Scheff, 2010) can be used upstream of 
proteomic analysis to provide a more detailed proteomic profile of how individual 
cell types and subcellular compartments are affected by different experimental 
conditions.  However, by increasing technicality upstream of protein detection, the 
variance of the final dataset is also increased, as demonstrated by the analysis of 
proteomic data generated after a range of brain region dissection and fractionation 
techniques had been employed (Figure 6.3).  These data demonstrate that intricate 
upstream tissue handling techniques leads to larger coefficients of variance, with up 
to 20% increases in variance in the most technically demanding studies compared to 
whole brain homogenates.  Adding value to biological research through upstream 
tissue processing is beneficial in answering specific biological questions, however the 
effect of the associated increases in variance structure needs to be considered:  more 











Figure 6.3.  More complex tissue processing techniques increase variance.  Whole brain tissue samples show practically identical 
coefficients of variance in both sham and CCH (14% and 13% respectively).  White matter dissection introduces more variance into 
the system (20% and 21% for sham and CCH respectively). Technically demanding techniques such as microvessel dissection further 
increase variance (32% and 37% in WT and Tg mice respectively). Independent variables (surgery or transgene) had little effect on 
the coefficient of variance.   Mouse neuroproteomic data was generously made available for analysis by Dr JL Searcy.  
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6.2.4 Fold change is a misleading and inappropriate inclusion criterion in 
proteomic studies, excluding important proteins from data analysis 
 
In addition to the number of peptides used for identification, the magnitude of 
the detected change (fold change) is another popular inclusion / exclusion 
criteria used by researchers to dissect the huge data sets produced by LC-MS 
(Tiwari et al., 2012, Polisetty et al., 2012).  The level of fold change that can 
reliably be detected within a given experiment can be deduced through simple a 
priori power calculations, based on number of replicates and an estimate of the 
variance.  However, the nature of a priori power calculations means that 
without extensive pilot data, an estimate of variance needs to be made, which 
may or may not be appropriate to the specific study (where tissue type and 
sample processing upstream of LC-MS has a huge impact on variance structure).  
As a result, many published proteomic papers default to an inclusion criterion of 
a minimum 1.5 or 2 fold change, with no apparent explanation for the use of this 
value.  
 
Analysis of the in vitro proteomic data shows protein fold change inclusion 
criteria to be misleading, inappropriate and risks the creation of many false 
negatives.  In this in vitro study, the effect of global metabolic challenge on 
mitochondrial function and cellular proteomics was investigated. A total of 958 
proteins were identified with 2 or more peptides.  An a priori decision on 
statistical analysis dictated the use of a stringent significance threshold of 
p<0.01 for a protein change to be deemed significant, resulting in a final protein 
list of 193 significantly altered proteins.  However, as well as a p-value 
threshold, many investigators also employ a fold change cut-off to rapidly 
identify the most “important” protein changes.  Datasets with a low overall 
variance allow for the detection of subtle protein changes, however, employing 
an arbitrary fold change inclusion criterion such as the popular “minimum 1.5 
fold change” on these low variance datasets excludes the subtle yet significant 
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protein changes. The fold change cut-off drastically reduces the number of 
proteins included in the final analysis and increases the risk of creating false 
negatives (Figure 6.4) 
 
A similar analysis of the impact of arbitrary fold change cut-offs was carried out 
on the more variable microvessel extraction data (Figure 6.4). Due to the 
increased variability of these data (as shown in Figure 6.3), employing a 
stringent alpha value of P < 0.01 significantly reduces the number of proteins in 
the final list for analysis from 653 identified with two or more peptides to only 
12. In this more variable system, imposing a 1.5 fold change cut-off has no 
further effect on protein number, due to a large fold change required to 
overcome the variance for inclusion at the set alpha level. It is therefore 
concluded that inclusion of a fold change data cut-off is either dangerous in the 
creation of false negatives (in studies with low overall variance) or irrelevant 
(in studies with high overall variance). 
 
Alternatively, power calculations can be used to determine the magnitude of 
change required to detect a significant difference between two populations 
given the technical and biological variance (Levin, 2011).  Used a priori, power 
calculations are beneficial in study design, guiding decisions regarding the 
number of replicates needed to obtain a set level of power (Bezeau and Graves, 
2001).  However, the nature of a priori power calculations means these 
calculations are based on an estimate of overall biological and technical 
variance.  Our analysis reveals that the coefficient of variance is highly 
dependent upon the type of tissue being analysed and the degree of upstream 
tissue processing involved (Figure 6.3).  Using a coefficient of variance that is 
not specific to the dataset to decide detectable fold change can be problematic, 
and could lead to an over- or underestimation of proteins found to be 
differentially expressed.  To ensure maximum accuracy in a priori power 




Figure 6.4:  Arbitrary fold change cut-offs are associated with the increased 
likelihood false negatives.  A. Employing the common “minimum 1.5 fold change” 
inclusion criterion on datasets with low overall variance drastically reduces the 
number of proteins available for analysis.  A stringent alpha value of p<0.01 reduces 
the number of proteins in from 958 identified with 2 or more peptides to 193.  
Imposing an additional fold change cut-off of 1.5 on this reduced protein list results in 
a final list for analysis containing only 34 proteins.  B.  Analysis of the more variable 
microvessel enrichment data demonstrates that a stringent alpha value of p<0.01 
reduces the number of proteins available for analysis from 653 identified with 2 or 
more peptides to only 12.  Imposing a 1.5 fold change cut-off has no further effect on 
protein number, due to a large fold change required to overcome the variance for 
inclusion at the set alpha threshold.  Mouse neuroproteomic data was generously 
made available for analysis by Dr JL Searcy.   
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The question of whether inclusion of fold change cut-offs in addition to a p-
value adds any biological value to proteomic data remains.  To assess this, we 
identified two key proteins involved in the endoplasmic reticulum stress 
response: glucose regulated protein 78 (GRP78) and glucose regulated protein 
94 (GRP94).  In our in vitro study, experimental intervention with the metabolic 
challenge of OGD saw significant up-regulation of both of these proteins 
(p<0.01).  However, GRP78 underwent a fold change of 1.53, whereas GRP94 
only had a fold change of 1.48 (Figure 6.5) (Herrmann et al., 2013a).  The 
popular fold change cut-off of 2 would exclude both of these proteins from the 
analysis, and only GRP78 would be included if a fold change of 1.5 was used.   
 
The interplay between these two proteins is integral to the endoplasmic 
reticulum stress response, however one or both of these proteins would be lost 
from the final dataset if an arbitrary fold change inclusion criterion was 
employed.  Temporal evolution of protein level alterations is another important 
factor to be considered when elucidating complex protein pathways.  Data from 
the in vitro study demonstrates that following 6h of OGD, small increases in 
protein levels of GRP78 and GRP94 predict larger increases following 18h OGD 
(Figure 6.5).  These results suggest that protein fold change should not be used 
as threshold for inclusion, but rather as an indicator of evolving events 
occurring within the cell.  A protein exhibiting a small fold change at an early 
time point can be indicative of increasing abundance that might be detected as 








Figure 6.5: Conventional proteomic fold change inclusion criteria 
would exclude biological relevant proteins from further analysis. 
A.  GRP78, a critically important protein in the endoplasmic reticulum 
stress response is significantly increased following a severe metabolic 
challenge (18h OGD), and undergoes a fold change increase of 1.53 from 
control to OGD samples.  This protein would be included for further 
analysis in most proteomic studies  B.  Biologically related protein 
GRP94 is also  significantly increased following a severe metabolic 
challenge (18h OGD) however undergoes a fold change increase of 1.48.  
This protein would be excluded from further analysis in most proteomic 
studies, demonstrating the arbitrary and irrelevant nature of fold 
change inclusion criteria.  Each data point in A and B represent an 
independent biological replicate (n=6 for each condition, *** p < 0.0001, 




The ability to detect a fold change at a particular level of significance is 
intrinsically linked to the variance of the data, and this variance is dependent on 
tissue source and processing techniques used.  It is therefore misguided to 
include fold change in the initial stages of data dissection.  A protein reaching 
the threshold set by a stringent p-value (which in its nature incorporates the 
variance and the magnitude of change) should be sufficient for the initial 
inclusion criterion, resulting in a much reduced but relevant list of protein 
changes (Figure 6.4). 
 
The concept of excluding proteins based on fold change not only increases the 
likelihood of making type II errors, but is also fundamentally flawed, given that 
the biological relevance of a change in protein abundance is likely to be protein 
specific.  For example, proteins in the Bcl-2 family are important evolutionarily 
conserved regulators of apoptosis.  However, even within this family, certain 
proteins are more influential that others: PUMA (p53 up-regulated modulator 
of apoptosis) being one of the most potent (Yu and Zhang, 2008).  Subtle 
changes in this protein are likely to have important cellular effects, however 
may be ruled out if stringent fold change cut-offs are employed when analysing 
data.  The importance of subtle protein changes needs to be recognised in the 
analysis of large proteomic datasets to avoid the loss of valuable data through 









6.3 The future of proteomics in Alzheimer’s disease research 
 
The field of AD research is in desperate need of novel hypotheses as to the 
causes of cellular dysfunction and cognitive decline associated with this 
devastating disease.  The research presented in this thesis demonstrates the 
utility of proteomics for this much needed hypothesis generation.  The 
experiments evolved from a highly descriptive protein quantification study, 
through to the identification of interesting protein candidates that might link 
metabolic stress and AD, and finally to the development of a novel hypothesis 
relating ABAD protein, the MAM and APP processing.     
 
The promise of novel proteomic based AD hypotheses is enhanced by the 
current evolution of proteomic research into its 3rd generation.  3rd generation 
proteomics will focus on investigating the spatial and temporal response of 
proteins, above and beyond simple protein identification and quantification.   In 
order to achieve these aims and enhance the field of AD research, mass 
spectrometry based experiments will need to be carried out in combination 
with other experimental techniques.   
 
Improved spatial resolution of proteomic data can be achieved through 
subcellular fractionation in advance of mass spectrometry.  However, as 
discussed, fractionation methods are associated with increased variance within 
the final proteomic data set.  Careful experimental design will therefore need to 
be undertaken in order to maximize the utility of such proteomic datasets in 
future AD studies.   
 
Alternatively, advances in imaging techniques are making localization of 
proteins within cell or tissue samples highly effective.  For example, the spatial 
resolution of light microscopy has been greatly advanced through the 
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development of array tomography.  The ultrathin tissue sectioning used in this 
technique overcomes the limitations of axial resolution associated with 
standard confocal microscopy.  Proteins of interest within these sections can be 
labelled with immunofluorescent antibodies and imaged at high resolution, 
even to the level of individual synapses (Kay et al., 2013).  Employing array 
tomography in conjunction with hypothesis generating AD proteomic studies 
will increase the spatial resolution of novel protein biomarkers, greatly 
enhancing our understanding of specific proteins involved in AD pathogenesis.    
 
In addition to high-resolution imaging, a host of experimental methods exist 
that could be used to investigate the functionality of novel protein biomarkers 
identified in AD proteomic studies.  Electrophysiological investigations of native 
vs genetically manipulated cells can provide insight as to the role of proteins of 
interest in neuronal excitability.  In addition, evolution of genetic manipulation 
technology, for example, by tetracycline-controlled transcriptional activation, 
allows the control of specific protein expression to be manipulated in living 
animals.  This tool, in combination with discovery proteomics, would allow the 
function and effect of novel AD related proteins on animal phenotypes and 
behaviours to be examined.    
 
In conclusion, the power of proteomics lies in its role as a hypothesis 
generator, and a tool for generating novel biomarkers and drug targets of 
disease.  With the availability of a host of in vitro and in vivo AD models, 
and a wide range of complementary experimental technologies, 
proteomics is poised to make significant advances in our understanding of 
AD pathophysiology.   
 
Data from this discussion are published in Proteomics                    
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Calculating an appropriate enrichment ratio for the identification of putative 






Total proteins detected in all samples with liquid chromatography mass spectrometry (LC-MS).  958 proteins were detected with 2 or 
more peptides.  14 proteins were significantly altered following 6h OGD (p<0.01).  193 proteins were significantly altered following 18h 
OGD (p<0.01).  Significant protein changes are designated by bold typescript.  Proteins are displayed alphabetically with p value, fold 
change, and direction of the protein change reported. 
    6h OGD 18h OGD 











NP_002148.1 10 kDa heat shock protein, mitochondrial  0.879 1.01 Down  0.00001 1.51 Up 
NP_004238.3 
116 kDa U5 small nuclear ribonucleoprotein component isoform 
a  
0.420 1.03 Up 0.007 1.19 Up 
NP_054891.2 14 kDa phosphohistidine phosphatase isoform 3  0.493 1.09 Up 0.004 1.21 Up 
NP_003395.1 14-3-3 protein beta/alpha  0.569 1.03 Down  0.242 1.13 Up 
NP_006752.1 14-3-3 protein epsilon  0.725 1.02 Down  0.006 1.30 Up 
NP_003396.1 14-3-3 protein eta  0.495 1.05 Down  0.174 1.18 Up 
NP_036611.2 14-3-3 protein gamma  0.802 1.01 Down  0.004 1.15 Up 
NP_006817.1 14-3-3 protein theta  0.832 1.01 Down  0.098 1.19 Up 
NP_003397.1 14-3-3 protein zeta/delta  0.992 1.00 Up 0.061 1.21 Up 
NP_002797.3 26S protease regulatory subunit 10B  0.409 1.04 Up 0.040 1.11 Up 
NP_002793.2 26S protease regulatory subunit 4  0.796 1.01 Up 0.646 1.07 Up 
NP_002795.2 26S protease regulatory subunit 6A  0.414 1.06 Down  0.007 1.27 Up 
NP_006494.1 26S protease regulatory subunit 6B isoform 1  0.706 1.03 Down  0.001 1.20 Up 
NP_002794.1 26S protease regulatory subunit 7  0.886 1.02 Down  0.395 1.09 Up 
NP_002796.4 26S protease regulatory subunit 8 isoform 1  0.240 1.06 Down  0.012 1.13 Up 
NP_002798.2 26S proteasome non-ATPase regulatory subunit 1 isoform 1  0.271 1.03 Up 0.0002 1.18 Up 
NP_002806.2 26S proteasome non-ATPase regulatory subunit 11  0.765 1.02 Down  0.001 1.18 Up 
NP_002807.1 26S proteasome non-ATPase regulatory subunit 12 isoform 1  0.527 1.04 Up 0.183 1.15 Up 
NP_002808.3 26S proteasome non-ATPase regulatory subunit 13 isoform 1  0.674 1.03 Up 0.094 1.11 Up 
NP_005796.1 26S proteasome non-ATPase regulatory subunit 14  0.045 1.07 Down  0.144 1.13 Up 
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NP_002799.3 26S proteasome non-ATPase regulatory subunit 2  0.816 1.01 Down  0.001 1.22 Up 
NP_002800.2 26S proteasome non-ATPase regulatory subunit 3  0.299 1.09 Up 0.011 1.32 Up 
NP_002801.1 26S proteasome non-ATPase regulatory subunit 4  0.086 1.13 Down  0.263 1.10 Down  
NP_055629.1 26S proteasome non-ATPase regulatory subunit 6  0.471 1.02 Up 0.005 1.61 Up 
NP_002802.2 26S proteasome non-ATPase regulatory subunit 7  0.475 1.06 Up 0.018 1.21 Up 
NP_055706.1 28 kDa heat- and acid-stable phosphoprotein  0.457 1.07 Up 0.776 1.04 Up 
NP_055899.2 28S ribosomal protein S27, mitochondrial  0.916 1.01 Down  0.571 1.06 Down  
NP_006076.4 3'(2'),5'-bisphosphate nucleotidase 1  0.893 1.02 Down  0.052 1.21 Up 
NP_002940.2 39S ribosomal protein L12, mitochondrial precursor  0.506 1.06 Down  0.157 1.23 Up 
NP_004484.1 3-hydroxyacyl-CoA dehydrogenase type-2 isoform 1  0.370 1.05 Down  0.004 1.27 Up 
NP_064524.3 3-hydroxybutyrate dehydrogenase type 2  0.766 1.02 Up 0.016 1.17 Up 
NP_006102.2 3-ketoacyl-CoA thiolase, mitochondrial  0.190 1.09 Down  0.007 1.26 Up 
NP_001013454.1 3-mercaptopyruvate sulfurtransferase isoform 2  0.863 1.01 Down  0.001 1.25 Up 
NP_001005.1 40S ribosomal protein S10  0.615 1.06 Up 0.027 1.16 Down  
NP_001006.1 40S ribosomal protein S11  0.713 1.04 Up 0.093 1.22 Down  
NP_001007.2 40S ribosomal protein S12  0.152 1.09 Down  0.025 1.16 Up 
NP_001008.1 40S ribosomal protein S13  0.676 1.05 Up 0.108 1.29 Down  
NP_005608.1 40S ribosomal protein S14  0.615 1.04 Down  0.0004 1.35 Down  
NP_001009.1 40S ribosomal protein S15  0.002 1.20 Down  0.048 1.22 Down  
NP_001010.2 40S ribosomal protein S15a  0.952 1.01 Down  0.185 1.13 Down  
NP_001011.1 40S ribosomal protein S16  0.832 1.02 Up 0.0001 1.43 Down  
NP_001012.1 40S ribosomal protein S17  0.052 1.16 Down  0.0005 1.25 Down  
NP_072045.1 40S ribosomal protein S18  0.170 1.12 Down  0.018 1.34 Down  
NP_001013.1 40S ribosomal protein S19  0.562 1.07 Up 0.043 1.28 Down  
NP_002943.2 40S ribosomal protein S2  0.671 1.03 Down  0.048 1.34 Down  
NP_001014.1 40S ribosomal protein S20 isoform 2  0.914 1.01 Up 0.190 1.15 Down  
NP_001015.1 40S ribosomal protein S21  0.111 1.12 Down  0.981 1.00 Up 
NP_001016.1 40S ribosomal protein S23  0.740 1.04 Up 0.0004 1.32 Down  
NP_001017.1 40S ribosomal protein S24 isoform c  0.503 1.05 Up 0.763 1.03 Down  
NP_001019.1 40S ribosomal protein S25  0.960 1.00 Down  0.449 1.08 Down  
NP_001020.2 40S ribosomal protein S26  0.879 1.01 Down  0.311 1.06 Down  
NP_001021.1 40S ribosomal protein S27  0.943 1.01 Up 0.119 1.17 Down  
NP_001023.1 40S ribosomal protein S29 isoform 1  0.652 1.04 Down  0.077 1.14 Down  
238 
 
NP_000996.2 40S ribosomal protein S3  0.786 1.03 Down  0.696 1.03 Down  
NP_000997.1 40S ribosomal protein S3a  0.808 1.02 Down  0.651 1.07 Down  
NP_000998.1 40S ribosomal protein S4, X isoform X isoform  0.697 1.03 Up 0.137 1.13 Down  
NP_001000.2 40S ribosomal protein S5  0.910 1.01 Up 0.430 1.04 Down  
NP_001001.2 40S ribosomal protein S6  0.812 1.03 Up 0.138 1.14 Down  
NP_001002.1 40S ribosomal protein S7  0.086 1.08 Down  0.474 1.05 Down  
NP_001003.1 40S ribosomal protein S8  0.797 1.01 Up 0.672 1.03 Down  
NP_001004.2 40S ribosomal protein S9  0.904 1.01 Down  0.0002 1.29 Down  
NP_002286.2 40S ribosomal protein SA  0.374 1.05 Down  0.243 1.09 Up 
NP_065737.2 4-aminobutyrate aminotransferase, mitochondrial precursor  0.921 1.01 Down  0.357 1.06 Up 
NP_000687.3 4-trimethylaminobutyraldehyde dehydrogenase  0.433 1.06 Up 0.385 1.07 Up 
NP_036387.2 5'-3' exoribonuclease 2  0.193 1.07 Down  0.694 1.05 Down  
NP_002147.2 60 kDa heat shock protein, mitochondrial  0.302 1.08 Down  0.001 1.31 Up 
NP_004591.2 60 kDa SS-A/Ro ribonucleoprotein isoform 2  0.091 1.08 Down  0.987 1.00 Down  
NP_000993.1 60S acidic ribosomal protein P0  0.972 1.00 Down  0.026 1.17 Up 
NP_000994.1 60S acidic ribosomal protein P1 isoform 1  0.201 1.07 Down  0.261 1.06 Up 
NP_000995.1 60S acidic ribosomal protein P2  0.042 1.11 Down  0.060 1.13 Up 
NP_006004.2 60S ribosomal protein L10  0.275 1.06 Down  0.012 1.13 Down  
NP_009035.3 60S ribosomal protein L10a  0.910 1.01 Down  0.107 1.23 Up 
NP_000966.2 60S ribosomal protein L11 isoform 1  0.337 1.09 Down  0.394 1.13 Down  
NP_000967.1 60S ribosomal protein L12  0.635 1.03 Down  0.061 1.25 Up 
NP_150254.1 60S ribosomal protein L13  0.818 1.02 Down  0.0004 1.19 Down  
NP_036555.1 60S ribosomal protein L13a  0.305 1.04 Down  0.406 1.06 Up 
NP_003964.3 60S ribosomal protein L14  0.237 1.46 Up 0.566 1.10 Up 
NP_002939.2 60S ribosomal protein L15  0.693 1.05 Up 0.321 1.06 Up 
NP_000976.1 60S ribosomal protein L17 isoform a  0.668 1.04 Down  0.882 1.02 Down  
NP_000970.1 60S ribosomal protein L18  0.369 1.07 Down  0.165 1.12 Down  
NP_000971.1 60S ribosomal protein L18a  0.246 1.07 Down  0.215 1.07 Down  
NP_000972.1 60S ribosomal protein L19  0.454 1.05 Down  0.057 1.13 Down  
NP_000973.2 60S ribosomal protein L21  0.335 1.05 Down  0.433 1.07 Down  
NP_000974.1 60S ribosomal protein L22 proprotein  0.595 1.05 Up 0.120 1.09 Down  
NP_000969.1 60S ribosomal protein L23  0.498 1.12 Up 0.0001 1.35 Down  
NP_000975.2 60S ribosomal protein L23a  0.947 1.00 Up 0.233 1.09 Down  
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NP_000977.1 60S ribosomal protein L24  0.588 1.08 Up 0.042 1.24 Down  
NP_000978.1 60S ribosomal protein L26  0.624 1.04 Up 0.036 1.18 Down  
NP_000979.1 60S ribosomal protein L27  0.017 1.16 Down  0.616 1.04 Up 
NP_000981.1 60S ribosomal protein L27a  0.575 1.03 Down  0.469 1.03 Up 
NP_000982.2 60S ribosomal protein L28 isoform 2  0.549 1.06 Up 0.117 1.20 Down  
NP_000983.1 60S ribosomal protein L29  0.418 1.06 Down  0.605 1.04 Up 
NP_000958.1 60S ribosomal protein L3 isoform a  0.615 1.04 Down  0.397 1.03 Down  
NP_000980.1 60S ribosomal protein L30  0.740 1.03 Up 0.021 1.28 Up 
NP_000984.1 60S ribosomal protein L31 isoform 1  0.812 1.03 Up 0.075 1.14 Down  
NP_000985.1 60S ribosomal protein L32  0.244 1.05 Up 0.643 1.05 Down  
NP_000986.2 60S ribosomal protein L34  0.729 1.05 Up 0.270 1.13 Up 
NP_009140.1 60S ribosomal protein L35  0.766 1.03 Up 0.002 1.22 Down  
NP_000987.2 60S ribosomal protein L35a  0.102 1.16 Down  0.083 1.26 Down  
NP_056229.2 60S ribosomal protein L36  0.120 1.12 Down  0.186 1.20 Down  
NP_000990.1 60S ribosomal protein L38  0.279 1.16 Up 0.0001 1.55 Down  
NP_000959.2 60S ribosomal protein L4  0.750 1.01 Up 0.355 1.06 Down  
NP_000960.2 60S ribosomal protein L5  0.918 1.00 Down  0.288 1.06 Down  
NP_000961.2 60S ribosomal protein L6  0.140 1.06 Down  0.156 1.08 Up 
NP_000962.2 60S ribosomal protein L7  0.411 1.04 Down  0.802 1.01 Down  
NP_000963.1 60S ribosomal protein L7a  0.921 1.00 Up 0.298 1.05 Up 
NP_000964.1 60S ribosomal protein L8  0.440 1.03 Down  0.791 1.03 Up 
NP_000652.2 60S ribosomal protein L9  0.710 1.03 Down  0.123 1.11 Down  
NP_002618.1 6-phosphofructokinase type C  0.296 1.05 Up 0.205 1.10 Up 
NP_000280.1 6-phosphofructokinase, muscle type isoform 2  0.916 1.01 Down  0.045 1.16 Down  
NP_002622.2 6-phosphogluconate dehydrogenase, decarboxylating  0.749 1.03 Up 0.893 1.01 Down  
NP_036220.1 6-phosphogluconolactonase  0.775 1.02 Down  0.489 1.04 Up 
NP_005338.1 78 kDa glucose-regulated protein precursor  0.268 1.10 Up 0.00004 1.53 Up 
NP_005882.2 acetyl-CoA acetyltransferase, cytosolic  0.843 1.01 Up 0.016 1.12 Up 
NP_000010.1 acetyl-CoA acetyltransferase, mitochondrial precursor  0.646 1.04 Down  0.0001 1.38 Up 
NP_006296.1 acidic leucine-rich nuclear phosphoprotein 32 family member A  0.574 1.04 Up 0.678 1.02 Up 
NP_006392.1 acidic leucine-rich nuclear phosphoprotein 32 family member B  0.316 1.05 Down  0.347 1.17 Down  
NP_112182.1 
acidic leucine-rich nuclear phosphoprotein 32 family member E 
isoform 1  
0.218 1.04 Up 0.003 1.08 Up 
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NP_001089.1 aconitate hydratase, mitochondrial precursor  0.983 1.00 Down  0.190 1.27 Up 
NP_005150.1 actin, alpha cardiac muscle 1 proprotein  0.834 1.05 Up 0.613 1.20 Down  
NP_001092.1 actin, cytoplasmic 1  0.702 1.03 Down  0.201 1.17 Up 
NP_004292.1 actin-like protein 6A isoform 1  0.251 1.12 Down  0.283 1.20 Up 
NP_005713.1 actin-related protein 2 isoform b  0.438 1.03 Up 0.280 1.05 Up 
NP_006400.2 actin-related protein 2/3 complex subunit 1A isoform 1  0.663 1.02 Down  0.943 1.00 Up 
NP_005711.1 actin-related protein 2/3 complex subunit 1B  0.766 1.02 Up 0.480 1.11 Up 
NP_005722.1 actin-related protein 2/3 complex subunit 2  0.338 1.06 Down  0.542 1.08 Down  
NP_005710.1 actin-related protein 2/3 complex subunit 3  0.915 1.01 Down  0.161 1.26 Up 
NP_005709.1 actin-related protein 2/3 complex subunit 4 isoform a  0.124 1.13 Down  0.624 1.05 Down  
NP_005712.1 actin-related protein 3  0.912 1.00 Up 0.043 1.08 Up 
NP_006704.3 activated RNA polymerase II transcriptional coactivator p15  0.820 1.02 Down  0.178 1.15 Down  
NP_036243.1 activator of 90 kDa heat shock protein ATPase homolog 1  0.695 1.03 Up 0.111 1.11 Up 
NP_004994.1 acyl carrier protein, mitochondrial precursor  0.111 1.13 Down  0.020 1.23 Up 
NP_009191.1 acyl-protein thioesterase 2  0.249 1.06 Up 0.135 1.09 Up 
NP_005197.3 adapter molecule crk isoform b  0.246 1.12 Down  0.137 1.11 Up 
NP_000476.1 adenine phosphoribosyltransferase isoform a  0.199 1.06 Up 0.004 1.24 Up 
NP_000678.1 adenosylhomocysteinase isoform 1  0.738 1.02 Down  0.032 1.15 Up 
NP_001616.1 adenylate kinase 2, mitochondrial isoform a  0.535 1.05 Down  0.900 1.01 Down  
NP_000467.1 adenylate kinase isoenzyme 1  0.118 1.10 Down  0.022 1.13 Up 
NP_006358.1 adenylyl cyclase-associated protein 1  0.034 1.16 Down  0.000005 1.42 Down  
NP_001627.2 ADP/ATP translocase 3  0.674 1.11 Down  0.013 2.79 Down  
NP_001649.1 ADP-ribosylation factor 1  0.355 1.08 Down  0.129 1.17 Down  
NP_001651.1 ADP-ribosylation factor 4  0.660 1.03 Down  0.117 1.09 Down  
NP_001653.1 ADP-ribosylation factor 5  0.736 1.04 Up 0.342 1.14 Down  
NP_004302.1 ADP-ribosylation factor-like protein 3  0.263 1.08 Down  0.007 1.23 Up 
NP_054861.2 ADP-sugar pyrophosphatase  0.414 1.04 Up 0.024 1.22 Up 
NP_001596.2 alanyl-tRNA synthetase, cytoplasmic  0.457 1.05 Down  0.008 1.11 Up 
NP_000662.3 alcohol dehydrogenase class-3  0.172 1.04 Up 0.010 1.19 Up 
NP_000681.2 aldehyde dehydrogenase, mitochondrial precursor  0.518 1.05 Down  0.024 1.32 Up 
NP_001619.1 aldose reductase  0.358 1.04 Up 0.187 1.15 Up 
NP_001093.1 alpha-actinin-1 isoform b  0.715 1.04 Down  0.060 1.21 Up 
NP_004915.2 alpha-actinin-4  0.572 1.03 Up 0.319 1.08 Up 
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NP_005727.1 alpha-centractin  0.585 1.03 Up 0.003 1.23 Up 
NP_001419.1 alpha-enolase  0.690 1.02 Down  0.011 1.18 Up 
NP_116116.1 alpha-internexin  0.560 1.04 Down  0.00005 1.24 Up 
NP_001073901.1 alpha-ketoglutarate-dependent dioxygenase FTO  0.797 1.01 Down  0.933 1.00 Up 
NP_003818.2 alpha-soluble NSF attachment protein  0.565 1.03 Down  0.0003 1.35 Up 
NP_002694.3 amidophosphoribosyltransferase proprotein  0.175 1.11 Up 0.013 1.41 Up 
NP_004030.1 annexin A2 isoform 2  0.204 1.14 Down  0.004 2.06 Down  
NP_001145.1 annexin A5  0.485 1.08 Down  0.381 1.13 Up 
NP_001146.2 annexin A6 isoform 1  0.483 1.07 Down  0.007 1.18 Up 
NP_663782.2 AP-1 complex subunit beta-1 isoform b  0.884 1.03 Up 0.019 1.40 Down  
NP_055018.2 AP-2 complex subunit alpha-1 isoform 1  0.099 1.14 Up 0.371 1.10 Up 
NP_001273.1 AP-2 complex subunit beta isoform b  0.962 1.01 Down  0.073 1.15 Down  
NP_004635.2 AP-3 complex subunit beta-2  0.157 1.25 Down  0.430 1.21 Down  
NP_658985.2 apolipoprotein A-I-binding protein precursor  0.901 1.01 Down  0.012 1.36 Up 
NP_004315.1 apoptosis regulator BAX isoform beta  0.312 1.14 Down  0.138 1.22 Down  
NP_055792.1 apoptotic chromatin condensation inducer in the nucleus isoform 1  0.580 1.03 Up 0.045 1.09 Up 
NP_002878.2 arginyl-tRNA synthetase, cytoplasmic  0.648 1.04 Up 0.306 1.09 Down  
NP_000781.1 aromatic-L-amino-acid decarboxylase  0.957 1.01 Up 0.026 1.38 Up 
NP_004530.1 asparaginyl-tRNA synthetase, cytoplasmic  0.802 1.01 Up 0.012 1.11 Down  
NP_002071.2 aspartate aminotransferase, mitochondrial precursor  0.761 1.05 Up 0.026 1.85 Up 
NP_001340.2 aspartyl-tRNA synthetase, cytoplasmic  0.619 1.02 Down  0.363 1.06 Up 
NP_003759.1 astrocytic phosphoprotein PEA-15  0.248 1.11 Down  0.135 1.14 Down  
NP_037368.1 ataxin-10 isoform 1  0.207 1.11 Down  0.0001 1.49 Down  
NP_004037.1 ATP synthase subunit alpha, mitochondrial precursor  0.369 1.09 Down  0.002 1.21 Up 
NP_001677.2 ATP synthase subunit beta, mitochondrial precursor  0.241 1.10 Down  0.030 1.26 Up 
NP_005165.1 
ATP synthase subunit gamma, mitochondrial isoform H (heart) 
precursor  
0.986 1.00 Up 0.145 1.18 Up 
NP_001688.1 ATP synthase subunit O, mitochondrial precursor  0.807 1.03 Up 0.329 1.15 Up 
NP_001676.2 
ATP synthase-coupling factor 6, mitochondrial isoform a 
precursor  
0.232 1.11 Down  0.002 1.44 Up 
NP_004308.2 ATPase ASNA1  0.694 1.03 Up 0.032 1.24 Up 
NP_001087.2 ATP-citrate synthase isoform 1  0.102 1.11 Down  0.0005 1.47 Down  
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NP_001348.2 ATP-dependent RNA helicase A  0.509 1.04 Up 0.598 1.02 Up 
NP_004930.1 ATP-dependent RNA helicase DDX1  0.946 1.00 Up 0.973 1.00 Down  
NP_006764.3 ATP-dependent RNA helicase DDX18  0.606 1.05 Down  0.068 1.25 Down  
NP_060802.1 ATP-dependent RNA helicase DDX19A  0.410 1.14 Down  0.792 1.07 Up 
NP_005795.2 ATP-dependent RNA helicase DDX39  0.203 1.07 Down  0.00003 1.48 Down  
NP_001347.3 ATP-dependent RNA helicase DDX3X isoform 1  0.294 1.15 Down  0.001 1.45 Down  
NP_003851.1 barrier-to-autointegration factor  0.393 1.12 Up 0.004 1.46 Up 
NP_055485.2 basic leucine zipper and W2 domain-containing protein 1  0.239 1.07 Down  0.049 1.22 Down  
NP_055554.1 bcl-2-associated transcription factor 1 isoform 1  0.393 1.05 Down  0.983 1.00 Down  
NP_110517.2 beta-catenin-like protein 1  0.311 1.13 Up 0.257 1.18 Down  
NP_001187.1 BH3-interacting domain death agonist isoform 2  0.141 1.19 Down  0.974 1.00 Down  
NP_004437.2 bifunctional aminoacyl-tRNA synthetase  0.509 1.07 Down  0.012 1.30 Down  
NP_004035.2 bifunctional purine biosynthesis protein PURH  0.753 1.01 Up 0.293 1.12 Up 
NP_000703.2 biliverdin reductase A precursor  0.543 1.04 Up 0.051 1.18 Up 
NP_001026997.1 BolA-like protein 2  0.177 1.09 Up 0.162 1.35 Up 
NP_006308.3 brain acid soluble protein 1  0.519 1.08 Up 0.302 1.11 Down  
NP_653296.2 BRO1 domain-containing protein BROX  0.316 1.05 Up 0.014 1.16 Up 
NP_005947.3 C-1-tetrahydrofolate synthase, cytoplasmic  0.218 1.08 Down  0.094 1.08 Up 
NP_004332.2 CAD protein  0.558 1.18 Up 0.729 1.25 Down  
NP_055066.1 calcium-binding mitochondrial carrier protein Aralar2 isoform 2  0.667 1.11 Down  0.011 2.82 Down  
NP_001035941.1 calcium-regulated heat stable protein 1  0.225 1.06 Up 0.037 1.19 Up 
NP_055227.1 calcyclin-binding protein isoform 1  0.788 1.03 Up 0.581 1.10 Up 
NP_004333.1 caldesmon isoform 2  0.407 1.10 Up 0.046 1.23 Down  
NP_001734.1 calmodulin  0.815 1.01 Up 0.006 1.17 Up 
NP_001737.1 calnexin precursor  0.169 1.21 Up 0.120 1.26 Down  
NP_001740.1 calpain small subunit 1  0.679 1.02 Down  0.951 1.00 Up 
NP_001830.1 calponin-3  0.079 1.12 Down  0.500 1.04 Down  
NP_004334.1 calreticulin precursor  0.096 1.12 Up 0.0000001 1.56 Up 
NP_001210.1 calumenin isoform a precursor  0.374 1.05 Up 0.011 1.28 Up 
NP_002727.2 cAMP-dependent protein kinase type II-beta regulatory subunit  0.638 1.03 Up 0.224 1.11 Up 
NP_005889.3 caprin-1 isoform 1  0.131 1.16 Down  0.00004 1.45 Down  
NP_001748.1 carbonyl reductase [NADPH] 1  0.483 1.03 Down  0.351 1.10 Up 
NP_001886.1 casein kinase II subunit alpha isoform a  0.631 1.03 Up 0.008 1.27 Up 
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NP_001899.1 cathepsin B preproprotein  0.813 1.01 Down  0.005 1.18 Down  
NP_001782.1 cell division control protein 42 homolog isoform 1  0.828 1.03 Down  0.216 1.13 Down  
NP_060707.2 cell division cycle and apoptosis regulator protein 1  0.056 1.11 Up 0.225 1.10 Up 
NP_001777.1 cell division protein kinase 1 isoform 1  0.541 1.08 Down  0.002 1.75 Down  
NP_004926.1 cell division protein kinase 5 isoform 1  0.245 1.26 Down  0.014 2.31 Down  
NP_003409.1 cellular nucleic acid-binding protein isoform 3  0.156 1.13 Down  0.122 1.08 Down  
NP_001869.1 cellular retinoic acid-binding protein 2  0.963 1.01 Down  0.244 1.38 Up 
NP_057494.3 charged multivesicular body protein 5 isoform 1  0.903 1.01 Down  0.180 1.07 Up 
NP_001279.2 chloride intracellular channel protein 1  0.981 1.00 Up 0.139 1.15 Up 
NP_039234.1 chloride intracellular channel protein 4  0.008 1.19 Down  0.018 1.16 Down  
NP_006798.1 chromobox protein homolog 1  0.832 1.01 Up 0.365 1.08 Up 
NP_009207.2 chromobox protein homolog 3  0.226 1.07 Down  0.862 1.01 Up 
NP_036249.1 chromobox protein homolog 5  0.927 1.01 Up 0.078 1.20 Up 
NP_004068.2 citrate synthase, mitochondrial precursor  0.288 1.12 Down  0.458 1.10 Up 
NP_004850.1 clathrin heavy chain 1  0.778 1.01 Up 0.00005 1.16 Up 
NP_001824.1 clathrin light chain A isoform a  0.190 1.09 Down  0.201 1.17 Up 
NP_008937.1 cleavage and polyadenylation specificity factor subunit 5  0.442 1.03 Down  0.965 1.00 Up 
NP_008938.2 cleavage and polyadenylation specificity factor subunit 6  0.368 1.02 Down  0.021 1.19 Up 
NP_001129512.1 cleavage and polyadenylation specificity factor subunit 7 isoform 2  0.668 1.03 Up 0.455 1.06 Up 
NP_057535.1 coatomer subunit beta  0.761 1.02 Down  0.294 1.10 Down  
NP_004757.1 coatomer subunit beta'  0.300 1.06 Down  0.016 1.18 Up 
NP_001646.2 coatomer subunit delta isoform 1  0.166 1.13 Down  0.889 1.01 Up 
NP_009194.2 coatomer subunit epsilon isoform a  0.467 1.05 Down  0.184 1.13 Down  
NP_057212.1 coatomer subunit gamma  0.004 1.34 Down  0.066 1.28 Down  
NP_036265.3 coatomer subunit gamma-2  0.267 1.09 Down  0.716 1.04 Down  
NP_057141.1 coatomer subunit zeta-1  0.285 1.13 Down  0.887 1.02 Up 
NP_005498.1 cofilin-1  0.136 1.07 Up 0.018 1.18 Up 
NP_057223.1 
coiled-coil-helix-coiled-coil-helix domain-containing protein 2, 
mitochondrial precursor  
0.581 1.06 Up 0.010 1.43 Down  
NP_009089.4 cold shock domain-containing protein E1 isoform 2  0.019 1.31 Down  0.000001 1.61 Down  




complement component 1 Q subcomponent-binding protein, 
mitochondrial precursor  
0.385 1.05 Down  0.037 1.33 Up 
NP_997657.1 COP9 signalosome complex subunit 1 isoform 1  0.401 1.09 Down  0.707 1.04 Up 
NP_057213.2 COP9 signalosome complex subunit 4  0.568 1.04 Down  0.080 1.15 Up 
NP_006824.2 COP9 signalosome complex subunit 6  0.801 1.02 Up 0.521 1.05 Up 
NP_690902.1 copine-1 isoform a  0.086 1.09 Down  0.842 1.01 Up 
NP_004884.1 core histone macro-H2A.1 isoform 2  0.288 1.33 Up 0.229 1.27 Down  
NP_055140.1 coronin-1C isoform 1  0.567 1.09 Up 0.539 1.10 Up 
NP_001814.2 creatine kinase B-type  0.986 1.00 Up 0.003 1.16 Up 
NP_066270.1 creatine kinase U-type, mitochondrial precursor  0.243 1.10 Up 0.580 1.05 Up 
NP_005198.1 crk-like protein  0.170 1.17 Up 0.036 1.20 Up 
NP_001319.1 C-terminal-binding protein 1 isoform 1  0.860 1.01 Up 0.652 1.05 Down  
NP_001896.2 CTP synthase 1  0.212 1.06 Down  0.591 1.04 Down  
NP_060918.2 cullin-associated NEDD8-dissociated protein 1  0.689 1.01 Down  0.053 1.11 Up 
NP_000062.1 cystathionine beta-synthase  0.421 1.03 Up 0.008 1.20 Up 
NP_001303.1 cysteine-rich protein 2  0.153 1.07 Up 0.280 1.17 Up 
NP_003356.2 cytochrome b-c1 complex subunit 1, mitochondrial precursor  0.339 1.20 Down  0.010 2.17 Down  
NP_003357.2 cytochrome b-c1 complex subunit 2, mitochondrial precursor  0.571 1.16 Down  0.002 3.26 Down  
NP_004246.2 cytochrome c oxidase subunit 5A, mitochondrial precursor  0.108 1.17 Down  0.347 1.19 Down  
NP_001854.1 cytochrome c oxidase subunit 6B1  0.030 1.31 Down  0.169 1.16 Down  
NP_001367.2 cytoplasmic dynein 1 heavy chain 1  0.991 1.00 Up 0.927 1.02 Down  
NP_006132.1 cytoplasmic dynein 1 light intermediate chain 2  0.420 1.05 Up 0.159 1.08 Up 
NP_863654.1 cytosolic acyl coenzyme A thioester hydrolase isoform hBACHb  0.467 1.06 Up 0.001 1.19 Up 
NP_060705.2 cytosolic non-specific dipeptidase isoform 1  0.698 1.03 Up 0.019 1.20 Up 
NP_006614.2 D-3-phosphoglycerate dehydrogenase  0.073 1.10 Down  0.079 1.13 Up 
NP_061832.2 DAZ-associated protein 1 isoform b  0.741 1.02 Down  0.060 1.24 Up 
NP_077001.1 dCTP pyrophosphatase 1  0.521 1.07 Up 0.983 1.00 Down  
NP_001346.1 D-dopachrome decarboxylase  0.999 1.00 Up 0.022 1.27 Up 
NP_001389.2 
delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial 
precursor  
0.153 1.09 Down  0.005 1.28 Up 
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NP_002851.2 delta-1-pyrroline-5-carboxylate synthase isoform 1  0.967 1.00 Up 0.212 1.10 Up 
NP_001939.1 
deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial 
isoform 2  
0.376 1.07 Down  0.462 1.07 Down  
NP_006861.1 destrin isoform a  0.821 1.02 Down  0.952 1.01 Up 
NP_000099.2 dihydrolipoyl dehydrogenase, mitochondrial precursor  0.836 1.02 Up 0.005 1.36 Up 
NP_001924.2 
dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial  
0.922 1.01 Down  0.185 1.36 Up 
NP_001304.1 dihydropyrimidinase-related protein 1 isoform 2  0.655 1.02 Down  0.532 1.03 Up 
NP_001184222.1 dihydropyrimidinase-related protein 2 isoform 1  0.722 1.02 Down  0.069 1.11 Up 
NP_001378.1 dihydropyrimidinase-related protein 3 isoform 2  0.471 1.04 Down  0.390 1.09 Up 
NP_006417.2 dihydropyrimidinase-related protein 4  0.593 1.06 Up 0.442 1.07 Up 
NP_064519.2 dihydropyrimidinase-related protein 5  0.792 1.01 Down  0.033 1.09 Up 
NP_005691.2 dipeptidyl peptidase 3  0.588 1.06 Up 0.057 1.27 Up 
NP_001914.3 DNA damage-binding protein 1  0.365 1.03 Down  0.455 1.03 Up 
NP_000242.1 DNA mismatch repair protein Msh2  0.388 1.04 Down  0.167 1.08 Down  
NP_000170.1 DNA mismatch repair protein Msh6  0.919 1.01 Up 0.017 1.65 Down  
NP_004517.2 DNA replication licensing factor MCM2  0.277 1.08 Down  0.019 1.26 Down  
NP_002379.2 DNA replication licensing factor MCM3  0.677 1.05 Up 0.023 1.32 Down  
NP_877423.1 DNA replication licensing factor MCM4  0.136 1.10 Down  0.067 1.16 Down  
NP_005906.2 DNA replication licensing factor MCM6  0.459 1.03 Down  0.103 1.07 Down  
NP_005907.3 DNA replication licensing factor MCM7 isoform 1  0.108 1.11 Down  0.033 1.18 Down  
NP_001632.2 DNA-(apurinic or apyrimidinic site) lyase  0.317 1.11 Up 0.913 1.01 Down  
NP_008835.5 DNA-dependent protein kinase catalytic subunit isoform 1  0.230 2.46 Up 0.314 1.57 Up 
NP_002686.2 DNA-directed RNA polymerases I, II, and III subunit RPABC1  0.437 1.11 Down  0.362 1.11 Down  
NP_001530.1 dnaJ homolog subfamily A member 1  0.006 1.18 Down  0.089 1.24 Down  
NP_005871.1 dnaJ homolog subfamily A member 2  0.353 1.08 Down  0.002 1.25 Up 
NP_002941.1 
dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 1 precursor  
0.722 1.09 Up 0.009 1.46 Down  
NP_002942.2 
dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 2 isoform 1 precursor  
0.856 1.04 Up 0.170 1.18 Down  
NP_000778.3 dopamine beta-hydroxylase precursor  0.170 1.11 Down  0.037 1.18 Down  
NP_001102.2 double-stranded RNA-specific adenosine deaminase isoform a  0.798 1.03 Up 0.010 1.25 Down  
NP_004386.2 drebrin isoform a  0.922 1.01 Up 0.030 1.18 Up 
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NP_054782.2 drebrin-like protein isoform a  0.531 1.05 Up 0.010 1.18 Up 
NP_001177765.1 dynactin subunit 1 isoform 5  0.263 1.17 Down  0.467 1.03 Up 
NP_006391.1 dynactin subunit 2  0.780 1.03 Up 0.120 1.31 Up 
NP_001005336.1 dynamin-1 isoform 2  0.393 1.06 Down  0.827 1.02 Down  
NP_036192.2 dynamin-1-like protein isoform 1  0.202 1.08 Down  0.560 1.02 Up 
NP_003737.1 dynein light chain 1, cytoplasmic  0.370 1.08 Up 0.137 1.18 Up 
NP_054902.1 dynein light chain roadblock-type 1  0.649 1.03 Down  0.211 1.17 Up 
NP_006510.1 dynein light chain Tctex-type 1  0.952 1.00 Up 0.353 1.05 Up 
NP_113584.3 E3 ubiquitin-protein ligase HUWE1  0.863 1.02 Down  0.852 1.03 Up 
NP_055063.1 E3 ubiquitin-protein ligase RBX1  0.651 1.03 Down  0.407 1.09 Up 
NP_009143.1 E3 ubiquitin-protein ligase RING2  0.744 1.03 Up 0.874 1.01 Down  
NP_061936.2 echinoderm microtubule-associated protein-like 4 isoform a  0.436 1.24 Up 0.392 1.17 Down  
NP_001410.2 ELAV-like protein 1  0.497 1.07 Up 0.047 1.23 Up 
NP_001411.2 ELAV-like protein 3 isoform 1  0.990 1.00 Down  0.103 1.16 Up 
NP_068771.2 ELAV-like protein 4 isoform 1  0.664 1.05 Up 0.006 1.55 Up 
NP_000117.1 
electron transfer flavoprotein subunit alpha, mitochondrial 
isoform a  
0.715 1.02 Down  0.0005 1.33 Up 
NP_001393.1 elongation factor 1-alpha 1  0.696 1.03 Down  0.048 1.16 Down  
NP_001949.1 elongation factor 1-alpha 2  0.967 1.00 Up 0.045 1.24 Down  
NP_001950.1 elongation factor 1-beta  0.583 1.03 Down  0.801 1.02 Up 
NP_001951.2 elongation factor 1-delta isoform 2  0.028 1.15 Down  0.874 1.02 Up 
NP_001395.1 elongation factor 1-gamma  0.514 1.03 Down  0.674 1.04 Down  
NP_001952.1 elongation factor 2  0.007 1.14 Down  0.056 1.08 Down  
NP_003312.3 elongation factor Tu, mitochondrial precursor  0.682 1.03 Down  0.582 1.06 Up 
NP_006808.1 endoplasmic reticulum resident protein 29 isoform 1 precursor  0.484 1.05 Down  0.0003 1.23 Up 
NP_055866.1 endoplasmic reticulum resident protein 44 precursor  0.233 1.21 Up 0.001 1.23 Up 
NP_003290.1 endoplasmin precursor  0.338 1.06 Up 0.0001 1.49 Up 
NP_004441.1 enhancer of rudimentary homolog  0.699 1.03 Down  0.004 1.46 Up 
NP_004083.3 enoyl-CoA hydratase, mitochondrial precursor  0.913 1.01 Down  0.004 1.33 Up 
NP_055399.1 ERO1-like protein alpha precursor  0.387 1.06 Up 0.018 1.25 Up 
NP_004640.3 ES1 protein homolog, mitochondrial isoform Ia precursor  0.272 1.21 Up 0.060 1.27 Up 
NP_001407.1 eukaryotic initiation factor 4A-I  0.00003 1.30 Down  0.00004 1.52 Down  
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NP_001958.2 eukaryotic initiation factor 4A-II  0.014 1.32 Down  0.028 1.38 Down  
NP_055555.1 eukaryotic initiation factor 4A-III  0.830 1.02 Down  0.362 1.10 Up 
NP_002085.2 
eukaryotic peptide chain release factor GTP-binding subunit ERF3A 
isoform 1  
0.345 1.05 Down  0.203 1.13 Up 
NP_004721.1 eukaryotic peptide chain release factor subunit 1  0.643 1.05 Down  0.015 1.27 Down  
NP_004271.1 eukaryotic translation elongation factor 1 epsilon-1 isoform 1  0.759 1.03 Up 0.142 1.12 Down  
NP_005792.1 eukaryotic translation initiation factor 1  0.003 1.38 Down  0.000002 2.00 Down  
NP_004085.1 eukaryotic translation initiation factor 2 subunit 1  0.490 1.05 Down  0.438 1.10 Down  
NP_001406.1 eukaryotic translation initiation factor 2 subunit 3  0.321 1.12 Up 0.058 1.28 Down  
NP_003741.1 eukaryotic translation initiation factor 3 subunit A  0.512 1.05 Down  0.062 1.22 Down  
NP_003742.2 eukaryotic translation initiation factor 3 subunit B  0.819 1.02 Down  0.472 1.10 Down  
NP_003743.1 eukaryotic translation initiation factor 3 subunit C  0.234 1.12 Down  0.242 1.12 Down  
NP_001559.1 eukaryotic translation initiation factor 3 subunit E  0.536 1.04 Down  0.615 1.02 Up 
NP_003745.1 eukaryotic translation initiation factor 3 subunit F  0.086 1.11 Down  0.567 1.03 Up 
NP_003747.1 eukaryotic translation initiation factor 3 subunit H  0.076 1.10 Down  0.366 1.10 Up 
NP_003748.1 eukaryotic translation initiation factor 3 subunit I  0.002 1.17 Down  0.009 1.12 Down  
NP_057175.1 eukaryotic translation initiation factor 3 subunit L  0.097 1.19 Up 0.971 1.00 Up 
NP_006351.2 eukaryotic translation initiation factor 3 subunit M  0.705 1.02 Down  0.335 1.06 Down  
NP_937884.1 eukaryotic translation initiation factor 4 gamma 1 isoform 5  0.271 1.15 Down  0.008 1.29 Down  
NP_001408.2 eukaryotic translation initiation factor 4B  0.073 1.20 Down  0.777 1.01 Down  
NP_001959.1 eukaryotic translation initiation factor 4E isoform 1  0.500 1.05 Down  0.264 1.18 Up 
NP_071496.1 eukaryotic translation initiation factor 4H isoform 1  0.418 1.04 Down  0.612 1.03 Down  
NP_001960.2 eukaryotic translation initiation factor 5  0.230 1.06 Down  0.929 1.01 Up 
NP_001961.1 eukaryotic translation initiation factor 5A-1 isoform B  0.952 1.00 Down  0.023 1.12 Up 
NP_002203.1 eukaryotic translation initiation factor 6 isoform a  0.132 1.07 Down  0.012 1.11 Up 
NP_852480.1 exosome complex exonuclease RRP43  0.746 1.04 Down  0.823 1.02 Down  
NP_005024.2 exosome complex exonuclease RRP45 isoform 2  0.741 1.04 Up 0.653 1.05 Up 
NP_003391.1 exportin-1  0.801 1.01 Up 0.779 1.03 Up 
NP_001307.2 exportin-2  0.443 1.04 Up 0.271 1.06 Up 
NP_065801.1 exportin-5  0.953 1.01 Down  0.658 1.07 Up 
NP_056107.1 extended synaptotagmin-1 isoform 2  0.518 1.16 Up 0.615 1.07 Up 
NP_003370.2 ezrin  0.026 1.17 Down  0.328 1.10 Down  
NP_009123.1 FACT complex subunit SPT16  0.760 1.02 Up 0.916 1.01 Up 
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NP_003137.1 FACT complex subunit SSRP1  0.652 1.02 Up 0.152 1.11 Up 
NP_006126.1 F-actin-capping protein subunit alpha-1  0.127 1.10 Up 0.004 1.35 Up 
NP_004921.1 F-actin-capping protein subunit beta  0.533 1.10 Up 0.00003 1.25 Up 
NP_003893.2 far upstream element-binding protein 1  0.784 1.02 Down  0.038 1.20 Up 
NP_003676.2 far upstream element-binding protein 2  0.305 1.05 Down  0.075 1.15 Up 
NP_003925.1 far upstream element-binding protein 3  0.172 1.09 Down  0.932 1.01 Down  
NP_001995.1 farnesyl pyrophosphate synthase isoform a  0.582 1.06 Up 0.123 1.18 Up 
NP_003079.1 fascin  0.896 1.00 Up 0.002 1.18 Up 
NP_004095.4 fatty acid synthase  0.114 1.08 Down  0.048 1.20 Down  
NP_001435.1 fatty acid-binding protein, epidermal  0.315 1.10 Down  0.607 1.07 Up 
NP_078941.2 F-box-like/WD repeat-containing protein TBL1XR1  0.917 1.01 Down  0.005 1.17 Up 
NP_001447.2 filamin-A isoform 1  0.740 1.04 Down  0.553 1.08 Down  
NP_001448.2 filamin-B isoform 2  0.843 1.03 Up 0.726 1.04 Down  
NP_004102.1 flap endonuclease 1  0.681 1.04 Up 0.300 1.09 Down  
NP_001440.2 four and a half LIM domains protein 1 isoform 2  0.514 1.02 Up 0.230 1.12 Up 
NP_005078.2 fragile X mental retardation syndrome-related protein 1 isoform a  0.880 1.01 Down  0.013 1.27 Down  
NP_000025.1 fructose-bisphosphate aldolase A  0.986 1.00 Down  0.013 1.20 Up 
NP_005156.1 fructose-bisphosphate aldolase C  0.738 1.03 Up 0.006 1.34 Up 
NP_000134.2 fumarate hydratase, mitochondrial precursor  0.409 1.05 Up 0.004 1.27 Up 
NP_002296.1 galectin-1  0.512 1.07 Down  0.299 1.13 Down  
NP_001966.1 gamma-enolase  0.977 1.00 Down  0.0001 1.23 Up 
NP_076956.1 gamma-glutamylcyclotransferase isoform 1  0.165 1.19 Down  0.084 1.55 Up 
NP_127492.1 general transcription factor II-I isoform 1  0.414 1.18 Down  0.011 1.57 Down  
NP_003706.1 general vesicular transport factor p115  0.912 1.01 Up 0.739 1.03 Up 
NP_001035810.1 glucose-6-phosphate 1-dehydrogenase isoform b  0.585 1.03 Up 0.475 1.04 Up 
NP_000166.2 glucose-6-phosphate isomerase isoform 2  0.077 1.07 Up 0.001 1.27 Up 
NP_002734.2 glucosidase 2 subunit beta isoform 1  0.666 1.03 Down  0.002 1.33 Up 
NP_005262.1 glutamate dehydrogenase 1, mitochondrial precursor  0.701 1.04 Down  0.073 1.28 Up 
NP_055720.3 glutaminase kidney isoform, mitochondrial precursor  0.802 1.02 Down  0.941 1.01 Up 
NP_006532.2 glutaredoxin-3  0.921 1.00 Down  0.894 1.01 Up 
NP_000628.2 glutathione reductase, mitochondrial isoform 1 precursor  0.606 1.03 Down  0.446 1.13 Up 
NP_000840.2 glutathione S-transferase Mu 3  0.009 1.08 Up 0.101 1.17 Up 
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NP_004823.1 glutathione S-transferase omega-1 isoform 1  0.504 1.08 Up 0.135 1.10 Up 
NP_000843.1 glutathione S-transferase P  0.467 1.03 Up 0.001 1.20 Up 
NP_002037.2 glyceraldehyde-3-phosphate dehydrogenase  0.729 1.01 Up 0.014 1.10 Up 
NP_002038.2 glycyl-tRNA synthetase  0.130 1.06 Down  0.014 1.14 Up 
NP_057164.3 glyoxalase domain-containing protein 4  0.510 1.05 Down  0.058 1.15 Up 
NP_003866.1 GMP synthase  [glutamine-hydrolyzing]  0.462 1.06 Down  0.353 1.11 Down  
NP_002083.3 G-rich sequence factor 1 isoform 1  0.174 1.11 Down  0.781 1.03 Down  
NP_002077.1 growth factor receptor-bound protein 2 isoform 1  0.179 1.14 Down  0.882 1.01 Up 
NP_006316.1 GTP-binding nuclear protein Ran  0.665 1.02 Down  0.245 1.03 Up 
NP_064535.1 GTP-binding protein SAR1a  0.186 1.07 Down  0.389 1.09 Up 
NP_002065.1 guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1  0.321 1.07 Up 0.451 1.13 Down  
NP_005264.2 guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2  0.930 1.00 Down  0.455 1.08 Down  
NP_006089.1 guanine nucleotide-binding protein subunit beta-2-like 1  0.105 1.08 Down  0.079 1.09 Up 
NP_001354.1 H/ACA ribonucleoprotein complex subunit 4 isoform 1  0.296 1.21 Down  0.490 1.09 Down  
NP_005337.2 heat shock 70 kDa protein 1A/1B  0.666 1.03 Up 0.531 1.03 Down  
NP_002145.3 heat shock 70 kDa protein 4  0.821 1.02 Up 0.025 1.18 Up 
NP_006588.1 heat shock cognate 71 kDa protein isoform 1  0.594 1.03 Down  0.232 1.05 Down  
NP_006635.2 heat shock protein 105 kDa  0.787 1.02 Down  0.294 1.04 Up 
NP_057376.2 heat shock protein 75 kDa, mitochondrial precursor  0.363 1.09 Down  0.772 1.03 Down  
NP_001531.1 heat shock protein beta-1  0.987 1.00 Down  0.506 1.12 Up 
NP_005339.3 heat shock protein HSP 90-alpha isoform 2  0.677 1.02 Up 0.003 1.11 Up 
NP_031381.2 heat shock protein HSP 90-beta  0.671 1.02 Down  0.222 1.05 Up 
NP_057269.1 hematological and neurological expressed 1 protein isoform 1  0.306 1.06 Down  0.306 1.09 Down  
NP_653171.1 hematological and neurological expressed 1-like protein  0.636 1.03 Down  0.109 1.19 Up 
NP_000508.1 hemoglobin subunit alpha  0.085 1.48 Up 0.0003 1.97 Up 
NP_004485.1 hepatoma-derived growth factor isoform a  0.842 1.01 Down  0.140 1.12 Up 
NP_057371.2 heterochromatin protein 1-binding protein 3  0.313 1.58 Up 0.390 1.24 Down  
NP_004490.2 heterogeneous nuclear ribonucleoprotein A/B isoform b  0.979 1.00 Up 0.015 1.16 Down  
NP_006796.1 heterogeneous nuclear ribonucleoprotein A0  0.494 1.06 Up 0.088 1.28 Down  
NP_002127.1 heterogeneous nuclear ribonucleoprotein A1 isoform a  0.641 1.04 Up 0.761 1.03 Up 
NP_919223.1 heterogeneous nuclear ribonucleoprotein A3  0.419 1.09 Up 0.273 1.08 Up 
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NP_002129.2 heterogeneous nuclear ribonucleoprotein D0 isoform c  0.589 1.04 Up 0.016 1.14 Down  
NP_112740.1 heterogeneous nuclear ribonucleoprotein D-like  0.420 1.04 Down  0.893 1.01 Up 
NP_004957.1 heterogeneous nuclear ribonucleoprotein F  0.563 1.04 Down  0.286 1.12 Up 
NP_002130.2 heterogeneous nuclear ribonucleoprotein G isoform 1  0.328 1.13 Up 0.726 1.04 Down  
NP_005511.1 heterogeneous nuclear ribonucleoprotein H  0.998 1.00 Up 0.410 1.12 Up 
NP_062543.1 heterogeneous nuclear ribonucleoprotein H2  0.516 1.06 Down  0.554 1.12 Up 
NP_036339.1 heterogeneous nuclear ribonucleoprotein H3 isoform a  0.111 1.08 Up 0.260 1.06 Up 
NP_112552.1 heterogeneous nuclear ribonucleoprotein K isoform b  0.269 1.05 Down  0.036 1.10 Up 
NP_001524.2 heterogeneous nuclear ribonucleoprotein L isoform a  0.700 1.01 Down  0.545 1.03 Down  
NP_612403.2 heterogeneous nuclear ribonucleoprotein L-like isoform 1  0.131 1.09 Up 0.807 1.02 Down  
NP_005959.2 heterogeneous nuclear ribonucleoprotein M isoform a  0.425 1.05 Down  0.536 1.04 Up 
NP_006363.4 heterogeneous nuclear ribonucleoprotein Q isoform 1  0.515 1.10 Up 0.191 1.14 Down  
NP_005817.1 heterogeneous nuclear ribonucleoprotein R isoform 2  0.686 1.06 Up 0.589 1.04 Down  
NP_004492.2 heterogeneous nuclear ribonucleoprotein U isoform b  0.618 1.04 Up 0.011 1.26 Down  
NP_001073027.1 heterogeneous nuclear ribonucleoprotein U-like protein 2  0.077 1.07 Up 0.059 1.07 Up 
NP_112533.1 heterogeneous nuclear ribonucleoproteins A2/B1 isoform B1  0.874 1.01 Up 0.065 1.11 Up 
NP_112604.2 heterogeneous nuclear ribonucleoproteins C1/C2 isoform a  0.561 1.04 Down  0.001 1.24 Down  
NP_000179.2 hexokinase-1 isoform HKI  0.603 1.04 Up 0.248 1.08 Down  
NP_002119.1 high mobility group protein B1  0.174 1.24 Up 0.316 1.13 Down  
NP_002120.1 high mobility group protein B2  0.167 1.30 Up 0.312 1.14 Down  
NP_665906.1 high mobility group protein HMG-I/HMG-Y isoform a  0.396 1.21 Up 0.446 1.07 Down  
NP_002140.2 hippocalcin-like protein 1  0.378 1.12 Down  0.866 1.04 Down  
NP_005331.1 histidine triad nucleotide-binding protein 1  0.606 1.01 Up 0.0002 1.15 Up 
NP_002100.2 histidyl-tRNA synthetase, cytoplasmic  0.302 1.06 Down  0.417 1.06 Down  
NP_001518.3 histone deacetylase 2  0.152 1.06 Down  0.847 1.02 Down  
NP_005309.1 histone H1.0  0.264 2.32 Up 0.864 1.03 Down  
NP_005310.1 histone H1.2  0.291 3.56 Up 0.077 1.62 Down  
NP_005312.1 histone H1.4  0.281 4.29 Up 0.086 1.47 Down  
NP_005313.1 histone H1.5  0.296 3.71 Up 0.314 1.31 Down  
NP_006017.1 histone H1x  0.136 1.47 Up 0.936 1.01 Up 
NP_003507.1 histone H2A type 2-A  0.518 1.13 Up 0.020 1.81 Down  
NP_002097.1 histone H2A.Z  0.802 1.04 Up 0.075 1.35 Down  
NP_003509.1 histone H2B type 1-C/E/F/G/I  0.287 1.19 Up 0.913 1.01 Down  
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NP_003520.1 histone H3.1  0.292 3.26 Up 0.406 1.34 Down  
NP_003529.1 histone H4  0.294 4.16 Up 0.476 1.28 Down  
NP_005601.1 histone-binding protein RBBP4 isoform a  0.815 1.01 Down  0.841 1.01 Up 
NP_002884.1 histone-binding protein RBBP7 isoform 2  0.417 1.07 Down  0.806 1.03 Up 
NP_057123.1 homeobox prox 1  0.691 1.01 Down  0.064 1.12 Up 
NP_005325.2 host cell factor 1  0.292 1.05 Up 0.647 1.03 Down  
NP_003923.2 hsc70-interacting protein  0.236 1.07 Up 0.320 1.13 Up 
NP_036399.3 hsp70-binding protein 1  0.388 1.09 Down  0.328 1.17 Down  
NP_008996.1 hsp90 co-chaperone Cdc37  0.685 1.02 Down  0.167 1.08 Up 
NP_001171634.2 
hydroxyacyl-coenzyme A dehydrogenase, mitochondrial isoform 1 
precursor  
0.163 1.09 Down  0.113 1.22 Up 
NP_055121.1 hypothetical protein LOC51493  0.239 1.02 Down  0.641 1.04 Down  
NP_061980.1 hypothetical protein LOC56005 precursor  0.430 1.07 Up 0.001 1.73 Up 
NP_000185.1 hypoxanthine-guanine phosphoribosyltransferase  0.351 1.05 Up 0.0005 1.24 Up 
NP_006380.1 hypoxia up-regulated protein 1 precursor  0.553 1.04 Down  0.578 1.05 Up 
NP_001007562.1 immunity-related GTPase family Q protein  0.244 1.14 Up 0.699 1.02 Down  
NP_002257.1 importin subunit alpha-2  0.028 1.25 Down  0.0001 1.44 Down  
NP_002258.2 importin subunit alpha-3  0.491 1.05 Up 0.179 1.09 Up 
NP_002256.2 importin subunit beta-1  0.184 1.07 Down  0.042 1.08 Up 
NP_078934.3 importin-4  0.970 1.01 Up 0.735 1.05 Down  
NP_002262.3 importin-5  0.510 1.03 Down  0.221 1.12 Up 
NP_006382.1 importin-7  0.937 1.00 Down  0.966 1.00 Up 
NP_060555.2 importin-9  0.879 1.01 Up 0.017 1.12 Up 
NP_066952.1 inorganic pyrophosphatase  0.822 1.01 Down  0.003 1.24 Up 
NP_258412.1 inosine triphosphate pyrophosphatase isoform a  0.569 1.03 Down  0.228 1.10 Up 
NP_000875.2 inosine-5'-monophosphate dehydrogenase 2  0.276 1.07 Up 0.0001 1.48 Up 
NP_005527.1 inositol monophosphatase 1 isoform 1  0.731 1.02 Down  0.485 1.10 Up 
NP_004506.2 interleukin enhancer-binding factor 2  0.072 1.10 Down  0.046 1.15 Up 
NP_060090.2 interleukin enhancer-binding factor 3 isoform d  0.560 1.04 Down  0.016 1.13 Up 
NP_057132.2 isochorismatase domain-containing protein 1  0.765 1.03 Up 0.287 1.08 Up 
NP_005887.2 isocitrate dehydrogenase [NADP] cytoplasmic  0.808 1.02 Down  0.218 1.15 Up 
NP_002159.2 isocitrate dehydrogenase [NADP], mitochondrial precursor 0.933 1.01 Down  0.450 1.14 Up 
NP_060530.3 isoleucyl-tRNA synthetase, mitochondrial precursor  0.587 1.06 Down  0.045 1.50 Up 
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NP_006112.3 keratin, type II cytoskeletal 1  0.990 1.00 Up 0.973 1.01 Up 
NP_006550.1 
KH domain-containing, RNA-binding, signal transduction-associated 
protein 1  
0.645 1.04 Up 0.060 1.24 Down  
NP_891556.1 kinectin isoform a  0.025 1.63 Up 0.885 1.02 Down  
NP_004513.1 kinesin heavy chain isoform 5C  0.809 1.02 Down  0.469 1.06 Up 
NP_005543.2 kinesin light chain 1 isoform 1  0.871 1.01 Down  0.252 1.06 Up 
NP_004512.1 kinesin-1 heavy chain  0.731 1.05 Up 0.630 1.08 Down  
NP_006699.2 lactoylglutathione lyase  0.262 1.08 Down  0.449 1.07 Down  
NP_005564.1 lamin-B1 isoform 1  0.431 1.11 Up 0.999 1.00 Up 




0.872 1.03 Down  0.402 2.46 Up 
NP_006046.1 lanC-like protein 1  0.926 1.01 Down  0.014 1.20 Up 
NP_542433.1 large proline-rich protein BAT3 isoform b  0.041 1.20 Down  0.010 1.30 Down  
NP_573566.2 leucine-rich PPR motif-containing protein, mitochondrial precursor  0.490 1.05 Down  0.761 1.03 Up 
NP_065761.1 leucine-rich repeat-containing protein 47  0.889 1.01 Down  0.005 1.22 Down  
NP_060979.2 leucine-rich repeat-containing protein 59  0.508 1.26 Up 0.005 1.57 Down  
NP_064502.9 leucyl-tRNA synthetase, cytoplasmic  0.389 1.20 Up 0.092 1.24 Down  
NP_000886.1 leukotriene A-4 hydrolase  0.865 1.01 Down  0.081 1.23 Up 
NP_005557.1 L-lactate dehydrogenase A chain isoform 1  0.385 1.04 Up 0.005 1.22 Up 
NP_002291.1 L-lactate dehydrogenase B chain  0.258 1.05 Down  0.061 1.08 Up 
NP_004784.2 lon protease homolog, mitochondrial precursor  0.963 1.01 Down  0.943 1.01 Down  
NP_004291.1 low molecular weight phosphotyrosine protein phosphatase isoform c  0.295 1.05 Down  0.016 1.14 Up 
NP_057508.2 luc7-like protein 3  0.335 1.09 Down  0.111 1.18 Up 
NP_003133.1 lupus La protein  0.220 1.04 Down  0.680 1.03 Up 
NP_057370.1 L-xylulose reductase isoform 1  0.505 1.04 Down  0.610 1.06 Up 
NP_005031.1 lysosomal Pro-X carboxypeptidase isoform 1 preproprotein  0.068 1.12 Down  0.335 1.07 Up 
NP_005497.1 lysosome membrane protein 2  0.562 1.05 Down  0.014 1.43 Down  
NP_005552.3 lysosome-associated membrane glycoprotein 1 precursor  0.562 1.07 Down  0.027 1.19 Down  
NP_005539.1 lysyl-tRNA synthetase isoform 2  0.607 1.03 Down  0.680 1.03 Down  
NP_002406.1 macrophage migration inhibitory factor  0.358 1.10 Down  0.246 1.15 Up 
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NP_005908.1 malate dehydrogenase, cytoplasmic isoform 2  0.538 1.04 Down  0.770 1.01 Up 
NP_005909.2 malate dehydrogenase, mitochondrial precursor  0.657 1.03 Down  0.001 1.32 Up 
NP_075385.1 MARCKS-related protein  0.014 1.22 Up 0.009 1.40 Up 
NP_061322.2 matrin-3 isoform a  0.452 1.04 Down  0.016 1.16 Down  
NP_000007.1 
medium-chain specific acyl-CoA dehydrogenase, mitochondrial 
isoform a precursor  
0.064 1.20 Down  0.008 1.27 Down  
NP_004981.2 methionyl-tRNA synthetase, cytoplasmic  0.608 1.04 Down  0.0004 1.28 Down  
NP_001284.1 methylosome subunit pICln  0.333 1.07 Down  0.087 1.16 Down  
NP_005900.2 microtubule-associated protein 1B  0.939 1.01 Up 0.408 1.11 Up 
NP_002365.3 microtubule-associated protein 2 isoform 1  0.135 1.13 Up 0.592 1.08 Up 
NP_036457.1 microtubule-associated protein RP/EB family member 1  0.417 1.11 Up 0.026 1.22 Up 
NP_057152.2 mitochondrial fission 1 protein  0.211 1.20 Down  0.523 1.15 Up 
NP_036590.1 mitochondrial import inner membrane translocase subunit Tim13  0.386 1.05 Down  0.033 1.09 Down  
NP_001001563.1 mitochondrial import inner membrane translocase subunit TIM50  0.181 1.73 Down  0.044 1.77 Down  
NP_064628.1 mitochondrial import receptor subunit TOM22 homolog  0.334 1.22 Down  0.003 2.16 Down  
NP_055635.3 mitochondrial import receptor subunit TOM70  0.751 1.07 Down  0.046 1.45 Down  
NP_001093639.1 mitochondrial inner membrane protein isoform 2  0.524 1.13 Down  0.055 1.37 Down  
NP_004716.1 mitotic checkpoint protein BUB3 isoform a  0.038 1.10 Down  0.957 1.00 Down  
NP_071757.4 MMS19 nucleotide excision repair protein homolog  0.169 1.19 Down  0.553 1.07 Down  
NP_006443.1 multifunctional protein ADE2 isoform 2  0.787 1.01 Down  0.001 1.21 Up 
NP_055335.2 myb-binding protein 1A isoform 2  0.708 1.16 Up 0.951 1.02 Up 
NP_066299.2 myosin light polypeptide 6 isoform 1  0.148 1.11 Down  0.724 1.03 Up 
NP_006462.1 myosin regulatory light chain 12A  0.369 1.06 Down  0.136 1.15 Up 
NP_005955.1 myosin-10  0.999 1.00 Down  0.098 1.15 Up 
NP_002464.1 myosin-9  0.441 1.04 Down  0.961 1.00 Down  
NP_036355.2 myosin-Ib isoform 2  0.399 1.06 Up 0.016 1.25 Down  
NP_665807.1 myotrophin  0.273 1.05 Up 0.001 1.13 Up 
NP_002347.5 myristoylated alanine-rich C-kinase substrate  0.309 1.13 Up 0.044 1.33 Up 
NP_036269.1 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 isoform 1  0.992 1.00 Down  0.038 1.14 Up 
NP_039268.1 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2  0.540 1.03 Up 0.047 1.19 Up 
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NP_002387.1 NAD-dependent malic enzyme, mitochondrial isoform 1 precursor  0.427 1.07 Down  0.535 1.06 Down  
NP_004991.1 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5  0.988 1.00 Down  0.002 1.20 Up 
NP_004542.1 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, 
mitochondrial precursor  
0.790 1.02 Down  0.003 1.38 Up 
NP_004997.4 
NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 
isoform 1 precursor  
0.910 1.01 Up 0.200 1.16 Up 
NP_005585.1 nascent polypeptide-associated complex subunit alpha isoform b  0.348 1.05 Down  0.061 1.09 Down  
NP_006147.1 NEDD8 precursor  0.755 1.02 Up 0.008 1.16 Up 
NP_003960.1 NEDD8-conjugating enzyme Ubc12  0.275 1.07 Down  0.251 1.11 Up 
NP_006608.1 nestin  0.160 1.16 Down  0.950 1.01 Down  
NP_000606.3 neural cell adhesion molecule 1 isoform 1  0.021 1.45 Down  0.0002 2.11 Down  
NP_005373.2 neurofilament medium polypeptide isoform 1  0.560 1.03 Down  0.045 1.13 Up 
NP_835364.1 neuronal migration protein doublecortin isoform c  0.925 1.01 Up 0.011 1.38 Down  
NP_003369.2 neurosecretory protein VGF precursor  0.331 1.10 Up 0.003 1.39 Up 
NP_938148.1 neutral alpha-glucosidase AB isoform 2  0.535 1.05 Up 0.002 1.27 Up 
NP_004999.1 NHP2-like protein 1  0.286 1.07 Down  0.328 1.09 Up 
NP_005737.1 nicotinamide phosphoribosyltransferase precursor  0.692 1.02 Down  0.681 1.03 Down  
NP_001018146.1 NME1-NME2 protein  0.924 1.01 Down  0.013 1.09 Up 
NP_031389.3 non-POU domain-containing octamer-binding protein isoform 1  0.196 1.09 Down  0.115 1.11 Down  
NP_004394.1 non-syndromic hearing impairment protein 5 isoform a  0.666 1.06 Down  0.063 1.25 Up 
NP_057227.2 NSFL1 cofactor p47 isoform a  0.814 1.02 Up 0.489 1.07 Up 
NP_002473.2 nuclear autoantigenic sperm protein isoform 2  0.514 1.03 Down  0.038 1.07 Up 
NP_002477.1 nuclear cap-binding protein subunit 1  0.423 1.13 Up 0.218 1.22 Up 
NP_006591.1 nuclear migration protein nudC  0.486 1.06 Down  0.261 1.15 Up 
NP_006176.2 nuclear mitotic apparatus protein 1  0.910 1.01 Down  0.051 1.23 Down  
NP_065134.1 nuclear pore complex protein Nup107  0.958 1.01 Down  0.174 1.09 Down  
NP_004289.1 nuclear pore complex protein Nup155 isoform 2  0.561 1.04 Up 0.193 1.06 Up 
NP_056046.1 nuclear pore complex protein Nup160  0.905 1.01 Down  0.586 1.06 Up 
NP_079120.1 nuclear pore complex protein Nup85  0.124 1.19 Down  0.345 1.25 Up 
NP_055484.3 nuclear pore complex protein Nup93  0.637 1.03 Down  0.208 1.10 Up 
NP_036478.2 nuclear pore glycoprotein p62  0.490 1.06 Down  0.024 1.27 Up 
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NP_005787.1 nuclear transport factor 2  0.051 1.20 Down  0.969 1.00 Up 
NP_073568.2 nuclear ubiquitous casein and cyclin-dependent kinases substrate  0.538 1.10 Down  0.590 1.13 Down  
NP_004550.2 nuclease-sensitive element-binding protein 1  0.564 1.06 Down  0.148 1.14 Up 
NP_004732.2 nucleolar and coiled-body phosphoprotein 1  0.168 1.08 Down  0.007 1.28 Down  
NP_036473.2 nucleolar GTP-binding protein 1  0.488 1.08 Down  0.001 2.10 Down  
NP_056277.2 nucleolar protein 11  0.342 1.06 Down  0.198 1.15 Up 
NP_057018.1 nucleolar protein 58  0.689 1.05 Up 0.561 1.09 Up 
NP_004719.2 nucleolar RNA helicase 2  0.412 1.41 Up 0.002 1.44 Down  
NP_005372.2 nucleolin  0.710 1.03 Up 0.034 1.25 Up 
NP_002511.1 nucleophosmin isoform 1  0.184 1.08 Down  0.012 1.15 Up 
NP_076962.2 nucleoporin Nup37  0.010 1.30 Up 0.006 1.52 Up 
NP_003283.2 nucleoprotein TPR  0.411 1.06 Up 0.0001 1.24 Up 
NP_000260.1 nucleoside diphosphate kinase A isoform b  0.346 1.06 Down  0.016 1.16 Up 
NP_004528.1 nucleosome assembly protein 1-like 1  0.866 1.01 Down  0.118 1.10 Up 
NP_005960.1 nucleosome assembly protein 1-like 4  0.585 1.02 Down  0.001 1.20 Up 
NP_116258.2 nudC domain-containing protein 1 isoform 1  0.671 1.02 Down  0.147 1.11 Up 
NP_056147.2 nudC domain-containing protein 3  0.574 1.10 Down  0.030 1.27 Down  
NP_037473.3 obg-like ATPase 1 isoform 1  0.856 1.01 Up 0.490 1.06 Down  
NP_000265.1 ornithine aminotransferase, mitochondrial isoform 1 precursor  0.987 1.00 Down  0.001 1.30 Up 
NP_066997.3 p30 DBC protein  0.119 1.08 Down  0.378 1.05 Up 
NP_001035879.1 paraspeckle component 1  0.699 1.03 Up 0.001 1.23 Up 
NP_066953.1 peptidyl-prolyl cis-trans isomerase A  0.987 1.00 Up 0.015 1.14 Up 
NP_000933.1 peptidyl-prolyl cis-trans isomerase B precursor  0.188 1.16 Up 0.314 1.85 Up 
NP_005029.1 peptidyl-prolyl cis-trans isomerase D  0.423 1.11 Up 0.941 1.01 Up 
NP_002004.1 peptidyl-prolyl cis-trans isomerase FKBP3  0.992 1.00 Up 0.002 1.28 Down  
NP_002005.1 peptidyl-prolyl cis-trans isomerase FKBP4  0.260 1.07 Down  0.438 1.03 Up 
NP_006338.1 peptidyl-prolyl cis-trans isomerase H  0.309 1.11 Down  0.973 1.00 Up 
NP_057161.1 peptidyl-tRNA hydrolase 2, mitochondrial precursor  0.956 1.02 Up 0.004 1.96 Down  
NP_005808.3 perilipin-3 isoform 1  0.512 1.09 Up 0.007 1.37 Up 
NP_002565.1 peroxiredoxin-1  0.878 1.01 Down  0.001 1.20 Up 
NP_005800.3 peroxiredoxin-2 isoform a  0.638 1.02 Down  0.001 1.14 Up 
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NP_036226.1 peroxiredoxin-5, mitochondrial isoform a precursor  0.579 1.03 Up 0.001 1.26 Up 
NP_004896.1 peroxiredoxin-6  0.360 1.04 Up 0.011 1.16 Up 
NP_000405.1 peroxisomal multifunctional enzyme type 2 isoform 2  0.041 1.15 Up 0.016 1.17 Up 
NP_065090.1 PEST proteolytic signal-containing nuclear protein  0.214 1.07 Down  0.732 1.05 Up 
NP_116147.1 PHD finger-like domain-containing protein 5A  0.672 1.03 Up 0.016 1.30 Up 
NP_005678.3 phenylalanyl-tRNA synthetase beta chain  0.394 1.06 Up 0.162 1.15 Up 
NP_002626.1 phosphate carrier protein, mitochondrial isoform b precursor  0.818 1.05 Down  0.189 1.46 Down  
NP_002558.1 phosphatidylethanolamine-binding protein 1  0.771 1.02 Up 0.007 1.24 Up 
NP_036531.1 phosphatidylinositol transfer protein beta isoform  0.827 1.06 Up 0.571 1.10 Down  
NP_002624.2 phosphoglucomutase-1 isoform 1  0.464 1.07 Down  0.058 1.22 Up 
NP_060760.2 phosphoglucomutase-2  0.938 1.01 Down  0.587 1.07 Up 
NP_000282.1 phosphoglycerate kinase 1  0.227 1.06 Up 0.001 1.40 Up 
NP_002620.1 phosphoglycerate mutase 1  0.652 1.03 Up 0.0001 1.25 Up 
NP_001026866.1 phospholipase D3  0.001 1.32 Down  0.002 1.63 Down  
NP_006547.1 phosphomevalonate kinase  0.923 1.01 Up 0.616 1.06 Up 
NP_036525.1 phosphoribosylformylglycinamidine synthase  0.845 1.02 Up 0.405 1.12 Down  
NP_066977.1 phosphoserine aminotransferase isoform 2  0.022 1.22 Down  0.307 1.08 Up 
NP_001018077.1 plasminogen activator inhibitor 1 RNA-binding protein isoform 1  0.255 1.27 Up 0.00003 1.25 Down  
NP_000421.1 platelet-activating factor acetylhydrolase IB subunit alpha  0.699 1.02 Down  0.023 1.26 Up 
NP_002563.1 
platelet-activating factor acetylhydrolase IB subunit beta isoform 
a  
0.928 1.00 Down  0.0002 1.17 Up 
NP_002564.1 platelet-activating factor acetylhydrolase IB subunit gamma  0.800 1.01 Down  0.002 1.10 Up 
NP_001609.2 poly  0.336 1.52 Up 0.052 1.37 Down  
NP_006187.2 poly(rC)-binding protein 1  0.003 1.09 Down  0.077 1.09 Down  
NP_114366.1 poly(rC)-binding protein 2 isoform b  0.019 1.13 Down  0.551 1.04 Down  
NP_055096.2 poly(U)-binding-splicing factor PUF60 isoform b  0.209 1.07 Down  0.230 1.10 Up 
NP_002559.2 polyadenylate-binding protein 1  0.039 1.15 Down  0.216 1.07 Down  
NP_004634.1 polyadenylate-binding protein 2  0.791 1.03 Up 0.399 1.06 Up 
NP_003810.1 polyadenylate-binding protein 4 isoform 2  0.156 1.14 Down  0.402 1.20 Down  
NP_005701.1 polyglutamine-binding protein 1 isoform 1  0.330 1.06 Down  0.098 1.29 Down  
NP_002810.1 polypyrimidine tract-binding protein 1 isoform a  0.520 1.02 Down  0.042 1.08 Down  
NP_036526.2 prefoldin subunit 2  0.381 1.07 Down  0.992 1.00 Down  
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NP_003363.1 prefoldin subunit 3  0.119 1.11 Down  0.190 1.10 Up 
NP_002615.2 prefoldin subunit 5 isoform alpha  0.094 1.11 Down  0.136 1.06 Up 
NP_055075.1 prefoldin subunit 6  0.965 1.00 Down  0.286 1.07 Up 
NP_005563.1 prelamin-A/C isoform 2  0.695 1.04 Down  0.229 1.13 Down  
NP_055317.1 pre-mRNA-processing factor 19  0.816 1.01 Up 0.021 1.09 Up 
NP_060362.3 pre-mRNA-processing factor 40 homolog A  0.909 1.01 Down  0.036 1.35 Up 
NP_006436.3 pre-mRNA-processing-splicing factor 8  0.396 1.07 Up 0.891 1.01 Up 
NP_002769.1 proactivator polypeptide isoform a preproprotein  0.112 1.13 Down  0.691 1.03 Up 
NP_006377.2 probable ATP-dependent RNA helicase DDX17 isoform 1  0.613 1.04 Down  0.142 1.14 Down  
NP_004387.1 probable ATP-dependent RNA helicase DDX5  0.162 1.15 Down  0.000003 1.71 Down  
NP_001075.1 procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 precursor  0.049 1.30 Up 0.0001 1.87 Up 
NP_005013.1 profilin-1  0.427 1.05 Down  0.014 1.15 Up 
NP_002619.1 profilin-2 isoform b  0.798 1.02 Up 0.271 1.11 Up 
NP_037506.2 programmed cell death 6-interacting protein isoform 1  0.509 1.02 Down  0.018 1.15 Up 
NP_004699.1 programmed cell death protein 5  0.250 1.08 Down  0.113 1.18 Up 
NP_037364.1 programmed cell death protein 6  0.557 1.05 Down  0.037 1.24 Up 
NP_002625.1 prohibitin  0.764 1.02 Down  0.057 1.15 Up 
NP_009204.1 prohibitin-2 isoform 2  0.605 1.07 Down  0.016 1.24 Down  
NP_002583.1 proliferating cell nuclear antigen  0.089 1.12 Down  0.176 1.11 Down  
NP_006182.2 proliferation-associated protein 2G4  0.447 1.05 Down  0.856 1.02 Up 
NP_055204.2 proline-, glutamic acid- and leucine-rich protein 1  0.445 1.07 Down  0.278 1.11 Up 
NP_002717.3 prolyl endopeptidase  0.141 1.11 Up 0.063 1.21 Up 
NP_006592.3 prostaglandin E synthase 3  0.833 1.01 Down  0.603 1.05 Down  
NP_008933.2 proteasomal ubiquitin receptor ADRM1 precursor  0.848 1.04 Up 0.016 1.26 Up 
NP_006254.1 proteasome activator complex subunit 1 isoform 1  0.597 1.02 Up 0.183 1.27 Up 
NP_002809.2 proteasome activator complex subunit 2  0.083 1.07 Up 0.588 1.04 Up 
NP_005780.2 proteasome activator complex subunit 3 isoform 1  0.310 1.08 Down  0.717 1.03 Down  
NP_002777.1 proteasome subunit alpha type-1 isoform 2  0.940 1.00 Down  0.100 1.14 Up 
NP_002778.1 proteasome subunit alpha type-2  0.777 1.01 Up 0.179 1.08 Up 
NP_002779.1 proteasome subunit alpha type-3 isoform 1  0.831 1.02 Down  0.056 1.11 Up 
NP_002780.1 proteasome subunit alpha type-4 isoform 1  0.987 1.00 Down  0.015 1.07 Up 
NP_002781.2 proteasome subunit alpha type-5 isoform 1  0.628 1.02 Down  0.004 1.16 Up 
NP_002782.1 proteasome subunit alpha type-6  0.893 1.01 Down  0.076 1.09 Up 
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NP_002783.1 proteasome subunit alpha type-7  0.405 1.05 Down  0.352 1.06 Up 
NP_002784.1 proteasome subunit beta type-1 precursor  0.989 1.00 Down  0.170 1.21 Up 
NP_002785.1 proteasome subunit beta type-2 isoform 1  0.991 1.00 Down  0.141 1.11 Up 
NP_002786.2 proteasome subunit beta type-3  0.381 1.04 Up 0.068 1.09 Up 
NP_002787.2 proteasome subunit beta type-4  0.280 1.09 Down  0.138 1.07 Up 
NP_002788.1 proteasome subunit beta type-5 isoform 1  0.712 1.03 Down  0.806 1.02 Down  
NP_002789.1 proteasome subunit beta type-6 precursor  0.572 1.02 Up 0.553 1.04 Up 
NP_002790.1 proteasome subunit beta type-7 proprotein  0.670 1.03 Up 0.166 1.12 Up 
NP_000507.1 protein ALEX GNASL  0.048 1.13 Down  0.015 1.25 Down  
NP_938074.2 protein arginine N-methyltransferase 1 isoform 3  0.462 1.06 Down  0.181 1.11 Down  
NP_006100.2 protein arginine N-methyltransferase 5 isoform a  0.620 1.04 Down  0.051 1.16 Up 
NP_055070.1 protein canopy homolog 2 isoform 1 precursor  0.405 1.08 Up 0.005 1.38 Up 
NP_057005.1 protein CutA isoform 2  0.860 1.01 Down  0.418 1.07 Up 
NP_005304.3 protein disulfide-isomerase A3 precursor  0.162 1.09 Up 0.00003 1.45 Up 
NP_004902.1 protein disulfide-isomerase A4 precursor  0.627 1.03 Up 0.00001 1.38 Up 
NP_005733.1 protein disulfide-isomerase A6 precursor  0.523 1.04 Up 0.00001 1.36 Up 
NP_000909.2 protein disulfide-isomerase precursor  0.767 1.03 Up 0.007 1.25 Up 
NP_009193.2 protein DJ-1  0.978 1.00 Up 0.046 1.13 Up 
NP_115963.1 protein dpy-30 homolog  0.422 1.10 Down  0.930 1.01 Up 
NP_060682.2 protein enabled homolog isoform b  0.907 1.01 Up 0.988 1.00 Up 
NP_002728.1 protein kinase C alpha type  0.401 1.07 Up 0.330 1.07 Down  
NP_002361.1 protein mago nashi homolog  0.072 1.08 Up 0.071 1.23 Up 
NP_003625.2 protein NipSnap homolog 1  0.732 1.03 Down  0.057 1.13 Up 
NP_619634.1 protein phosphatase 1 regulatory subunit 14B  0.490 1.09 Up 0.542 1.07 Down  
NP_002697.1 protein phosphatase 1B isoform 1  0.810 1.04 Up 0.797 1.05 Down  
NP_817092.1 protein phosphatase 1G  0.207 1.06 Down  0.473 1.06 Up 
NP_057231.1 protein phosphatase methylesterase 1  0.724 1.02 Up 0.955 1.00 Down  
NP_061185.1 protein RCC2  0.363 1.09 Up 0.343 1.17 Down  
NP_055776.1 protein RUFY3 isoform 2  0.310 1.07 Up 0.024 1.18 Up 
NP_899195.1 protein SEC13 homolog isoform 1  0.203 1.06 Down  0.052 1.17 Up 
NP_003002.2 protein SET isoform 2  0.555 1.04 Up 0.788 1.02 Up 
NP_006314.2 protein transport protein Sec24B isoform a  0.902 1.04 Down  0.677 1.18 Up 
NP_004913.2 protein transport protein Sec24C  0.232 1.12 Down  0.406 1.05 Down  
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NP_055748.2 protein transport protein Sec31A isoform 1  0.648 1.07 Down  0.339 1.18 Up 
NP_002814.3 prothymosin alpha isoform 2  0.291 1.08 Up 0.977 1.00 Up 
NP_000261.2 purine nucleoside phosphorylase  0.934 1.01 Up 0.215 1.09 Up 
NP_006301.3 puromycin-sensitive aminopeptidase  0.518 1.03 Down  0.078 1.06 Up 
NP_001349.2 
putative pre-mRNA-splicing factor ATP-dependent RNA helicase 
DHX15  
0.855 1.02 Up 0.00001 1.29 Down  
NP_006734.1 putative RNA-binding protein 3  0.254 1.13 Down  0.00004 1.84 Down  
NP_057103.2 putative RNA-binding protein Luc7-like 2  0.682 1.02 Down  0.069 1.08 Up 
NP_060117.3 putative rRNA methyltransferase 3  0.770 1.02 Down  0.024 1.70 Down  
NP_722546.1 pyrroline-5-carboxylate reductase 1, mitochondrial isoform 2  0.908 1.01 Up 0.054 1.32 Up 
NP_000916.2 
pyruvate dehydrogenase E1 component subunit beta, mitochondrial 
isoform 1 precursor  
0.463 1.06 Down  0.017 1.59 Up 
NP_002645.3 pyruvate kinase isozymes M1/M2 isoform M2  0.192 1.04 Up 0.119 1.17 Up 
NP_001880.2 quinone oxidoreductase isoform a  0.623 1.09 Up 0.163 1.42 Up 
NP_001484.1 rab GDP dissociation inhibitor alpha  0.361 1.07 Down  0.003 1.19 Up 
NP_001485.2 rab GDP dissociation inhibitor beta isoform 1  0.214 1.07 Down  0.037 1.13 Up 
NP_002897.1 radixin  0.331 1.07 Up 0.796 1.03 Up 
NP_002874.1 ran GTPase-activating protein 1  0.976 1.00 Down  0.761 1.02 Down  
NP_015561.1 ran-binding protein 3 isoform RANBP3-d  0.580 1.07 Down  0.705 1.11 Down  
NP_002873.1 ran-specific GTPase-activating protein  0.520 1.02 Down  0.003 1.15 Up 
NP_001093896.1 rap1 GTPase-GDP dissociation stimulator 1 isoform 1  0.981 1.00 Down  0.155 1.07 Up 
NP_005745.1 ras GTPase-activating protein-binding protein 1  0.065 1.15 Down  0.001 1.34 Down  
NP_036429.2 ras GTPase-activating protein-binding protein 2 isoform a  0.034 1.16 Down  0.863 1.01 Up 
NP_008839.2 ras-related C3 botulinum toxin substrate 1 isoform Rac1  0.657 1.05 Down  0.013 1.39 Down  
NP_057215.3 ras-related protein Rab-10  0.230 1.15 Up 0.370 2.03 Up 
NP_004654.1 ras-related protein Rab-11A  0.363 1.05 Down  0.003 1.31 Down  
NP_057406.2 ras-related protein Rab-14  0.605 1.04 Up 0.831 1.02 Down  
NP_112243.1 ras-related protein Rab-1B  0.186 1.09 Up 0.202 1.08 Down  
NP_002856.1 ras-related protein Rab-2A  0.701 1.03 Down  0.676 1.05 Up 
NP_004574.2 ras-related protein Rab-5C isoform b  0.680 1.02 Down  0.717 1.03 Down  
NP_002860.2 ras-related protein Rab-6A isoform a  0.549 1.08 Down  0.828 1.03 Down  
NP_004628.4 ras-related protein Rab-7a  0.341 1.08 Up 0.367 1.11 Up 
NP_002938.1 replication protein A 14 kDa subunit  0.354 1.06 Down  0.008 1.11 Up 
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NP_002937.1 replication protein A 32 kDa subunit  0.658 1.03 Up 0.004 1.19 Up 
NP_002936.1 replication protein A 70 kDa DNA-binding subunit  0.788 1.01 Down  0.026 1.16 Up 
NP_002893.1 reticulocalbin-2 precursor  0.769 1.03 Up 0.761 1.04 Up 
NP_996734.1 reticulon-1 isoform C  0.577 1.10 Up 0.006 1.41 Up 
NP_722550.1 reticulon-4 isoform B  0.501 1.09 Up 0.003 1.32 Up 
NP_002890.2 retinol-binding protein 1 isoform a  0.797 1.01 Down  0.030 1.24 Up 
NP_001128360.1 retrotransposon-like protein 1  0.002 1.34 Down  0.00005 1.58 Down  
NP_004300.1 rho GDP-dissociation inhibitor 1 isoform a  0.180 1.05 Up 0.017 1.19 Up 
NP_002930.2 ribonuclease inhibitor  0.673 1.02 Down  0.432 1.04 Up 
NP_002755.1 ribose-phosphate pyrophosphokinase 1  0.819 1.01 Up 0.014 1.28 Up 
NP_056474.2 ribosomal L1 domain-containing protein 1  0.582 1.06 Up 0.018 1.23 Down  
NP_006319.1 RNA-binding protein 14 isoform 1  0.419 1.05 Down  0.009 1.18 Down  
NP_004893.1 RNA-binding protein 39 isoform b  0.575 1.02 Down  0.339 1.04 Up 
NP_002887.2 RNA-binding protein 4 isoform 1  0.588 1.03 Down  0.857 1.02 Down  
NP_005096.1 RNA-binding protein 8A  0.362 1.09 Down  0.456 1.08 Down  
NP_055124.1 RNA-binding protein 9 isoform 2  0.428 1.35 Up 0.730 1.11 Down  
NP_005234.1 RNA-binding protein EWS isoform 2  0.904 1.01 Up 0.246 1.17 Up 
NP_004951.1 RNA-binding protein FUS isoform 1  0.311 1.07 Down  0.802 1.02 Up 
NP_620412.1 RNA-binding protein Musashi homolog 2 isoform a  0.643 1.04 Down  0.020 1.35 Up 
NP_057951.1 RNA-binding protein Raly long isoform  0.902 1.01 Down  0.001 1.51 Down  
NP_006702.1 RNA-binding protein with serine-rich domain 1  0.738 1.02 Down  0.019 1.20 Up 
NP_001427.2 rRNA 2'-O-methyltransferase fibrillarin  0.901 1.01 Up 0.398 1.10 Down  
NP_003698.1 ruvB-like 1  0.544 1.02 Down  0.0001 1.29 Up 
NP_006657.1 ruvB-like 2  0.671 1.04 Down  0.004 1.31 Up 
NP_005902.1 S-adenosylmethionine synthase isoform type-2  0.057 1.11 Down  0.809 1.01 Up 
NP_149073.1 SAP domain-containing ribonucleoprotein  0.928 1.01 Down  0.797 1.03 Down  
NP_055581.3 secernin-1 isoform a  0.393 1.05 Up 0.055 1.31 Up 
NP_005689.2 secretory carrier-associated membrane protein 3 isoform 1  0.566 1.05 Up 0.413 1.13 Up 
NP_060713.1 septin-11  0.918 1.01 Up 0.014 1.23 Up 
NP_004395.1 septin-2  0.571 1.02 Up 0.013 1.19 Up 
NP_055944.2 septin-6 isoform B  0.359 1.09 Up 0.112 1.20 Up 
NP_001011553.2 septin-7 isoform 2  0.449 1.05 Up 0.289 1.14 Down  
NP_001106965.1 septin-9 isoform b  0.420 1.04 Down  0.931 1.01 Up 
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NP_005403.2 serine hydroxymethyltransferase, mitochondrial isoform 1 precursor  0.515 1.06 Down  0.047 1.18 Up 
NP_005830.2 serine/arginine repetitive matrix protein 1  0.614 1.05 Up 0.393 1.16 Up 
NP_057417.3 serine/arginine repetitive matrix protein 2  0.934 1.01 Down  0.173 1.14 Down  
NP_008855.1 serine/arginine-rich splicing factor 1 isoform 1  0.849 1.01 Up 0.00001 1.42 Up 
NP_006616.1 serine/arginine-rich splicing factor 10 isoform 1  0.793 1.02 Up 0.091 1.10 Up 
NP_004759.1 serine/arginine-rich splicing factor 11 isoform 1  0.392 1.06 Down  0.222 1.16 Up 
NP_003007.2 serine/arginine-rich splicing factor 2  0.071 1.13 Down  0.145 1.14 Up 
NP_003008.1 serine/arginine-rich splicing factor 3  0.408 1.11 Up 0.001 1.22 Up 
NP_006266.2 serine/arginine-rich splicing factor 6  0.510 1.07 Up 0.003 1.28 Up 
NP_001026854.1 serine/arginine-rich splicing factor 7 isoform 1  0.854 1.01 Up 0.001 1.34 Up 
NP_003760.1 serine/arginine-rich splicing factor 9  0.493 1.08 Up 0.003 1.16 Up 
NP_005100.1 serine/threonine-protein kinase OSR1  0.539 1.18 Up 0.694 1.20 Up 
NP_002568.2 serine/threonine-protein kinase PAK 2  0.347 1.07 Down  0.326 1.10 Up 
NP_055040.2 
serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A 
alpha isoform  
0.313 1.05 Down  0.781 1.01 Up 
NP_002712.1 serine/threonine-protein phosphatase 6 catalytic subunit isoform b  0.824 1.03 Up 0.626 1.07 Down  
NP_001164014.1 
serine/threonine-protein phosphatase PGAM5, mitochondrial isoform 
1  
0.906 1.01 Down  0.915 1.01 Down  
NP_002699.1 
serine/threonine-protein phosphatase PP1-alpha catalytic subunit 
isoform 1  
0.956 1.00 Down  0.291 1.06 Up 
NP_009109.3 serine-threonine kinase receptor-associated protein  0.386 1.06 Down  0.129 1.11 Up 
NP_001226.2 serpin H1 precursor  0.986 1.00 Up 0.317 1.07 Up 
NP_056992.4 serrate RNA effector molecule homolog isoform a  0.743 1.03 Up 0.890 1.01 Up 
NP_006504.2 seryl-tRNA synthetase, cytoplasmic  0.765 1.03 Up 0.482 1.08 Down  
NP_001975.1 S-formylglutathione hydrolase  0.506 1.02 Down  0.024 1.12 Up 
NP_112576.1 SH3 domain-binding glutamic acid-rich-like protein 3  0.622 1.06 Up 0.212 1.11 Up 
NP_073591.2 sideroflexin-1  0.684 1.08 Up 0.100 1.53 Down  
NP_003125.3 signal recognition particle 14 kDa protein  0.605 1.03 Up 0.079 1.16 Down  
NP_055045.2 signal recognition particle 68 kDa protein  0.046 1.11 Up 0.794 1.02 Up 
NP_008878.3 signal recognition particle 72 kDa protein  0.104 1.06 Down  0.713 1.03 Down  
NP_003124.1 signal recognition particle 9 kDa protein isoform 2  0.466 1.05 Up 0.132 1.11 Down  
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NP_003012.1 small glutamine-rich tetratricopeptide repeat-containing protein alpha  0.539 1.06 Down  0.631 1.06 Up 
NP_003085.1 small nuclear ribonucleoprotein E  0.447 1.05 Down  0.110 1.10 Up 
NP_003086.1 small nuclear ribonucleoprotein F  0.050 1.19 Down  0.544 1.06 Up 
NP_003087.1 small nuclear ribonucleoprotein G  0.100 1.08 Down  0.651 1.02 Up 
NP_008869.1 small nuclear ribonucleoprotein Sm D1  0.438 1.05 Down  0.523 1.06 Up 
NP_004588.1 small nuclear ribonucleoprotein Sm D2 isoform 1  0.347 1.08 Down  0.527 1.05 Down  
NP_004166.1 small nuclear ribonucleoprotein Sm D3  0.085 1.16 Down  0.822 1.04 Up 
NP_003082.1 
small nuclear ribonucleoprotein-associated proteins B and B' isoform 
B  
0.969 1.00 Up 0.614 1.04 Up 
NP_003343.1 small ubiquitin-related modifier 1 isoform a precursor  0.442 1.04 Down  0.055 1.18 Down  
NP_008868.3 small ubiquitin-related modifier 2 isoform a precursor  0.956 1.00 Down  0.506 1.05 Up 
NP_002442.2 S-methyl-5'-thioadenosine phosphorylase  0.579 1.03 Up 0.001 1.22 Up 
NP_689509.1 sodium/potassium-transporting ATPase subunit alpha-3  0.103 1.18 Down  0.001 1.49 Down  
NP_006507.2 solute carrier family 2, facilitated glucose transporter member 1  0.385 1.24 Up 0.375 1.27 Up 
NP_003095.2 sorbitol dehydrogenase  0.872 1.01 Up 0.001 1.20 Up 
NP_003121.1 sorcin isoform a  0.943 1.01 Up 0.558 1.10 Up 
NP_037478.2 sorting nexin-12  0.602 1.11 Down  0.176 1.15 Down  
NP_003118.2 spectrin alpha chain, brain isoform 2  0.207 1.08 Down  0.068 1.12 Down  
NP_003119.2 spectrin beta chain, brain 1 isoform 1  0.180 1.10 Down  0.009 1.24 Down  
NP_003123.2 spermidine synthase  0.906 1.01 Down  0.001 1.58 Up 
NP_004586.2 spermine synthase  0.700 1.09 Down  0.601 1.12 Down  
NP_008861.2 S-phase kinase-associated protein 1 isoform a  0.445 1.10 Down  0.007 1.26 Down  
NP_004631.1 spliceosome RNA helicase BAT1  0.872 1.01 Up 0.674 1.02 Up 
NP_973727.1 splicing factor 1 isoform 3  0.042 1.12 Down  0.860 1.02 Up 
NP_005868.1 splicing factor 3A subunit 1 isoform 1  0.802 1.02 Down  0.765 1.03 Up 
NP_006793.1 splicing factor 3A subunit 3  0.834 1.01 Down  0.418 1.07 Up 
NP_036565.2 splicing factor 3B subunit 1 isoform 1  0.993 1.00 Up 0.704 1.09 Down  
NP_006833.2 splicing factor 3B subunit 2  0.090 1.10 Down  0.751 1.02 Up 
NP_036558.3 splicing factor 3B subunit 3  0.788 1.01 Up 0.162 1.14 Up 
NP_005841.1 splicing factor 3B subunit 4  0.0099 1.24 Down  0.029 1.19 Down  
NP_112577.1 splicing factor 3B subunit 5  0.571 1.08 Down  0.148 1.20 Up 
NP_006749.1 splicing factor U2AF 35 kDa subunit isoform a  0.554 1.04 Up 0.006 1.23 Up 
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NP_009210.1 splicing factor U2AF 65 kDa subunit isoform a  0.444 1.06 Down  0.724 1.05 Up 
NP_005057.1 splicing factor, proline- and glutamine-rich  0.244 1.09 Down  0.053 1.14 Down  
NP_055521.1 squamous cell carcinoma antigen recognized by T-cells 3  0.100 1.15 Up 0.041 1.25 Up 
NP_112487.1 
SRA stem-loop-interacting RNA-binding protein, mitochondrial 
precursor  
0.569 1.05 Down  0.454 1.08 Up 
NP_055205.2 staphylococcal nuclease domain-containing protein 1  0.900 1.01 Down  0.024 1.16 Down  
NP_005554.1 stathmin isoform a  0.054 1.10 Up 0.003 1.32 Up 
NP_055892.2 sterile alpha and TIR motif-containing protein 1  0.664 1.06 Down  0.202 1.24 Down  
NP_038470.1 stomatin-like protein 2  0.798 1.02 Down  0.005 1.36 Up 
NP_004125.3 stress-70 protein, mitochondrial precursor  0.639 1.05 Down  0.084 1.16 Up 
NP_006810.1 stress-induced-phosphoprotein 1  0.891 1.01 Up 0.001 1.17 Up 
NP_005436.1 structural maintenance of chromosomes protein 3  0.641 1.07 Up 0.008 1.41 Down  
NP_005491.1 SUMO-activating enzyme subunit 1 isoform a  0.490 1.04 Down  0.038 1.14 Up 
NP_005490.1 SUMO-activating enzyme subunit 2  0.290 1.03 Down  0.938 1.00 Down  
NP_000445.1 superoxide dismutase [Cu-Zn]  0.039 1.06 Up 0.190 1.07 Up 
NP_006695.1 suppressor of G2 allele of SKP1 homolog isoform SGT1A  0.374 1.05 Up 0.653 1.05 Up 
NP_149351.1 surfeit locus protein 4  0.750 1.04 Down  0.639 1.04 Down  
NP_003065.3 SWI/SNF complex subunit SMARCC1  0.893 1.01 Down  0.013 1.16 Down  
NP_003066.2 SWI/SNF complex subunit SMARCC2 isoform a  0.808 1.02 Down  0.134 1.17 Up 
NP_003070.3 
SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily E member 1  
0.803 1.04 Up 0.812 1.02 Down  
NP_006364.2 synaptic vesicle membrane protein VAT-1 homolog  0.785 1.02 Up 0.393 1.07 Up 
NP_006280.3 talin-1  0.050 1.19 Down  0.207 1.10 Down  
NP_031401.1 TAR DNA-binding protein 43  0.766 1.02 Up 0.467 1.03 Up 
NP_003478.1 TATA-binding protein-associated factor 2N isoform 2  0.341 1.08 Down  0.788 1.03 Up 
NP_110379.2 T-complex protein 1 subunit alpha isoform a  0.598 1.02 Down  0.049 1.09 Up 
NP_006422.1 T-complex protein 1 subunit beta isoform 1  0.165 1.05 Down  0.107 1.08 Up 
NP_006421.2 T-complex protein 1 subunit delta  0.941 1.00 Down  0.095 1.09 Up 
NP_036205.1 T-complex protein 1 subunit epsilon  0.382 1.04 Down  0.020 1.10 Up 
NP_006420.1 T-complex protein 1 subunit eta isoform a  0.287 1.03 Down  0.161 1.06 Up 
NP_005989.3 T-complex protein 1 subunit gamma isoform a  0.016 1.11 Down  0.695 1.03 Down  
NP_006576.2 T-complex protein 1 subunit theta  0.892 1.01 Up 0.014 1.13 Up 
NP_001753.1 T-complex protein 1 subunit zeta isoform a  0.351 1.04 Down  0.336 1.04 Up 
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NP_003320.2 thioredoxin  0.503 1.13 Up 0.055 1.21 Up 
NP_116120.1 thioredoxin domain-containing protein 17  0.728 1.02 Down  0.028 1.17 Up 
NP_110437.2 thioredoxin domain-containing protein 5 isoform 1 precursor  0.141 1.12 Up 0.002 1.40 Up 
NP_877393.1 thioredoxin reductase 1, cytoplasmic isoform 2  0.449 1.05 Down  0.005 1.18 Up 
NP_006784.1 
thioredoxin-dependent peroxide reductase, mitochondrial 
isoform a precursor  
0.996 1.00 Up 0.001 1.57 Up 
NP_004777.1 thioredoxin-like protein 1  0.214 1.12 Down  0.812 1.03 Up 
NP_005773.3 THO complex subunit 4  0.477 1.11 Up 0.001 1.33 Down  
NP_689508.3 threonyl-tRNA synthetase, cytoplasmic  0.779 1.02 Up 0.090 1.16 Down  
NP_060206.2 THUMP domain-containing protein 1  0.358 1.19 Up 0.040 1.22 Up 
NP_003267.1 thymopoietin isoform alpha  0.496 1.27 Up 0.001 1.80 Down  
NP_066926.1 thymosin beta-10  0.174 1.09 Down  0.068 1.17 Down  
NP_066932.1 thymosin beta-4  0.813 1.03 Up 0.852 1.02 Up 
NP_005110.2 thyroid hormone receptor-associated protein 3  0.371 1.07 Up 0.651 1.06 Up 
NP_690866.1 TIP41-like protein isoform 1  0.064 1.31 Down  0.923 1.01 Down  
NP_006746.1 transaldolase  0.999 1.00 Up 0.107 1.15 Up 
NP_006747.1 transcription elongation factor A protein 1 isoform 1  0.113 1.12 Down  0.105 1.09 Down  
NP_005639.1 transcription elongation factor B polypeptide 1  0.248 1.09 Down  0.587 1.04 Up 
NP_009039.1 transcription elongation factor B polypeptide 2 isoform a  0.789 1.02 Up 0.008 1.13 Up 
NP_001198.2 transcription factor BTF3 isoform B  0.001 1.30 Down  0.001 1.39 Down  
NP_005753.1 transcription intermediary factor 1-beta  0.119 1.06 Down  0.318 1.05 Up 
NP_003225.2 transferrin receptor protein 1  0.552 1.09 Down  0.0002 1.72 Down  
NP_004584.1 transformer-2 protein homolog beta  0.048 1.07 Up 0.0001 1.31 Up 
NP_001655.1 transforming protein RhoA precursor  0.753 1.03 Down  0.027 1.27 Down  
NP_003555.1 transgelin-2  0.691 1.02 Down  0.434 1.06 Up 
NP_037391.2 transgelin-3  0.668 1.04 Up 0.007 1.20 Up 
NP_009057.1 transitional endoplasmic reticulum ATPase  0.490 1.03 Down  0.007 1.15 Up 
NP_001055.1 transketolase  0.978 1.00 Up 0.496 1.04 Down  
NP_001405.1 translation initiation factor eIF-2B subunit alpha  0.467 1.08 Down  0.181 1.29 Up 
NP_006827.1 translational activator GCN1  0.851 1.04 Down  0.474 1.07 Down  
NP_003286.1 translationally-controlled tumor protein  0.018 1.13 Down  0.142 1.09 Down  
NP_004613.1 translin  0.943 1.00 Up 0.060 1.14 Up 
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NP_694858.1 transportin-1 isoform 2  0.462 1.06 Up 0.391 1.03 Down  
NP_036602.1 transportin-3 isoform 1  0.924 1.01 Down  0.743 1.02 Up 
NP_000347.2 treacle protein isoform b  0.776 1.03 Down  0.131 1.36 Down  
NP_000173.2 trifunctional enzyme subunit alpha, mitochondrial precursor  0.688 1.06 Down  0.795 1.03 Down  
NP_000174.1 trifunctional enzyme subunit beta, mitochondrial precursor  0.691 1.06 Up 0.974 1.00 Up 
NP_000810.1 trifunctional purine biosynthetic protein adenosine-3 isoform 1  0.180 1.05 Down  0.254 1.09 Up 
NP_000356.1 triosephosphate isomerase isoform 1  0.457 1.18 Up 0.100 1.65 Up 
NP_003282.2 tripeptidyl-peptidase 2  0.366 1.10 Down  0.062 1.22 Up 
NP_057488.1 tRNA methyltransferase 112 homolog  0.016 1.73 Down  0.001 2.43 Down  
NP_003266.1 tropomodulin-1  0.037 1.25 Down  0.001 1.57 Down  
NP_001018004.1 tropomyosin alpha-1 chain isoform 3  0.949 1.01 Down  0.233 1.20 Down  
NP_705935.1 tropomyosin alpha-3 chain isoform 2  0.947 1.01 Up 0.016 1.23 Up 
NP_003281.1 tropomyosin alpha-4 chain isoform 2  0.789 1.02 Down  0.127 1.17 Up 
NP_004175.2 tryptophanyl-tRNA synthetase, cytoplasmic isoform a  0.730 1.02 Down  0.079 1.09 Up 
NP_006073.2 tubulin alpha-1B chain  0.968 1.00 Up 0.027 1.13 Up 
NP_821133.1 tubulin beta chain  0.949 1.00 Down  0.002 1.23 Up 
NP_821080.1 tubulin beta-2B chain  0.442 1.05 Down  0.017 1.14 Up 
NP_006077.2 tubulin beta-3 chain isoform 1  0.698 1.03 Up 0.069 1.21 Up 
NP_001272.2 tubulin-folding cofactor B  0.682 1.03 Up 0.086 1.16 Up 
NP_004598.1 tubulin-specific chaperone A  0.322 1.06 Down  0.666 1.03 Down  
NP_005984.3 tubulin-specific chaperone D  0.315 1.08 Down  0.151 1.12 Down  
NP_003279.2 tumor protein D54 isoform e  0.129 1.10 Down  0.038 1.10 Up 
NP_003671.1 tyrosyl-tRNA synthetase, cytoplasmic  0.284 1.11 Down  0.931 1.01 Up 
NP_003080.2 U1 small nuclear ribonucleoprotein 70 kDa  0.740 1.02 Down  0.290 1.12 Up 
NP_004587.1 U1 small nuclear ribonucleoprotein A  0.691 1.03 Up 0.011 1.33 Up 
NP_003084.1 U1 small nuclear ribonucleoprotein C  0.279 1.06 Down  0.888 1.02 Down  
NP_003081.2 U2 small nuclear ribonucleoprotein A'  0.353 1.06 Up 0.026 1.25 Up 
NP_005137.1 U4/U6.U5 tri-snRNP-associated protein 1  0.613 1.07 Up 0.230 1.14 Up 
NP_054733.2 U5 small nuclear ribonucleoprotein 200 kDa helicase  0.783 1.05 Down  0.036 1.41 Down  
NP_004805.2 U5 small nuclear ribonucleoprotein 40 kDa protein  0.544 1.05 Down  0.029 1.28 Up 
NP_067000.1 U6 snRNA-associated Sm-like protein LSm2  0.779 1.02 Up 0.092 1.43 Up 
NP_055278.1 U6 snRNA-associated Sm-like protein LSm3  0.991 1.00 Down  0.163 1.16 Up 
NP_009011.1 U6 snRNA-associated Sm-like protein LSm6  0.329 1.08 Down  0.069 1.17 Up 
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NP_005142.1 ubiquitin carboxyl-terminal hydrolase 14 isoform a  0.314 1.10 Down  0.042 1.24 Up 
NP_003472.2 ubiquitin carboxyl-terminal hydrolase 5 isoform 2  0.600 1.01 Up 0.00003 1.15 Up 
NP_003461.2 ubiquitin carboxyl-terminal hydrolase 7  0.869 1.01 Down  0.782 1.03 Up 
NP_004172.2 ubiquitin carboxyl-terminal hydrolase isozyme L1  0.067 1.09 Up 0.002 1.14 Up 
NP_060140.2 ubiquitin thioesterase OTUB1  0.555 1.02 Down  0.030 1.17 Up 
NP_002945.1 ubiquitin-40S ribosomal protein S27a precursor  0.523 1.06 Up 0.493 1.06 Down  
NP_001120792.1 ubiquitin-associated protein 2-like isoform b  0.976 1.01 Up 0.150 1.11 Down  
NP_003338.1 ubiquitin-conjugating enzyme E2 L3  0.518 1.05 Down  0.054 1.32 Up 
NP_003339.1 ubiquitin-conjugating enzyme E2 N  0.437 1.07 Down  0.032 1.14 Up 
NP_001027459.1 ubiquitin-conjugating enzyme E2 variant 1 isoform d  0.839 1.02 Down  0.528 1.04 Up 
NP_003325.2 ubiquitin-like modifier-activating enzyme 1  0.912 1.00 Up 0.005 1.14 Up 
NP_001988.1 ubiquitin-like protein fubi and ribosomal protein S30 precursor  0.781 1.02 Up 0.001 1.42 Down  
NP_056937.2 UBX domain-containing protein 1  0.324 1.13 Down  0.150 1.30 Up 
NP_064505.1 UDP-glucose:glycoprotein glucosyltransferase 1 precursor  0.340 1.06 Up 0.007 1.23 Up 
NP_000364.1 uridine 5'-monophosphate synthase  0.479 1.07 Down  0.044 1.19 Up 
NP_002865.1 UV excision repair protein RAD23 homolog B  0.857 1.01 Up 0.001 1.22 Up 
NP_060676.2 vacuolar protein sorting-associated protein 35  0.957 1.00 Up 0.209 1.10 Up 
NP_006286.1 valyl-tRNA synthetase  0.373 1.07 Down  0.079 1.19 Down  
NP_006169.2 vesicle-fusing ATPase  0.572 1.05 Up 0.958 1.00 Down  
NP_003371.2 vimentin  0.874 1.01 Up 0.426 1.11 Down  
NP_003364.1 vinculin isoform VCL  0.200 1.10 Down  0.007 1.29 Down  
NP_003365.1 voltage-dependent anion-selective channel protein 1  0.734 1.12 Down  0.008 3.89 Down  
NP_003366.2 voltage-dependent anion-selective channel protein 2 isoform 2  0.472 1.21 Down  0.015 2.32 Down  
NP_001681.2 V-type proton ATPase catalytic subunit A  0.434 1.05 Down  0.007 1.33 Up 
NP_001684.2 V-type proton ATPase subunit B, brain isoform  0.542 1.03 Down  0.010 1.16 Up 
NP_059830.1 WD repeat-containing protein 1 isoform 1  0.463 1.03 Down  0.150 1.04 Up 
NP_077005.2 WD repeat-containing protein 18  0.898 1.01 Up 0.012 1.40 Up 
NP_079510.1 WD repeat-containing protein 61  0.392 1.04 Down  0.465 1.04 Down  
NP_065116.3 xaa-Pro aminopeptidase 1 isoform 1  0.796 1.02 Up 0.014 1.33 Up 
NP_000276.2 xaa-Pro dipeptidase isoform 1  0.060 1.35 Down  0.477 1.15 Down  
NP_066964.1 X-ray repair cross-complementing protein 5  0.302 1.05 Down  0.208 1.06 Up 
NP_001460.1 X-ray repair cross-complementing protein 6  0.508 1.17 Up 0.031 1.20 Down  





The top 10 protein interactomes obtained from the oxygen glucose deprivation (OGD) 18hr data.  Functional protein-protein interactions for the 193 
proteins altered with OGD (18h) were defined using Ingenuity Pathway Analysis (IPA) software.  Upward arrows denote significantly increased proteins; 
downward arrows denote significantly decreased proteins; proteins names in plain type are proteins inserted into the network by IPA to augment functional 
coherence.  The IPA generated score is a putative measure of network probability (see Deighton et al, 2010 for critical analysis).  The focus molecules are the 
number of proteins identified by LC-MS contained within the network. 






60S ribosomal subunit, Actin, ↑ACTR1A, ATP synthesis, ↑ATP5A1, ↑ATP5J, ↑ATP6V1B2, ↑BANF1, ↓CAP1, ↓DDX5, 
↓DDX21, ↓DDX3X, ↑EFTUD2, H+-transporting two-sector ATPase, ↑HINT1, ↓HNRNPC, ↑LMNB2, Mediator, ↑NAPA, 
RNA polymerase II, ↓RPL13, ↓RPL23, ↓RPL35, ↓RPL38, ↑RTN4, ↑RUVBL1, ↑RUVBL2, ↓SMC3, ↑SRSF6, ↑SRSF9, 






[2.] 40s Ribosome 
↑CALR, ↓CDK1, ↓CSDE1, ↓DDX39A, ↓DHX15, E2f, ↑ERH, ↑FAU, ↑GSTP1, ↓GTPBP4, Histone h3, Histone h4, ↑P4HB, 
peroxidase (miscellaneous), ↑PGK1, ↑PRDX1, ↑PRDX2, ↑PRDX5, Ribosomal 40s subunit, ↑RPA2, ↑RPA3, RPA, ↓RPS9, 









Alpha Actinin, Alpha catenin, Alpha tubulin, ↓ANXA2, Calmodulin, ↑CAPZA1, ↑CAPZB, Ck2, ↑CLTC, ↑CSNK2A1, ↓CTSB, 
↑DBNL, ↑ECHS1, F Actin, ↓FKBP3, ↑FSCN1, ↑GANAB, ↑LDHA, ↓LRRC59, ↑MARCKSL1, ↑MTPN, ↓NCAM1, ↓NOLC1, 






[4.] Protein folding + 
protein degradation 
19S proteasome, 20s proteasome, 26s proteasome, ↑ANXA6, ATPase, ↑DNAJA2, ↓EIF3I, ↑GDI1, Hsp70, Hsp90, 
↑HSP90AA1, ↑HSP90B1, ↑HSPA5, ↑HSPD1, ↓MARS, MHC Class I (complex), ↑PAICS, ↑PDIA3, ↑PDIA4, ↑PSMA5, 










↑AARS, ↑APRT, ↓ATP1A3, C22orf28, Creatine Kinase, ↑ECH1, ↑ECHS1, EDIL3, EEF1B2, ↓EIF4A1, FAM65B, FAM82A2, 
↑FSCN1, ↑HSPD1, HSPH1, ↑INA, KIAA1949, ↑LDHA, ↓LRRC47, MAPK3, MAPK6, ↑MPST, PABPC4, ↑PAFAH1B2, 







↑ANP32E, ATP5I, ↑ATP6V1A, ↑C19orf10, ↓CSDE1, FOS, IGF2R, ↓LRRC59, M6PR, ↑MTAP, MYCN, NAE1, ↑NEDD8, 
NFYB, NUAK2, ↑NUP37, ↑OAT, ↑PDIA4, ↑PDIA6, ↑PLIN3, ↓RPL35, ↓RPL38, RPS7, ↓RPS9, RPS25, ↓RPS17/RPS17L, 






[7.] NF kappaB 
↓ACADM, AHNAK, ALDH16A1, ↑ATP5J, BHMT, ↓BTF3, ↑CALM1 (includes others), CCD15, ↑CKB, ↑CNPY2, EIF4B, 
↑ETFA, ETFB, HNRNPK, ↑HPRT1, IKBKE, ↑IMPDH2, ↓LOC728622/SKP1, MATR3, MPG, MT-CO2, MYL6, NFKB1, 






[8.] Lipid  + Ketone 
metabolism 
↑ACAA2, ↑ACAT1, ↓ACLY, ↑ACOT7, APP, BCL2L1, BNIP1, ↑CBS, ↓CHCHD2, ↓CTSB, DLG4, FAM160A2, FZD1, 
↑HBA1/HBA2, HBQ1, HNF4A, MT-ND3, ↑NDUFA5, NDUFA6, NDUFAF1, NDUFB1, NDUFB6, ↑NDUFS3, NDUFS4, 







[9.] Protein synthesis 
↓CAPRIN1, CELF1, ↓EIF1, ↓EIF4A1, EIF4A, ↓EIF4G1, EIF4G3, ↑ELAVL4, EP300, ERO1LB, ↑ERP29, ↑ERP44, FBXW8, 
↓G3BP1, ↑GPI, IGK, INTS6, KIAA1524, ↓KPNA2, mir-127, miR-127/miR-127-3p, MYC, ↑NAPIL4, OGFOD1, ↑PSPC1, 







↑ALDOC, ↑ARL3, ↓ATXN10, C4orf41, COL18A1, ↑DLD, DNAJB11, DNAJC1, DNAJC3, DNAJC6, DNAJC10, ↑ENO2, ↑ERH, 
ETFB, FBXO11, FDXR, ↑FH, ↑HSD17B10, HSP, HSPA14, HSPB6, ↑HSPE1, HTT, ILK, MCMBP, ↑MDH2, NDUFS7, ↑PLOD3, 
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Adaptive changes in the neuronal proteome: mitochondrial energy
production, endoplasmic reticulum stress, and ribosomal
dysfunction in the cellular response to metabolic stress
Abigail G Herrmann1, Ruth F Deighton1, Thierry Le Bihan2,3, Mailis C McCulloch4, James L Searcy1, Lorraine E Kerr2 and
James McCulloch1
Impaired energy metabolism in neurons is integral to a range of neurodegenerative diseases, from Alzheimer’s disease to stroke.
To investigate the complex molecular changes underpinning cellular adaptation to metabolic stress, we have defined the
proteomic response of the SH-SY5Y human neuroblastoma cell line after exposure to a metabolic challenge of oxygen glucose
deprivation (OGD) in vitro. A total of 958 proteins across multiple subcellular compartments were detected and quantified by
label-free liquid chromatography mass spectrometry. The levels of 130 proteins were significantly increased (Po0.01) after OGD
and the levels of 63 proteins were significantly decreased (Po0.01) while expression of the majority of proteins (765) was not
altered. Network analysis identified novel protein–protein interactomes involved with mitochondrial energy production, protein
folding, and protein degradation, indicative of coherent and integrated proteomic responses to the metabolic challenge.
Approximately one third (61) of the differentially expressed proteins was associated with the endoplasmic reticulum and
mitochondria. Electron microscopic analysis of these subcellular structures showed morphologic changes consistent with the
identified proteomic alterations. Our investigation of the global cellular response to a metabolic challenge clearly shows the
considerable adaptive capacity of the proteome to a slowly evolving metabolic challenge.
Journal of Cerebral Blood Flow & Metabolism (2013) 33, 673–683; doi:10.1038/jcbfm.2012.204; published online 16 January 2013
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INTRODUCTION
Impaired energy metabolism in neurons is integral to many
central nervous system diseases. An acute, intense metabolic
challenge during conditions such as stroke and brain trauma can
induce irreversible neuronal damage.1 By contrast, age-related
chronic metabolic impairment is thought to contribute to the
evolution of neurodegenerative diseases such as Alzheimer’s
disease, Parkinson’s disease, and Huntington’s disease.2,3
Neurochemical cascades initiated by both acute and prolonged
metabolic challenges can induce cell death via an elevation of
proapoptotic proteins. These metabolic challenges can also
activate genomic and proteomic responses promoting cell
survival in the immediate phase as well as preparing the cell to
deal with similar challenges in the future (conditioning).4
Subcellular organelles display complex proteomic responses to
impaired energy metabolism, with these responses ultimately
determining the death or survival of the cell. In mitochondria,
metabolic stress can disrupt energy generation, provoke mito-
chondrial swelling, and initiate apoptosis, all with potentially lethal
consequences.5 In response to cell stress, the endoplasmic
reticulum (ER) detects and reconfigures misfolded proteins in a
process known as the unfolded protein response (UPR). The UPR is
integral to cell survival as excessive accumulation of these
damaged proteins in the ER lumen can result in the suppression
of protein synthesis and irreversible pathology.6 In the nucleus
and ribosomes, metabolic stress leads to a genomic response and
the synthesis of proteins such as heat-shock proteins and trophic
factors, which contribute to protein repair and neuronal survival.7
The genomic response to metabolic challenge has been well
characterized both in vitro and in vivo.8–10 In the present study, we
provide a comprehensive cellular proteomic response and explore
the extent to which proteins are altered after a metabolic
challenge.
Oxygen glucose deprivation (OGD) induces metabolic stress in
neurons in culture.11,12 The intensity of the metabolic challenge
can be controlled by adjusting experimental conditions such as
the choice of cell line and alterations in the duration of OGD. Mass
spectrometry-based proteomics provides an excellent platform to
quantify OGD-dependent protein changes and to gain a fresh
perspective on adaptations that occur within the proteome in
response to metabolic stress.13 We have used human SH-SY5Y
neuroblastoma cells and label-free liquid chromatography mass
spectrometry (LC-MS) to define the integrated proteomic response
to metabolic stress that induces severe mitochondrial dysfunction
but only limited cell death. The majority of proteins analyzed
(800 out of 1,000) were not significantly altered by OGD.
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Protein increases after OGD was more than twice as frequent as
was decreases, consistent with an integrated cellular survival
response. Protein interactomes highlight coordinated proteomic
responses after OGD in relation to mitochondrial energy
production, ER stress, and ribosomal dysfunction.
MATERIALS AND METHODS
Reagents
All standard growth media used was obtained from Invitrogen (Paisley,
UK), unless otherwise stated, and all procedures were conducted in
compliance with all relevant legislation in the United Kingdom. Cells were
routinely maintained in standard 75 cm2 cell culture-treated flasks (Greiner
Bio One, Stonehouse, UK) within a continuous flow incubator at 371C, with
5% CO2 in fully humidified air. All growth media and solutions were
prewarmed to 371C before contact with cells, unless otherwise stated. The
acetonitrile and water used in the LC-MS buffer solutions were of HPLC
grade (Fisher, Loughborough, UK). Formic acid was of 98% to 100% purity
(Merck, Darmstadt, Germany) and trifluoroacetic acid was 99% sequencing
grade (Sigma-Aldrich, Gillingham, UK). All other chemicals used in the
processing of the protein samples were of reagent grade or better. The
trypsin used for protein digestion was from Promega (Southampton, UK).
Cell Culture and Oxygen Glucose Deprivation
SH-SY5Y cells (ATCC, Manassas, VA, USA) were cultured in Dulbecco’s
Modified Eagle Medium: Nutrient Mixture F12 (DMEM/F12) supplemented
with 2 mmol/L L-Glutamine, 100 U/mL Penicillin, 100 mg/mL Streptomycin,
and fetal bovine serum. Cells were routinely maintained at 371C, 5% CO2,
with culture medium replaced biweekly. Oxygen glucose deprivation (for 3,
6, 9, 12, and 18 hour durations) was achieved through incubation of the
cells at 371C in 95% N2:5% CO2. Aglycemia was induced by replacing
standard culture medium with glucose-free DMEM supplemented with
fetal bovine serum, after a glucose-free wash step. Control cells underwent
the same glucose-free wash step, followed by incubation with glucose
containing media (4,500 mg/L glucose). The osmolality of the DMEM
solutions used was within the range of 300 to 340 mOsm/kg for the no
glucose solutions, and 320 to 360 mOsm/kg for the glucose containing
media. All media were equilibrated overnight before experimentation in
either normoxic or anoxic chambers. Oxygen content in the media was
recorded in preliminary studies using a fiber optic dual oxygen-temperature
sensing probe (OxyLite 2000 E Series, Oxford Optronix, Oxford, UK). A rapid
oxygen depletion phase was recorded, with oxygen partial pressure falling
exponentially from 140 to 7 mm Hg over the initial 3 hours of OGD. Oxygen
depletion plateaued and remained severely hypoxic between 4 and 18 hours
with a recorded average partial pressure of 2 mm Hg.
Assessment of Mitochondrial Function (MTS Assay)
Cells were seeded onto poly-D-lysine coated flat-bottomed 96-well plates
at a density of 125,000 cells per well overnight. After OGD, glucose-free
DMEM was replaced with 200mL glucose-containing DMEM and cell
viability was assessed using 20 mL of CellTiter 96 AQueous One Solution
Cell Proliferation Assay (MTS) (Promega, Madison, USA) as per the
manufacturer’s guidelines. Cells were incubated for 2 hours in glucose
containing, normoxic media (371C, 5% CO2) to allow residual mitochondrial
function after OGD to be assessed using a Dynex MRX plate reader (Dynex
Technologies Ltd., Worthing, UK) at 490l.
Assessment of Global Cell Death (Trypan Blue)
Trypan blue staining was carried out to assess the extent of cell death
occurring after each OGD time point. Cells were collected immediately
at the end of each time point by trypsinization, centrifugation (200 g,
7 minutes) and resuspension in glucose-containing DMEM. Cells were
incubated with 0.1% trypan blue as per the manufacturer’s instructions
(Invitrogen). A hemocytometer was used to count stained and unstained
cells. The percentage of stained cells in each OGD and time-matched
control sample was calculated.
Preparation of Protein Samples for Liquid-Chromatography
Mass Spectrometry
SH-SY5Y cells were treated with 6 hours OGD (n¼ 6 independent samples
per group) and 18 hours OGD (n¼ 6), with a time-matched control for each
sample. After OGD or ‘control’ incubations, SH-SY5Y cells were immediately
scraped and centrifuged (200 g, 7 minutes). Cell pellets were washed in
Hanks Buffered Saline Solution and recentrifuged. Washed cell pellets were
resuspended in 1 ml Hanks Buffered Saline Solution and centrifuged
(6,000 g, 3 minutes). Supernatants were removed and the pellets snap
frozen for temporary storage at  801C. Cell pellets were defrosted and
lysed in 100mL 8 M urea using a cordless motor pellet pestle (Sigma-
Aldrich, Dorset, UK). Samples were then centrifuged (14,000 g, 15 minutes)
and supernatants recovered. Total protein content was determined using
the Pierce BCA Protein Assay Kit (Thermo-Fisher, Loughborough, UK).
Protein extract (140mg) from OGD and control samples were digested as
previously described.14
Liquid Chromatography Mass Spectrometry
Label-free intensity-based LC-MS was used to identify proteins differen-
tially expressed after 6 and 18 hours OGD relative to time-matched
controls. Capillary LC-MS data were acquired on an online system
consisting of a micro-pump (1200 binary HPLC system, Agilent, Edinburgh,
UK) coupled to a hybrid LTQ-Orbitrap XL instrument controlled through
Xcalibur 2.0.7 (Thermo-Fisher). Peptides were reconstituted in 20 mL of
loading buffer before injection and 8 mL was loaded. The HPLC separation
was provided by a gradient between buffer A (97.5% H2O, 2.5%
acetonitrile, 0.1% formic acid) and buffer B (90% acetonitrile, 10% H2O,
0.025% trifluoroacetic acid, 0.1% formic acid). The peptide mixture was
separated on a 140-minute gradient. The mass spectrometer was operated
in ‘data-dependent mode’, with a single MS scan (400 to 2,000 m/z)
followed by MS/MS scans in the linear ion trap on the five most abundant
ions and excluded for 120 seconds.
Protein Identification and Quantification
All LC-MS runs were analyzed using a label-free intensity-based approach
with Progenesis (version 4.0 Nonlinear Dynamics, Newcastle, UK), under
randomized conditions. The MS/MS data were searched using MASCOT
versions 2.3 (Matrix Science Ltd, London, UK) against a human subset of
the NCBI database (downloaded on 12 January 2011) with 34,281
sequences using a maximum missed-cut of 2. Variable methionine
oxidation, STY phosphorylation, protein N-terminal acetylation, and fixed
cysteine carbamidomethylation were used in all searches.
LC-MS label-free quantification was performed using Progenesis 4.0
(Nonlinear Dynamics). Protein conflict (peptides shared between different
proteins) was solved as followed: conflict resulting from multiple sequence
assignment to the same peak; we kept only the sequence having the
highest score. Conflict resulting from same peptide sequences assigned to
different proteins, the assignment was singly attributed to the protein that
had the highest number of peptides. Regarding the label-free quantitation,
the total number of Features (i.e., intensity signal at a given retention time
and m/z) was reduced to MSMS peaks with charge of 2, 3, or 4þ and we
only kept the five most intense MSMS spectra per ‘Feature’. The subset of
multicharged ions (2þ , 3þ , and 4þ ) was extracted from each LC-MS run
and the ions intensities summed for normalization. Protein quantitation
was performed as follows; for a specific protein, the associated unique
peptide ions were summed to generate an abundance value. The
measured protein abundances were transformed using an ArcSinH
function (as the method of detection can generate a significant amount
of near zero measurement for which a log transform is not ideal). The
within-group means were calculated to determine the fold change and the
transformed data were then used to calculate the P values using one-way
analysis of variance. Significant changes in protein expression (Po0.01)
between control and OGD experimental groups were determined for each
time point (6 and 18 hours) using Student’s t-test.
Analysis of Protein Subcellular Localization
All 958 proteins identified by LC-MS by at least two or more peptides were
uploaded to the Database for Annotation, Visualization and Integrated
Discovery (DAVID) (http://david.abcc.ncifcrf.gov15) to determine subcellular
localization based on gene ontology (GO). Protein clusters founded on
subcellular localization with DAVID scores 42 were used. Proteins
significantly altered (Po0.01) after 18 hours OGD were also assessed by
DAVID according to subcellular localization.
Interactome Analysis of Proteins Altered with Oxygen Glucose
Deprivation
Protein identifiers of all the proteins significantly altered after 18 hours
OGD (Po0.01) were uploaded with their corresponding fold change values
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to Ingenuity Pathway Analysis software (IPA; http://www.ingenuity.com).
Interactomes were algorithmically generated based on direct relationships
(physical interactions and associations) between eligible proteins.
The interactomes are color coded with green nodes representing proteins
that were downregulated after 18 hours OGD and red protein nodes
representing proteins that were upregulated after 18 hours OGD. The
shading of the interactome nodes is positively correlated with the
magnitude of fold change. The IPA generates a score for each interactome,
which is a putative measure of probability (see Deighton et al16 for critical
analysis).
Subcellular Morphology with Electron Microscopy
SH-SY5Y cells were exposed to OGD using the same paradigm as the LC-
MS study. Samples were collected immediately after 3, 9, and 18 hours of
OGD and fixed for a minimum of 20 hours in aldehyde fixative (4%
paraformaldehyde and 5% glutaradehyde in 0.08 M sodium cacodylate
buffer, pH 7.2). Once fixed, cells were centrifuged at 100 g, the supernatant
removed and replaced with a 3% solution of agar (type VII, low gelling
temperature; Sigma-Aldrich, Gillingham, UK). The gels were set at 41C for
5 minutes before being cut into 1 mm3 blocks and processed for electron
microscopy (EM). Processing, embedding, and staining were performed, as
described previously.17 Briefly, the blocks were cut into 70 nm thick
sections, collected on 300 mesh copper grids, stained with Reynold’s lead
citrate and contrasted with uranyl acetate.
The EM sections were evaluated on a JEOL CX-100 II transmission
electron microscope (Tokyo, Japan). The evaluator was blinded to the
treatment condition of all samples. Cells were chosen from grid squares in
a predetermined pattern. Fifty cells were assessed from each treatment.
For each cell, the condition of mitochondria and rough ER was assessed.
Mitochondria were graded as ‘normal’ (cristae clearly visible across 450%
of the matrix), ‘swollen’ (with a proportion of the matrix lost) and ‘abnormal’
(with most/ the entire matrix lost). The ER in each cell was graded similarly,
i.e., ‘normal’ (where ER outer membranes ran parallel to each other),
‘swollen’ (where modest swelling of ER outer membrane was present), or
‘abnormal’ where ER displayed extensive membrane swelling and
distortions. A Chi-Squared 3 2 matrix was used to test the null hypothesis
that OGD would have no effect on the ultrastructure of organelles.
RESULTS
Mitochondrial Function, Cell Viability, and Ultrastructure after
Oxygen Glucose Deprivation
Normal mitochondrial function was significantly reduced in
SH-SY5Y cells after OGD relative to time-matched control cells
(Po0.0001, at each time point analyzed), with longer durations of
OGD inducing more severe mitochondrial dysfunction (Figure 1A).
Viability of SH-SY5Y cells treated with OGD was quantified using
Trypan Blue staining (Figure 1B). Minimal cell death was detected
after OGD, with 91% of cells remaining viable after 18 hours OGD.
Ultrastructural morphologic changes in subcellular organelles
were analyzed relative to time-matched controls by EM after OGD.
With increasing OGD duration, the number of cells displaying
abnormal ER was significantly increased (Chi-Square, Po0.01)
(Figures 2A and 2C). SH-SY5Y cells also showed changes
in mitochondrial morphology with increasing OGD duration
(Figures 2B and 2D). It should be noted that even after 18 hours
OGD exposure, only 26% of cells displayed abnormal ER, and only
34% had abnormal mitochondria.
Global Proteomic Response after Oxygen Glucose Deprivation
(6 and 18 hours)
A total of 958 proteins were identified across all samples with two
or more peptides by LC-MS (Supplementary Table 1). Minimal
protein changes were observed after 6 hours OGD, with only 14
proteins significantly altered in expression level (Po0.01). After
18 hours OGD, 193 proteins were significantly altered in expres-
sion level (Po0.01) with 130 proteins increased and 63 proteins
decreased. For 765 proteins, no significant difference was
observed between control and OGD samples after 18 hours OGD.
Subcellular distribution of all the 958 proteins identified by
LC-MS was examined using DAVID software. Proteins were
detected from across many subcellular compartments, including
the nuclear lumen, cytoskeleton, mitochondria, ER, golgi appara-
tus, ribosomes, and vesicles (Figure 3A).
The ascribed subcellular locations of the significantly altered
proteins with OGD (18 hours) indicate that organelles are not
uniformly affected by the metabolic challenge. None of the
197 detected nuclear lumen proteins were significantly altered
after OGD, while 41% of the 56 detected ER proteins and 32% of
the 118 detected mitochondrial proteins were significantly altered
(Figure 3B). The significantly increased and decreased proteins
after OGD (18 hours) are listed by subcellular location in Table 1
and Table 2, respectively.
Functional protein–protein interactions for the 193 proteins
altered with 18 hours OGD were defined using IPA software.
IPA-generated 10 protein interactomes (Supplementary Table 2)
and three high-scoring interactomes (IPA scores 440) are
discussed in context below. These interactomes highlight a shift
in mitochondrial energy production, enhanced ER stress, and
ribosomal dysfunction.
Mitochondrial Protein Alterations after Oxygen Glucose
Deprivation (18 hours)
In all, 38 mitochondrial proteins (out of 118 detected; assigned
using the GO term mitochondrion GO:0005739) were significantly
Figure 1. Mitochondrial function decreases after oxygen glucose deprivation (OGD), whereas cell viability is largely maintained.
(A) Mitochondrial function is significantly decreased at each OGD time point compared with time-matched controls. Mitochondrial function
was assessed using an MTS assay, with data presented as mean±s.d., n¼ 8 for each time point. (B) Cell viability is maintained up to 12 hours
OGD, with an increase in cell death after 18 hours OGD. Cell viability was assessed using a trypan blue dye exclusion assay. Data are presented
as mean±s.d., n¼ 3 for each time point. All data are expressed as a percentage of contemporaneous time matched controls (*Po0.05,
***Po0.0001, T-test).
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altered after OGD (18 hours): 29 were increased and 9 were
decreased. VDAC1 and TOM22, proteins involved in mediating the
movement of metabolites across the mitochondrial membrane,
were significantly reduced after OGD. UQCRC1 and UQCRC2,
integral components of complex III of the electron transport chain
(ETC), were also significantly reduced (Figure 4A). Coordinated
changes in other regions of the ETC were observed after 18 hours
OGD treatment: ETC complex V proteins ATP5J and ATP5A1, and
ETC complex I proteins NDUFS3 and NDUFA5 were all significantly
increased (Po0.01).
Numerous mitochondrial proteins that have a role in lipid
metabolism were also found to be altered after 18 hours OGD.
ACADM, the enzyme involved in the first step of fatty acid
beta oxidation was significantly decreased (Po0.01); and
ECH1, HSD17B10 and ACAA2, enzymes downstream in the
beta-oxidation process were significantly increased. ACAT1, a
mitochondrial protein involved in ketone metabolism was also
significantly increased.
The highest scoring protein interactome generated by IPA
features some of the alterations in energy production described
above, namely increases in Complex V proteins (including ATP5J
and ATP5A1) and decreases in Complex III proteins (UQCRC1 and
UQCRC2) (Figure 4B). This Energy Production Interactome also
highlights interactions between altered components of the ETC
and other cellular machinery. Both UQCRC1 and UQCRC2 interact
with RTN4, a protein predominantly associated with regulating ER
function that was significantly upregulated after OGD (Figure 4A).
UQCRC2 is also shown to interact with upregulated RUVBL2, a
cytoskeletal protein involved in numerous cellular activities
including transcription and cellular transformation (Figure 4A).
The Energy Production Interactome also contains a cluster
of ribosomal proteins that are distinct but intersect with the
ribosomal interactome described below.
Endoplasmic Reticulum Protein Alterations after Oxygen Glucose
Deprivation (18 hours)
In all, 23 ER proteins (out of 56 detected; assigned using the GO
term Endoplasmic reticulum GO:0005783) were significantly altered
after 18 hours OGD: 19 were increased and 4 were decreased. A
number of proteins centrally involved in the UPR were signifi-
cantly increased, including, HSPA5, HSP90B1, PDIA3, and PDIA4
(Po0.01) (Figure 5A). Other proteins including CALR, UGGT1,
ERP29, ERP44, and VCP that are integral to ER stress response and
protein folding were significantly increased.
Multiple proteins that have a role in protein degradation were
significantly altered after OGD (18 hours). Protein subunits of the
20S and 19S core structures of the 26S proteasome (PSMA5,
PSMC3, PSMC4, PSMD1, PSMD2, PSMD6, and PSMD11) were
increased. These proteasomal proteins, along with proteins
involved in the UPR and heat-shock response after OGD dominate
the high scoring, Protein Folding and Degradation Interactome
generated by IPA (Figure 5B).
Ribosomal Protein Alterations after Oxygen Glucose Deprivation
(18 hours)
In all, 11 ribosomal proteins (out of 82 detected; assigned using
the GO term Ribosome GO:0005840) were significantly altered
after 18 hours OGD: 1 was increased and 10 were decreased.
The decreased ribosomal proteins were associated with both the
60S (RPL38, RPL23, RPL35, and RPL13) and 40S (RPS1, RPS14,
RPS23, RPS9, and RPS17) ribosomal subunits (Figure 5C). These
downregulated ribosomal proteins feature prominently in another
of the high scoring protein interactomes generated by IPA
(Figure 5D). An additionally important feature of this Ribosomal
Interactome is the cluster of upregulated peroxidases (PRDX1,
PRDX2, and PRDX5) (Figure 5C) involved in redox homeostasis and
Figure 2. The endoplasmic reticulum (ER) and mitochondria display progressive morphologic changes after oxygen glucose deprivation
(OGD). (A) OGD induced increases in the number of cells containing swollen and abnormal ER. Significant changes in the distribution of
‘normal’, ‘swollen’, and ‘abnormal’ ER within cells were seen after 3, 9, and 18 hours OGD compared with the time-matched controls (*Po0.05,
**Po0.01, w2). (B) The occurrence of mitochondrial morphologic abnormality increases after longer OGD durations. (C) Representative
electron micrographs of the three grades of ER morphology. Scale bar¼ 0.1 mm. (D) Representative electron micrographs of the three grades
of mitochondrial morphology. Scale bar¼ 0.1mm.
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protecting neurons from oxidative insults (for a review, see
Bell and Hardingham, 201118).
DISCUSSION
This study provides the first comprehensive analysis of the
proteomic and morphologic response of human SH-SY5Y cells to
prolonged metabolic challenge. The robustness of SH-SY5Y cells
to external stressors has allowed the evolving proteomic changes
occurring in response to OGD induced metabolic stress to be
defined, in the absence of cell death. The observed protein
changes provide insight into the complex molecular alterations
underpinning cellular adaptation to metabolic stress. The lack of
acute ischemic cell death in our in vitro model of neuronal
Figure 3. Subcellular distribution of detected proteins contrasted with subcellular distribution of proteins significantly altered after oxygen
glucose deprivation (OGD). Proteins were ascribed to subcellular compartment by DAVID software based on gene ontology. Proteins were
significantly altered after OGD (Po0.01) relative to their original levels in time-matched control samples. (A) Liquid chromatography mass
spectrometry (LC-MS) detected 958 proteins from across many subcellular compartments, showing the utility of LC-MS in providing a global
overview of cellular proteomics. (B) Organelles are differentially affected by 18 hours OGD. The 193 significant proteins changed (Po0.01)
were not distributed evenly across subcellular compartments: the endoplasmic reticulum and the mitochondria contained the largest
proportion of significantly altered proteins, whereas no significant protein changes were detected in the golgi apparatus or nuclear pore.
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Table 1. Proteins significantly increased with OGD (18hours)
Uniprot accn no. Gene name Protein name P value Fold change Protein function
Mitochondria
P30048 PRDX3 Peroxiredoxin III 0.0006 1.57 Cell redox homeostasis
P61604 HSPE1 10 kDa heat-shock protein 6.1E-06 1.51 Stress response
P18859 ATP5J ATP synthase-coupling factor 6 0.0016 1.44 ETC complex V
O75489 NDUFS3 NADH-ubiquinone oxidoreductase 30 kDa subunit 0.0030 1.38 ETC complex I
P24752 ACAT1 Acetyl-CoA acetyltransferase 9.1E-05 1.38 Ketone body metabolism
P09622 DLD Dihydrolipoyl dehydrogenase 0.0051 1.36 Gycine cleavage
Q9UJZ1 STOML2 Stomatin-like protein 2 0.0052 1.36 Receptor binding
P09972 ALDOC Fructose-bisphosphare aldolase C 0.0061 1.34 Glycolysis
P38606 ATP6V1A V-type proton ATPase catalytic subunit A 0.0067 1.33 ATP hydrolysis transport
P13804 ETFA Electron transfer flavoprotein subunit alpha 0.0005 1.33 Respiratory ETC
P30084 ECHS1 Enoyl-CoA hydratase 0.0043 1.33 Fatty acid metabolism
P40926 MDH2 Malate dehydrogenase 0.0009 1.32 Citric acid cycle
P10809 HSPD1 60 kDa heat-shock protein 0.0012 1.31 Protein folding
P62258 YWHAE 14-3-3 protein epsilon 0.0056 1.30 Apoptosis
P04181 OAT Orthinine aminotransferase 0.0012 1.30 Amino acid biosynthesis
Q13011 ECH1 Delta (3,5)-delta(2,4)-dienoyl-CoA isomerase 0.0048 1.28 Lipid metabolism
Q99714 HSD17B10 3-hydroxyacyl-CoA dehydrogenase type 2 0.0037 1.27 Lipid metabolism
P07954 FH Fumarate hydratase 0.0038 1.27 Citric acid cycle
P30044 PRDX5 Peroxiredoxin 5 0.0014 1.26 Redox homeostasis
P42765 ACAA2 3-ketoacyl-CoA thiolase 0.0067 1.26 Lipid metabolism
P25325 MPST 3-mercaptopyruvate sulfurtransferase 0.0012 1.25 Response to Toxins
P30086 PEBP1 Phosphatidylethanolamine binding protein 1 0.0067 1.24 Protease inhibition
P25705 ATP5A1 ATP synthase subunit alpha 0.0019 1.21 ETC complex V
Q06830 PRDX1 Peroxiredoxin 1 0.0009 1.20 Redox homeostasis
P43686 PSMC4 26S protease regulatory subunit 6B 0.0007 1.20 Protein degradation
Q16718 NDUFA5 NADH-ubiquinone oxidoreductase 13 kDa subunit 0.0022 1.20 ETC complex I
O00154 ACOT7 Cytosolic acyl-coenzyme A thioester hydrolase 0.0009 1.19 Acyl-CoA hydrolysis
Q00610 CLTC Clathrin heavy chain 1 4.9E-05 1.16 Endocytosis
P12277 CKB Creatine Kinase B type 0.0027 1.16 Creatine metabolism
Endoplasmic reticulum
O60568 PLOD3 Procollagen-lysine 2-oxoglutarate 5-dioxygenase 3 7.7E-05 1.87 Lysyl hydroxylation
P27797 CALR Calreticulin 1.0E-07 1.56 Protein folding
P11021 HSPA5 Heat-shock protein 5 3.9E-05 1.53 Protein complex assembly
P14625 HSP90B1 Heat-shock Protein 90 kDa beta member 1 5.5E-05 1.49 Protein transport
P30101 PDIA3 Protein disulfide isomerase A3 2.7E-05 1.45 Protein folding
Q16799 RTN1 Reticulon 1 0.0055 1.41 Neuron differentiation
Q8NBS9 TXNDC5 Thioredoxin-domain containing protein 5 0.0017 1.40 Cell redox homeostasis
P13667 PDIA4 Protein disulfide isomerase A4 1.4E-05 1.38 Cell redox homeostasis
Q9Y2B0 CNPY2 Protein canopy homolog 2 0.0051 1.38 Protein binding
Q15084 PDIA6 Protein disulfide isomerase A6 6.1E-06 1.37 Chaperone
P54920 NAPA Alpha soluble NSF attachment protein 0.0003 1.35 ER-golgi vesicle transport
P14314 PRKCSH Glucosidase 2 subunit beta 0.0016 1.33 Glycoprotein formation
Q9NQC3 RTN4 Reticulon 4 0.0033 1.32 Neurogenesis/apoptosis
Q14697 GANAB Neutral alpha-glucosidase AB/GNAB protein 0.0018 1.27 Glycoprotein cleavage
P07237 P4HB Protein disulfide isomerase 0.0073 1.25 Redox homeostasis
Q9BS26 ERP44 Endoplasmic reticulum resident protein 44 0.0007 1.23 ER stress response
Q9NYU2 UGGT1 UDP glucose:glycoprotein glucosyltransferase 1 0.0074 1.23 ER protein folding
P30040 ERP29 Endoplasmic reticulum resident protein 29 0.0003 1.23 ER protein folding
P55072 VCP Valosin-containing protein 0.0069 1.15 ER stress response
Ribosomes
P69905 HBA1 Hemoglobin subunit alpha 0.0003 1.97 O2 transport
Vesicle
O15240 VGF Neurosecretory protein VGF 0.0035 1.39 Cell–cell interactions
P08133 ANXA6 Annexin 6 0.0075 1.18 Ca2þ binding
P21281 ATP6V1B2 V-type proton ATPase subunit B 0.0098 1.16 Hþ ion transport
P07900 HSP90AA1 Heat Shock Protein HSP90-alpha 0.0030 1.11 Stress response
Q9BTT0 ANP32E Acidic leucine-rich nuclear phosphoprotein 32E 0.0034 1.08 Phosphatase inhibitor
Cytoskeleton
P52907 CAPZA1 F-actin capping protein subunit alpha 1 0.0039 1.35 Protein complex assembly
P16949 STMN1 Stathmin 0.0029 1.32 Microtubule disassembly
Q9Y230 RUVBL2 RuvB like 2 0.0037 1.31 Transcription
P47756 CAPZB F-actin-capping protein subunit beta 3.2E-05 1.25 Protein complex assembly
Q03252 LMNB2 Lamin B2 0.0076 1.24 Cytoskeleton regulation
Q16352 INA Alpha-internexin 4.9E-05 1.24 Neurogenesis
P07437 TUBB Tubulin beta chain 0.0016 1.23 Microtubule constituent
P36405 ARL3 ADP-ribosylation factor-like protein 3 0.0071 1.23 Cell division
P61163 ACTR1A Alpha centractin 0.0029 1.23 Vesicle mediated transport
Q9UJU6 DBNL Debrin-like protein 0.0095 1.18 Endocytosis
Q16658 FSCN1 Fascin 0.0018 1.18 Cytoskeleton organization
P62158 CALM Calmodulin 0.0059 1.17 Calcium modulation
Q9BZK7 TBL1XR1 F-box like/WD repeat containing protein TBL1XR1 0.0046 1.17 Protein degradation
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Table 1. (Continued )
Uniprot accn no. Gene name Protein name P value Fold change Protein function
P49773 HINT1 Histidine triad nucleotide-binding protein 1 0.0002 1.15 Signal transduction
P43487 RANBP1 Ran-specific GTPase-activating protein 0.0029 1.15 Signal transduction
Spliceosome
Q07955 SRSF1 Serine/Arginine-rich splicing factor 1 1.1E-05 1.42 mRNA splicing
Q01081 U2AF1 Splicing factor U2AF 35 kDa subunit 0.0062 1.23 mRNA splicing
Q15029 EFTUD2 116 kDa U5 small nuclear ribonucleoprotein 0.0069 1.19 mRNA splicing
Proteosome
Q15008 PSMD6 26s proteasome non ATPase regulatory subunit 6 0.0053 1.61 Protein degradation
P17980 PSMC3 26S protease regulatory subunit 6A 0.0071 1.27 Protein degradation
Q13200 PSMD2 26S proteasome non-ATPase regulatory subunit 2 0.0005 1.22 Protein degradation
P54727 RAD23B UV excision protein RAD23 homolog B 0.0009 1.22 Protein degradation
Q99460 PSMD1 26S proteasome non-ATPase regulatory subunit 1 0.0002 1.18 Protein degradation
O00231 PSMD11 26S proteasome non-ATPase regulatory subunit 11 0.0008 1.18 Protein degradation
P28066 PSMA5 Proteasome subunit alpha type 5 0.0036 1.16 Protein degradation
ER, endoplasmic reticulum; ETC, electron transport chain; OGD, oxygen glucose deprivation.
Proteins are grouped according to subcellular compartment based on gene ontology and ranked according to magnitude of fold change. The significance
threshold was set a priori at Po0.01.
Table 2. Proteins Significantly Decreased with OGD (18 hours)
Uniprot accn no. Gene name Protein name P-value Fold change Protein function
Mitochondria
P21796 VDAC1 Voltage-dependent anion selective channel protein 1 0.0079 0.26 Ion transport
P22695 UQCRC2 Cytochrome b-c1 complex subunit 2 0.0017 0.31 ETC complex III
P31930 UQCRC1 Cytochrome b-c1 complex subunit 1 0.0097 0.46 ETC complex III
Q9NS69 TOM22 Translocase of outer membrane 22 kDa subunit 0.0027 0.46 Protein transport
Q9Y3E5 BIT1 Peptidyl-tRNA hydrolase 2 0.0038 0.51 Apoptosis
P02786 TFRC Transferrin receptor protein 1 0.0002 0.58 Endocytosis
O75534 CSDE1 Cold shock domain containing protein E1 1.0E-06 0.62 Transcription
Q9Y6H1 CHCHD2 Coiled-coil helix–coiled-coil helix domain protein 2 0.0099 0.70 unknown
P11310 ACADM Medium chain specific acyl-CoA dehydrogenase 0.0084 0.79 Lipid metabolism
Endoplasmic reticulum
Q81V08 PLD3 Phospholipase D3 0.0016 0.61 Lipid degradation
Q96AG4 LRRC59 Leucine rich repeat-containing protein 59 0.0048 0.64 ER membrane interactions
P13637 ATP1A3 Naþ /Kþ ATPase alpha (III) subunit 0.0008 0.67 ATP hydrolysis catalyst
P04843 RPN1 Ribophorin 1 0.0094 0.68 Glycosyltransferase activity
Ribosomes
P63173 RPL38 60s ribosomal protein L38 0.0001 0.65 Protein biosynthesis
P62249 RPS16 40S ribosomal protein S16 7.9E-05 0.70 Protein biosynthesis
P35544 FAU Ubiquitin-like protein FUB 1 0.0012 0.70 Ubiquitination modulation
P62263 RPS14 40S ribosomal protein S14 0.0004 0.74 Protein biosynthesis
P62829 RPL23 60S ribosomal protein L23 5.3E-05 0.74 Protein biosynthesis
P62266 RPS23 40S ribosomal protein S23 0.0004 0.76 Protein biosynthesis
P46781 RPS9 40S ribosomal protein S9 0.0002 0.78 Protein biosynthesis
P08708 RPS17 40S ribosomal protein S17 0.0004 0.80 Protein biosynthesis
P42766 RPL35 60S ribosomal protein L35 0.0018 0.82 Protein biosynthesis
P26373 RPL13 60S ribosomal protein L13 0.0004 0.84 Protein biosynthesis
Vesicle
P07355 ANXA2 Annexin A2 0.0038 0.49 Ca2þ binding
P62491 RAB11A Ras-related protein Rab 11A 0.0026 0.76 Endocytic cycling
P07858 CTSB Cathepsin B 0.0053 0.85 Protein degradation
Cytoskeleton
P06493 CDK1 Cyclin-dependent kinase 1 0.0022 0.57 Cell-cycle control
P28289 TMOD1 Tropomodulin 1 0.0005 0.64 Cytoskeleton organization
Q01518 CAP1 Adenylyl cyclase-associated protein 1 4.7E-06 0.70 Signal transduction
Q9UQE7 SMC3 Structural maintenance of chromosomes protein 3 0.0084 0.71 Cell cycle
P18206 VCL Viniculin 0.0067 0.78 Cell adhesion
Q01082 SPTBN1 Spectrin beta chain brain 1 0.0092 0.81 Cytoskeleton movement
Spliceosome
P17844 DDX5 Probable ATP-dependent RNA helicase DDX5 2.9E-06 0.58 mRNA processing
Q9UKM9 RALY RNA-binding protein Raly 0.0014 0.66 mRNA splicing
Q86V81 THOC4 THO complex subunit 4 0.0007 0.75 mRNA splicing
O43143 DHX15 Pre-mRNA splicing factor ATP-dep. RNA helicase 5.5E-06 0.78 mRNA splicing
P07910 HNRNPC Heterogeneous nuclear ribonucleoproteins Ca/C2 0.0005 0.81 mRNA splicing
ER, endoplasmic reticulum; ETC, electron transport chain; OGD, oxygen glucose deprivation.
Proteins are grouped according to subcellular compartment based on gene ontology and ranked according to magnitude of fold change. The significance
threshold was set a priori at Po0.01.
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metabolic stress makes the proteomic results particularly
pertinent to mild, sustained ischemia challenges and the
compromised energy metabolism associated with slowly evolving
neurodegenerative disorders such as Alzheimer’s disease.3
Proteomics has showed alterations and interactions in mito-
chondrial, ER, and ribosomal proteins after OGD. The ETCproteins
displayed bidirectional changes (Complex I and V proteins
increased and Complex III proteins decreased) in response to
OGD. Other mitochondrial proteins involved in lipid and ketone
metabolism, including AD-related HSD17B10 (more commonly
known as ABAD), were also increased after OGD (18 hours). The ER
stress response proteins along with proteins involved in protea-
somal/ubiquitination degradation also formed an important part
of the upregulated proteomic response to the metabolic
challenge of OGD.
A significant mitochondrial proteomic response was observed
after OGD. Two of the most markedly decreased proteins after
18 hours OGD were subunits 1 and 2 (UQCRC1 and UQCRC2) of
ETC complex III. Complex III is the third component of the ETC
located within the inner mitochondrial membrane. Complex III
mediates the transfer of electrons from ubiquinone to cytochrome
C, and in doing so translocates a proton into the inner-membrane
space and contributes to the generation of the electrochemical
gradient used for the production of ATP.19 Complex III is also
intrinsically involved in the generation of reactive oxygen species
from the mitochondria during hypoxia, and these reactive oxygen
species work to stabilize HIF1a and initiate protein transcription.20
A significant decrease in UQCRC1 and UQCRC2 might be an
attempt by the cells to reduce the production of reactive oxygen
species from the mitochondria under stress conditions.
Interestingly, UQCRC1 has also been recorded as significantly
decreased in the brains of AD patients.21 The similar decrease in
UQCRC1 expression observed in AD patients and cells in vitro after
OGD may provide a link between chronic oxidative challenge and
the onset and progression of AD.
The Energy Production Interactome (Figure 4B) also highlighted
putative functional protein–protein interactions between UQCRC1,
UQCRC2, and RTN4 (a protein increased after 18 hours OGD). RTN4
is increased in hippocampal neurons of AD patients22 and is
known to interact with BACE1, reducing AB40 and AB42 levels.23
The dysregulation of RTN4 after a metabolic challenge (18 hours
OGD), its interaction with complex III proteins, and its potential
role in APP processing, highlights RTN4 protein as a compelling
target for future investigation.
Mitochondrial complex I and V proteins were significantly
increased in expression after OGD in sharp contrast to the
reduction in complex III proteins after OGD. Complex I is the first
protein complex of the ETC and initiates the transfer of electrons
required for oxidative phosphorylation. The process is initiated
through binding and oxidation of NADH, with the concurrent
transfer of two electrons from NADH to ubiquinone, and
the translocation of four protons into the intermembrane space.24
An increase in Complex I proteins after OGD may reflect a
compensatory mechanism to counteract the impact of decreased
complex III proteins on energy production. Similarly, the increase
in Complex V proteins may reflect a compensation for
downregulated Complex III proteins or a general remodeling of
the ETC, as has previously been shown in studies investigating
ischemic preconditioning.25 Functional assays of the five
complexes that constitute the ETC, in ischemic conditions will
need to be carried out to confirm whether such remodeling
occurs. Determining the regulatory mechanisms of these protein
changes could provide valuable insight that would allow
therapeutic intervention to alter the course of mitochondrial
dysfunction after OGD and metabolic challenges in vivo.
Concurrent with the dysregulation of the oxidative phosphor-
ylation pathway, OGD (18 hours) induced an increase in mito-
chondrial proteins involved in lipid and ketone metabolism.
The increase in these proteins (ACAT1 in ketone metabolism, and
ACADM, ECH1, HSD17B10, and ACAA2 in lipid metabolism)
Figure 4. Mitochondrial energy production proteins and associated interacting partners are affected by oxygen glucose deprivation (OGD).
(A) Key mitochondrial energy production proteins (UQCRC1/UQCRC2) and their putative interacting partners (RTN4/RUVBL2) are significantly
altered by OGD (18 hours). Each data point represents an independent sample with the mean abundance line shown (**Po0.01, T-test).
(B) Energy Production Interactome. One of the highest scoring Ingenuity Pathway Analysis (IPA) networks gained from the 18-hour OGD
proteomic data set is presented. The network contains numerous proteins involved in mitochondrial energy production, the colored nodes
indicate proteins detected in our study as significantly altered by OGD. Red nodes are upregulated proteins and green nodes are
downregulated. Unshaded nodes were manually inserted by IPA to augment functional coherence. Only direct protein–protein interactions
were included in the analysis.
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indicates a shift toward using lipid and ketone bodies as
alternative sources of energy for SH-SY5Y cells faced with glucose
restriction. The availability of such alternative energy sources is
likely to be important in preventing cells hitting the point where
energy provision is insufficient for cell survival, leading to a
downward spiral of metabolic and cognitive decline. A recent
study using a triple transgenic model of AD showed an induction
of ketogenesis after a 2-deoxy-D-glucose diet was introduced. This
correlated with an increase in nonamyloidogenic APP processing
pathways, reduced AD pathology and reduced oxidative stress,26
indicating a potential therapeutic role for enhanced ketone
metabolism.
To use ketones as an alternative energy source in the brain,
acetoacetate and b-hydroxybutyrate (the main ketone bodies
used for energy) need to be synthesized from acetyl-coA. Acetyl-
coA is released after beta oxidation of fatty acids, a four step
process within the mitochondrial matrix requiring beta-oxidation
enzymes at each stage (namely, ACAD, ECH1, HSD17B10, and
ACAA2). Each of these beta-oxidation enzymes, as noted above,
was significantly altered after 18 hours OGD. Of note, the third
beta-oxidative enzyme HSD17B10 (ABAD) is now emerging as an
important player in AD. ABAD has been shown to directly interact
with Ab in the mitochondria of AD patients and AD transgenic
mouse models. Inhibition of the ABAD-Ab interaction suppresses
Figure 5. Protein production, folding, and degradation pathways are affected by oxygen glucose deprivation (OGD). (A) Key proteins involved
in protein folding and the endoplasmic reticulum stress response (HSPA5/HSP90B1/PDIA3/PDIA4) are significantly altered by OGD (18 hours).
(B) Protein Folding and Degradation Interactome. A high scoring Ingenuity Pathway Analysis (IPA) network generated from the 18-hour OGD
proteomic data set contained numerous proteins involved in protein folding and degradation is presented. The colored nodes indicate
proteins detected in our study as significantly altered by OGD. Red nodes are upregulated proteins and green nodes are downregulated
proteins. Unshaded nodes were manually inserted by IPA to augment functional coherence. Only direct protein–protein interactions were
included in the analysis. (C) Representative ribosomal proteins (RPS9/RPS16) and the cellular stress response proteins (PRDX1/PRDX2) are
significantly altered by OGD (18 hours). Each data point represents an independent sample (**Po0.01, ***Po0.0001, T-test). (D) 40S
Ribosomal Interactome. A further high scoring IPA network was dominated by the downregulation of 40S ribosomal proteins and cell stress
response proteins.
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induced apoptosis by increasing levels of Ab, and conversely
overexpression of ABAD in transgenic mice with high levels of Ab
has been shown to cause heightened neuronal oxidative stress
and memory impairments.27 The direct involvement of ABAD in
AD pathophysiology makes ABAD an interesting candidate
to investigate further in terms of its upregulation upon
metabolic challenge.
Pore forming proteins VDAC1 and TOM22 were significantly
downregulated after OGD. VDAC1 is thought to be involved in the
formation of the mPTP, which in turn allows calcium and solutes
o1.5 kDa to pass across the mitochondrial membranes, resulting
in osmotic swelling, loss of the mitochondrial membrane
potential, and damage to the electron transport respiratory
chain.28 Mitochondrial swelling after OGD was clearly showed in
the human cells under the electron microscope (Figure 2D).
The role that these mitochondrial pore forming proteins have in
mediating mitochondrial swelling after OGD needs to be defined
to facilitate the discovery of novel pathways that might be
manipulated to restore mitochondrial normality.
A major proteomic response in the ER was identified after OGD.
The ER stress response (also known as the unfolded protein
response, UPR) is a cellular reaction activated to clear misfolded
proteins that accumulate upon ER stress, thus returning the cell to
a state of proteostasis.29 Two central molecular chaperones,
HSPA5 and HSP90B1, involved in the early and late stages of the
UPR respectively were upregulated after OGD in SH-SY5Y cells
(as well as numerous other UPR proteins and ER stress proteins)
(Figure 5A). These data are consistent with recent results from
OGD in mixed primary cortical cultures where increases in both
HSPA5 and HSP90B1 were detected.30 The induction of the UPR in
response to OGD was also implied in the electron microscopic
data. The ER showed a progressive morphologic swelling that
significantly increased after longer durations of OGD exposure
compared with time-matched controls (Po0.01, Figure 2C).
An expanded ER forms an important part of the UPR as it enables
larger numbers of misfolded proteins to be incorporated within
the ER membrane, thus increasing cellular capacity to deal with
abundant protein damage.31 A larger ER volume also reduces the
concentration of protein intermediates, therefore reducing the risk
of protein aggregate formation.32 The morphologic observation of
enlarged ER along with the significant increase in UPR proteins
HSPA5 and HSP90B1 detected in our proteomic data provides
telling insights into how the human neuronal cells respond to the
metabolic challenge of OGD.
In accord with activation of the UPR, an upregulation of
numerous proteins involved in proteasomal degradation was
highlighted by the Protein Folding and Degradation Interactome.
Subunits of the 20S and 19S (core and regulatory) particles that
constitute the 26S proteasome were increased, suggesting
26S proteasomal degradation to be a fundamental mechanism
for degrading the misfolded proteins that accumulate in response
to metabolic challenge. There has been a long-standing
hypothesis that protein aggregates in diseased brain impair the
protein degradation function of the 26S proteasome.33–35 Our
proteomic data show proteasomal proteins to be upregulated
after a metabolic challenge. It is therefore possible to hypothesize
that any proteasomal response to metabolic challenge might be
adversely affected in the presence of protein aggregates
associated with neurodegenerative diseases such as AD. In this
situation, the cellular capacity to cope with metabolic stress
would be impaired, potentially leading to a deterioration in
cellular function.
A coordinated response after OGD (18 hours) was also observed
in the ribosomal proteome. Numerous ribosomal proteins that
constitute the core ribosomal machinery were downregulated,
and in line with this, several eukaryotic initiation factors central to
protein synthesis were also decreased. It is well established
that cells undergoing severe metabolic stress experience a
downregulation of protein translation, which can be reversible
in more resistant brain areas, and irreversible in vulnerable
regions.36 Further work involving a recovery phase would need to
be undertaken to understand whether the decrease in protein
synthesis machinery is a survival mechanism to conserve energy,
or whether it ultimately pushes the cells down a cell death route.
The proteomic data does suggest that activation of the UPR
correlates with a decrease in global protein synthesis, perhaps to
deal with the accumulation of misfolded proteins.37
Substrate deprivation both in vivo and in vitro has long been
recognized to evoke a marked genomic response. Whether this
genomic response translates into distinct alterations in protein
expression has been a matter of debate. The present study clearly
shows the considerable adaptive capacity of the SH-SY5Y
proteome to a prolonged metabolic challenge in vitro, but caution
must be exercised in the extrapolation of the present data to
cerebral ischemia in vivo. No single cell culture system can model
the complexity of the response of cerebral tissue to substrate
deprivation. Astrocyte cultures and neuronal cells of neuroblas-
toma lineage (such as SH-SY5Y cells) can tolerate prolonged OGD,
whereas primary neuronal and oligodendrocyte cultures are
irreversibly damaged within a few hours.38,39 The temporal
susceptibility of these different cultures to metabolic challenge,
their ability to generate energy from various sources (SH-SY5Y
cells have considerable capacity to perform anaerobic glycolysis40)
and their intrinsic energy demands will all impact on the evoked
proteomic response to OGD.
Additional proteomic and biochemical analyses (not just LC-MS
as in the present study) including protein–protein interaction
assays, membrane potential recordings, and in vitro ATP levels
across a range of different cell types would enhance our
understanding of the true nature of the metabolic challenge
posed by OGD. These studies would also provide more detail as to
the subtleties of the proteomic changes, not only in terms of
abundance, but also in cellular and subcellular localization, and
the interacting partners of altered proteins.
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handling strategies in third generation
proteomic studies
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Quantitative proteomics is entering its “third generation,” where intricate experimental designs
aim to increase the spatial and temporal resolution of protein changes. This paper re-analyses
multiple internally consistent proteomic datasets generated from whole cell homogenates and
fractionated brain tissue samples providing a unique opportunity to explore the different factors
influencing experimental outcomes. The results clearly indicate that improvements in data
handling are required to compensate for the increased mean CV associated with complex study
design and intricate upstream tissue processing. Furthermore, applying arbitrary inclusion
thresholds such as fold change in protein abundance between groups can lead to unnecessary
exclusion of important and biologically relevant data.
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Proteomics is entering its “third generation,” where MS is
increasingly being used, not only to quantify total protein lev-
els, but also to investigate how proteins within specific cell
types and subcellular organelles respond both spatially and
temporally to a host of experimental stimuli. [1]. As proteomic
studies embark on more intricate designs, it is essential to re-
evaluate whether the currently used data-handling strategies
remain appropriate. Fundamental weaknesses and arbitrary
design decisions still permeate proteomic research, despite
efforts to improve the rigor of data handling [2–7]. This article
compares primary datasets generated contemporaneously in
our laboratory using peak intensity based LC-MS to provide a
novel perspective on the suitability of various inclusion crite-
ria and data-handling strategies in analyzing third generation
proteomic data.
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Many quantitative LC-MS proteomic studies use an ini-
tial inclusion criterion that proteins should be identified with
two or more peptides. Though seemingly arbitrary, this in-
clusion criterion is important for two reasons: first, removal
of proteins identified with only one peptide increases the re-
liability of LC-MS protein identification and helps avoid false
detections. A single peptide feature may be found in several
proteins or protein isoforms, therefore a truly definitive iden-
tification is less likely [8]. Second, this cut-off of two peptides
for identification purposes significantly reduces the overall
variance within the dataset, defined as the mean of the coeffi-
cient of variances for all proteins in the dataset. This reduction
is variance considerably increases the power to detect subtle
protein changes (Fig. 1). There is clearly a trade-off between
reducing variance and the number of proteins remaining
for analysis. Extending the inclusion criterion to identifica-
tion of proteins with three or more peptides further reduces
variance, however, also drastically reduces the number of
proteins by nearly half of those originally identified by one
peptide.
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Subcellular proteomics will be a dominant theme in third
generation proteomic research, yet sample fractionation can
greatly impact variance within protein datasets. Sample pro-
cessing techniques including the enrichment of microvessels,
mitochondria [9] or white matter [10] can be used upstream of
proteomic analysis to provide a more in-depth proteomic pro-
file of how individual cell types and subcellular compartments
are responding to experimental stimuli. However, increasing
technicality upstream of protein detection increases the to-
tal variance of the final dataset, as demonstrated by analysis
of our own proteomic data generated using a range of en-
richment techniques (Fig. 2). White matter enrichment via
micropunches of the corpus callosum and microvessel en-
richment using density gradient centrifugation, two intricate
upstream tissue handling techniques, induce a 7 and 15%
increase in total variance in control tissue, respectively, com-
pared to whole brain homogenates. We hypothesise that this
increase in variance might be linked to varying degrees of
protein degradation occurring when samples are handled at
room temperature for extended periods of time. Upstream
tissue processing enriches samples with targeted proteins,
improving the spatial resolution of detected protein changes.
However, the associated increases in variance make detection
of subtle protein changes more difficult.
The magnitude of the change in protein abundance (fold
change) is a popular but arbitrary inclusion criterion often
used to dissect proteomic data. Analysis of our in vitro human
cell line data shows that employing an arbitrary fold change
value as a data dissection tool can exclude important pro-
teins from the final analysis. This in vitro study investigated
the effects of a global metabolic challenge on mitochondrial
function and cellular proteomics. A total of 958 proteins were
identified with two or more peptides (n = 6/group). A strin-
gent a priori inclusion criterion of a p < 0.01 was set for a
protein change to be deemed significant, resulting in a final
protein list of 193 significantly altered proteins [11] (Fig. 3A).
However, as well as a p-value threshold, many investigators
also utilize a fold change cut-off to rapidly identify the most
“important” protein changes. Datasets with a low overall vari-
ance allow for the detection of subtle protein changes, how-
ever, employing an arbitrary fold change inclusion criterion
such as the popular “minimum 1.5 fold change” on these low
variance datasets excludes the subtle yet significant protein
changes. The fold change cut-off drastically reduces the num-
ber of proteins included in the final analysis and increases the
risk of creating false negatives (Fig. 3A).
A similar analysis of the impact of arbitrary fold change
cut-offs was carried out on the more variable microvessel
extraction data (Fig. 3B). Due to the increased variability of
these data (as shown in Fig. 2C), employing a stringent al-
pha value of p < 0.01 significantly reduces the number of
proteins in the final list for analysis from 653 identified with
two or more peptides to only 12. In this more variable sys-
tem, imposing a 1.5 fold change cut-off has no further effect
on protein number, due to a large fold change required to
overcome the variance for inclusion at the set alpha level. It
is therefore concluded that inclusion of a fold change data
cut-off is either dangerous in the creation of false negatives
(in studies with low overall variance) or irrelevant (in studies
with high overall variance).
Alternatively, power calculations can be used to determine
the magnitude of change required to detect a significant
Figure 1. Variance structure is affected by the number of peptides used for protein identification. (A) Quantifying proteins with at least two
peptides reduces the mean CV by 5% in a human cell line and (B) by 7% in mouse whole brain, reducing the total list of proteins by 31–38%.
More stringent inclusion criteria (>3 peptides) has minimal effect on the variance but reduces the overall protein number by ∼50%. A set
initial inclusion criterion in proteomic data analysis should therefore be protein identification by at least two peptides. Each data point is
the CV of the abundance measurements for each individual protein. The CV is calculated for individual proteins using abundance values
from independent biological replicates.
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Figure 2. Complex tissue processing techniques have a direct effect on the total variance of the dataset. (A) Whole brain tissue samples
show very similar overall CV in both sham and chronic cerebral hypoperfusion groups (17 and 16%, respectively). (B) White matter
dissection introduces more variance into the system (24% for both sham and chronic cerebral hypoperfusion). (C) Technically demanding
techniques such as microvessel dissection further increase variance (32 and 37% in wild type (WT) and transgenic (Tg) mice, respectively).
Independent variables (surgery or transgene) have little effect on the variance structure of the data. The internal consistency of the three
datasets controls for the technical variance introduced by the LC-MS technique, allowing the effect of tissue processing on the total variance
to be assessed. Each data point represents the CV for the abundance measurement of individual proteins across independent replicates in
each study, with the mean CV across all proteins shown.
difference between two populations given the technical and
biological variance [5]. Used a priori, power calculations
are beneficial in study design, guiding decisions regarding
the number of replicates needed to obtain a set level of
power [12]. However, the nature of a priori power calculations
means these calculations are based on an estimate of overall
biological and technical variance. Our analysis reveals that
the CV is highly dependent upon the type of tissue being an-
alyzed and the degree of upstream tissue processing involved
(Fig. 2). Using a CV that is not specific to the dataset to decide
detectable fold change can be problematic, and could lead to
an over- or underestimation of proteins found to be differ-
entially expressed. To ensure maximum accuracy in a priori
power calculations, extensive and specific pilot data should be
obtained.
The question of whether inclusion of fold change cut-offs
in addition to a p-value cut-off adds biological value to
proteomic data remains. To assess this, we identified
two key proteins involved in the endoplasmic reticulum
stress response: glucose regulated protein 78 (GRP78) and
glucose regulated protein 94 (GRP94). In our in vitro study,
experimental intervention with the metabolic challenge of
oxygen-glucose deprivation (OGD) saw significant upregu-
lation of GRP78 and GRP94 (p < 0.01). However, GRP78
underwent a fold change of 1.53, whereas GRP94 only had
a fold change of 1.48 (Fig. 3C and D) [11]. The popular fold
change cut-off of 2 would exclude both of these proteins from
the analysis, and only GRP78 would be included if a fold
change of 1.5 was used. The interplay between these two pro-
teins is integral to the endoplasmic reticulum stress response;
however, one or both of these proteins would be lost from the
final dataset if an arbitrary fold change inclusion criterion
was employed. Temporal evolution of protein level change is
another important factor to be considered in understanding
third generation proteomics. Data from the in vitro study
demonstrate that following 6 h of OGD, small increases in
protein levels of GRP78 and GRP94 predict larger increases
following 18 h OGD (Fig. 3C and D). These results suggest
that protein fold change should not be used as threshold
for inclusion, but rather as an indicator of evolving events
occurring within the cell. A protein exhibiting a small fold
change at an early time point can be indicative of increasing
abundance that might be detected as significant at a later time.
The ability to detect a fold change at a particular level of
significance is intrinsically linked to the variance of the data,
and this variance is dependent on tissue source and process-
ing techniques (Fig. 2). It is therefore misguided to include
fold change in the initial stages of data dissection. A protein
reaching the threshold set by a stringent p-value (which in
its nature incorporates the variance and the magnitude of
change) should be sufficient for the initial inclusion crite-
rion, resulting in a much reduced but relevant list of protein
changes (Fig. 3).
The concept of excluding proteins based on fold change
not only increases the likelihood of making type II errors,
but is also fundamentally flawed given that the biological
relevance of a change in protein abundance is likely to be
protein specific. For example, proteins in the Bcl-2 family are
important evolutionarily conserved regulators of apoptosis.
However, even within this family, certain proteins are more
influential than others: PUMA (p53 upregulated modulator of
apoptosis) being one of the most potent [13]. Subtle changes
in this protein are likely to have important cellular effects;
however, may be ruled out if stringent fold change cut-offs
are employed when analyzing data. The importance of subtle
protein changes needs to be recognized in the analysis of
large proteomic datasets to avoid the loss of valuable data
through the use of inappropriate fold change cut-offs.
The issue of multiple hypothesis testing, where inves-
tigating changes in many separate proteins can lead to
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Figure 3. Arbitrary fold change cut-offs are associated with the increased likelihood false negatives. (A) Employing the common “minimum
1.5 fold change” inclusion criterion on datasets with low overall variance drastically reduces the number of proteins available for analysis.
A stringent alpha value of p < 0.01 reduces the number of proteins in from 958 identified with two or more peptides to 193. Imposing an
additional fold change cut-off of 1.5 on this reduced protein list results in a final list for analysis containing only 34 proteins. (B) Analysis
of the more variable microvessel enrichment data demonstrates that a stringent alpha value of p < 0.01 reduces the number of proteins
available for analysis from 653 identified with two or more peptides to only 12. Imposing a 1.5 fold change cut-off has no further effect
on protein number, due to a large fold change required to overcome the variance for inclusion at the set alpha threshold. (C) Biologically
relevant protein GRP78 is significantly increased following a severe metabolic challenge (18 h OGD), and undergoes a fold change increase
of 1.53 from control to OGD samples. This protein would be included for further analysis in most proteomic studies (D) Biologically related
protein GRP94 is also significantly increased following a severe metabolic challenge (18 h OGD), however, undergoes a fold change increase
of 1.48. This protein would be excluded from further analysis in most proteomic studies, demonstrating the arbitrary and irrelevant nature
of fold change inclusion criteria. Each data point in C and D represent an independent biological replicate (n = 6 for each condition).
significant results purely by chance, is an important and
widely reviewed issue that is not formally dealt with in this
article [4, 14–16]. However, consideration should be given to
the fact that overly stringent corrections for multiple compar-
isons can limit the ability to glean biologically meaningful
conclusions from data. Typical methods, such as the Bonfer-
roni correction, are too stringent when studying changes in
hundreds of gene or protein abundances in microarray and
proteomic experiments. A less stringent method for dealing
with multiple comparisons is to employ the false discovery
rate, described by Benjamini and Hochberg, based on the fre-
quency distribution of the statistically generated p-values [17].
It must be noted that a level of arbitrariness remains when
implementing a false discovery rate. The rate of incorrectly
rejecting the null hypotheses is chosen by the individual,
depending on the perceived acceptability of false-positives re-
maining in the final dataset.
As proteomic technology advances, it is important to re-
member where the true power of proteomics lies: as a hy-
pothesis generator and a tool for generating candidates of
potential biomarkers and drug targets of disease. The utility
of proteomics is greatest when a maximum number of pro-
teins are identified and included for further analysis. Data
processing techniques such as an initial inclusion of a pro-
tein identification threshold of two or more peptides give the
researcher confidence in the protein identification. Statistical
significance should then be considered as a sufficient thresh-
old in detecting important protein changes. Pushing proteins
to clear too many hurdles on their way to the final dataset in-
creases the likelihood of omitting biologically interesting and
relevant data.
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